10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-14-188620.txt : 20140508 0001193125-14-188620.hdr.sgml : 20140508 20140508070452 ACCESSION NUMBER: 0001193125-14-188620 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20140331 FILED AS OF DATE: 20140508 DATE AS OF CHANGE: 20140508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ORASURE TECHNOLOGIES INC CENTRAL INDEX KEY: 0001116463 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 364370966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-16537 FILM NUMBER: 14822918 BUSINESS ADDRESS: STREET 1: 150 WEBSTER ST CITY: BETHLEHEM STATE: PA ZIP: 18015 BUSINESS PHONE: 5036416115 MAIL ADDRESS: STREET 1: 150 WEBSTER ST CITY: BETHLEHEM STATE: PA ZIP: 18015 10-Q 1 d703744d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014.

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number 001-16537

ORASURE TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in Its Charter)


DELAWARE		36-4370966
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

220 East First Street, Bethlehem, Pennsylvania		18015
(Address of Principal Executive Offices)		(Zip code)

(610) 882-1820

(Registrant’s Telephone Number, Including Area Code)

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Number of shares of Common Stock, par value $.000001 per share, outstanding as of May 5, 2014: 55,841,785 shares.

PART I. FINANCIAL INFORMATION


	Page No.

Item 1. Financial Statements (unaudited)

Consolidated Balance Sheets at March 31, 2014 and December 31, 2013		3

Consolidated Statements of Operations for the three months ended March 31, 2014 and 2013		4

Consolidated Statements of Comprehensive Loss for the three months ended March 31, 2014 and 2013		5

Consolidated Statements of Cash Flows for the three months ended March 31, 2014 and 2013		6

Notes to the Consolidated Financial Statements		7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		16

Item 3. Quantitative and Qualitative Disclosures About Market Risk		24

Item 4. Controls and Procedures		24

PART II. OTHER INFORMATION

Item 1A. Risk Factors		25

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		25

Item 6. Exhibits		25

Signatures		26

- 2-

Item 1.

FINANCIAL STATEMENTS

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(Unaudited)

(in thousands, except per share amounts)


	MARCH 31, 2014			DECEMBER 31, 2013
ASSETS

CURRENT ASSETS:
Cash	$	84,193		$	93,191
Accounts receivable, net of allowance for doubtful accounts of $284 and $299		13,287			12,957
Inventories		11,994			11,444
Prepaid expenses		2,016			1,712
Deferred income taxes		68			71
Other current assets		197			200

Total current assets		111,755			119,575

PROPERTY AND EQUIPMENT, net		17,826			17,933

INTANGIBLE ASSETS, net		20,659			22,226

GOODWILL		22,860			23,782

OTHER ASSETS		980			729

	$	174,080		$	184,245

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable	$	4,114		$	4,834
Deferred revenue		954			1,119
Accrued expenses		9,902			13,032

Total current liabilities		14,970			18,985

OTHER LIABILITIES		961			677

DEFERRED INCOME TAXES		3,435			3,437

COMMITMENTS AND CONTINGENCIES (Note 6)

STOCKHOLDERS’ EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued		—			—
Common stock, par value $.000001, 120,000 shares authorized, 55,842 and 55,632 shares issued and outstanding		—			—
Additional paid-in capital		339,651			338,674
Accumulated other comprehensive loss		(5,575	)		(3,797	)
Accumulated deficit		(179,362	)		(173,731	)

Total stockholders’ equity		154,714			161,146

	$	174,080		$	184,245

See accompanying notes to the consolidated financial statements.

- 3-

ORASURE TECHNOLOGIES, INC. AND SUBIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

(in thousands, except per share amounts)


	Three Months ended March 31,
	2014			2013
NET REVENUES:
Product	$	23,537		$	20,962
Licensing and product development		—			202

		23,537			21,164

COST OF PRODUCTS SOLD		9,610			9,135

Gross profit		13,927			12,029

OPERATING EXPENSES:
Research and development		2,481			3,357
Sales and marketing		11,340			13,874
General and administrative		5,724			5,387

		19,545			22,618

Operating loss		(5,618	)		(10,589	)

OTHER INCOME (EXPENSE)		118			(47	)

Loss before income taxes		(5,500	)		(10,636	)

INCOME TAX EXPENSE (BENEFIT)		131			(410	)

NET LOSS	$	(5,631	)	$	(10,226	)

LOSS PER SHARE:
BASIC	$	(0.10	)	$	(0.18	)

DILUTED	$	(0.10	)	$	(0.18	)

SHARES USED IN COMPUTING LOSS PER SHARE:
BASIC		55,762			55,449

DILUTED		55,762			55,449

See accompanying notes to the consolidated financial statements.

- 4-

ORASURE TECHNOLOGIES, INC. AND SUBIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

(in thousands)


	Three Months Ended March 31,
	2014			2013
NET LOSS	$	(5,631	)	$	(10,226	)
OTHER COMPEHENSIVE LOSS
Currency translation adjustments		(1,778	)		(1,125	)

Other comprehensive loss		(1,778	)		(1,125	)
COMPREHENSIVE LOSS	$	(7,409	)	$	(11,351	)

See accompanying notes to the consolidated financial statements.

- 5-

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(in thousands)


	Three Months Ended March 31,
	2014			2013
OPERATING ACTIVITIES:
Net loss	$	(5,631	)	$	(10,226	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		1,406			1,394
Depreciation and amortization		1,539			1,602
Deferred income taxes		131			(410	)
Changes in assets and liabilities
Accounts receivable		(402	)		512
Inventories		(586	)		(312	)
Prepaid expenses and other assets		(280	)		(1,545	)
Accounts payable		(683	)		2,263
Deferred revenue		(153	)		37
Accrued expenses and other liabilities		(3,009	)		(989	)

Net cash used in operating activities		(7,668	)		(7,674	)

INVESTING ACTIVITIES:
Purchases of property and equipment		(647	)		(480	)

Net cash used in investing activities		(647	)		(480	)

FINANCING ACTIVITIES:
Proceeds from exercise of stock options		93			301
Repurchase of common stock		(521	)		(743	)

Net cash used in financing activities		(428	)		(442	)

EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH		(255	)		(16	)

NET DECREASE IN CASH		(8,998	)		(8,612	)

CASH, BEGINNING OF PERIOD		93,191			87,888

CASH, END OF PERIOD	$	84,193		$	79,276

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for:
Income taxes	$	40		$	27

See accompanying notes to the consolidated financial statements.

- 6-

ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements

(Unaudited)

(in thousands, except per share amounts, unless otherwise indicated)

1.	The Company

We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our OTC HIV and cryosurgical products are sold to retail pharmacies and mass merchandisers as well as to consumers over the internet.

2.	Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Fair Value of Financial Instruments. As of March 31, 2014, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.

- 7-

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

We offer a nonqualified deferred compensation plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2014 and December 31, 2013 was $1,111 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments.

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:


	March 31, 2014		December 31, 2013
Raw materials	$	6,815	$	6,700
Work in process		890		833
Finished goods		4,289		3,911

	$	11,994	$	11,444

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2014 and December 31, 2013 was $29,081 and $28,390, respectively.

- 8-

Intangible Assets. Intangible assets consist of the following:


		March 31, 2014
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,338	$	(2,866	)	$	8,472
Patents and product rights	3-10		10,449		(7,601	)		2,848
Acquired technology	7		8,807		(3,132	)		5,675
Tradename	15		4,346		(759	)		3,587
Non-compete agreements	1-3		615		(538	)		77

		$	35,555	$	(14,896	)	$	20,659


		December 31, 2013
	Amortization Period (Years)	Gross		Accumulated Amortization			Net
Customer list	10	$	11,795	$	(2,701	)	$	9,094
Patents and product rights	3-10		10,449		(7,466	)		2,983
Acquired technology	7		9,162		(2,952	)		6,210
Tradename	15		4,521		(715	)		3,806
Non-compete agreements	1-3		787		(654	)		133

		$	36,714	$	(14,488	)	$	22,226

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.

We performed our annual impairment assessment as of July 31, 2013 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We performed our last quantitative impairment test for goodwill as of July 31, 2012 and determined there was no impairment. That quantitative assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179) of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2014, we believe no indicators of impairment exist.

The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation.

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are

- 9-

recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV tests, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first quarter of 2014 were recorded based upon shipments into the distribution channel while revenues in the first quarter of 2013 were recorded based upon the consummation of a sale to the consumer.

Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Customer Sales Returns and Allowances. We do not grant product return rights to our customers, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2014 and December 31, 2013, the reserve for sales returns and allowances was $329 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at March 31, 2014 and December 31, 2013 included customer prepayments of $954 and $1,119, respectively.

Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 11% of our accounts receivable balance as of March 31, 2014. We had no significant concentrations in accounts receivable as of December 31, 2013. We had no significant concentrations (greater than 10%) in revenues for the three months ended March 31, 2014 or 2013.

We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

- 10-

Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,792 and 5,997 shares were outstanding as of March 31, 2014 and 2013, respectively. As a result of our net losses for the three months ended March 31, 2014 and 2013, these shares were excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.

Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,778 and $1,125 currency translation adjustments recorded in the first three months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

3.	Stockholders’ Equity

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue new restricted stock, we normally issue new shares rather than purchase shares on the open market.

Total compensation cost related to stock options for the three months ended March 31, 2014 and 2013 was $719 and $662, respectively. Net cash proceeds from the exercise of stock options were $93 and $301 for the three months ended March 31, 2014 and 2013, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

- 11-

The following table summarizes the stock option activity for the three months ended March 31, 2014:


	Options
Outstanding on January 1, 2014		5,271
Granted		1,168
Exercised		(22	)
Expired		(319	)
Forfeited		(70	)

Outstanding on March 31, 2014		6,028

Compensation cost of $687 and $732 related to restricted shares was recognized during the three months ended March 31, 2014 and 2013, respectively. In connection with the vesting of restricted shares, during the three months ended March 31, 2014 and 2013, 89 and 106 shares, respectively, with aggregate values of $521 and $743, respectively, were withheld and retired in satisfaction of minimum tax withholding obligations.

The following table summarizes restricted stock award activity for the three months ended March 31, 2014:


	Shares
Issued and unvested, January 1, 2014		653
Granted		403
Vested		(276	)
Forfeited		(16	)

Issued and unvested, March 31, 2014		764

4.	Accrued Expenses


	March 31, 2014		December 31, 2013
Payroll and related benefits	$	2,763	$	5,827
Royalties		4,813		4,374
Professional fees		733		749
Other		1,593		2,082

	$	9,902	$	13,032

5.	Income Taxes

During the three months ended March 31, 2014, we recorded foreign deferred tax expense of $131. During the three months ended March 31, 2013, we recorded a foreign deferred tax benefit of $410. The foreign deferred tax benefit is associated with certain Canadian research and development and investment tax credits and DNAG’s loss before income taxes in 2013. The 2013 income tax benefit associated with DNAG was considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2014 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.

In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of March 31, 2014 and December 31, 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three months ended March 31, 2014 and 2013.

- 12-

6.	Commitments and Contingencies

From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

7.	Business Segment Information

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products primarily result from sales to retail pharmacies and mass merchandisers and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing, as well as, products sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.

- 13-

The following table summarizes segment information for the three months ended March 31, 2014 and 2013.


	Three Months Ended March 31,
	2014			2013
Net revenues:
OSUR	$	17,778		$	17,232
DNAG		5,759			3,932

Total	$	23,537		$	21,164

Operating income (loss):
OSUR	$	(6,394	)	$	(10,040	)
DNAG		776			(549	)

Total	$	(5,618	)	$	(10,589	)

Depreciation and amortization:
OSUR	$	776		$	777
DNAG		763			825

Total	$	1,539		$	1,602

Capital expenditures:
OSUR	$	439		$	243
DNAG		208			237

Total	$	647		$	480


	March 31, 2014			December 31, 2013
Total assets:
OSUR	$	122,675		$	130,848
DNAG		51,405			53,397

Total	$	174,080		$	184,245

Our products are sold principally in the United States and Europe.

The following table represents total revenues by geographic area, based on the location of the customer:


	Three Months Ended March 31,
	2014		2013
United States	$	17,406	$	16,040
Europe		4,001		2,846
Other regions		2,130		2,278

	$	23,537	$	21,164

- 14-

The following table represents total long-lived assets by geographic area:


	March 31, 2014		December 31, 2013
United States	$	16,729	$	16,925
Canada		1,069		975
Other regions		28		33

	$	17,826	$	17,933

- 15-

Item 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Statements below regarding future events or performance are “forward-looking statements” within the meaning of the Federal securities laws. These may include statements about our expected revenues, earnings/loss per share, net income (loss), expenses, cash flow or other financial performance or developments, clinical trial or development activities, expected regulatory filings and approvals, planned business transactions, views of future industry, competitive or market conditions, and other factors that could affect our future operations, results of operations or financial position. These statements often include the words “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates,” “may,” “will,” “should,” “could,” or similar expressions. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: ability to market and sell products, whether through our internal, direct sales force or third parties; ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; ability to effectively resolve warning letters and other audit observations, findings or comments from the FDA or other regulators; changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for our products; impact of replacing distributors; inventory levels at distributors and other customers; ability of DNA Genotek to achieve its financial and strategic objectives and continue to increase its revenues; ability to identify, complete, integrate and realize the full benefits of future acquisitions; impact of competitors, competing products and technology changes; impact of negative economic conditions, high unemployment and poor credit conditions; reduction or deferral of public funding available to customers; competition from new or better technology or lower cost products; ability to develop, commercialize and market new products, including the OraQuick® In-Home HIV test; market acceptance of oral fluid testing or other products; changes in market acceptance of products based on product performance or other factors; ability to fund research and development and other products and operations; ability to obtain and maintain new or existing product distribution channels; reliance on sole supply sources for critical products and components; availability of related products produced by third parties or products required for use of our products; history of losses and ability to achieve sustained profitability; ability to utilize net operating loss carry forwards or other deferred tax assets; volatility of OraSure’s stock price; uncertainty relating to patent protection and potential patent infringement claims; uncertainty and costs of litigation relating to patents and other intellectual property; availability of licenses to patents or other technology; ability to enter into international manufacturing agreements; obstacles to international marketing and manufacturing of products; ability to sell products internationally, including the impact of changes in international funding sources and testing algorithms; adverse movements in foreign currency exchange rates; loss or impairment of sources of capital; ability to retain qualified personnel; exposure to product liability and other types of litigation; changes in international, federal or state laws and regulations; customer consolidations and inventory practices; equipment failures and ability to obtain needed raw materials and components; the impact of terrorist attacks and civil unrest; and general political, business and economic conditions. These and other factors are discussed more fully in our Securities and Exchange Commission (“SEC”) filings, including our registration statements, Annual Report on Form 10-K for the year ended December 31, 2013, Quarterly Reports on Form 10-Q, and other filings with the SEC. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. The forward-looking statements are made as of the date of this Report, and we undertake no duty to update these statements.

The following discussion should be read in conjunction with our consolidated financial statements contained herein and the notes thereto, along with the Section entitled “Critical Accounting Policies and Estimates,” set forth below.

- 16-

Overview

We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the OraQuick® In-Home HIV test, the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail market. We also manufacture and sell oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our over-the-counter (“OTC”) HIV and cryosurgery products are sold to retail pharmacies and mass merchandisers and to consumers over the internet.

Current Consolidated Financial Results

During the three months ended March 31, 2014, our consolidated net revenues were $23.5 million compared to $21.2 million in the three months ended March 31, 2013. Net product revenues during the three months ended March 31, 2014 increased 12% when compared to the first three months of 2013, primarily due to higher sales of our Oragene®, OraQuick® HCV, cryosurgical systems and OraQuick® In-Home HIV products.

Our consolidated net loss for the three months ended March 31, 2014 was $5.6 million, or $0.10 per share, compared to a net loss of $10.2 million, or $0.18 per share, for the three months ended March 31, 2013.

Cash used in operating activities was $7.7 million in both the three months ended March 31, 2014 and 2013. As of March 31, 2014, we had $84.2 million in cash compared to $93.2 million at December 31, 2013.

Economic Outlook

Many of our customers rely on public funding provided by federal, state and local governments, and this funding has been and may continue to be reduced or deferred as a result of current economic conditions. These circumstances may adversely impact our customers and suppliers, which, in turn, could adversely affect their ability to purchase our products or supply us with necessary equipment, raw materials or components. In addition, these circumstances could adversely affect our access to liquidity that may be needed to conduct or expand our business, conduct future acquisitions or make other discretionary investments.

In 2011, President Obama signed into law the Budget Control Act of 2011, which was designed to reduce federal spending over the next 10 years by $2.5 trillion. Under that law, certain automatic cuts to discretionary, national defense and Medicare spending (often referred to as Federal sequestration) have become effective. We cannot predict whether Congress will attempt to suspend or restructure the automatic budget cuts or what other deficit reduction initiatives may be proposed by Congress. Although the full impact of sequestration is difficult to ascertain, the spending cuts implemented under this new law have adversely affected, and are expected to continue to adversely affect, our customers’ ability to purchase our products. In addition, other legislative or regulatory changes may be adopted which could adversely affect our ability to sell our current products or successfully develop and commercialize new products.

- 17-

Business Segments

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products, specimen collection devices, and medical devices used for the removal of benign skin lesions by cryosurgery; and our “DNAG” or molecular collection systems business, which consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold into the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products primarily result from sales to retail pharmacies and mass merchandisers and to consumers over the internet. DNAG revenues result primarily from products sold into the commercial market, which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal genetic testing, as well as products sold into the academic research market which consists of research laboratories, universities and hospitals.

Results of Operations

Three months ended March 31, 2014 compared to March 31, 2013

CONSOLIDATED NET REVENUES

The table below shows the amount of total net product revenues (dollars in thousands) generated by each of our business segments and net revenues from licensing and product development activities for the three months ended March 31, 2014 and 2013.


	Three Months Ended March 31,
	Dollars							Percentage of Total Net Revenues
	2014		2013		% Change			2014			2013
OSUR	$	17,778	$	17,030		4	%		76	%		80	%
DNAG		5,759		3,932		46			24			19

Net product revenues		23,537		20,962		12			100			99
Licensing and product development		—		202		(100	)		—			1

Net revenues	$	23,537	$	21,164		11	%		100	%		100	%

Consolidated net revenues increased 11% to $23.5 million in the first quarter of 2014 from $21.2 million in the comparable period of 2013, primarily as a result of higher sales of our molecular collection systems, cryosurgical systems, OraQuick^® HCV and OraQuick^® In-Home HIV products. These increases were partially offset by lower sales of our OraQuick® HIV product in the domestic professional market and our substance abuse testing and insurance risk assessment products, as well as the absence of licensing and product development revenues in the current quarter.

Consolidated net revenues derived from products sold to customers outside the U.S. were $6.1 million and $5.1 million, or 26% and 24% of total net revenues, in the first quarters of 2014 and 2013, respectively. Because the majority of our international sales are denominated in U.S. dollars, the impact of fluctuating foreign currency exchange rates was not material to our total net revenues.

- 18-

Net Revenues by Segment

OSUR Segment

The table below shows the amount of total net revenues (dollars in thousands) generated by our OSUR segment in each of our principal markets and by licensing and product development activities.


	Three Months Ended March 31,
	Dollars							Percentage of Total Net Revenues
Market	2014		2013		% Change			2014			2013
Infectious disease testing	$	11,064	$	10,687		4	%		63	%		62	%
Substance abuse testing		1,830		2,249		(19	)		10			13
Cryosurgical systems		3,967		3,085		29			22			18
Insurance risk assessment		917		1,009		(9	)		5			6

Net product revenues		17,778		17,030		4			100			99
Licensing and product development		—		202		(100	)		—			1

Net revenues	$	17,778	$	17,232		3	%		100	%		100	%

Infectious Disease Testing Market

Sales to the infectious disease testing market increased 4% to $11.1 million in the first quarter of 2014 from $10.7 million in the first quarter of 2013, primarily due to higher sales of both our OraQuick® HCV and OraQuick® In-Home HIV products.

The table below shows a breakdown of our total net OraQuick^® revenues (dollars in thousands) during the first quarters of 2014 and 2013.


	Three Months Ended March 31,
Market	2014		2013		% Change
Domestic HIV	$	6,618	$	7,672		(14	)%
International HIV		558		554		1
Domestic OTC HIV		1,953		1,442		35

Net HIV revenues		9,129		9,668		(6	)

Domestic HCV		663		428		55
International HCV		896		240		273

Net HCV revenues		1,559		668		133

Net OraQuick® revenues	$	10,688	$	10,336		3	%

Domestic OraQuick® HIV sales decreased 14% to $6.6 million for the three months ended March 31, 2014 from $7.7 million for the three months ended March 31, 2013. This decrease was primarily caused by delayed purchasing in certain jurisdictions resulting from an underlying delay in the release of funding by the federal government. We expect this funding delay should be resolved over the next few quarters. Also contributing to the lower domestic OraQuick® HIV sales were changes in customer ordering patterns and reduced testing as a result of the inclement winter weather experienced on the East Coast during the first quarter of 2014. Although we do not forsee any ongoing negative impact from inclement weather, we do anticipate that future sales of our professional HIV product may continue to be challenged by reductions in government funding and a shift to automated laboratory-based blood tests by certain customers.

- 19-

During the first quarter of 2014, we recorded $2.2 million in gross revenues from sales of our OraQuick® In-Home HIV test. These revenues were partially offset by $210,000 in customer allowances, including cooperative advertising, cash discounts, and other allowances, which were netted against gross revenues in accordance with U.S. generally accepted accounting principles. Thus, net revenues from this product were $2.0 million for the first quarter of 2014 as compared to net revenues of $1.4 million in the first quarter of 2013 ($1.5 million in gross revenues, partially offset by $109,000 of allowances and discounts).

OraQuick® In-Home HIV revenues recorded in the current and prior year periods are not readily comparable due to the December 2013 change in our revenue recognition policy related to this product. Since the product launch in late 2012, revenues had been recognized upon consummation of a purchase by consumers either in a store or over the internet. In December 2013, as a result of our growing experience with this product, we began recognizing revenues upon shipment of product to the retailers or distributors. Based on available point-of-sale data, consumer purchases increased 22% in the first quarter of 2014 as compared to the first quarter of 2013 due to increased awareness about the product.

Sales of our OraQuick® In-Home HIV test in both the first quarter of 2014 and 2013 included approximately $183,000 and $128,000, respectively, of direct sales to certain public health customers. We anticipate that some public health entities may choose to use a portion of their funding to purchase our OTC product in lieu of professional rapid HIV testing products.

Domestic OraQuick® HCV sales increased 55% to $663,000 in the first quarter of 2014 from $428,000 in the first quarter of 2013, primarily due to the addition of new HCV customers and higher sales to current customers who have expanded their HCV testing programs. International OraQuick® HCV sales increased 273% to $896,000 in the first quarter of 2014 from $240,000 in the first quarter of 2013, primarily as a result of purchases by a multi-national humanitarian organization which did not occur during the first quarter of 2013. We believe our HCV product represents an opportunity for future sales growth, especially as new therapies for treating HCV come to market. However, demand for our HCV product, particularly in the public health marketplace, has been, and will likely continue to be, tempered by the limited availability of government funding allocated to HCV testing efforts and the time and effort required to build awareness and demand for rapid HCV testing.

International orders for both our HIV and HCV products can be sporadic in nature and are often predicated upon the availability of governmental funding, the impact of competition and other factors. As such, there is no assurance that such sales will continue at the same levels in future periods.

Substance Abuse Testing Market

Sales to the substance abuse testing market decreased 19% to $1.8 million in the first quarter of 2014 from $2.2 million in the first quarter of 2013, primarily as a result of lower sales of our Intercept^® drug testing system. The table below shows a breakdown of our total net Intercept^® revenues (dollars in thousands) generated in each market during the first quarters of 2014 and 2013.


	Three Months Ended March 31,
Market	2014		2013		% Change
Domestic	$	1,250	$	1,404		(11	)%
International		40		258		(84	)

Net Intercept® revenues	$	1,290	$	1,662		(22	)%

Domestic Intercept® sales for the first quarter of 2014 decreased slightly to $1.3 million compared to $1.4 million for the first quarter of 2013. First quarter 2013 revenues included $130,000 of equipment sales which did not repeat

- 20-

in the first quarter of 2014. International Intercept® sales decreased 84% to $40,000 in the first quarter of 2014 from $258,000 in 2013 largely due the discontinuance of purchases by our UK distributor who in 2012 began selling its own competing oral specimen collection device. Sales to this distributor were $237,000 in the first quarter of 2013.

Cryosurgical Systems Market

Sales of our cryosurgical systems products (which includes both the physicians’ office and OTC markets) increased 29% to $4.0 million in the first quarter of 2014, compared to $3.1 million in the same period of the prior year.

The table below shows a breakdown of our total net cryosurgical systems revenues (dollars in thousands) generated in each market during the first quarters of 2014 and 2013.


	Three Months Ended March 31,
Market	2014		2013		% Change
Domestic professional	$	1,542	$	891		73	%
International professional		310		348		(11	)
International OTC		2,115		1,846		15

Net cryosurgical systems revenues	$	3,967	$	3,085		29	%

Sales of our Histofreezer® product to physicians’ offices in the United States increased 73% to $1.5 million in the first quarter of 2014, compared to $891,000 in the first quarter of 2013. This increase reflects below normal sales in the first quarter of 2013, resulting from higher distributor purchases in the fourth quarter of 2012 in advance of a price increase implemented in January 2013. During the first quarter of 2014, international sales of Histofreezer® decreased slightly to $310,000, compared to $348,000 in the same period of the prior year.

Sales of our OTC cryosurgical products during the first quarter of 2014 increased 15% to $2.1 million compared to $1.8 million in the first quarter of 2013, largely due to higher sales to our European distributor, Reckitt Benckiser. In the first quarter of 2014, sales to Reckitt Benckiser increased to $1.4 million, compared to $1.1 during the first quarter of 2013, primarily due to the launch of our product into new geographic territories and new market segments. Sales to our Latin American distributor, Genomma, decreased slightly to $709,000 in the first quarter of 2014 from $769,000 in the first quarter of 2013 due to customer ordering patterns.

Insurance Risk Assessment Market

Sales to the insurance risk assessment market decreased 9% to $917,000 in the first quarter of 2014 from $1.0 million in the first quarter of 2013, as a result of reduced demand in the domestic life insurance market, as well as the adoption by some underwriters of a “Simplified Issues” policy, pursuant to which lab-based testing is replaced by having applicants respond to a questionnaire about their behaviors.

Licensing and Product Development

We had no licensing and product development revenues in the first quarter of 2014. Licensing and product development revenues were $202,000 in the first quarter of 2013 and represented royalties paid on domestic outsales of Merck’s OTC cryosurgical wart removal product, pursuant to a license and settlement agreement executed in January 2008. We stopped receiving royalties under this license when certain of our cryosurgical patents expired in August 2013.

- 21-

DNAG Segment

Molecular Collection Systems

Net molecular collection systems revenues, which primarily represent sales of our Oragene® product line, increased 46% to $5.8 million in the first quarter of 2014 from $3.9 million in the first quarter of 2013. Sales of Oragene® in the commercial market increased approximately 83% in the first quarter of 2014 primarily as a result of higher sales to DNAG’s largest commercial customer. Sales of Oragene® in the academic market increased 29% largely due to the timing of orders placed by one of DNAG’s UK customers.

CONSOLIDATED OPERATING RESULTS

Consolidated gross margin was 59% for the first quarter of 2014 compared to 57% for the first quarter of 2013. Gross margin for the current quarter primarily benefited from improved overhead absorption due to the absence of production issues which negatively impacted overhead absorption in the first quarter of 2013 and a more favorable product mix driven largely by the increased DNAG sales.

Consolidated operating loss for the first quarter of 2014 was $5.6 million, a $5.0 million decrease from the $10.6 million operating loss reported in the first quarter of 2013. This improvement in operating loss resulted primarily from higher revenues and lower sales and marketing costs during the current quarter.

OPERATING INCOME (LOSS) BY SEGMENT

OSUR Segment

OSUR’s gross margin was 55% in the first quarter of 2014 compared to 54% in the first quarter of 2013. OSUR’s 2014 margin benefited from improved overhead absorption due to the absence of production issues which negatively impacted overhead absorption in the first quarter of 2013.

Research and development expenses decreased 33% to $1.8 million in the first quarter of 2014 from $2.7 million in the first quarter of 2013 largely due to lower clinical trial, supply, and staffing costs. Sales and marketing expenses decreased 21% to $9.5 million in the first quarter of 2014 from $12.1 million in the first quarter of 2013. This decrease was primarily the result of lower advertising and promotional costs for our OraQuick® In-Home HIV test which totaled $4.6 million in the first quarter of 2014, compared to $6.9 million in first quarter of 2013. This reduction was the result of a decision made in the second half of 2013 to narrow our marketing and promotional efforts to focus on increasing brand awareness among men who have sex with men and African American consumers. General and administrative expenses increased 6% to $4.9 million in the first quarter of 2014 from $4.6 million in the first quarter of 2013 due to an increase in consulting expenses.

All of the above contributed to OSUR’s first quarter 2014 operating loss of $6.4 million, which included non-cash charges of $776,000 for depreciation and amortization and $1.3 million for stock-based compensation.

DNAG Segment

DNAG’s gross margin was 71% in the first quarter of 2014 compared to 67% in the first quarter of 2013. This increase was directly attributable to increased volume of high margin sales experienced in the first quarter of 2014 when compared to the first quarter of 2013.

DNAG operating expenses increased to $3.3 million in the first quarter of 2014 from $3.2 million in the first quarter of 2013. Research and development expenses remained relatively flat at $659,000 in the first quarter of 2014 compared to $622,000 in the first quarter of 2013. Sales and marketing expenses were also flat at $1.8 million in both the first quarters of 2014 and 2013. General and administrative expenses increased 10% to $863,000 in the first quarter of 2014 from $785,000 in the first quarter of 2013 largely due to higher staffing related expenses.

All of the above contributed to DNAG’s first quarter 2014 operating income of $776,000, which included non-cash charges of $763,000 for depreciation and amortization and $96,000 for stock-based compensation.

- 22-

CONSOLIDATED INCOME TAXES

We continue to believe the full valuation allowance established in 2008 against OSUR’s total U.S. net deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. income tax benefit was recorded for OraSure’s pre-tax loss in the first quarter of 2014 or 2013. For the quarter ended March 31, 2014, we recorded Canadian income tax expense of $131,000. For the quarter ended March 31, 2013, we recorded a Canadian income tax benefit of $410,000 associated with the DNAG loss before income taxes and certain Canadian research and development and investment tax credits.

Liquidity and Capital Resources


	March 31, 2014		December 31, 2013
	(In thousands)
Cash	$	84,193	$	93,191
Working capital		96,785		100,590

Our cash balances decreased $9.0 million to $84.2 million at March 31, 2014 from $93.2 million at December 31, 2013. Our working capital also decreased to $97.0 million at March 31, 2014 from $100.6 million at December 31, 2013.

During the first quarter of 2014, we used $7.7 million in cash to finance our operating activities. Our net loss of $5.6 million was partially offset by non-cash stock-based compensation expense of $1.4 million, depreciation and amortization expense of $1.5 million and deferred income tax expense of $131,000. Additional uses of cash in operating activities included a $3.0 million decrease in accrued expenses and other liabilities associated with payment of our 2013 management incentive bonuses, royalty obligations, and certain year-end accruals, a $683,000 decrease in accounts payable associated with payment for year-end inventory purchases and advertising and marketing services, a $586,000 increase in inventory associated with our infectious disease products, a $402,000 increase in accounts receivable resulting from the increase in orders placed at the end of the current quarter, a $280,000 increase in prepaid expenses and a $153,000 increase in deferred revenues.

We used a total of $647,000 in investing activities during the first three months of 2014 to acquire property and equipment.

Net cash used in financing activities was $428,000 for the three months ended March 31, 2014, which resulted from the use of $521,000 for the repurchase of common stock related to the vesting of restricted shares, partially offset by $93,000 in proceeds received from the exercise of stock options.

Our current cash balance is expected to be sufficient to fund our current operating and capital needs through at least the next twelve months. Our cash requirements, however, may vary materially from those now planned due to many factors, including, but not limited to, the timing and amount of promotional costs for our products including our OraQuick® In-Home HIV test, the scope and timing of future strategic acquisitions, the progress of our research and development programs, the scope and results of clinical testing, the cost of any future litigation, the magnitude of capital expenditures, changes in existing and potential relationships with business partners, the timing and cost of obtaining regulatory approvals, the costs involved in obtaining and enforcing patents, proprietary rights and any necessary licenses, the cost and timing of expansion of sales and marketing activities, market acceptance of new products, competing technological and market developments, the impact of the ongoing economic downturn and other factors.

- 23-

Summary of Contractual Obligations

A summary of our obligations to make future payments under contracts existing at December 31, 2013 is included in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the year ended December 31, 2013. As of March 31, 2014, there were no significant changes to this information, including the absence of any off-balance sheet arrangements.

Critical Accounting Policies and Estimates

This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires that we make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our judgments and estimates, including those related to the valuation of accounts receivable, inventories and intangible assets, as well as calculations related to contingencies and accruals. We base our judgments and estimates on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

A more detailed review of our critical accounting policies is contained in our 2013 Annual Report on Form 10-K filed with the SEC. During the first three months of 2014, there were no material changes in our critical accounting policies.

Item 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not hold any amounts of derivative financial instruments or derivative commodity instruments and, accordingly, we have no material derivative risk to report under this Item.

As of March 31, 2014, we did not have any foreign currency exchange contracts or purchase currency options to hedge local currency cash flows. We have operations in Canada and Europe, which are subject to foreign currency fluctuations. As currency rates change, translation of revenues and expenses for these operations from foreign currencies to U.S. dollars affects year-to-year comparability of operating results. Sales denominated in a foreign currency comprised 9.1% of our total revenues for the three months ended March 31, 2014 (including revenues from DNAG). We expect our international business will continue to grow and our exposure to fluctuations in foreign currency exchange rates may increase.

Item 4.

CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures. The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of March 31, 2014. Based on that evaluation, the Company’s management, including such officers, concluded that the Company’s disclosure controls and procedures were adequate and effective as of March 31, 2014 to ensure that information required to be disclosed by the Company in the reports that we file or submit under the Securities Exchange Act of 1934 was accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure and was recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC.

(b) Changes in Internal Control Over Financial Reporting. There was no change in the Company’s internal control over financial reporting that occurred during the three months ended March 31, 2014 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

- 24-

PART II. OTHER INFORMATION

Item 1A.

RISK FACTORS

There have been no material changes to the factors disclosed in Item 1A., entitled “Risk Factors,” in our Annual Report on
Form 10-K for the year ended December 31, 2013.

Item 2.

UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS

During the quarter ended March 31, 2014, pursuant to the OraSure Technologies, Inc. Stock Award Plan, and in connection with the vesting of restricted shares, we retired 88,906 shares of our common stock to satisfy minimum tax withholding obligations at an average price paid per share of $5.86.

Item 6.

EXHIBITS

Exhibits are listed on the Exhibit Index following the signature page of this Report.

- 25-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.


		ORASURE TECHNOLOGIES, INC.

		/s/ Ronald H. Spair
Date: May 8, 2014		Ronald H. Spair
		Chief Operating Officer and
		Chief Financial Officer
		(Principal Financial Officer)

		/s/ Mark L. Kuna
Date: May 8, 2014		Mark L. Kuna
		Senior Vice President, Finance and Controller
		(Principal Accounting Officer)

- 26-

EXHIBIT INDEX


Exhibit

31.1		Certification of Douglas A. Michels required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certification of Ronald H. Spair required by Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification of Douglas A. Michels required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Ronald H. Spair required by Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934, as amended, and 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB		XBRL Taxonomy Extension Labels Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

- 27-

EX-31.1 2 d703744dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

Certification

I, Douglas A. Michels, certify that:

1.	I have reviewed this report on Form 10-Q of OraSure Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d –15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within the entity, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2014

/s/ Douglas A. Michels

Douglas A. Michels

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 d703744dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

Certification

I, Ronald H. Spair, certify that:

1.	I have reviewed this report on Form 10-Q of OraSure Technologies, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 8, 2014

/s/ Ronald H. Spair

Ronald H. Spair

Chief Operating Officer and

Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 d703744dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of OraSure Technologies, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas A. Michels, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Douglas A. Michels

Douglas A. Michels

President and Chief Executive Officer

May 8, 2014

EX-32.2 5 d703744dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of OraSure Technologies, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ronald H. Spair, Chief Operating Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Ronald H. Spair

Ronald H. Spair

Chief Operating Officer and

Chief Financial Officer

May 8, 2014

EX-101.INS 6 osur-20140331.xml XBRL INSTANCE DOCUMENT 55841785

1125000

79276000

55842000

764000

0.13

6028000

25000000

120000000

0.000001

9902000

29081000

1593000

4114000

733000

14970000

-5575000

2763000

1778000

961000

154714000

339651000

284000

4813000

-179362000

954000

14896000

174080000

3435000

111755000

22860000

20659000

980000

890000

174080000

84193000

6815000

13287000

11994000

35555000

2016000

197000

68000

4289000

17826000

0.10 1111000 1

28000

16729000

1069000

51405000

122675000

954000

25179000

538000

77000

615000

759000

3587000

4346000

3132000

5675000

8807000

7601000

2848000

10449000

2866000

8472000

11338000

87888000

55632000

653000

5271000

25000000

120000000

0.000001

13032000

28390000

2082000

4834000

749000

18985000

-3797000

5827000

677000

161146000

338674000

299000

4374000

-173731000

1119000

14488000

184245000

3437000

119575000

23782000

22226000

729000

833000

184245000

93191000

6700000

12957000

11444000

36714000

1712000

200000

71000

3911000

17933000

677000

33000

16925000

975000

53397000

130848000

1119000

654000

133000

787000

715000

3806000

4521000

2952000

6210000

9162000

7466000

2983000

10449000

2701000

9094000

11795000

279000

P3Y

P10Y

P1Y

P3Y

P15Y

P7Y

P10Y

-0.18

55449000

-0.18

-7674000

55449000

5997000

21164000

1545000

-11351000

12029000

27000

20962000

-47000

-1125000

-10589000

-10636000

-1125000

-512000

202000

-10226000

312000

743000

480000

5387000

9135000

-442000

37000

1394000

-8612000

13874000

-480000

-989000

2263000

3357000

301000

1602000

-410000

22618000

-410000

-16000

2278000

16040000

2846000

3932000

-549000

237000

825000

17232000

-10040000

243000

777000

106000

732000

743000

662000

301000

OSUR ORASURE TECHNOLOGIES INC false Accelerated Filer 2014 10-Q 2014-03-31 0001116463 --12-31 Q1

16000

<div> The following table summarizes restricted stock award activity for the three months ended March 31, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="90%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Shares</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Issued and unvested, January 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">653</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">403</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(276</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Issued and unvested, March 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">764</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

403000

<div> Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values. We performed our annual impairment assessment as of July 31, 2013 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We performed our last quantitative impairment test for goodwill as of July 31, 2012 and determined there was no impairment. That quantitative assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179) of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2014, we believe no indicators of impairment exist. The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation. </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">7.</td> <td valign="top" align="left">Business Segment Information</td> </tr> </table> We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products primarily result from sales to retail pharmacies and mass merchandisers and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing, as well as, products sold into the academic research market, which consists of research laboratories, universities and hospitals. We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.   The following table summarizes segment information for the three months ended March 31, 2014 and 2013.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,778</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,232</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,759</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,932</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,537</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,164</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss): </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,394</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,040</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">776</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(549</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,618</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,589</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">776</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">777</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">763</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">825</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,539</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,602</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Capital expenditures: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">439</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">243</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">208</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">237</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">647</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">480</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">122,675</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">130,848</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51,405</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,397</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">174,080</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">184,245</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Our products are sold principally in the United States and Europe. The following table represents total revenues by geographic area, based on the location of the customer:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,406</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,040</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,001</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,846</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,130</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,278</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,537</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,164</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following table represents total long-lived assets by geographic area:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,729</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,925</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Canada </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,069</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">975</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,826</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,933</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV tests, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred. We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first quarter of 2014 were recorded based upon shipments into the distribution channel while revenues in the first quarter of 2013 were recorded based upon the consummation of a sale to the consumer. Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations. Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. </div>

<div> The following table represents total revenues by geographic area, based on the location of the customer:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"> Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,406</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,040</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Europe </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,001</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,846</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,130</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,278</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,537</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,164</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   The following table represents total long-lived assets by geographic area:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> United States </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,729</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16,925</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Canada </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,069</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">975</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Other regions </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">28</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,826</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,933</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-0.10

319000

55762000

<div> The following table summarizes the stock option activity for the three months ended March 31, 2014:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Options</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Outstanding on January 1, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,271</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,168</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Expired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(319</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Forfeited </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(70</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Outstanding on March 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,028</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,778 and $1,125 currency translation adjustments recorded in the first three months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars. </div>

<div> Intangible Assets. Intangible assets consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">March 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,338</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,866</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,472</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,601</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,848</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,807</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,132</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,675</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,346</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(759</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,587</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">615</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(538</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">77</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,555</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,896</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,659</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="2"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,795</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,701</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,094</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,466</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,983</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,952</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,210</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(715</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,806</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(654</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,714</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,488</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,226</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-0.10

<div> The following table summarizes segment information for the three months ended March 31, 2014 and 2013.   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="10%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three Months Ended March 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net revenues: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,778</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">17,232</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,759</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,932</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23,537</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21,164</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Operating income (loss): </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(6,394</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,040</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">776</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(549</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(5,618</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(10,589</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">776</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">777</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">763</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">825</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,539</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,602</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Capital expenditures: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">439</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">243</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">208</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">237</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">647</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">480</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total assets: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"> </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> OSUR </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">122,675</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">130,848</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> DNAG </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">51,405</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">53,397</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">174,080</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">184,245</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="67%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Payroll and related benefits </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,763</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5,827</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Royalties </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,813</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,374</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Professional fees </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">733</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">749</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,593</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,082</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,902</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,032</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

-7668000

<div> Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,815</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,700</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">890</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">833</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,289</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,911</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,994</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,444</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,815</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,700</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">890</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">833</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,289</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,911</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,994</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,444</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2014 and December 31, 2013 was $29,081 and $28,390, respectively. </div>

1168000

55762000

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">5.</td> <td align="left" valign="top">Income Taxes</td> </tr> </table> During the three months ended March 31, 2014, we recorded foreign deferred tax expense of $131. During the three months ended March 31, 2013, we recorded a foreign deferred tax benefit of $410. The foreign deferred tax benefit is associated with certain Canadian research and development and investment tax credits and DNAG’s loss before income taxes in 2013. The 2013 income tax benefit associated with DNAG was considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG. Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2014 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes. In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of March 31, 2014 and December 31, 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three months ended March 31, 2014 and 2013. </div>

<div> Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results of operations expected for the full year. </div>

<div> Customer Sales Returns and Allowances. We do not grant product return rights to our customers, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2014 and December 31, 2013, the reserve for sales returns and allowances was $329 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected. </div>

<div> Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 11% of our accounts receivable balance as of March 31, 2014. We had no significant concentrations in accounts receivable as of December 31, 2013. We had no significant concentrations (greater than 10%) in revenues for the three months ended March 31, 2014 or 2013. We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations. </div>

22000

<div> Intangible assets consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">March 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,338</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,866</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,472</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,601</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,848</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,807</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,132</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,675</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,346</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(759</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,587</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">615</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(538</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">77</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,555</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,896</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,659</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="2"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,795</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,701</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,094</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,466</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,983</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,952</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,210</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(715</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,806</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(654</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,714</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,488</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,226</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">2.</td> <td valign="top" align="left">Summary of Significant Accounting Policies</td> </tr> </table> Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results of operations expected for the full year. Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods. Fair Value of Financial Instruments. As of March 31, 2014, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.   Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). We offer a nonqualified deferred compensation plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2014 and December 31, 2013 was $1,111 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="11%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">March 31, 2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Raw materials </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,815</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">6,700</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Work in process </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">890</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">833</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Finished goods </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,289</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,911</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,994</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,444</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2014 and December 31, 2013 was $29,081 and $28,390, respectively.   Intangible Assets. Intangible assets consist of the following:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="61%"></td> <td valign="bottom" width="5%"></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">March 31, 2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,338</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,866</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,472</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,601</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,848</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,807</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,132</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,675</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,346</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(759</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,587</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">615</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(538</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">77</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">35,555</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,896</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20,659</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr> <td height="16"></td> <td height="16" colspan="2"></td> <td height="16" colspan="12"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center">December 31, 2013</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center">Amortization Period (Years)</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Customer list </td> <td valign="bottom">  </td> <td valign="bottom" align="center">10</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">11,795</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(2,701</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,094</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Patents and product rights </td> <td valign="bottom">  </td> <td valign="bottom" align="center">3-10</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,449</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,466</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,983</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Acquired technology </td> <td valign="bottom">  </td> <td valign="bottom" align="center">7</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9,162</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,952</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,210</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Tradename </td> <td valign="bottom">  </td> <td valign="bottom" align="center">15</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,521</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(715</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3,806</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Non-compete agreements </td> <td valign="bottom">  </td> <td valign="bottom" align="center">1-3</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(654</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom" align="right">133</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36,714</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(14,488</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom"> </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,226</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom"> </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values. We performed our annual impairment assessment as of July 31, 2013 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We performed our last quantitative impairment test for goodwill as of July 31, 2012 and determined there was no impairment. That quantitative assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179) of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2014, we believe no indicators of impairment exist. The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation. Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV tests, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred. We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first quarter of 2014 were recorded based upon shipments into the distribution channel while revenues in the first quarter of 2013 were recorded based upon the consummation of a sale to the consumer. Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations. Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee. We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues. Customer Sales Returns and Allowances. We do not grant product return rights to our customers, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2014 and December 31, 2013, the reserve for sales returns and allowances was $329 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected. Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at March 31, 2014 and December 31, 2013 included customer prepayments of $954 and $1,119, respectively. Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 11% of our accounts receivable balance as of March 31, 2014. We had no significant concentrations in accounts receivable as of December 31, 2013. We had no significant concentrations (greater than 10%) in revenues for the three months ended March 31, 2014 or 2013. We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.   Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,792 and 5,997 shares were outstanding as of March 31, 2014 and 2013, respectively. As a result of our net losses for the three months ended March 31, 2014 and 2013, these shares were excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive. Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs. Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet. We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,778 and $1,125 currency translation adjustments recorded in the first three months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars. </div>

70000

6792000

<div> Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs. </div>

<div> Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods. </div>

<div> Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,792 and 5,997 shares were outstanding as of March 31, 2014 and 2013, respectively. As a result of our net losses for the three months ended March 31, 2014 and 2013, these shares were excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive. </div>

<div> Fair Value of Financial Instruments. As of March 31, 2014, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.   Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). We offer a nonqualified deferred compensation plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2014 and December 31, 2013 was $1,111 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. </div>

<div> Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at March 31, 2014 and December 31, 2013 included customer prepayments of $954 and $1,119, respectively. </div>

276000

23537000

280000

-7409000

13927000

40000

329000

23537000

118000

-1778000

-5618000

-5500000

-1778000

402000

-5631000

586000

521000

647000

5724000

9610000

-428000

-153000

1406000

-8998000

11340000

-647000

-3009000

-683000

2481000

93000

1539000

131000

19545000

131000

-255000

2130000

17406000

4001000

5759000

776000

208000

763000

17778000

-6394000

439000

776000

P40Y

P3Y

P10Y

P20Y

P1Y

P2Y

P3Y

89000

687000

521000

719000

93000

0.11

P15Y

P7Y

P10Y

0001116463 us-gaap:CustomerRelationshipsMember 2014-01-01 2014-03-31 0001116463 us-gaap:PatentedTechnologyMember 2014-01-01 2014-03-31 0001116463 us-gaap:TradeNamesMember 2014-01-01 2014-03-31 0001116463 us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2014-01-01 2014-03-31 0001116463 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-03-31 0001116463 us-gaap:RestrictedStockMember 2014-01-01 2014-03-31 0001116463 osur:DnaGenotekMember 2014-01-01 2014-03-31 0001116463 us-gaap:IntellectualPropertyMemberus-gaap:MinimumMember 2014-01-01 2014-03-31 0001116463 us-gaap:OtherIntangibleAssetsMemberus-gaap:MinimumMember 2014-01-01 2014-03-31 0001116463 us-gaap:NoncompeteAgreementsMemberus-gaap:MinimumMember 2014-01-01 2014-03-31 0001116463 us-gaap:BuildingMemberus-gaap:MinimumMember 2014-01-01 2014-03-31 0001116463 us-gaap:IntellectualPropertyMemberus-gaap:MaximumMember 2014-01-01 2014-03-31 0001116463 us-gaap:OtherIntangibleAssetsMemberus-gaap:MaximumMember 2014-01-01 2014-03-31 0001116463 us-gaap:NoncompeteAgreementsMemberus-gaap:MaximumMember 2014-01-01 2014-03-31 0001116463 us-gaap:BuildingMemberus-gaap:MaximumMember 2014-01-01 2014-03-31 0001116463 us-gaap:ParentCompanyMember 2014-01-01 2014-03-31 0001116463 osur:DnagMember 2014-01-01 2014-03-31 0001116463 us-gaap:EuropeMember 2014-01-01 2014-03-31 0001116463 country:US 2014-01-01 2014-03-31 0001116463 osur:OtherForeignCountriesMember 2014-01-01 2014-03-31 0001116463 2014-01-01 2014-03-31 0001116463 us-gaap:EmployeeStockOptionMember 2013-01-01 2013-03-31 0001116463 us-gaap:RestrictedStockMember 2013-01-01 2013-03-31 0001116463 us-gaap:ParentCompanyMember 2013-01-01 2013-03-31 0001116463 osur:DnagMember 2013-01-01 2013-03-31 0001116463 us-gaap:EuropeMember 2013-01-01 2013-03-31 0001116463 country:US 2013-01-01 2013-03-31 0001116463 osur:OtherForeignCountriesMember 2013-01-01 2013-03-31 0001116463 2013-01-01 2013-03-31 0001116463 us-gaap:CustomerRelationshipsMember 2013-01-01 2013-12-31 0001116463 us-gaap:PatentedTechnologyMember 2013-01-01 2013-12-31 0001116463 us-gaap:TradeNamesMember 2013-01-01 2013-12-31 0001116463 us-gaap:IntellectualPropertyMemberus-gaap:MinimumMember 2013-01-01 2013-12-31 0001116463 us-gaap:NoncompeteAgreementsMemberus-gaap:MinimumMember 2013-01-01 2013-12-31 0001116463 us-gaap:IntellectualPropertyMemberus-gaap:MaximumMember 2013-01-01 2013-12-31 0001116463 us-gaap:NoncompeteAgreementsMemberus-gaap:MaximumMember 2013-01-01 2013-12-31 0001116463 2013-01-01 2013-12-31 0001116463 osur:DnaGenotekMember 2012-07-01 2012-07-31 0001116463 us-gaap:CustomerRelationshipsMember 2013-12-31 0001116463 us-gaap:IntellectualPropertyMember 2013-12-31 0001116463 us-gaap:PatentedTechnologyMember 2013-12-31 0001116463 us-gaap:TradeNamesMember 2013-12-31 0001116463 us-gaap:NoncompeteAgreementsMember 2013-12-31 0001116463 us-gaap:UpFrontPaymentArrangementMember 2013-12-31 0001116463 us-gaap:ParentCompanyMember 2013-12-31 0001116463 osur:DnagMember 2013-12-31 0001116463 country:CA 2013-12-31 0001116463 country:US 2013-12-31 0001116463 osur:OtherForeignCountriesMember 2013-12-31 0001116463 2013-12-31 0001116463 2012-12-31 0001116463 us-gaap:CustomerRelationshipsMember 2014-03-31 0001116463 us-gaap:IntellectualPropertyMember 2014-03-31 0001116463 us-gaap:PatentedTechnologyMember 2014-03-31 0001116463 us-gaap:TradeNamesMember 2014-03-31 0001116463 us-gaap:NoncompeteAgreementsMember 2014-03-31 0001116463 osur:DnaGenotekMember 2014-03-31 0001116463 us-gaap:UpFrontPaymentArrangementMember 2014-03-31 0001116463 us-gaap:ParentCompanyMember 2014-03-31 0001116463 osur:DnagMember 2014-03-31 0001116463 country:CA 2014-03-31 0001116463 country:US 2014-03-31 0001116463 osur:OtherForeignCountriesMember 2014-03-31 0001116463 2014-03-31 0001116463 2013-03-31 0001116463 2014-05-05 shares iso4217:USD pure iso4217:USD shares osur:Customer osur:Segment

EX-101.SCH 7 osur-20140331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - The Company link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Summary of Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Stockholders' Equity link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Business Segment Information link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Summary of Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Summary of Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Stockholders' Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Business Segment Information (Tables) link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Summary of Significant Accounting Policies - Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Business Segment Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Business Segment Information - Summary of Segment Information (Detail) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 osur-20140331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 osur-20140331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 osur-20140331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable And Accrued Liabilities Disclosure [Text Block] Accrued Expenses Accounts Payable Current Accounts payable Accounts Receivable [Member] Accounts Receivable [Member] Accounts Receivable Net Current Accounts receivable, net of allowance for doubtful accounts of $284 and $299 Accrued Liabilities Current Accrued expenses Accrued Expenses, Total Accrued Liabilities Current [Abstract] Schedule of Accrued Expenses [Abstract] Accrued Professional Fees Current Professional fees Accrued Royalties Current Royalties Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Accumulated depreciation of property and equipment Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax Accumulated foreign currency adjustments included in other comprehensive loss amounted Accumulated Other Comprehensive Income Loss Net Of Tax Accumulated other comprehensive loss Additional Paid In Capital Common Stock Additional paid-in capital Adjustments Related To Tax Withholding For Share Based Compensation Restricted shares of common stock, aggregate values Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Allowance For Doubtful Accounts Receivable Current Allowance for doubtful accounts Amendment Flag Amendment Flag Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Number of anti-dilutive securities excluded from EPS computation Assets Total assets TOTAL ASSETS Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] CURRENT ASSETS: Award Type [Axis] Award Type [Axis] Basis Of Accounting Policy Policy [Text Block] Principles of Consolidation and Basis of Presentation Building [Member] Building [Member] Business Acquisition Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] C A Canada [Member] Cash And Cash Equivalents At Carrying Value CASH, END OF PERIOD CASH, BEGINNING OF PERIOD Cash Cash And Cash Equivalents Period Increase Decrease NET DECREASE IN CASH Commitments And Contingencies COMMITMENTS AND CONTINGENCIES (Note 6) Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments And Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, par value $.000001, 120,000 shares authorized, 55,842 and 55,632 shares issued and outstanding Comprehensive Income Net Of Tax COMPREHENSIVE LOSS Comprehensive Income Policy Policy [Text Block] Accumulated Other Comprehensive Loss Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk By Type [Axis] Concentration Risk Type [Axis] Concentration Risk Percentage 1 Percentage of concentration risk Concentration Risk Supplier Number of third-party suppliers to manufacture DNAG's products Concentration Risk Type [Domain] Concentration Risk Type [Domain] Cost Of Goods Sold COST OF PRODUCTS SOLD Current Federal Tax Expense Benefit U.S. federal income tax benefits Current Fiscal Year End Date Current Fiscal Year End Date Current State And Local Tax Expense Benefit U.S. state income tax benefits Customer Concentration Risk [Member] Customer Concentration Risk [Member] Customer Relationships [Member] Customer List [Member] Deferred compensation plan fair value of plan assets. Deferred Compensation Plan Fair Value Of Plan Assets Fair value of plan assets Deferred Foreign Income Tax Expense Benefit Foreign deferred tax expense (benefits) Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type [Domain] Deferred Revenue [Domain] Deferred Revenue Current Deferred revenue Deferred Tax Assets Net Current Deferred income taxes Deferred Tax Expense From Stock Options Exercised Income tax benefit realized from stock option exercises during period Deferred Tax Liabilities Noncurrent DEFERRED INCOME TAXES Depreciation Depletion And Amortization Depreciation and amortization DNA Genotek Dna Genotek [Member] DNA Genotek [Member] DNAG. Dnag [Member] DNAG [Member] Document and entity information. Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share [Abstract] LOSS PER SHARE: Earnings Per Share Basic BASIC Earnings Per Share Diluted DILUTED Earnings Per Share Policy [Text Block] Loss Per Share Effect Of Exchange Rate On Cash And Cash Equivalents EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH Employee Related Liabilities Current Payroll and related benefits Employee Stock Option [Member] Stock Options [Member] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Entity Wide Revenue Major Customer Threshold Percentage Entity Wide Revenue Major Customer Threshold Percentage Concentration rate of accounts receivable Equity [Abstract] Equity [Abstract] Europe [Member] Europe [Member] Fair Value Of Financial Instruments Policy Fair Value of Financial Instruments Finite Lived Intangible Assets Accumulated Amortization Accumulated Amortization Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite Lived Intangible Assets Gross Gross Finite Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Finite Lived Intangible Assets Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite Lived Intangible Asset Useful Life Amortization Period (Years) Foreign Currency Transactions And Translations Policy [Text Block] Foreign Currency Translation General And Administrative Expense General and administrative Goodwill Amount of goodwill at period end GOODWILL Goodwill And Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill And Intangible Assets Goodwill Policy Goodwill Goodwill Fair Value Disclosure Fair value of goodwill Goodwill Impairment Loss Impairment of goodwill Gross Profit Gross profit Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Loss before income taxes Income Statement [Abstract] Income Statement [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid Net Income taxes Income Tax Expense Benefit Deferred income taxes INCOME TAX EXPENSE (BENEFIT) Increase Decrease In Accounts Payable Accounts payable Increase Decrease In Accounts Receivable Accounts receivable Increase Decrease In Accrued Liabilities Accrued expenses and other liabilities Increase Decrease In Deferred Revenue Deferred revenue Increase Decrease In Inventories Inventories Increase Decrease In Operating Capital [Abstract] Changes in assets and liabilities Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other assets Intangible Assets Finite Lived Policy Intangible Assets Intangible Assets Net Excluding Goodwill INTANGIBLE ASSETS, net Net Intellectual Property [Member] Patent and Product Rights [Member] Inventory Finished Goods Finished goods Inventory Net Inventories Inventories Inventory Net [Abstract] Inventories [Abstract] Inventory Policy [Text Block] Inventories Inventory Raw Materials Raw materials Inventory Work In Process Work in process Liabilities And Stockholders Equity Total liabilities and stockholders' equity Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Current Total current liabilities Liabilities Current [Abstract] CURRENT LIABILITIES: License And Maintenance Revenue Licensing and product development Major Customers Policy Policy [Text Block] Customer and Vendor Concentrations Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Net Cash Provided By Used In Financing Activities Continuing Operations Net cash used in financing activities Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] FINANCING ACTIVITIES: Net Cash Provided By Used In Investing Activities Continuing Operations Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] INVESTING ACTIVITIES: Net Cash Provided By Used In Operating Activities Continuing Operations Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] OPERATING ACTIVITIES: Net Income Loss Net loss NET LOSS Noncompete Agreements [Member] Non-compete Agreements [Member] Number Of Reportable Segments Number of reportable segments of company Number of significant concentrations in accounts receivable. Number Of Significant Concentrations In Accounts Receivable Number of our customers, accounted for significant concentrations Operating Expenses Total operating expenses Operating Expenses [Abstract] OPERATING EXPENSES: Operating Income Loss Operating income (loss) Operating loss Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block] The Company Other Accrued Liabilities Current Other Other Assets Current Other current assets Other Assets Noncurrent OTHER ASSETS Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax Currency translation adjustments Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent Other comprehensive loss Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent [Abstract] OTHER COMPREHENSIVE LOSS Other foreign countries. Other Foreign Countries [Member] Other Regions [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Other Liabilities Noncurrent OTHER LIABILITIES Other Nonoperating Income Expense OTHER INCOME (EXPENSE) Parent Company [Member] OSUR [Member] Patented Technology [Member] Acquired Technology [Member] Payables And Accruals [Abstract] Payables and Accruals [Abstract] Payments For Repurchase Of Common Stock Repurchase of common stock Payments To Acquire Property Plant And Equipment Capital expenditures Purchases of property and equipment Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, shares issued Preferred Stock Value Preferred stock, par value $.000001, 25,000 shares authorized, none issued Prepaid Expense And Other Assets Current Prepaid expenses Proceeds From Stock Options Exercised Net cash proceeds from the exercise of stock options Proceeds from exercise of stock options Product Information [Line Items] Product Information [Line Items] Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type [Axis] Property Plant And Equipment Net Long-lived assets PROPERTY AND EQUIPMENT, net Property Plant And Equipment Policy [Text Block] Property and Equipment Property Plant And Equipment Type [Domain] Property, Plant and Equipment, Type [Domain] Property Plant And Equipment Useful Life Useful life of building and other assets Range [Axis] Range [Axis] Range [Member] Range [Domain] Reconciliation Of Revenue From Segments To Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Reporting Unit Percentage Of Fair Value In Excess Of Carrying Amount Percentage of excess of fair value on carrying value Research And Development Expense Research and development Restricted Stock [Member] Restricted Stock [Member] Retained Earnings Accumulated Deficit Accumulated deficit Revenue Recognition Deferred Revenue Deferred Revenue Revenue Recognition Policy [Text Block] Revenue Recognition Revenue Recognition Sales Returns Customer Sales Returns and Allowances Revenue Recognition Sales Returns Reserve For Sales Returns Reserve for sales return and allowances Revenues Net revenues Total revenue Revenues Revenues [Abstract] NET REVENUES: Sales Revenue Goods Net Product Schedule Of Accrued Liabilities Table [Text Block] Schedule of Accrued Expenses Schedule Of Finite Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Schedule Of Finite Lived Intangible Assets Table [Text Block] Intangible Assets Schedule Of Inventory Current Table [Text Block] Inventories Schedule Of Product Information [Table] Schedule of Product Information [Table] Schedule Of Revenues From External Customers And Long Lived Assets By Geographical Areas Table [Text Block] Presentation of Total Revenues and Long-Lived Assets by Geographic Area Schedule Of Segment Reporting Information By Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule Of Segment Reporting Information By Segment [Text Block] Summary of Segment Information Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule Of Sharebased Compensation Restricted Stock And Restricted Stock Units Activity Table [Text Block] Summary of Restricted Stock Award Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Summary of Company's Stock Option Activity Segment [Domain] Segments [Domain] EX-101.PRE 11 osur-20140331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!F'MSGR0$``(03```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F%U/PC`4AN]-_`]+;\W6 MM2JB87#AQZ62B#^@K@>VL+5-6Q#^O=WXB"$((9)X;EA@[7D?>O%D>WN#15U% M<["NU"HC+$E)!"K7LE23C'R,7N(NB9P72HI**\C($AP9]"\O>J.E`1>%W/%#J\@)JX1)M0(4[8VUKX<-7.Z%&Y%,Q`.*TKBK@$'H MWH3FSN\!ZWUOX6AL*2$:"NM?11TPZ**B7]I./[6>)H>'[*'4XW&9@]3YK`XG MD#AC04A7`/BZ2MIK4HM2;;@/Y+>+'6TO[,P@S?]K!Y_(P9%P7"/AN$'"<8N$ MHX.$XPX)1Q<)QST2#I9B`<%B5(9%J0R+4QD6J3(L5F58M,JP>)5A$2O#8E:. MQ:PP"3N'[6- MHR1`]_:$`X)*8]O1]N?//UO>[N9I5!\<8B].P[HH0;$S8GO7:GBMGU8/H&(B M9VD4QQJ.'&%7W=YL7WBDE)MBU_NHLHN+&KJ4_"-B-!U/%`OQ['*ED3!1RF%H MT9,9J&74"T\U<%J"`=[!ZH^^CSYLK$SO+ M=N5#9@NIS]NHFD++28,5\YS3$$X4UD^&'!Q0]47P```/__`P!02P,$%``&``@````A M`%"KK)4XNI9!KFWZ`L!7;Q):,I#[R]Q4F.`V$[27LQ2`)K\:SZ]F1 MUMN?KDV^M/.--;F`22H2;0I;-J;*Q&PO=V]R:V)O;VLN>&ULE)9-<]HP$(;OG>E_\/C>^(M\3B"3I'3* MITH3*G0DDV]7=,^W>SSY]N-ZI^>U7JS0.`U%._ M,*:Z"0*=%:RD^DQ53,*;E:I+:F!9KP-=U8SFNF#,E"*(P_`B*"F7_IYP4_\/ M0ZU6/&-?5=:43)H]I&:"&DA?%[S2_NQVQ05[WE?DT:KZ04O(>RM\3U!MYCDW M+)_ZY[!4&W;TH&ZJAX8+>'N=A(D?S+HBGVHO9RO:"+.$\@YTT"N>Q/&%_:65 MXIFSC>Z#[-+;OG"9JXW]*4B[ZU8))+!I7[WPW!3P/@S#[MEWQM>%.3P$?(#X MK8*P3_OIR;:\@R($3HK,I>%F1Q9RKSY7<(16]054%OE>?:(8@U-IU?YG*JF!C.R!:Z)6Y&?% M$&:"DIF,)G-,>50EHH#R74GG'Z%0K,P%HK2NP!6!#V, MA;WJ!NPPWT)':^C^WDO6PYUJ43B,7,`<*1E9TNUQ%%8I.N'!LN1F?]C6S.!) M`\,(AA(_QESBS1T;/C2:2Z8U2=G:PE`WP,1IS\6V0P+CK2_!<>&X_F#@'G2- M08X1QT'@@0XTP=T5.5Y,W:,$A5_%D383W%J1X\3AD9X`8%=&CBW'Q"5+7`RV M9>3Z$-NK@CT:.28=EQ=B>Q#V+(SDP009)LX+EC6!V2-VC MA":XSV/'R'@ZD%Z9]SY%'+A?^Q;=7[:M>.\WWZ@7C_+!`R/^F*=3G`\>&;'C MZ=%\GC`'3XRXM730%@97>T9%!O\Y[(>=4JU-@\,_KME?````__\#`%!+`P04 M``8`"````"$`59J?Z)<$``#P$0``&````'AL+W=OK"5>F]=OULLA8>8$0^[S(F\\VJ&F4V>K'J6)UNB\@[P_B MI=D]=OLP"E_F6S7M@)_U,:! M'M-KT?S);K_2_'1NH-P^9"026QT^7RC/0%$(LW1\$2EC!1"`OT:9B]8`1=*/ M]O\M/S3GC>D&2S^T70)P8T]Y\YJ+D*:177G#RG\11&0H#.+(("ZPE^/.LT$L M)-3F]Y(VZ79=LYL!30-+\DLJ6I"L(/`],:31I?HH4TA1!/DNHK2Q(`D.Y7G? M!O':>@=%,PE)$`(;HH,0%;&[(T0A@%U'$?+6*;I0P:^UOS,2DU1&OLYH#'$T M1F-$:'<0A2-(-^0XS4V`-Z8WD"+4M$@0`KW1J>5U"[>2[Z80"C58YWEJ`@S- M.5@WU$1)$!*W579K$2B9&:Q;[7;SS)#(/(:CL!Z=M!I3;+],G8]:/>'F4Y M$8,K+_SARI*:`B"V'_4=H7(3/OR\;.C:2CUUZQ=O8B"MWYHL&6@BF0V'%]ZC M:LYR?C*V_DAKHT1B[I+YMM:'.Q5`[,#M'5&5;);]D['_1UHC)1(C)7-'KH$A M<'CA#L$X",CX"H3UBV&6+P[0+:;,Q,`1#;U#&@#Z%RFW48../#8+#U M)3?$3'`;`1YQTTX#<6%YXC:`IP)85/<^'6N[,7$0`V;18;0=O9N$J!+..AN< M+\Z&/G\IX=#Z?3\^[WD/_!?NR3/\MT5KG=<'EM2&UO\E-14P MIH87;[R8EK0^T1TM"FYD["HNU00ZNOL6+_P)7/C;V['5#Z.]I?&PO=V]R M:W-H965T45-V^.%"-!%T]%+1795E#W M:SPF],CM%B?T@E,EM4:ZE/M/BF=?>,W`;&B3;E`:Z/8&";%V+[.V!:0J&`DTPFE@F*BL0`+](<'LRP!#RZO[W/#-E MBI-I,)E%20QPM&7:/')+B1'=:2/%;P^*#U2>9'0@24#](3ZZEB3T@EQ]#\20 MU5+)/8(S`UOJAM@3&"^`^%B8E]&6^EZE4*(EN;9^G:8^!TM':-^XC-)41/&VS4U69[_&__ M;!+@.OLGDZ%&CYF[AL?)L)W=Z,TX?L_;LO:8B1/U=T]G MZN9\K&?6]'_T6/!`SW2PY]ICO$F#&(PLFS^,>3U^&/G+*I@JV(95E494[NR@ MB:&^]JV?@6N8@6YBA&T`9E!#"O:5J(+7&E4LA]0HF($/RD\QOS"R<7=E*PU, M'_=8PL>&P=V.`@#G4IKCPM[.]O.U^@,``/__`P!02P,$%``&``@````A`-2\ MET;U`@``;P@``!D```!X;"]W;W)K&ULE%9=;YLP M%'V?M/^`>"^?(0044C54W2JMTC3MX]D!`U8!(]MIVG^_:SLEX'9=\A+`]_AP M[KF7ZZROG[O6>L*,$]IGMN]XMH7[@I:DKS/[U\^[JY5M<8'Z$K6TQYG]@KE] MO?G\:7V@[)$W&`L+&'J>V8T00^JZO&APA[A#!]Q#I**L0P(>6>WR@6%4JDU= MZP:>MW0[1'I;,Z3L'`Y:5:3`M[38=[@7FH3A%@G0SQLR\%>VKCB'KD/L<3]< M%;0;@&)'6B)>%*EM=45Z7_>4H5T+>3_["U2\@QF0YED M`7:4/DKH?2F78+/[9O>=*L!W9I6X0OM6_*"'KYC4C8!J1Y"0S"LM7VXQ+\!0 MH'&"2#(5M`4!\&MU1'8&&(*>U?5`2M%D=KATHM@+?8!;.\S%'9&4ME7LN:#= M'PWRCU2:)#B2P/5(X@<7DX1'$KB>2()5Y$?+_TMQ=5K*I5LDT&;-Z,&"S@/A M?$"RC_T4F*4](9C\OCW@B]QS(S>IK8#F4-*G31@MUNX3U*$X8K8:`U_1B`GF MB/P=1#Q"7-`WB@3?+AP,_-+1I3*+J&L1+(YQ/P]$J M^$?)(+7S54FPJ?Q-YL+''2_!*=7JN_O&G8#[WP%->R](#7HZO#K,8Y;EMN%70OAW<`!1A7];FR M]5/XOF&@&^LYG#=JW1T#,.\'5.,'Q&K2S#7D$8A5:NJNY5VI6JUEV?'F&`58V0[(?W['>.4-DE;)2^` MX:$&%9S24V@.M["ETII22TL]9J83G-:#D&R M(7$83HFDHL6>8:[/X5!5)1B_4VPC>6L]B>8-M9"_J45G7M@D.X=.4OVTZ29, MR0XH5J(1]GD@Q4BR^<.Z59JN&O"]BU+*7KB'Q0F]%$PKHRH;`!WQB9YZOB)7 M!)B6BU*``U=VI'E5X)MH?CO#9+D8ZO-7\-Z\>4:F5OTW+-2IY13>-_:7Z[URL:PO=SL"0\S4OG^^X85!0H`GB MS#$QU4`"<$52N,F`@M#=<.]%:>L")],@R\,D`CA:<6/OA:/$B&V,5?*?!T5[ M*D\2[TG@OB>)LB"-LWQV!@OQ&0T&[ZBERX56/8*A`4W343>"T1R8G;,$ZO.^ M,[#D8FYL.> MI%J$.";]4_]^W`1ZI9./)Z58_QJFGX@>KT$E4'/E9] M'2.OZC%>=1+GKV-P8#:_1-:!CV7C([,>LY>-/E!UY__%N\L%':N_%M.;]ABO MGD^/Q\L?9'Z?=W3-?U*]%JU!#:]@),,@ATYI?XSYA57=L)M6RL+Q,SS6\+?A ML-G#`,"54O9EX0[*\?^U_`\``/__`P!02P,$%``&``@````A`)@X$).Q`@`` M?0<``!D```!X;"]W;W)K&ULE%5=;YLP%'V?M/]@ M^;V8CP!)E*1J576KM$G5M(]G!TRPBC&RG:;]][NV$Q)(US4O`<*YYYQ[KFT6 MUR^B0<],:2[;)8Z"$"/6%K+D[6:)?_V\OYIBI`UM2]K(EBWQ*]/X>O7YTV(G MU9.N&3,(&%J]Q+4QW9P07=1,4!W(CK7PII)*4`./:D-TIQ@M79%H2!R&&1&4 MM]@SS-5'.&15\8+=R6(K6&L\B6(-->!?U[S3!S91?(1.4/6T[:X**3J@6/.& MFU='BI$HY@^;5BJZ;J#OEVA"BP.W>SBC%[Q04LO*!$!'O-'SGF=D1H!IM2@Y M=&!C1XI52WP3S6]GF*P6+I_?G.WTR3W2M=Q]4;S\QEL&8<.8[`#64CY9Z$-I M_X)BW*@$#HB[ON>&GJ)4ZR(,W#)`(X6C-M[KFEQ*C8:B/%'P^*]E2>)-Z3 MP'5/$J7!)$[SZ0=8B'?D&KRCAJX62NX0+!K0U!VU2S":`[/M;/+/SJ`E6W-C MBUPIH#5,XWF53,(%>88(BSWF]AP3]0@"XKT#4!T[2&!";V=[<&"+A@[BK*=W M)F_?@/2(@8'DW$#V7P.V"*+"Z"2"8X/>@<=`FCUF\K8#H+D\`EL$"^F$/9G$ M/;]WX#&Y&U$:YT>#@P#`X:G\^\E;\%@V&-HFS:OQ[(9I?(6O!8]IBF M[]9C4M?M57S,8J":7Z)JP6/5M._&JWK,7C6)9OWK@:S]$ISLL_\Q>-C_NOH'J[!)5"QZKYGTWOEF/\9/-PG@\67^"^@.FHQOVG:H-;S5J6`5[ M(`QR6!G*GY_^P.U-'#NN=L:/G,,3IDP`'`EI3D\V!.Z_W"N_@(``/__ M`P!02P,$%``&``@````A`-;QV(F5`P``J@P``!D```!X;"]W;W)K&ULG)==;]HP%(;O)^T_1+DOB0D?!0%5DZI;I4V:IGUG^./P^+NM2J]%$%9?721X/0]TB=LHS6 MFZ7_^]?CS:WO"8GK#)>L)DO_C0C_;O7YTV+'^+,H")$>.-1BZ1=2-O,@$&E! M*BP&K"$UC.2,5UC"(]\$HN$$9SJH*H-A&$Z""M/:-PYS?HT'RW.:D@>6;BM2 M2V/"28DE\(N"-N+@5J77V%68/V^;FY15#5BL:4GEFS;UO2J=/VUJQO&ZA'F_ MHA%.#][ZX<2^HBEG@N5R`':!`3V=\RR8!>"T6F049J#2[G&2+_U[-$_0V`]6 M"YV@/Y3L1.>S)PJV^$I]HW6!+(-=5(56#/VK*1/F?H*@H.3Z$==@1_+!EXI&JR6()J#\6%B!J.=ZGLS!3IE0?D%20C32<.$1G)+8B.55, MPU9B,4+N7,;1NPODP*B"EOZHDY(H&K;^.K6QT8!5F[:1K4CZ%!8CO*C+V)\_ M)89EVGEO%$7VFV.CF>F"HU'HY#>QAJ/9D=NB@JEUJ=0*O%Q=%>32'?U-YHQF MK.EF#GK2'8S"XTJTT";_@Z:"7+2QDSBC,6C'!:6QD_-C%M?4YNHOI!*[/$ZE M8J.!G+R[R/H4%INZ\IP#Y?)&4$&7-H+1]#'V*2S&F`6$X(3S4WB8>IO/N23Z:XK,P6YS.8F)]Z*^%=5N#_>>4(T&ULG)I=;YM( M%(;O5]K_@+B/[9GAPXZ25#55=RMMI=5J/ZX)QC&J,1:0IOWW>X8S@3DS9(#T MHHD[#X>7\S$OF-Y]^%&>O>]YW135Y=YGJXWOY9>L.A27IWO_G[\_WVQ]KVG3 MRR$]5Y?\WO^9-_Z'AU]_N7NIZF_-*<];#R)5YS7?;*)UF187'R/6?JNRYS"\M M!JGS<]J"_N947)O7:&4V)UR9UM^>KS=955XAQ&-Q+MJ?75#?*[/;+T^7JDX? MSW#=/UB09J^QNP]6^++(ZJJICNT*PJU1J'W-N_5N#9$>[@X%7(%,NU?GQWO_ M([M-@LA?/]QU"?JWR%\:[7>O.54OO]7%X8_BDD.VH4ZR`H]5]4VB7P[RG^#@ MM77TYZX"?];>(3^FS^?VK^KE][QX.K50[A"N2%[8[>'GI[S)(*,09L5#&2FK MSB``_O;*0K8&9"3]T?U\*0[MZ=X7T2J,-X(![CWF3?NYD"%]+WMNVJK\#R&F M0F$0KH+`3Q6$A:N`A_%V212AHL#/URC1["AKO*XN39_2-GVXJZL7#WH/E#?7 M5'8RNX7(,C_!F_F!Q,AC/LJ#ND.!;J"HWQ\$"^[6WZ$0F6+V-L,HD=@$CW<] MLP:!O4K(G*E20"^,5_%5I3R(JN11'[Z[D/T(0HEDA(A[A&B$["W7*`^"C/N> MELFPCX\BD8&B](R1Z\1%$(UP(EVC.W\2AG[7SLN"X=I1&S([[($0_E#M"5F/ M8JU+B"ZXN/FZ)$QU"686%IFXTW7#@NW.`!(#"+;;7CE1%BU1)F&JC`5#1V/& MD$%E?!.%QGI"UCG76I;HBI?HDC#5)9A9260@+6]VF8L@VJ1Y&GO*]+3*@Z8F M`1F71A=!-.ZH1OA+=`CN:*K1G54'8 M>HP)85Q"8@#Q;IAFJLTPC0EMN,_K^X@]KPPA-;!\&YGS:@#Q9G`3JLVPB@EM MN+WKVNR)90BAMFT0\WZGZ"J?D/7=1JLZ529W:6TL)I1)FE94,&.OV#.$]*8S M6\Z)4'V&.FQ9;C#P]_]OB'8T#,$&4,H-H6V06S_6)D,G1#N(DCK?%5^U$@T$:':EMD&!M:&0]=U6])-#E;W+,!CN]?KL"K[ISZ`ZSV4(*G\NA.HT3&/FA."N M/S$AMC58D^Q"B$Z^R#LZFDZ(8$8E]PJ",1C&G`];,&9R`J(:#0^9ETL^XB7< MV(_W"M*UFKET(E2GX2]A!<+X5I)_>JC7&&4>H/F!T?3-K+8^:NG.5WQ8`-"Y" M38\+H3H7N0P?.HPBHU[LX2L1YP-#DJ4R3M!?3;T80KL/4)ET0Z@1WP;C:\YK^I1_3>NGXM)XY_P(WUYL M5C%DHL9WP?BAK:[=B\+'JH5WN-VO)WAGG\.[SLT*X&-5M:\?Y-OF_G\!//P/ M``#__P,`4$L#!!0`!@`(````(0`H(>S09@(``*,%```9````>&PO=V]R:W-H M965T:L[*.@K6'JW>/]NOM-F8QL`1Y"ALP5MG.MGC%G1@.(V MT3UT^*721G&'6U,SVQO@Y7!)M2P;C:9,<=G1P#`SEW#HJI("'K38*NA<(#'0 MV!3XA(ZQ!E!(E9H]UIPU?MQCW2SKFXL`] M;,[HE11&6UVY!.E8,'H>\RV[9M^ZIWGT#6 MC<-J3S`@']>L?'T`*S"A2)-D@PVA6S2`*U'2=P8FA+\,SYTL75/0?)I,KD=Y MBG"R!NM6TE-2(K;6:?4S@%)O*I)D>Q)\[DG223+.)M^Y;,)TA\]\C0A<>N_3@@F)3HUF+57A>Y--TSIXQ=6*/N0\87"/F M-X*A:%1&M&PO=V]R:W-H965T^?M44X!=C0/XQ5N=/CZU=%73FV^?>:9]\+)*1;'5V<+4-5XDXI`6IZW^ M]U^O+TM=J^JX.,29*/A6_^*5_FWW\T^;JRC?JC/GM08,1;75SW5]61M&E9QY M'E<+<>$%6(ZBS.,:OI8GH[J4/#XTB_+,L$S3,_(X+71D6)=S.,3QF"8\$LE[ MSHL:24J>Q37HK\[II>K8\F0.71Z7;^^7ET3D%Z#8IUE:?S6DNI8GZQ^G0I3Q M/@._/YD3)QUW\V5`GZ=)*2IQK!=`9Z#0H<\K8V4`TVYS2,$#&7:MY,>M_IVM M(\O2C=VF"=`_*;]6=Y^UZBRNOY3IX;>TX!!MR)/,P%Z(-PG]<9`_P6)CL/JU MR<`?I7;@Q_@]J_\4UU]Y>CK7D&X7/)*.K0]?$:\2B"C0+"Q7,B4B`P'PJN6I M+`V(2/S9O%_30WW>ZK:W<'W39@#7]KRJ7U-)J6O)>U6+_%\$L98*2:R6Q`;U MK=UZFL1I2>#]1F(M7>9ZTU(,=*N)4A37\6Y3BJL&I0?"JTLL"YFM@;D+#SK3 M!^S_X@6!DB3?)4O#!:&H(,D?.]MS-L8')"9I,0%B8%_U&$8188>069"T44]$03U6T#97Q.*>=1KF(:K0\*B!X`*&(<(CP30J)AA#+[R'$#2B'Y]V0 MB[8ZI*H/H^VY/7\3MP`Q4)\]1DE&.(F(QA#$"Y!R[\5X$B08MM"=,MM3LX"8 M55-&ENW:M^@UWH7$SIA::!':'WM/E`-DOG()5I4KR@+$^(WR%]=C2YJ7D-B9 MZ2Y7%!`A`%X?)(Y(]YZ1+L%4.C,M^L\!8E`ZJ;55--L@6-.3(-B48AU!4YS697$,4I/*5W1DP!+7]TK-7ZI2B`&::CKJ%6\0<_7*@S=/\HZ%7"B-H*+FPR+J MS=/2(3-/2)=H&G7;4WNG/+T#J"UZR_+\6^?#`T*+>%P4V#TIB6TNG5N$:-G+ MT38_]C@(2>Q]Y9@;L+%IV7HP"8E&6:@+4.3P>^`9-]_&P>[:@ MMGMZ2H\)B7EI*7L\ZLW3TI^:N]:CN7OK#4U-!RT(I5NF8@ZI67U^B7KSM/2G M9BYE,.V5[>RQ*+!VQB\9\AY>>(AS[)*2\2[ MO&EA<%CO?\5;H("MX>E?/N;W!KB$N<0G_GMKNB_R#_@)O]Q\```#__P,`4$L#!!0` M!@`(````(0#%R@/_<00``/`1```9````>&PO=V]R:W-H965TV>)F*;5;N5_9__SY] MGMF6K)-RF^2BY"O[C4O[R_JO3\NSJ)[E@?/:`H92KNQ#71\7CB/3`R\2.1)' M7L+(3E1%4L/7:N_(8\63;3.IR!W/=:=.D62E30R+ZA$.L=ME*8]%>BIX61-) MQ?.D!OWRD!WEA:U('Z$KDNKY=/R?U+G/_AV?Y00[HGX`B-+;9O,9 MNF@?*N-^3B\:<9*JT9NJ`L([$!41W2("5X7$MQ`OZ""*#2B'C]O`22L;4M6% MT0_\CK^)6T@8J,\.,U81T2`B-B$4%R"E[\*5-&GC_Q MK]%KW$7*.&-3;7Y,X_?=*\H!\KAR!.O*)VI40\($C7(6S/3ZBF@<7M_+2ZPR MS/UK9A7ETX\H1["N7*]\PAB418.(V(10U`>J>MQSAI\*87`PB8A-" M<8$GA-[.::Y[!.LYT.HV),RE>L:NEJ-(&9^Z8WWCH?'[[A7E\X\H1["N7*][ MPK3*IX$W5]=%1./WE=%.KS+,O>L3%.4,=OG'@]Z@=>W:;A*V((.X:!@2&R&J M!6QJO;IYK/H9M4+8VKJMXW;;;T%&*\1C@,1&%M4*MKJ>%?,28-08S7M_"Z)2 M&KONS1&!2&CC^PZEW#4-B(T2U M@)VN9^'!4J+^.%!*!#):&83$S`11K<"3^E8&2@G1^L+6MU,\Y0.H+17F:]ME MI(Y[@9;-N!V_'P)5/':^7AX&Q%.?5$OINM_1"8Y=FBF>I3U-6M2-7G<#S7W< M09K#^#O'"(;-[G'AU!I5X=I6'S:4*_M^U-HU8&JQU`Z,+&KLL>OU+#RX!JA7 M#JP!4T-MK0Q"8F:"J%:P"?:L#)01M4PU&S=E1"`Z2S-WJF4K@ILWKA%#MO!R MCA"BF`?7)Y!VNGC3E;+@U9Y'/,^EE8H37JH9'(6[7^G"'[(%7/3P1M<-P'W[ MF.SYCZ3:9Z6TXH`%D5W=CI2RV.S05N(VJX:3KHCL"\$Z( M^O(%']#]5[/^'P``__\#`%!+`P04``8`"````"$`UC^4-H4%``"1%@``&``` M`'AL+W=O(3;W*,EH MH-6[(^U(J]5>GFGB)*@#CH"^S-]OF7+PA70FO'0ZU''YN*I\BM3ZRT=]MT?='LBA-OV,;]P3KWR_;77];OO'WI MCHSU#GAHNHU[[/OSRO.Z\LCJHEOP,VO`LN=M7?3PM3UXW;EEQ6Y85)\\NEQ& M7EU4C8L>5NT]/OA^7Y7LD9>O-6MZ=-*R4]$#_^Y8G;N+M[J\QUU=M"^OYX>2 MUV=P\5R=JO['X-1UZG+U[=#PMG@^P;D_2%"4%]_#EXG[NBI;WO%]OP!W'A*= MGCGU4@\\;=>["DX@PNZT;+]QOY)5[A/7VZZ'`/U;L?=.^]_ICOS]M[;:_5$U M#*(->1(9>.;\14"_[<0C6.Q-5C\-&?BS=79L7[R>^K_X^^^L.AQ[2'<()Q(' M6^U^/+*NA(B"FP4-A:>2GX``_'7J2I0&1*3X&#[?JUU_W+A^M`CCI4\`[CRS MKG^JA$O7*5^[GM?_(6@XT>B$2B?P*9T0.MN)+YW`IW)"DY"$T<^I>'BL(4J/ M15]LURU_=Z#T@'AW+D0ADQ5XOAX6B(?`?A7@80F(/REA&0( M@=NC("8BOX*(1X@'M$9N$"Z=FTB=#P5PFZ-89'&,1O?#,3*$)$.VQ;ER[8%! M``*B$[B]L0!OW$`_>6)MC!"HFS$X@8G(;R$,:K#/_=0$&&*G[4M3<^,,(>F0 MU"0@J6_:<]V>^B0EH]V@!6?3:=V7,K'(I.8,H3$`SWBTT15S&#/#3M- M0V4WZ$4FO=L)%6"+ECHUTD*(I$72U$ZG:0\"93=HQ7-H";!%BUK10@C2HDMB MU7^NFTE,U&J#E.B`=RN#`%NDK`K*$!(.*8RLFY'KQEA%V2"4SB$DP!8A%7Q, M'D*0$$E5Q6!%Z5;HV6.$#4H$Y.C^(`UHB]1$/X7'C7LI*1*'%B*77BX(J'6% M,,G-TW;495TD?*MP,H(8N76<4`N06X#45T5@4K.D_?9%)*C/!C4K79G$7&H^ M"BV!RTT`I1IWDYJ0X+OKG@BTE5*KMC.)D=1H$JEBPE(S`3[$]9-JFR7Z9*KZ MOA643&+P#J3)A!BZ0'.L]0PS8I;H_R294[4/K'TS\8*F+D$<+*?,#$02T."S M2S!+\@D*-AQ;=6BE1B@;$@,$%&;,ETPHNKD.,6,W2_K)5/L#52N2GJ[N`2&6 MZN72!U9CD/C*;A*;)?]DJO^!NOJ2F*[Q::CVE3%#L]060E2IFKQF=0$R;0-: M#Y:\$(,;I^G2"F@N?4AB_M)7`(,9G=4+!K0I'%H)(S.)D3L':6S=D]P$)&GR MR26@LSK!@+:H64*?28P4CLBZ([EACF(EUF;$9G4!.NT"@7(L(X88C)@?^"H> M6&32QVA7ZTUB5@^X[S663GM!8/<"B3&4056Z)(E^/L&81&=U!(IRKJM;:)54 M)C'&YI:ZW828],"-WDOOC*-89=9?:!58)G[Q`L:@.8GC38Q)U.H2@F@`RV^W M,HHR#^D:.T&HQ$%6Y)56,"%Z$V,2G=4OZ+1?A+8L2XR\$GX:V;'.+402Q4J[ M37)6S[@SW=/>83>'C.K-X2'47WGEG3$`?JR]SIL49[4/.FT?]NMX)C$8OP<2 MIWYDU4!N0_S85_5LT!/C#?W"W*Z_`6U=%%NH)0;ID3"()R\$)B*"-P;EPR1G M=9'[T@O#OYS"1')Y[HP$&@N?BP+X7[:%J.N?$]N!RN8A!(5H< M*>*7GI^'T=,S[V$4./Q[A-$O@QG3<@'@/>?]Y8L86H[#Y.W_````__\#`%!+ M`P04``8`"````"$`[XES%3(#``"1"@``&````'AL+W=O.6^8N[>KC]^6!XH>^(5QL(!AI:OW$J(;N'[/*]P@[A'.]S" MDY*R!@FX93N?=PRC0@4UM1\%0>(WB+2N9EBP]W#0LB0YOJ?YOL&MT"0,UTB` M?EZ1CI_8FOP]=`UB3_ON)J=-!Q1;4A/QJDA=I\D7C[N6,K2M(>^7<(KR$[>Z M&=`W)&>4TU)X0.=KH<.<4S_U@6F]+`AD(&UW&"Y7[EVXR,+0]==+9=!O@@_\ MXK?#*WKXS$CQE;08W(8ZR0IL*7V2T,="+D&P/XA^4!7XSIP"EVA?BQ_T\`63 M726@W#%D)!-;%*_WF.?@*-!X42R9)9 M,`D![FPQ%P]$4KI.ON>"-G\T2&74DT1'$K@>2<)H-,GD2`+7,TDTC\,X^;\4 M7Z>E7+I'`JV7C!X<:#T0SCLD&SE<`+.T9P(FOVT/^")C[F20"@4TAYH^K^/Y MTG^&,N1'R$9#8!?UD,A$9&\@9CW$!WF]1K!MO$899&E,>WJ5QD9#YJKJ,J_L M8L$0`,:,%R"#5N[TPH$DL`1H"/11;]+41&37$(9$>,^EQ.OUDV"H\\5[D]!\ M\49#4E7<:&[+,IZF9U\-29#7^R5)L"7):IB-AH2!TI1ZJ?F)/]VW@ M58@A3L[+B_^1Z_TGP9:XV/),0T84>T2`(3P=(UR"+>&))5Q#=+%#&/:#:E\! M&,(@]Q&6*K0ES=H/FR-&:XOC^=3:89D%2"9G@"G-FAK7JPWC?>#:8%QHS!5I M)F`H39\`]&QK,-OA#-M^_P`. M!!W:X6^([4C+G1J70!EX,]@[3!\I](V@G1HY6RK@**!^5G#TPS!;`@_`):7B M=",/+?UA&POMN',F5Y[\OL.^0$&2(#9!J7G3M:6M` M444UQVJ29E'M,8SYD*Q*DF45J\J559)H[`>_Q@"[0#_!/D0_BI]D?_]S(O): M6:1ZW,9B&C#<5&5D7$Z<\S_7B/SV7S_?C)./V3P?32>_?;#S>/M!DDT&T^%H M/$CR13H9IN/I)/OM@]LL?_"OK_[G__@VSQ<)[T[RWSZX7BQF MWWS]=3ZXSF[2_/%TEDUX)F_/7N]O:SKV_2 MT>1!,I@N)PO&??GLR8-D.1G]99D=^$][+[8?O/HV'[WZ=O'JS72PO,DFBX1Y M)+W)8K2X38XF/@#S_O;KQ:MOOU93;[Z7?#^=+*YSF@ZS8?/I]^G\<;*WLYGL M;N\\:3XL1MI?.5+RI_V+?#%/!XO_:+[YJ/E#T=7Y[2QK/GRTL[WU^^:/^ZQQ M:.L\'*=7S:>/+M-QWNJH&.4TFX^FHLXP>9,NNML=CO)!.D[^F*7SY!"ZYJUQ MUM(EO!Y&6]W![W>:?9[/4W%4TK^]N9B.FT\?G?3?GS5_#-M\EEV-1'$V_SB] M:2WKTP7?')^].WA[U^LG1\4%'=P=PT9SE'\$9GY/?9;?-=H^V MM[=W=G:>/7FVUWQTL)S/Q815"G:1^]'6UL[NUEZ+$&%5AZ-Q-D\.V*>KZ;P] MA_W!(*,!CX>,QE_-J81N#J8W-]-)TE],!Q\VD_YU.L_RY&2Y,(&%WLW7#J:3 M?#H>#:WCU^DXG0PR7D,J\V3C??]-\O"KYBM'D^3\>KK,D;Q\$PD=9WF>3!?7 MV?S3*,^2?)8-1I>CMI2]R0:%E+4I^?[LK'=\GNSW^[WS_C?-,0_2_+KY&R01 M+N3)/!MDHX_IQ3C;3";9(IE>)NEX//UD:P$2DN%T>;&X7(Z3-+Y"DX>[+YX8 M>CSH'(*UN]/3EY\X>C=^^:;Y^^L_\CV]_R/S3;P M8V"XW(5^!HQ_3,?++'GX&.@"O%!L3S?Y(\D=#]+EXAK>_FLVA`?0X`)6NZW=G=[NKWZ=/-%T]V3<#X\]G>;AS)JW1*OZSC"['`U&BV:W MSC2V]NOI>(@Y]"C)_K+$SEC=LL)6MK;[O+D6?$^!;DR6;#%".7]U/S#./@^R MV2)!%3OT)^!Z^B48W5]`1[,W3B[1,Q,@=,06G$YSVXTUQL[^>L1M$JV;:^]L MV6+B^[[Q15S>[+0N#'?.867S^TP@]+Q&-&I<4VP8*O@R.9G)1$!L.I5WU=3= M:Z[QN'>>G/5^Z!V_7X'2I_/I<#EHRSL1)S4%< ML#J@_."D?YZ<'";HM3?O#P#0/N#7[.'M')'64)=ML94ZW!?<)KU_/^T=]U2XR+!^0?8T14BJQ2*QDXW7O MN'=X=-[J4ZSQ[J3?4G;Z+8'F2?^[_;->2[6_WN\?'31I\>;HW?OS7FM;K8=^ M\KYO^C5!C9Z^MYV\8XPU\H`45C2!T:7#J"WD*`'XCIQH9G M]\9I26>][V#+HQ]Z*\GI#L7@-I%_DZ/4D&4XZ\_+?"%9:BFR8$?6EKEJ_'N, M7'4$"FH8JLCX3@XQJ#M1I92Z_8/SHQ\ZS+QR&2<7FW(Z.?^CU3>#6;.+I$N2$SL880#"`1N1%^"?C:"7@MR8SPKG* M#07++6U.YO#H>!^#&1Q?-YGY=)!EPSRYG$]O@-1L/I`'BB(TZPO>,5W8[/LL MFX55J"G\(H_9WFBV;$W]TDTB:;N"&YLO]0X/>P>FQ0Y/SGI';X]!UX/O\+UZ M":JIE_C?_>3D.#G8[W_7?%U(^Z9W<-;;[_?P,U:VT7N;R>O>VZ/C8]%(&K-W M=G32PE1OV,,Y[&XB:3.F1&&T)"L@WDHG]OPZ,WQ,)RV;.(B"--TIX84!SE:G M[3@GGJ>XX3?Y+!T03T1$\VS^,7OPZ@]9-"0VDYMTLKR$Z,LY7KXK9&.[/!N/ MDZF4\.5XB5L^'*57DRGL-8C&B.MP"TN`H>SW>)RQ>>PYRA_K)0=K--'I-RG]==%>,N2G-.UY:B&MT<[.<3)'O M]-;GXF_YQK-Z_>^4_QM]3;CRK_+="']N/^!?S)7P!4[`#739T2_S0^*8WN1\ M=,/;@TTN-"KV860A:B,HCAT,4XO8#'B0;>/$YC2>$[] M7([FQ+SU_G0"W7VD>N??'?U@G2?I#.;Z2(^*2+%>]:P^A@2)C%U1ASDQ[7DR MA_]&8NJ$]O,M&FU9I(M'&W__V_\^.3_X^]_^SU=!"&Q"A(&G50E9*1DK&9_Y MH'7#HTW%]14<^:L3!4R$/'EZ,Y,E#%9>8>]*LHCB$UN6S#')FRGRA`,.HP98 M#RLK%A1>VTP&8TQDQ9IC1^$-9&J0#K,;NI;PRSK?3&8$*V[2P92V4YX@>&QL MKI"`(A<)^PNN3$`#T3^=C&[*?O-`''CG79HOQK>;2.QJ`EDWO%EB0=@B[''-=&L/(^6=GG$_1A.8 M<[$T1;J)%!)Y'UTL80RZNQ)_3BQFGR:(8;Z\R$^PG>4SI:, M2BVER64ZDD57"I2ZD9573GX6`YNB'RV78WA#K3Q0HRU57Q#?%+:TWHW4$'E5 M=`LDXN>RMPJKYF3(@/L+Z9#48)\E_7DY,3Y)/HV`7^WHRG_?L>G"%S(\0"A%:_?+FJ#;"."Y@I@0'+R=F4$&H]P;9AY-+8E/"@D8E4C*]:WC'575_.,O]AO-X><)N:K"X*8ZQR4R7D=",`_%AIU[%AMF]E=#\4! M3"7:8PTJ*HV_5-))P_QY.;S2@AXGWQ>:`>XPJK%C(W:Y_D)U+#EX:)7)%0[= ME?MXI+O,G;]&?Y#DE+>A?<*K5VF#1G0G4\$$K%@L@1%[5\Z3.8Y'<*>%(QV_ MC'M,4A'923MHA!3CEN8"_'T?SJ1G*[JZ9JL/L MJ#&-T;S"[I_(8*+#S'U@UK4A8>J![*+'R=%X3(D4#NZ`FH/1@H4H5\&+S26H"&/J%`IFB=M&TZ4Z.',HI^L/(`\.BP2/$>X>?-"3\4289?A6:% MNZ!"PZC9="E.YW-308(B>)YV"JF+DU;4'14_AAH6VU9#4+8OZ@F/`7TV]:@Q MV`GX44:0;"4S5\-@!7YZ*ZS)^6)+O)W@1:#)2H.D8K';UEH'\@VD\&P[34G" M427W=*C,(AIW@5=R%?LP0YYYNCKUD%HYU1A7`_.#46"BCRP.Q@QCA6!&BZ"% MG9E5SORPQE)5W MMD`NLB!/#&(&8*/3$&%D+W`.7$6B/!FY0B/526@J:-(A$B"EH:H)-H?PA$E@ M(!DM*D;&O[B,13-U\Q]0RC":,H+XBDW82P0KI+<$+L->\YT;/H%M2_0L558E85ADQ+ZM%C4 M&(00>;'D9&/T.'M,.'(Y"VQ'J(V:K07JC/E,9&I*S3D%L6^_:G@,"^4.B#U! MM50E3G\!^YT7*??Q\CQYMC%/F,PH?#0Z7H^NKB%@\5#22_AS>ILI$'T.VT1. MEXIJ/,?%&'+,88M03M*H_-8XZ MK6;Q>_4L_J^"N6H$*,H8&GPFUD+J0UDJ>(`.AE?(';C\&_=XA:H7UN)7HJT4 MM8'77-H%XIEJ*D%W000)KBLV!O`.%N)C@G0S^2RN;0VB*Q4J]I;&Q$JI(AB` MD:*W%EORSK!K`"H8^",R(7R+3HS>R%0%/\9`"H"F">(FTINKM/ M*3/%89P.+;S#3]A'EIU"#_&'HG4XF[Y8:X69(@*5^_S4/$#UJ.J%.U`5.6^ M:"4-KF`%L9"5/9&79L^G;[U1VL?F(^J/F3P=+K"A5"8Q93_/AQN[FBV?/FK]^U3Y8<(K,*WXJL8-3 M%/M)YH*0AH)8O-IXOOELNW5H:7]@`6"P*Z;<6B5`&WN;.WN[S;F<8P@!@>UC M6QO/G[YL-CZ>3JA\P$S'.4NOR$48U#9;;3S=>]'Z;>?)YHN7+4KX]B0=NP/U MGK>7"@&>M&E*VY=/6ZO;>+[SM#659T^?M'YC>D]>-&9M4O,VQ&S]C8JP_(+% M0:4$:SQ5(OTRDME1%127#`C.0'_C2]-;'&8@AQ\,L:)DSPQTE7-8S5JAY=H. M!:4J'+Z*87$8W7W[2\[_H)CE3\5GP>F(/"VAB#ZRE1,H*.O8K.1;JG;A/`23 M4VI8L+V_O$(TA:<[CY-B36#[1)Y^H9"HG:!.B/5A/^`7H)SIF0`F'I-BCVY6 MQ!@__^)%(A/RLR$,+4:76GN(4:-=,(%#ODW!;.9321%DG\$(0IZL:S*MJS\>@# MVN\:)M949'$J`5&9$^!L"P"08RY?*^!_)).T5.M!WBI^E"AG*U37]0U6#FHF M)<^D5?"B]T$(&XLNND%>;1\&*]E)F@M4GZ6W-23,N.FB\H[D6N>K@#ELAF8T6^+UX M>=WH;#UA?EES@DG*A<+():T*^:'\C-(?8_TZY0@ZA6PTH9GT"B)>0<62=AZ1 MK.8XXK;:7FJA!9T]LL,*6MNCDTFJU%7S^OB6%RHG;)5:U6W`99XBD#7:0'AQ M9>'?6;>^R1$O*C27D<7\F=6$^KUS9E#MLR"A.^,BH2RTROL$3^KDY1DF'@9> M$4LPM1;%'\ACP+"ZM\B>!J>@:9=0+=1WXM M=U9?*#'FQ5KY-$0M"6_[5%OZKNU&P4E:&+DI6Q9AQI*"8AR0JB:-%:+6.J!= MUS*O*08)E2DN+&@.R88KNAIH^?,-SR5K9XIE(&`/.=&Y\_SE5V)WJRSUK`(* M8F?O-T:HJ"*`.\O,W6!XP95I'I*9R%!'GA[)*@)E)EDEGVLX+:V^>08$(<$6 MLE!PL-72R"$2SL(X,L#180XW9;[5Y+]S,J%P\];7(/]/-0;HAG)G@A\M'2QT M*2;@?BVO:,*1=H^30\\F5MX7C@L%451,$Y7"T5E>0S64S%9HZ#B*E]=80%=, M0:G!W`+Y^93D!KI=&$CRX(K*4.V=E3LD4QPVI=#WC0\;?H8M->Z:>,_+L[K4 M^K>-*RZ$:YYO%"7B>MT)?;B[M_G\!:QNXZ[P]%CNPUTY#]L='B(J2YBN314/ MH.;JB>3*>:4`43$K8F;MF=8/6<\`"S''P63F%UX6XY293S(?[@ MJ`.58;E\236H65BR6`D6&=;"\Y@SRB<;BIMMAUH3R[M)S,M$4*0!2!6%1+CG MCS!>L'@YMH/-C!Z0O2DH+\Y!\&8!#,0R,'.[7*^6D.I7J"P4S0HH+S`EXWNPD+<43+1)*BA=_OQP-/OST?W'9M[[3;0FQ M7%XQ)=7&&WA-4]-YF8JTP!B9^+EG7] MR8A(R(;".EYA8M^!2UXHHE1!^!E:8^,CN!;$*5ZR$[S5RL[1)-KFKM6I$?:X MK45GB.G01R@_#S&^U@PD<8"\C/35E9BPSP5&&;42G#K1G.Z@743"&CAIK_!- M=@%`A:7&*049JD&<3Y=7U\FQXIC4!JK)'C@&]4*E$_\M1!9R*V6)MG(0#V:* MZ"TV7+.=;":*P,LMI`.,#3R?XKL$N=%=!"B'EG%6 M(I/9(&4M=VZ4)&L0DLEQ%@6!"M8PY*)M?CV:S=BY MP`?A_(IR7O1[B-!!2:@1UZCF%LFQ25 MTX#>+?%=1#OP'CAYP4F%Y`^QE%C0+C'1FC@9MIE M&4_E2QW/H#)N83=%&(1]!/?L@A35:04D+;9"JC$J MZH1P;@G[H5>KF!.G^8&Q8"^*)LH0.C@6'.ZU/[5A]7X0KI5;$7--MH2U@^UU M#^:R(="]BSD;%M[BU0GZ0O9`L=QB,?"+RV,0M74Z`J<"C6+JP:X^X/%APJF58.J7>XUBEJ=@XBW?9B`E6ZM3M-!'>^+%5AFR M%76@6FAM`]Q.+03&]+3LA*[L5-,_.9O>T M`]RPM#CUO M3$-;$*&:ASZ7OBSF$PK1:,4:*S:K\Z5X/M3B&Z:YO2=#B(^C[!,,3MB:8PV<&I&*!D=P80,82BT9`% M[MNJ&B$9FU6T1LIH:2P"L&L*3`GYVH)=8V]5U(,5J.WMOK3?'^X^?]E(H"LE M$J)GY4:XEQ$*U*-3R>I,:$59J4IN20@`9[$G"SH5,&<&)B2RP)_IA:I=8V&W MFC'A29$+N1WH0H^#&'Z%6%U0[XWL5KTS,U#5VJ_%I`+^J]E9OO)%"_O1,QHQOV;;#<^EZQGCP;H MY1#J"T:3]-A4M4TFKF:KJN`IU.,62G)QW\)/CXS3652Z3(!RJUOS+37FPY=/ MG[C0J3RT*7;%7A:9%-OR0MD)D7[@;`M+.L!]`CAPE'&`?DV:[L0+]4T7+$,T M;3,YRP8?*,8FS#'A#X0:.,;K6>*4>GUR(R.Q\QOMACH)SV8A3[K;-` M/JT:"&RI#"5-"(A7CND@S-4=D;Y:U;5WV0;P>_:Z4"S; M4O4\>(F@P<-195K$`RL[_&H6X=*/MS')Y41I$+.TH;>_[_9UJ/>I#"SYB*.& M($,`6`XC_-E*T>WDLH)/$E(**'T5E;,*&.5CW8H#634,_P)(0/S`+K%[84J- M!^6+Y5/'_>*4.]%;919U`!"CF00Z?9;U]K::D>Z!H#.@BZAUW/'G+#["IVEZ+NU!) M.G9^W?CA0:G*X'K.^"D((^)'Q29B850Y.#5\\=*AD^#O9/+2UZ32)E8+0:CL94IE+7(U)`++^-5DZFMLX>8=4,N6!.$7L+ M9EA3?A1C?B+;=4;;*T<#FDST53$T-Z*FX28T>+.[>3EO.*VNN< M3WDGDP@IBMV)#9ABU3FJ'+,('J%]=@+I!Q\H'*HMZ#[O(%M8`J;5:BOFV9 MIR*853@@-R;FCY5>34-*;!1WTE:Q!QZ[NQ<@2WY\`!?@L(LVO;J#K.WWG2A" MMJN9R>26UI31F&6BATL@`P&X"42715MRG4CKJ)@@A<\NN'ECA%L=TJ9J, MMT&VI/>7$2BJ:,]9N"(/`;6K%7%"'`%3F&>)/J9.8BX8GK*PI:5HAJ0;*8G5 MD8V@[>0.$TU!F)2`X(D)D<@=+0+[.H2=S7-_K]"\VKT0/.$]>7J!0`S)`%%( M&P-$]I`#.B6_>6;I;%-V)7V#P^(VI+H.SJ,M1D;&G9=-HPLM@0.V$+J/Q[G$ M0D7*P.0K7"N-(Q:.:*]@A\4KVWIEW6`F58W3*8L/#(]PD)#7"DSKU]9;1`AY MTW;$S9&I$+18W"YN;-$,D+NMNI MJA[+L%S8WU#VX*Q;BRSM5^CI"6(P9U9>WOT.P6YQ_'_?4E@"2R%919R46X_< MND,D""S6Z%+13<"-GPD.>LXNNQ`&(KT5ZD:9DNAV=1B9-3K9U?=Q`LD4(5MP M'R%%LT)@#A7AL;#5*$&QIR%<>&<8HWVJ:B+8>8J66AU(V+E!%>F:0O@+:*W'M' MLU"?6@@0T]$3L7A1BLC)Q>?/7QA9=8AQ]VDI;Q'4S-ZKW([D;KD#DJW+N1_ICC$;PCM/3O%ES1#@B(/=NJ0= M@*>H'F8"&^J)6[S\#;7U2\7.^;G\3?8II==P9>5:XS`A')+B/++\J7Z8A]D]ZJI,&(P63+M5>F M%O!?)6_A0#6_**8JJU/316(L2&)?EBA;-9[Y/Q4F*`Z[>=K'0J/1#/4U%W75 M?G#.9ZQU.HY95[5=,^]>0N(%5T+.XJ!W3+G(%JC.R010^Q3.^X<)^F#ADQ55 MVEO[DNP(BM+TU6-XH<(`?R%(F)\:D'$^_TBJ2[NLSS,%4+"U8G3A=F-GYIR2:0VO;\*X-JU23O/2S>M^/$4KK.D:Q[E&W*YU><>) MNI?_:/F'NJ7;&JC.YG!/?BC8-KEO'F2T3'=+I$W@Z)HSPL/E0D MYL3"T;*1C.SL<0;Q2P9`DCY9(L\'X(3*JB&B-M(03W:V/42TMJ5B(&72SX0Z M)C8*IPRAH69'M2OL?^5[//9O%5?Z%2LFIW[)G<=`_$[>_\Q=JUZTOW MOUMA#,6&X?;"JFV$>R)#I9[U:Z:]+-X,UUQF]LU%C1DIK),,VH*&90)MQCAC MLJ'-E)'H5*A3K+^+.H0TNPX.LXWJTCBHNG?WI5)KLRY#E:8"P*K#:P^! M8QH=Q%MF%5M=UWB_V?A^"N30*BA)2VXMIEM>\@V&>Y#63@6;U1/A=LP)$K;- MK#M(%DZW!(ZU@F5!`OG*.8X#4A.SD688EGQB3DVXS3O6LQ:E[8HKX-CRMHH! M.*WBA5)$*82Z)HR>CBIFX8<#I;JL,!R9O%^N-!S&*#.CT8_2ECLWV'!%M*IM MRKT.Z59N7+/[9S&`D5.OOVWN5FQRE@&=%F_O_@08(4L?E?\B@Y&.9F**W*2E M'2?=[?+!\V^L,:$A??A8M[O']Y!]RR:8-E(&'>I*)BJ*LO9Q'-.:*D=30W`> MZ^9G?Q?'P)FQJMER_1:[_\=].\-N(C02E%\3J1Q0RV\Q614-GRMZYHK_;A)5 MIHVGHE,(_D7"+A)5!J0UG"Q76.DDG`I*"JR<+;3Y!WTIA7(#MAM^L&(HB:4V M=AZ+J6[\5)3Y^[%"X?_[SX@4-856,,4Z0P*(_FD[S';=)U)T$&9?+FB.L.'ZJAVWK M_GI/H.,7?:I'M+";R,Q15M4#I4UV(0J4PCPI"H"+0WO8'OX)G;##0LQR M%61"1W;]#+-\P*&YV#6/R\_65"WI52-LY'SMX9@2Z627#YVPWG@+NP*)IAMENDFM MK%Z]NT9$\0+W&KN75`H.RH:"H-[_T(_WRKS3M;]8:8@4=FXPUW3G2/@A.+=D M/%BRU5=@4,1_A8>F'FI>$'RR>JK*_4N3UU2PFQYV\)Y1MP*AXV+:!L0YQ%\3 M18WOY9A*#Z=IN!R#`1%+VB%9=$_S!:%/ M\S<+^3=_/($G\#W@T-J^M@;9>,:5<2LNP.+#X4]:4=2-IT]:4=@-OAZ^T[@J MBVO)=K8WG[YH-5Y[?6)K;@+@KW.KA!$DHI%K:VQ`* MM-8M2O"UCCN9N5;_E(:0IK?4Y8$KMK?-5=B+PB_E\]S?C5MJ!X*R*1F[&4:B M((&O?1=B*'0PR0IY7/T[EDJW5F)L]=./SE<__6B,Q3^+S[TT][^VH.9#7UOS M5PNIP8Y7"JTV'ZZ2IM:ZQWSI@4LN56L>8A/4YUW5"=!:F06:TN9X_1(7^^7U M_ZL^YY5LQ$]8?M7LY-0W6D8%L(C#Q_:/N"!8!-<>O^[^K%>9#'_O#E5I<2^E&(W$HYVW;L[^J(QD[%NDI]G@;>TRNK+[,S=O M`-&BQ+_Y:E%%W[_SR%C9;Q'+"@-T=BK:_D#>"7\`HK=*\\L>53_4K'PMGQ[> M66=7MB4P751^.2/C[R.6'/>VRSHT4G.^7\)CY])%[1LCCZH?AA&^>"$!7HE+ M-SE-L9XGD7[)BX]+2E38)@AA\$TU$S+UFO4?20;'4NO4$^DIF+F M41ZJ)#R9B+!Z7G(-W<\P)T)*WP8/91I=;[++M5Q%]^1"M%=K;K[4G,ZZ2$/W M`!5\NCM`<>KZP9&'*;G2"F+DSLT[8><[PTZ7=BF/MR5V[J,\FC.O;,%=(+E5 MW(U,R*$22DDVWM@1L:^2C??]-\G#%H9:8LNO'T!7GG,T+$>\<3=:WZM3VMTN M\6].E_$?S)5C! M;[X!&N/YEJZV<>`ZA"5GH_Q#TO7.]RGW?)&S['KNR%21T+#57>WC;<^='7X? MDJ1='7"7VN.8YV[EVC$FX;`)'D7WBE!5=OMLE67^]$[W6!\IY-.BL&E#OQH- M/I_9=?LKE1=JU2^[OC2?Y2+<:^U."3#%8:25[SW:V?8+IIM[^^A)UX/=CA=V M.UZHZI+[W=OYO M*=3CXM2%_+IHRX(5:>WX6=7113>ML0_J:Z^U30B1?VBNLV9M6-VZUAQ&MZ*, M(/7-%ZOP61O&SCY%>[[Y5KG>:OE>YTDF.6_HR.B0-'M[U!+0LO_:N83J^1'X MP4,5%GCJG?:Q-71@QE1-OI35EA5*I,56[ M5.&+M%+5@+I+%<6VMWQ5?;$F=?]%$Z@T;N/R73,ZU#5,65#;[=?7`65U+Q!/ MW8>_G0ID;O?2/Y7K2W&H7OU_D=>K6X[[PH_[WM)-6CYZLGPDD.CEXH6M=%AT<[3U>_6KT(?;^X M"+VSGSN:WX>8.S:1IGS?H^,["+G2`_BOV8ZA]E<^0E%45[75,'/-Q@SM"G/. MZB_729`;T0*FHE_Y62VB@!5?6HO:[..H79?R)>6>KFB;G;9\GRZ^4T68(GFH M,OR(Z"_E5G%&,+U:3]=1*+=F:.]&?4/)XGPD*KNX:MJ+^YI=N+L6RD8[6;V# MGRJ@*[Y8XSL6_DEK?"U?$1R"39V\]3KP5FA7YZTX]VIMZ)_.5+I&X$'6538[97XTF^D97/!C7G.KJUSJ*95T.JL?'JXLOX]-.2L4&*^>V MGF#8`?60QE;27Q.\*,C3Y:_'_M[Q'04^3&QYPP,[(KC.9(IO]4(1Z*:'*)J< M''#PW*Z]^MEJ`3)VUT=NQ%K15B2B5CJ$A:I23Q64Q1>:D[7V%I"+.9!UK==& M@>Y<:G/LOL>$FC^7!OV*&I.`P4+#YGMW3*X"IV'@+POQA`"6)]TDW/?U]JOY MJ^:<.S)0S6:KDCS--M4<3_.99?>[-*WD'4?U#,[DZ!C3M64%\7N%A] M@@7PR539@7V%6Y)UYE",)C8)9('%:E*FV:"6*NK4Y)XSZGSLD:TS3QYUMO)< MSXK'7^?YXM7_$P```/__`P!02P,$%``&``@````A`#8ZV\)S"P``#F0```T` M``!X;"]S='EL97,N>&UL[%UM;^/&$?Y>H/^!X+5%`M0GB:0LR;$#J M!CD7+=`4!2U1-FN^J"1U9Z?H?^_,\FU6$LFEM-+V0R/D+%'^#35__Q@7XQU+4F=<.GX4>A.]3NLTRP4>#WC'[_LA?0!ZNO`(HB5;I>Q#7BU8K;^'NHIST)CV0=',= M;@([2!-M$6W"=*H;Y2$M^^;CUW?_O)7?[]YV]VO_OY6[U7J"$R@8-FF>_[C6+AZTQR+[?@YGH5A<004,`< M=/421E]#&[^#8`#S\+2;Z^07[8OCPY$!PEM$?A1K*;`,]K$CH1.XV1ESQ_<> M8P]/6SF!Y[]EAPT\P`(C/R_P@"8\V,LTG%?/(Z(I;!HC#,XF$X]0FP(PR<&# MS38Y_]QC$Z=KV*[K&/]QNI@5S79)T[4;%SL^/$97R171$S\]3G7;AAHRZ/?1 MK92P$RF;S/N@[VS*+H=GL\RT37LDU3(N%G=Y0X6F+=.5+0KM#Z/;L[E3OK(Z MZ_(R?*X,P(23ZT4/4KE5M?/`"-]'NW:_: M3U'@A.A8VJFQL[D^F0L\^>(Y^D\C?D,C3+Z*,GC1ETVNES0V8F.IT^O9'1;) MC"3YTH5IZ)P!)XL?EF<))*#G^^6DPK1PV`U';JYA?I.Z<6C#!RU___"VAD%W M"%,QC+9>=E[+V4^Q\S8PV-!3K$$2^=X243S-V5`_'VK-+^_L^1W32Y")HJ@1 M:MOST0F$WLTF<_E(YY.);*&_)0C\,\259J`W_S:7Y-.]L+5D@2WE:ZN'4 MO/]^-)E,QH/+\7@\L7!H`I&^- MF:JS(C`!P&@X'`\'$\."_UD%/ST"V3X=ZJI9)0@4L4H0*&*5S0Y[$BI_GBFP M4*8X5PD"1:P2!(I8'4FNP"/EK!($BE@E"!2QRH;7$G,5UH<5YRI!H(A5@D`1 MJ](&GWD%GBAGE2!0Q"I!<&Y6BVG5_.[.9BMP>U=L M20UP]I@=N[GVW54*L\38>WK&OVFTAG\?HS2%O:Z;ZZ7G/$6AX\/;7M&B^-O0 M$G8#8>-OJJ?/WN(%E'$K$1G>3,6I-)25R,(1OC6R^B-K:%QFDRA)J@-WZ6V" M7>M*W7MC!=R(OFTWG/@P+)7DX5`M>/:0A9P^P1:,:L:T8`.(B2(D!%O(L+%: M_!>UD;00LY$T$+21M!"U$5)G7W(5GEQ&&]B(WB;8ML?]?K;.*JJG62`!OB=B M]H,@;7;]V=IDCT=;VW2U%>K+3F[,#'RQ$>L>2UM:[-K9TF"/E2TM1&WDXZ9@ MEQ->+B=@>=Z#9,O?W.F'P0!%6<,"SU81S.L3[O]D.T#"Y6Z_N:WBB=4@H5MW M5=BPY:9=&V0HZ6))`:RU31.)>7\-W?_"]?W/V"'_=56.`6"IZ^;Z=46N'X&+ M>O`""[P\!=_">G+^-NOOLP_@X[I&1FTCS5FO_;?[3?#HQC:[TH>I8$=QW;KZ M-&,#E>KS!]]["@.7+=;IF9@?XRAU%RF[$HGMT]3A,6OP#')!(GB.T6_5Z`<_ M"?OC&/VP&+271/"+4OT07,+Z9<8#7G.5!S500(.Z"8],!##E+Q``"2H0P/2T M0`#AJ0(!3*4*!!"@%0*`TQ`5Q^3!@%0SB(%*)>@_E4JH,865G,H36EE7?D%_ M@Y4V5WZ/[.5-O08]\C9WU@_L* M4]%LW^EUM;76RV:7^0JQ.$9^F;7`>E[DX+CVI>TMW]9ZL_(<;`OH6JO;B')Q MKPGZYP@L""M?#H6W7&GG@ZS6$:V6TX`15K<_7@X'@B6D17%)UJKV.)"L3Q#>I`S9<6Q;FR&>4"-%P94Y[@6 M8D7JR0'C!6'8X+!53O?_YLA>6M]$LT&J>Z0A;*V^="FL0_D5B3'A+N)H-\)8 M0]DB`6Z(JE..`XY.:RTM];TU7FARDST/*46RBW+:T4E13H-0?+K`'A37V]F1 M(%ZB0%L*-]^7'%"B9>*FI?L4N+N0C==>*`OS4Q/8=8Y1$UL*DR![8D93$M3W M+%#`I$PS:/H*=\7L"FP%FPML!Q?V;,D=,/S]+^4.KX;//H-GM?9_JUUH'Q9H M63FQ'N"._\;SX=YVW+K%W??%)H%;.&?9P7Q)K$E6.'U,I6_+%@WZ8H+FN2R>-\/!7UO M[>.175E6X4*317!1616/X#EBHPDF=Y55\0C$45E@'655;)HX5EL_+]4-#WEWMYY&,5+P,1P45E53SRL6H*QBJ55?'(QRJ: MW!57Q2-()?ZRX(NNLBH>^3IA"=8):F/%(^_[H:#OMRLJ'_&&8,1G4BKNX!WQ M$0Z>1'R42:E8XZ/<%(SR3$K%%Q_?EF!\9U(JID`>L>]:@MZ= M.U[X1.&L5O&E[:5(KC28=KN83$_2&*2A_Q$G!]7@30#_!D>WAH MO@9^R3S$QS"N1'414^8"[QZ\SZ&+&&B=H>'C#T?D7<1`ZTP,7U1Q_"0BYF.X MWI0,\;44NVX1$9^\\,5=\I'#>QBG6R*2[MU-&CME_/$I90@ZYA[O=2YE\"4B M>\1L<6-V/OZ\AUN;"R?BBA')'1Q#BP#_TR8E;F0W'%7]KB%8EQZ\%!Y)420Q MCP-@B>!XB.!RPU+$5D41E/$7)PXQ6[C4W8K1&HNJBS=A]+]\K>Y[9WY/\;U/]WW>ST>3VSC8NQOW9^,(RW>'%9#B[O1A:\]GMK3WI M&_WY?\!E^$,95_!+"T?\$`7[P0RX?'-@724^_%Q%G!N;@_]<'9OJY$,&GSTZ M`V##,R4*(WI)^4,>-_\%``#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<; M```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=U MBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3 M.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT M81C+RSPA,S*A/D%#3=+; MRHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI> MU?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=VJ^>?__J^5/T MZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_ M^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT M,X9Q)2"M.69EN`YQC7=70/$H`UZ?W7=D'81B MIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#UO5D"53,+ M2L?VW9`X8NXS'"LY1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0 M%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD".S1P1%H$B)Z9B1)?7B?-AOZ'&(KA\1J MCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU7 M69O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD M/M)Z+_NH9IR4Q>Q,O91&\ M\!)0.YF.+"XF)XO14=MK-=8:'O)QTO8F<%2&QR@!KTO=3&(6P'V3KX0-^U.3 MV63YPINM3#$W"6IP^V'MOJ2P4P<2(=4.EJ$-#3.5A@"+-2[\JIB4OR!5BF'\/U-%[R=P!;$^UA[PX7988*0SI>UQH4(.52@) MJ=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]E MR43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO M:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45% M],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_ MJ/"9_>"A-]0A/X#:BN#[A28&80-1?F#R`Y+<@,D?O.>Q\<^SF'^X;G(O2;6]Y2F949S4;*%_\*4_V'Y_MW\(.2CVC&F/7`HU<+?:5W-PE"E.U90%8B* ME3"R$;*@&B[E-E259#2K'RKR,(ZB<5A07OK&82;[>(C-AJ?L7J3[@I7:F$B6 M4PW\:L<_U2F_I>D3^3(4V/ MWO7%F7W!4RF4V.@`[$(#>C[G:3@-P6DYSSC,`-/N2;99^'=DEI"A'R[G=8)^ MVHG#1\FS+[QDD&U8)TW7/UC.4LTR6#G?PQ59"_&(CWZ&6Q$$4;4` M@ZB_QS!W,48)VS#=W\>0#_6R?9->QC9TG^OOXO")\>U.0Z01I`&S,[IE* M81D@5A"/T#45.5C`IU=PW$^01OILZ'BF=PM_,`Y&DVA`0.ZMF=(/'"U]+]TK M+8H_1D0:*V,2-R;P?3#C\228D&@ZF/0W&30F\-V8D"@@PVC\?Y#03*K.USW5 M=#F7XN#!;@5L55'<^V0&OI>3`ME`[1V*%SY4$\Q7PAB MX&89P#Y]/2_XT,(?=F8]:-T-GU'`4K=Y.<6O%PH5BFXNXY6NS`"C[9W MV[:RZ??:`6C0*KIE7ZG<\E)Y.=O`HU&`S90T+9ZYT**J>YRUT-":U3]WT+\S MZ!FB`,0;(?3Q`CN2]A_!\A\```#__P,`4$L#!!0`!@`(````(0!\U`U9VP(` M`-D'```9````>&PO=V]R:W-H965T'3!@%3"RG:;]][NV$Q)HU24O(?8]]W#NN?9E M=?O2M=8SX8*R/K.1X]D6Z0M6TK[.[-^_'FYBVQ(2]R5N64\R^Y4(^W;]^=-J MS_B3:`B1%C#T(K,;*8?4=471D`X+APVDATC%>(LP?]H--P7K!J#8 MTI;*5TUJ6UV1/M8]XWC;0MTO*,3%D5LOWM!WM.!,L$HZ0.<:H6]K3MS$!:;U MJJ10@;+=XJ3*[#N4YDO;7:^T/W\HV8NS_Y9HV/X+I^4WVA,P&]JD&K!E[$E! M'TNU!M_,GV7PFM&PG=CJ`@55=:OMX348"A0./XD6(J M6`L"X-?JJ#H98`A^T<\]+663V<'"B99>@`!N;8F0#U11VE:Q$Y)U?PT(':@, MB7\@@>>!!/E7DP0'$GB>2/PX0M'B_U)<4Y9VZ1Y+O%YQMK?@Y(%P,6!UCE$* MS,J>`$Q^WQ[P1>7@QTK]QGZ4!PP&X.!6S1B9HC\'<1R)'%! MWR@2?+M>I$J:BO07([VN8V,@L>Z5*BP_VY@(`&?.!7SLC@)G=GA6>8""V9L- M!D[0Z$XX1>0?(2;:X$67:U-@Z/#9>U$03]^\,9A$]W41HV@:SB?AI>>-X8DJ M*.UR50H\4Q6>>$VO#";2JN)D%LTGT>#D]D33XAI-"CS7A,9:C2:#66I-H1\G MTW!^'@X2=,J>J%I>HTJ!IZJ"$ZT192"F?0@ER?Q@3>-A>(H;66:4FB'1$5Z3 MG+2ML`JV4V/2AV+'73/!-RB%FP2C<[:?PV37^^X8@,DZX)I\Q[RFO;!:4@&E MYRRA?=S,9K.0;-!7=\LDS%3]MX%/*($[ZCD`KAB3QX6:_N-'>?T/``#__P,` M4$L#!!0`!@`(````(0!?68[A91```#I7```9````>&PO=V]R:W-H965TSW[?[`_;W>O- M>7(Q.3_;O-[O'K:O7V_.__-;^_WO[];Y]^ M[/;?#D^;S?$,/+P>;LZ?CL>WY>7EX?YI\[(^7.S>-J_PR>-N_[(^PC_W7R\/ M;_O-^J%M]/)\F4XF\\N7]?;UW'E8[D_QL7M\W-YO\MW]]Y?-Z]$YV6^>UT<8 M_^%I^W8@;R_WI[A[6>^_?7_[Y7[W\@8NOFR?M\<_6Z?G9R_W2_/U=;=??WF& MZ_XCR=;WY+O]AW+_LKW?[PZ[Q^,%N+MT`]77?'UY?0F>;C\];.$*K.QG^\WC MS?GG9-G,L_/+VT^M0/_=;GX<@O\_.SSM?E3[[<,_MJ\;4!OFR<[`E]WNFS4U M#Q9!XTO5NFQGX%_[LX?-X_K[\_'?NQ_U9OOUZ0C3/8,KLA>V?/@SWQSN05%P M4H"OG)$4G\+?'2:3A%!MFON%%DDWFMN](,_BT'33\Q?Z2 MQ`\ZTG".#>$O#?0B2V>+J_9J(PT7V!"63=?PA(%>8S/X^[Z!)A`(;EYL1.#$ M1(=ZZ2:VC9-\?5S??MKO?IS!XH.I.[RM[5).EM8M18B[VBYFAD(&8L5Z^6S= MW)S#]4,T'"#.?[]-%]FGR]\A-N_1YD[;)-QB118V$*W;7()"@E*"2H):`B-! M$X!+D*73!@+V9VACW5AMZ*KN"`1B"2'(@IKD$A02E!)4$M02&`F:`#`A8"'^ M#"&LFYMS6,T^2-(YO_([9Y.$1B*.5IU)IXXBA2*E(I4BM2)&D28D3"08\L\0 MR;J!Q0B;EU=I,1,JH5%,I. M8QVU.M'UW2&!W=LKEUYSY5:=$37+%2D4*16I%*D5,8HT(6&RP*"5+,GL8@$- M^L]JVGAM0RZ#(]FTVV]6BN2*%(J4BE2*U(H819J0L&N&4Y-=<_Q"K36_4"3! MA2J2*U(H4BI2*5(K8A1I0L(NU&;3^HQM)_?XM+W_=K>#@(5#J$>`*9RE[H2U M3OCU(UGXB>Z(7P')5.P=N3.:0G]^F4PG?)D4G1$MDU*12I%:$:-(XTC2CIJI M!%G07U?).N$J(0E4ZH@70*ODC&:)RV4FB3B$BN[S3J#.+9%*D;IKU69(DV3* M93?=Y^2C"7TPN6RRQO3JB1Y(E"E\6G.N#*(4'`61H'(RV\_->1K&BY:+?+G, MW^9NA4:E1I5&M49&HX8AKHS-Y\+U-J*,-1?*.)3![ALHD_+)6B78$#*"SJI' MF5XK<2P5Z"N];N,M62P65[RWDGJ#'&VXMXJL_*98>Q0V%`,P<@#I5%QN0WZ& M!L#GP*:2X1RXNN*=>U[B$E)(AF@]W"'*X%3I9$BG8AVMT&HL:)U[L"+W!35, MVWF8+69"IY(,HI->D97W7&MD"+G.IM=: M0S.^78IS864K%RLK)`-=?/8(AE:@6V`E8JU`7[@II-/9="$W!?0#<1+X$2=^ MY<=$<5X3B@[`B`$DR5Q<;D-^A@;`I\:FO[&I^6WW!M+U)D+A4899=#@W#K'( M[5!$FMS663!=T_8V6IMH%1J5B`+WE4:U;F@T:EA#+H_-E$-Y1A:P2ZS!'\WJ M7>*0.-%%.*S0*AL)4?3EM[""W'M4:E1Y]S2N6EL9C1J&N#(VM7Z',IB)A\HX M-':B8T/X,[R<R]RLY7.A6W.TKRQ=;/3!R]%5GY/;$F%!V$ MZ1^$V$4:\C4T"#X7-H$/Y^)C^RN6`>$4.31VLJ/5R!0Y*W:R.S2U%=7OMXN% MF@ELP@45:Z=*NNY]<*N^#%I!7^'>RVT(@E'UD<\"Z(=37 MH6`36R4=\N/L.:S0RD=?00T]*@F%IWOGWHNE?!EJZ'TUA/3I;KH]+[HG"M-*IU0Z-1 MPQIR>4!$)D]\(:?67,C@D)T4?[)DLF['AB.G/%K!<.F:"XU*C2KOGAK6VLIH MU##$E8%0?8\RUEPHX]#(*6\W7-MP9!&C%?SI5$[T(G96;7;:=ZI07VSER%MR M%5F%R_>4[@TV[+J7)SLY'NJ>ZV^+B?"(^=C>BB5);4T,?<85&):'@3->H)N1]&8T:0CUGNJTT0AD^%G>N7F'J M.#1VIF/#D;A#*QY$XK0N[#EDYP-OX\WD?E&B@;WS$XO%;D@^%D_IWXC^YQ-1 M231C_?/X!$FB$W/B26[=B(W:(1@-7>`J[5!$F1RMV$GN&@:H]+[(?:51K7T9 MC1K6D,MC$_\P;D>6KZL36(!BZP?5;>/8E5 M:RNC4<,05\9F^>]0QA4%3!F'QDYR;`@1,+R:X.#Q.[33!QB#5W$4/=,?U@+7/\/[:BM%[YN$8V(PHB]Y:[6A)D-]<<%ES1/?"NR7 MKV)'1!3NB![%HINL_.E;:%02\AMNI5%-R/LR&C6$]$D^A>ADZ_YC<6>]B+AS M:.0D;[L?3>S)BD^L/,G1"M?C/!.9=4E>AM:CJ\O)R@M:$XIV;WCWV96LR,G+ M4/<\.J&OZ+2<=H[;VUER7AQB4=NA:-0Z*UADM$8+=!^@$E'@OM*HU@V-1@UK MR.6Q:?[II]74507A:47(?^NZ(N077*Y1H5&I4:51K9'1J&&(7[,L/3ZV4G5% M,D7D(W[E430B7$.[N01GN;A+6Z`OL**X*;U[0I5&M6\8NA>KVG@K\M4P7UQ# MFY*_(VXP@P\*XZE#XDZ../I79,65$:=>[JUHZ(5&I4:51K5&1J.&(:Z,3FL M2*UBB@B?P8`'Z<6,EF3!]116%5GYO:+6R!#"WJ;3:[$I-&0QU!L7W6;[H>@C MF2`6!^&FX%!PZ*VF'8I*B59^ZRVHH4"V4^I0%HO M/!-$-)()4D-8BI&-@:SXQ(IE6:`5+4!$MH2=/.]^0CVS?EI]_)6G\GOG.[*"K+(+5?&4SOX)X+9O/F MORX89M]!0F5OG%L-0\$Z%!7,60W_"``]@X'7JO-,J/+]1SJKO:^!WP9X`_+< M>,]*3)M#AV*.K#B71"%5E%QU3W6XDQ&;)RU4$RGZAG8\AB:$P\QFV*_HYI<1D]FQ9,\L-T(95U MXBK#AD.#:A/2W%M11!6(,-G-)A/Q6$E);88234QU3^F_)E]^4S>\__1*;D\- MM1GJG\EMJP0F]X?VX-8+SW,1B1LW(GA69!4-Q-Q;=;-`R$5=FLB?9Y5D$)W? MBJRB_=?>BOHWA+#_5/X8I2&#H?[Y+$#_;!;B>Q'LIO+(0Q26%1Y%-M61'RZT@.^H:4Y79$5G$]= MG:%S!++B$RL"NT`KW"7Z?IA`?H:6J=LFR"HZIIJLHF,R8DP]OU4@/T-CXD$+ MO;&@E5O':37RS+H1<^,0"^8.1>?&604%<8'N`U0B"MQ7'D7$)?5)L[O""7,L\-0ZW$F,R9$5CNE9/ZI+%T)C8M,QE(1'?U5IS?NHCLL\'=Q*D,U%= MK:CAT*!:M**(*^>GKN67YTV MU&2H>ZZV+!@^M+?,=1V!2*P-(=6*K*)QF'LK$J%`!$^:M+=PQ)>W);6(BEN1 M5;3WVEM1[X;W+G\2WU"+H=[Y#,`\O6,;FEMS$>\.!6GH"JT`^26@*Q"R\OM_ MH5%)*"C9/(JXK\G*NS<:-81TR38'_9@R'XM-ZT4(YE!8LK5]@56T/,K)BD^L M".H"K;IO,:_DF[=*\C.T1'&'P)%'QU23K^B8C!S3M0Y:[&UH3#QH;:T0GIUR M:DXKV>!]C&IN'&+!W*%(M.7H*ZC/"HU*1('[RJ.(^UK[,AK9%TS:"W+NG6+N MA9'N18`OF_W7S6KS_'PXN]]]MR^#A$?>;S]UV+VI\BY;PDN]8+.1?+:$MUKU M\#F\V;*'?\[2Y6<844\+^,1^R=CWR10^:7-CV7MFA]7K;0:?0.'6XVUFA]P[ MYAD,&M)\W2;/YDO[;4;?)XME`??A]2=P1Q_:]'T"J>K2)J(];>`3FS#J3^!- MH9][M8$WB+9?/TAE0,Q>>Y"R3\G/V?(S?"6N.\YA1'T#RJ^7Q76/?7V]A-<8 M:3_P1.32/MRH/X'G&V%,?9_DT]G2/O*GV\#S?$O[M!Y\M'?3]N[=I^X?1WS-Q)?=$=Y9"ALLO/82WE&[@;<63>R; MZ!YWNR/]PW;0O?7V]O\"````__\#`%!+`P04``8`"````"$`X`COEK<'```: M(0``&````'AL+W=O MB5S="5N!17';`"U0%&G[3%.41%@2!9*.D[_O#/?LK*37':/?;_^_OK+PUM9O=3[/&]Z8.%4/_;W37..AL,ZV^?'M!Z4Y_P$WVS+ZI@V\&.U M&];G*D\WK=+Q,&1!,!T>T^+4%Q:BZAX;Y79;9/FZS%Z/^:D11JK\D#;@?[TO MSK6R=LSN,7=,JY?7\Z>L/)[!Q'-Q*)H?K=%^[YA%7W:GLDJ?#\#[>SA.,V6[ M_<$S?RRRJJS+;3,`<(,/)?E"XI^V2`$RD-/F[<9^*OJ;?)M M^GIH_B[??L^+W;Z!=$^`$1*+-C_6>9U!1,',@$W04E8>P`'XMW=;L6GV\+_%@,TGX60*\KWGO&YX@3;[O>RU;LKC?U)*VA)6F+0"G]+*:#J8 MS()1B$:N*(ZD(GPJQ7`PGTS&T_GLNN98:L*G)\,`N#Q>C& M@5.I!Y_*U6L4AR+0;=[6:9,N'ZKRK0?%`)&LSRF65AB!+94P$22=PDL9A-2A MD2>T\MB'*H;K[?#Q2F?@AD3*MZ MH8]J2S360LK]M8#0T4*: MCHZ/H/O*W48. M,3O($IKIN,>AAJSV,IK0DEQ+J1&<:34AI\0IQI4"^][Y,H\D9J8 MODH3C+/T?LIR\MH)%I"38"<-<2@5B4]6&F2"M92A+"#<2$S^%LY6Q)5YDN6+ ME''D6I3?UZ7DW+8C(2"2?'@>0EM2'`JI6\G74B82`B+)9X%7W5*1!/IB)'"X M6Y&XTQ!74FB?7%KNG[?F[]IK!3A;FJIT..HI,S,391YT:ZF`7/JA"L=$@.PU64I9T-J'$A_B!*(>XS9@>7PC MUG*=L%HXCAGTW)1L[$-K'TI\B!.(NHECW'+3K=N[UF0H3B_($C)--592-SJ5 M4"1K,@N<)2V1MD!*W2=NS'N5C'/;XG@C%6+*VZ.%"0@;HNZQ+'!7*25U?4TV M4LKS1$(P3?'IZ73B=`*N5*"&]/%VBZ<)Q:%[/UDQH@E9`3E+E).`F$G%2SZ) M)QS>,P>GMTUCW=#:";]J-P_D&'E]%^'#*M[9FTPCG ML?\-O'%^ZCP%'>N07Z%;73@XU77RTSAZ@G3X!Z\@NIW!G4;P^J%#?A;!Z=\BWD,J@?7Q8B7?;XH=&_E[S7#;P2AJR#>]1X6\0 M"U>Z@ M%@``YX```!@```!X;"]W;W)K?#_[+W>.W#Z?__Z_X M'Y>G)\\O-X]?;NYWC]L/IW]MGT__^?%__^?]S]W3;\_?M]N7$[+P^/SA]/O+ MRX_5V=GS[??MP\WSN]V/[2.5?-T]/=R\T'\^?3M[_O&TO?G257JX/YN>GR_/ M'F[N'D^MA=73(39V7[_>W6XWN]O?'[:/+];(T_;^YH7Z__S][L[+^7=XY:\37$R$?B\V_UFI-D7@ZCR&=2. MNPBT3R=?ME]O?K]_^;_=SW1[]^W["X5[05=D+FSUY:_-]OF6/$IFWDT7QM+M M[IXZ0/]_\G!GA@9YY.;/[N_/NR\OWS^7W<-_K*B[HM[(U!FAOP-&1BK.7$7Z.U#QP-;GS@C]'3`RTCI=8'?M]-=5 MG%R]NUPLYLO+"V(C-9>N)OUU-9?OYM/%Q67GM9&*%ZXB_3VR29JP76?I[W%- M7KF*]/?()BR4L M$QY/YA^NYFSR[J"J/(HF?A@=>JT\CLR\.I`F/)+,/_IK'1M*9W8"=^O! MYN;EYN/[I]W/$UIDR='//V[,DCU9&6N\$MC1V*\-^Y8&6A.,E4_&S(=3&F4T MZY]I/?OCXV0Z?W_V!ZU!MTYS/:"1BC4KS()CS&XTB#2(-4@T2#7(-,@U*#0H M-:@TJ#5H-&@#<$;.[R-`P_571,"8,1%@WUTS\"&9*G>S@JML-(@TB#5(-$@U MR#3(-2@T*#6H-*@U:#1H`R#<37/\5[C;F/EP2K,^&/#*O]=68Y:&7J3FQ+J7 M]#$`$@&)@21`4B`9D!Q(`:0$4@&I@31`VI"(@)![?D5`C!E:Q&@Q[9V-2Y`3 MC46DE_01`1(!B8$D0%(@&9`<2`&D!%(!J8$T0-J0B(B0#T5$AG>%O/0;=>=X M=MBU(Y/N/J`FQ;HO'(Z3Z`C=CT1'S,UINGA')HZ\/1E#LH^6S&E1#H;+0BV0 MO8@O;0,D`A(#28"D0#(@.9`"2`FD`E(#:8"T(1$AH"WGKPF!,21#X`@U'81@ MJ4+0B_H0`(F`Q$`2("F0#$@.I`!2`JF`U$`:(&U(1`C,H5MOT9:S=WY7>_`N MS5B2,;!$38,+%8->U,<`2`0D!I(`28%D0'(@!9`22`6D!M(`:4,B8D#'(!&# M\271J*6?+5%^OE1^[D6]GX%$0&(@"9`42`8D!U(`*8%40&H@#9`V),+/YO!X MA*,[N?2T0_-IOQ->(]H@BA#%B!)$*:(,48ZH0%0BJA#5B!I$K4#2R^8L$BXI MX\/9',O5>&8D%^\K-:"]JA_1B")$,:($48HH0Y0C*A"5B"I$-:(&42N0=+PY ME1SA>'N(H4TM^^_:9#=,+(3C9^?:\;V**VY\1481HAA1@BA%E"'*$16(2D05 MHAI1@Z@52#K>'#^.<+P[K82.=T@Z?J(=WZO8RQN35;(18Q0ABA$EB%)$&:(< M48&H1%0AJA$UB%J!I./-*>,(Q[M#2>AXAZ3C];'"G+*EES>((D0QH@11BBA# ME",J$)6(*D0UH@91*Y!TO#EHA8Y_\^')G*GU\N^0C,E,3X9>Q2-_P[:6_8H6 M(8H1)8A21!FB'%&!J$14(:H1-8A:@61,R%\B)J_<=XU<[6XLDAO)FW<]`;1!%"&*$26(4D09HAQ1@:A$5"&J$36(6H&DP\U)*G3X*UZV M!R^:.3Q@KR<.A5X&M$%5A"A&E"!*$66(OM_=_G:] MHT0'[:4'?#&C7)E[DF+/1L(5#EWTWEE/>A0D3V8J?[5QJIG(D'#K]+@C82>7BZ9#YH_/-,WTZ9M5TEG: MI<,J=?")6#7M4J#+RXDR$[.`]H9!EY0J8=5HE])AE>I2QBK7I8MS=6;(6;"O M2S(HU"4QU@?&-'T4@`?UU,A54"R:TK[->V"N.K7FBOLZ91\3>A6/I\BAK@]_ M?+R\4H9CKD(')=^\GD`)JT:;3[V*F\]4\S.U-YO+RQ3=R8, MUEB'3.2]$^;Z3,.JT5&X\2IV0L3(#KGY]%*-R9@%H^Y-6#7:?NI5W'[&R+8_ MNYJH*\M9L*]]&052B2B\,N2-7`UYBZ9^\[N>]BB(@!Z&&U;Y&T"$*&;DS2<> MC9A/6>7-9XAR1IUYZ1ES]OK[X].=X,+Q:='4/]5>F_7"N)4V7'[(HL.Y%^['^3-P3U)N'[C$9!*32#$8.Y1Z'5U4]NXBK/N$VJ=`R-$ M,9I//!HQGZ*M#%'N;=%J(3UF#DIZ,,\NS>?@CGWJ2+Z!):`_A@77,-?)#%%LUI^?7K[EQM M?M:N(JGX5KU!%"&*$26(4D09HAQ1@:A$5"&J$36(6H&DXT=.CJ^,=#PMTNW, MA"5,3R#:((H0Q8@21"FB#%&.J$!4(JH0U8@:1*U`PN%T\SEF/>GDI3X50F6K[%AI$PRKKF,OYA;+< MLD"T'_A%WJ/-F?V(\66/^&*NNU._V/,O])Y_YBKNZY1-Y#H578$97_/)Q;E: M/J.#[,1>Q=,U<8CVA';HSN?*L2E7HO7?1S?P6]?%C%6C%Y)[%7>@X`Z0([SY MA=I"E%Q1=&*A0ERQRN\^:T0-MV@O>7HY5\YLN8YH++AB.5)T8N25E0B3'S.+ MU$JDEMHUJT8G[,:IW$JD;NO1039BK^(@)8SSB]M[?( M9#F#::+"L.:*^SKEEA-KBX9Y-^?5E44'&8F]BJ.4..36DOE,[UE2KK-O8KFE MQ%W]Z$7D;,O/]8+;ETN)FMTE5Q2=P%'2=X(OK^:*OL6&6[1+R6QQJ0+2]%2IVFC@^S$7L4. M3MBT>>K_Q\>E?CJ/R6\=L6.QZ3"Q8[&(TLWENLRCP:Z5>.M@I$I;?%YBM$-59L$+6BH@P;!5>$;?S80`_H M]$V=D9^_:T9^*=L@BA#%B!)$*:(,48ZH0%0BJA#5B!I$K4#2RS05A9?UY#CH MLX?TS`B<[Y"?_6M6C2Y4&Z_BT15Y-#)X8Z>BM<'MNW0&)/$*-ITBRA#EB`I$ M):(*48VH0=0Z-)!F-\](1<1>F1],U;1+LOW2[>8LTJVJ`X_A5=Q MBR4CWV*%J&8DS:L[5^-5;+YEU(5#3DZ3^PIWK&^;G,:*NG%9)$8`H,W<511N M7:J44N14@:V8D=_()XA21GX89HAR1N*PHL=%BE!G+"*DZS M7URI=2!EA=SL*57&JM$+RX=5JD^%4\DDV%)EE$NV)?J%N]?>X3RB:JXHNZHZ MT;#*.N;J7'\VL&6!:#\(I5P":$4^9GP9N9KK%JF\F'+*>NXJ[NN4/<Q$6W3GGZE(%I>4ZHK&](X5N/,>,%"-7(\4BE013$W8]=RHY"Y1J MXU1[TNP'V8B]BKV8,'*3:Z+O1BD+1L=QQJK1:\B]BMLO'%(KC+KXDBN*3N`@ MZ1W)YFNN&-Z-G,I>\7(Z4>FVENN(QO8.$I.(.N)V9?-6XG9ED5I.U+YM/7<5 M]W7*+2=6M2_-?I"1V*O8C8E#G&9?3%4"(^4Z^R:66TH.N8B<;?F)77#[1NY5W'SAFP_O M1&J*E5Q1=`*&#ZO\BE(C:GR+YNA,'YF0BNN`CUIB%D:MA8E&8 M9W>J5_)J7L7.C#P*G!ETO9OJ,:O\82%!E#+RV:/,HQ'S.:N\^0)1R=*CLK*BH&<.4#0WR[*RB[9#?4VGG;UCEU[.(T6C% MF%5R6*KE)'$JSK,O+R9J4Y>RG7V+H[T=L&JT3SFK1OM4<)_D'4+E(DJV)?J% M4]SZW::*NJ[67'&T$PUWPNT_I].IOFNP'=&!('[BJ+*@UD8'UF%Y]LZ,&EG& MLLRS.]5KZP%4C`ZJ&#M5F&='E'I;O-QD'HV,^!QM%8A*;XO-5XAJK-@@:D5% M&3:33PNWA&8],,O'D:]*7+CD8/`)0H=,CM]/_Z6:GVNOXLO<((H0Q8@21"FB M#%&.J$!4(JH0U8@:1*U`,B(F[Z8C\K9ODBV,*369'*+\A@_*A3I5K+FBOQ=M M$$6(8D0)HA11ABA'5"`J$56(:D0-HE8@&123#PJ#,I[H6]CT47AR8B0=KXXF M:Z_RL\'9\K&(4!4C2A"EB#)$.:("48FH0E0C:A"U`DG'FUQ*Z'BS/KWI9:X+ M8TE-!HOD"J4_&+MV%4GE8])79!2A*D:4($H198AR1`6B$E&%J$;4(&H%DC$Q M20D=D[>]6G1A\QMBHC@D)XHZDZRYHI\5&T01HAA1@BA%E"'*$16(2D05HAI1 M@Z@52`;%9`IT4-XV45S.(;R5.R1CHC;2ZT6OXEFQ010ABA$EB%)$&:(<48&H M1%0AJA$UB%J!1$R6.I,R?M?HY'*%8B0=KS*.:Z_J'8\H0A0C2A"EB#)$.:(" M48FH0E0C:A"U`DG'FQ1".!E><;S-.(2KT-(AZ7AU0EI[E7=\7Y%1A*H848(H M190ARA$5B$I$%:(:48.H%4@ZWIQ&0\>;V_7;-J]+=[`-EB&'U/U:I<;67L41 MV""*$,6($D0IH@Q1CJA`5"*J$-6(&D2M0#(H^FC^RFRPQV8Q&RQ2CE<)B_6R M5WG'`XI0%2-*$*6(,D0YH@)1B:A"5"-J$+4"2<XO':(143?;SV M*A\3:RO8ST:HBA$EB%)$&:(<48&H1%0AJA$UB%J!9$R&CM=OBPF>KI=#I^M+ M?;KV*A^3OB*C"%4QH@11BBA#E",J$)6(*D0UH@91*Y","=UEQ5WCE07*R-4^ MR2+ZI"/[;[T$M$$4(8H1)8A21!FB'%&!J$14(:H1-8A:@:27?]E1>HE':8?D M:G2ITQM>Q6':((H0Q8@21"FB#%&.J$!4(JH0U8@:1*U`,B9#1^FWK49XDEY: MI&*B/L&W]BH?D[XBHPA5,:($48HH0Y0C*A"5B"I$-:(&42N0C(D^2;^R&N%Q M>=D?A(,DJ_Y\S]JKV,L;1!&B&%&"*$64(W`8?4B-=Y"J_J'8\H0A0C2A"EB#)$.:("48FH0E0C:A"U`DG'Z^/RFY.L M].NS^M;,B&['_HG#I4YA>)6/"9ZD414C2A"EB#)$.:("48FH0E0C:A"97^OM M_!4\J+>_OFM_;?-A^_1MN][>WS^?W.Y^-[^L2T'\^+[']F=_KY=7*S.MR'.Z MY.*<8H.222KH/$NB2!=6AQ/3`E2ZH#F5'ATK(.Y2C&RA9DGL)M4-OS1^J0SZP'T70=:94QWZD M1Y=0E4&OD=,&XTDN&_38A*))/UXTU"N*)OVZSE`)19-^_@5+Z#L>*_.-`2RA MKWJLS+<$L(2^R[$R7Q;`$OIA[D]#K5R;C@WHKZE;@WH*XU`4/\U7GV@IP8:O M38^&N)F5`YR^1D47-]3$-5W<]>#%K:ED/5A"7P9:F6^(8+_H"T`K\ZT0+$FI MQ'PY!$OHBSXK\QT1+*$O]ZS,5W>&2A94,E2'OM>S,M\2&:@SFZW,FYNPA%ZY MM3(O<,(2>O/6RKS'"4OH!5PK\^XF+*$W;%$TATKHBXHK\\U$K$-?3J2`#I70 M6_M7YIW\6(?>KK\R[\['$GH_'?5M<-Q0WZZ'^T8EZ\$2>L/:*AHLH;>JKO(4E],8TBD_G@[-^+:&?F?]Q\VU;W3Q]NWM\/KG? M?J6;Y7GW(PI/]H?J[7^\N!<7?]Z]T`_,T^Z1?KMZ>_-E2S\;?6Y^(?3K;O?" M_T%-G_W9IBB)B"@*)!TG?]^E7K45-4B!7$R1FAW/SBY7ZYLG M4:%'IC27=8I]Q\.(U51FO"Y2_//'W=4*(VU(G9%*UBS%STSCF\W'#^N35`^Z M9,P@8*AUBDMCFL1U-2V9(-J1#:OA32Z5(`:VJG!UHQC)VB!1N8'GQ:X@O,8= M0Z+>PB'SG%-V*^E1L-IT)(I5Q(!^7?)&#VR"OH5.$/5P;*ZH%`U0''C%S7-+ MBI&@R7U12T4.%>3]Y$>$#MSMY@6]X%1)+7/C`)W;"7V9\[5[[0+39IUQR,#: MCA3+4[SUDWV,W<79R=]]HQT*4^?%,^^\)J!V5`F6X"#E`\6>I_9(PAV M7T3?M07XIE#&;`M+GCEA,C>M1&BM\=RN^Y.I:@9X&U M9UDY?N3%\)>OA85]&*Q]6!@[BZ47^O.!;B>^]>*6&+)9*WE"T%^@3C?$=JN? M`-E@0J=XM.5?KH`=EF1K65(,%P/RU5#)QXT?^&OW$>RG/68W@[E$[`>$K1K( M&S6"-^^@T;)8C;:25O1N./@K.I@(&A!306#4.PBR+"F.+DR;*-AU&/\<%$U$ MCI"I2@AZ!Y66!9H#VO&5VO:@UV2.D*E,8#Z7.7_]AD:SX%;-6,7^Q.^Z;N+- M^')>_$67Q9I&5W==!5,%V[.J MTHC*HQU+2\AX/!TGYC:P#3XYW\$D;&PO=V]R:W-H965T&ULE%C;;J-($'U?:?\! M\6Y#<\>R/1J(LCO2CK1:[>69X+:-8F@+2)SY^ZVFVD"U'<:\)+;K<#A]JJAJ M>OWEHSP9[[QN"E%M3+:T38-7N=@5U6%C_O/W\R(RC:;-JEUV$A7?F#]X8W[9 M_OK+^B+JU^;(>6L`0]5LS&/;GE>6U>1'7F;-4IQY!9&]J,NLA:_UP6K.-<]V MW47ER7)L.[#*K*A,9%C5CW"(_;[(^9/(WTI>M4A2\U/6@O[F6)R;*UN9/T)7 M9O7KVWF1B_(,%"_%J6A_=*2F4>:K;X=*U-G+"=;]P;PLOW)W7V[HRR*O12/V M[1+H+!1ZN^;8BBU@VJYW!:Q`VF[4?+\QO[)5ZL2FM5UW!OU;\$LS^FPT1W'Y MK2YV?Q05![SX/GL[M7^)R^^\.!Q; M2+!9NGXDBD7)Q``?XVRD*4!CF0?W?]+L6N/&],-EGYH MNPS@Q@MOVN="4II&_M:THOP/04Q1(8FC2%Q0K^+.HR06"NK6]Y2UV79=BXL! M10.W;,Z9+$&V`N+KPE!&O]3/5@I+E"1?)4O'!8MH(#WOVSA:6^_@:*X@"4+@ M@>@AC"+2*T(F`M3U$F'=ND07,GC?^ZLB>1%5Y`3T?LD="$6DMXC0[B%$(U@W MUCBM38(WIC>R(HY[VL[0!"%0&[U;'D6D4P@B#>[SN#0)AN(1*UC]I`2]`XQ4]Y-(8C&@&J<3JL$ M4^^8K9F3(";LS&.>K95D2L)N/.2ITAQ$>K;JIL'%UX;*@!HBF>HTF"]=K212%FJK:F$$0; M@Q[VN&$=FCK&[*$^L/(5"#U;>*-,=?&4Q'WV22*9-A.F,]FAJ3`]68G"*%U^ MI)<]C<-0[.N3.J9-@I$P^X][F7,]GMFY1B"E#(G&NI(.89Q?#06S/<&`BI- MMN.'JY]A\QY+\X8U*V6(4V!N'P9%-MLUH_P\8-^>IW$;,F@,=6IM23-]E*-!43B/;=2ZJ^A88*.^C@XJ$.96 MWVBF).J.ME)4WJRAX-P9"DSK8(D"J9+S'E,;#48>DRF0'?[C'.=CO:#"EM\.!L6$>*H5D.CB^%D\=$F?#3H`* ME+W\<>NP\U/K!F8E#$&JQ4:Q_H*:RC?Q87Y$P:A:J;99\\&Y,Q^8UL,2!4)M ML/Z1@0QDXX.$^US9H- M#LX&J)9A=K%A8BMM"(+$]2#MB4D5SWT(U3=K0L!ID_X&PQQM]Y@H$+XK>UI4 M'EA)"HPZ0TV@*CR+PK.:DM<'GO+3J3%R\2;/F1B\%O6_XAE8`F=@W8&1U0?@ M".J<'?CWK#X456.<^!XNM9"]$>_TB3V?ZX\OM_P```/__`P!02P,$%``&``@````A`*PSO8C?`@``10@` M`!@```!X;"]W;W)KF\.WJ\Z?E7L@G53&F M$3"T*L.5UMW"]Q6M6$.4)SK60J00LB$:EK+T52<9R?M-3>U'03#S&$;;!D6 M\AH.412+,_J&4RF4*+0'=+X5>IYSZJ<^,*V6.8<,C.U( MLB+#=^%B,\?^:MG[\X>SO3KYC50E]E\DS[_QEH'94"93@*T03P;ZF)M'L-D_ MV_W0%^"'1#DKR*[6/\7^*^-EI:':4TC(Y+7(7^^9HF`HT'C1U#!148,`^$0- M-YT!AI"7_GO/5VFX])_!47J`K"T$WHG%B21@-];^S:0J!'!M%(A'-. M)5ZVSX"A24_.36/WX+6%I'VU;Z:S>%Q.)QX&T8G_CBY([GI=!CRR;&3(VD(N M678)X4B;?42:`8\LFXXLLY#$6A8FR=R-;]PXS(8A[LA*/B++@$>RQB^"A;PO MRXV_*\O<=2>CY'*#&?!(5C)D:WO?0@X-EDR"U(W#O#<4AW@8QM/_'6CMLN/< MCKN&R9)M6%TK1,7.C.H0RC`\M;?(&FZ1?N;Z0P"F>$=*]IW(DK<*U:R`K8&7 M0`])>P_8A19=/VZV0L/\[G]6<%TSF(Z!!^!""'U&ULG)I;;^(X&(;O5]K_@+@?(.&,VHXVYZ.T6NWA.H701@,$)>ET MYM_OYSA)8R?DI=.+`L[C%]OO9\?Y\,/7'^?3Z'N1PKD]EX%%_VZ2&Y MO#R.__G;^K(9C_(BNARB4WJ)'\<_XWS\]>GWWQ[>T^Q;_AK'Q8@4+OGC^+4H MKKOI--^_QNRTODT56>SU?0<)9)35%#[\]?DFM=JY_T]2>$Y. M2?&S%!V/SON=^W))L^CY1/W^H2RB?:U=?NC(GY-]EN;IL9B0W)0WM-OG[70[ M):6GAT-"/6##/LKBX^/X#V47JLIX^O10#M"_2?R>M]Z/\M?TWJ(&T/_1.6&A02,2_2A?WY-#\?HXGJ\FR_5LKA`^>H[S MPDJ8Y'BT?\N+]/P?A\H>-2)J)3*GUE?7U4^++"H1>JU%5I.%NEQO/M,4:G39 MGW6C\@O]HZ']O)9KE5#VO5^419S%8X/*8\U,K(-:(B>GK(TO<1+0?4I/P: ML<5%V3'A.F9YA#51?"N(*7J9RA],IA2C^,QIYGU_4M?KA^EWFBW[BM$X0SXV MC"(2>DVPJ<%DC3[9K5C)K)FZDB47V+7LS2]V:J+6<.4"3R[PY8*`%]#_IGOJ M9B:V->PR'T,P)4<:6\CKCBUSBK[^I:1V@=627=B(3=!Z&)'0.='V:2WUP^@B MJN2V";_'ZB$D$;L'$1OK0,*%A`<)'Q)!#[&1(C7L89K>".[3//P%]UDMYGX= MQ%I=T([(CW@K9YC.F4U3R9`+S#X5M6EWJ6+=P=A]S%S4'R-- M!/\.)NAAMM)<"(<9P5>ZG?Z"KZR6X*M0"NRYH!\M"''JG MCUF)C-O'2-/:ZV,D';^/D72"FJDC/FP5"`-/]WIAX(>7448_CDGK8R7?2O-& MXPS];QAIL'1(&)`P(6%!PH:$`PD7$AXD?$@$D`B'",'PU:<,9S1MMEMFJEMI MB=,XLRWW-@K]S6;20J!S@IIX*R2,ML9JO>Y(F%#"@H0-"0<2+B0\2/B0""`1 M#A&"W_2(\8D)SFC9;^E6I'%FP$T=$@8D3$A8D+`AX70)=2LM5VX?(]UZO3Y& M7K?[&'G=[C)2:\(A0C">MJF"\>SY!6^462TY`*3]@<:9-7^8V(P,Q M8@@BF_F6IKRT;)A0Q(*$#0D'$BXD/$CXD`@@$0X1@O7T4"]8/WQ39[1LN;1! MUS@SX*<."0,2)B0L2-B0<"#A0L*#A`^)`!(A)ZJ)ME36;)(TFTK!<9:(^83E M)2YZ/F])EX\N6@4-F8X1`R,F1BR,V!AQ,.)BQ,.(CY&@05A*Z,/5!CQ,1)@)!Q$Q"!@^9-V$`PO^"Q?VC%?WM574+7XJ)M5]P:M5\S`"F&( M,O/UAGYYD:+=Q#(61FR,.!AQ,>)AQ,=(@)%P$!$#@*5:V@%PWV:/I;4[@2!- M"#,5>$>Q#-E%3$8!OR;JF@2;V2EB(E%+(S8&'$PXF+$PXB/D0`CX2`B M!@'+\;2#`*P"/"74?K9?=+SG#+=MNUQTYJZN<&+0^[8(Y0>Z$616*K>_QQ*( M7A$;-\7!B(L1#R,^1@*,A(.(Z#T9('A_YP+`JLG[0.F)4V,_U!*TY`F>9O]9 MS?WZ8M].I42,IOY-Q,2(A1$;(PY&7(QX&/$Q$F`D'$3$`&`)H4],?IX_:D_^ M^4Q*:FC*4)*ILA\B!E8Q,6)AQ*Z19KLJ[6>=&KB]774QXF'$QTB`D7`0$)@Q,6(AQ$?(P%&PAYD/OM(RPJ!H,K9O_L"H:PF[?X4Z>%M-]"!01.@C908P*&0P#WIH!Q,(J-D8W)I2?N!74W9T MII!.ATCEMK*C\WO=TX).[)9O7^F$=DRG&V<3@H]I6M0?Z(NGS9GOI_\! M``#__P,`4$L#!!0`!@`(````(0"F+\2SZ`4``,T7```9````>&PO=V]R:W-H M965TC3KAK5UJM9G>? M:4(2U"&.@+[,WT\97\!V0J>U_=(T)U7'5:?*%_SP_;T\&:]Y51?XO#+1:&P: M^3G#N^)\6)G__`B^+4RC;M+S+CWA<[XR?^:U^7W]^V\/;[AZKH]YWAC`<*Y7 MYK%I+JYEU=DQ+]-ZA"_Y&7[9XZI,&WBM#E9]J?)TUSJ5)\L>CV=6F19GDS*X MU3T<>+\OLMS#V4N9GQM*4N6GM('XZV-QJ3E;F=U#5Z;5\\OE6X;+"U`\%:>B M^=F2FD:9N?'AC*OTZ01YOZ-)FG'N]D6C+XNLPC7>-R.@LVB@>LY+:VD!T_IA M5T`&1':CROC?(G^K>_\;]1&_A56Q^Z,XYZ`VU(E4X`GC M9V(:[P@$SI;F';05^*LR=OD^?3DU?^.W*"\.QP;*/86,2&+N[J>7UQDH"C0C MNPTCPR<(`/X:94%:`Q1)W]OG6[%KCBO3&8\F]G2^0&!O/.5U$Q2$TS2RE[K! MY7_4"I&H!(O-6.#)6&SG\RP.8X$G8T'3D;V8HNGL$[%,&`L\>48]DH$D(-U6 M"G@RQ\5H.A\[K1`#?C/F-Q=^:+283B>SQ?Q^!6$^MH/#4T1]S^!+Y@=/KAD: MH!0`5"%8A4(%:!I`=8((O0!B;'5VA#:(@V/*L-!WIBR5)MN05W\53`5X%` M!4(5B%0@5H&D!TA"P/S^"B$(S('Z]K)P4"FX`4"%WX1F0' M&(Z).,HQ463BB!F^U1!/0WP-"30DU)!(0V(-2?J(E#-L>%+.PXD2:SE1AO02 MU1!/0WP-"30DU)!(0V(-2?J(E"@Y+.N[6EO1DCD M_!DR[PHMD*[CD#.5%RR/&CFPS8@IC9R9;.0+(][J@>#F2"B0/I$R6B2(^D9S M>;18&''N1'`#(FD)!Q5)RRN:P6&/BT:L9=$H8L/90F1O(T>.9\N,9(F4S+RK M1DN9R6=&-CV$S&?*2`'['99Q$8Y6L?#J2$HXT54C)9Q8"F>ZL)5")!^$(U6" MG,\^48K67*X%@VQ8GD7V-E*74>XXJ)'76?$>\CG]DJ[."[7,`?>!@X887U>? M6PV.'W56?/Q8&=^9*YDEW.?6^++.VJK_;%[NW']R_9B)Y@I1I02&EY9?7=B00T MD)O'K;K-U=>A@$,=?=A!`_01M^KH8QU*.-32R\J0$^W_[T]V+J87.^03=T,^ M=4##R;(G&(/@>'.[93SF:,OS5IF$/K>B^^%R.5;Z(^`&4*3;@X4\RL&0(LXU M&%+,K6A(R!D[2DP)M[@5DUP9_>A83[ZXU%ZFD-3+`AI0RV-< M3GL3V"X=O@X%#.K1AQTT0!_I7+$.D4M,DA"EIXK12TEZ_U/FU2'?YJ=3;63X MA5PXDB5,H/0RU%NX<#"%Q4;!HX4+1T@=A\O31_L*OB&7JM=PVX5+!YUGX[CP MH:WCCQ/W$?+2?]A,7/CFO(+/7/@<`MP2&#"->,96**D_PKY^/ M-[<8&4NKE):JX@E^Y0;?KS]^6!V5?C(%YQ8!0V427%A;QX085G!)C:=J7L&3 M3&E)+6QU3DRM.4V;(%F28#:+B*2BPBU#K-_"H;),,/Z@V$'RRK8DFI?4@GY3 MB-KT;)*]A4Y2_72H;YB2-5#L12GL:T.*D63QE[Q2FNY+R/O%#RGKN9O-&;T4 M3"NC,NL!'6F%GN=\1^X(,*U7J8`,G.U(\RS!&S_>19BL5XT_OP4_FI/_R!3J M^$F+]*NH.)@-97(%V"OUY*!?4G<$P>0L^K$IP'>-4I[10VE_J.-G+O+"0K47 MD)#+*TY?'[AA8"C0>,'",3%5@@#X15*XS@!#Z$NS'D5JBP3/(V^QG,U]@*,] M-_91.$J,V,%8)?^T(+^C:DF"C@36CB3P;A>+,+I=`LF5P'D7".N%MY\'DE9] M8\8#M72]TNJ(H,%`GZFI:U<_!K+>A99A\.5?MH`?CF3C6!(,-P,R-E#*YW40 M!"OR#/ZS#K,]Q_ACQ*Y'N+*!O$$CN/,?-#H6I]&5THG>]@">L14$!@U M%32'!KS<.KU'+BC!XEY$.\NXN`AC4UD8E&ULK%C9CJ,X%'T?:?X!\=XA+-E0DE8E0`#-2*-1S\PS M19P$5<`14$O__5SC)=A.4>E2O13%R?&YOL?7"UY^?RO/Q@NJFP)7*],>C4T# M53G>%]5Q9?[S(_HV-XVFS:I]=L856ID_46-^7__^V_(5UT_-":'6`(6J69FG MMKWXEM7D)U1FS0A?4`6_''!=9BV\UD>KN=0HVW>-RK/EC,=3J\R*RJ0*?GV/ M!CXN3*KGYXOWW)<7D#BL3@7[<]. MU#3*W$^.%:ZSQS/D_69[66`L+E-;+?0$9 M$-N-&AU6YH/MI[9K6NME9]"_!7IM>O\;S0F_[NIB_T=1(7`;QHF,P"/&3X2: M[`D$C2VM==2-P%^UL4>'[/G<_HU?8U0<3RT,]P0R(HGY^Y\!:G)P%&1&SH0H MY?@,'8"_1EF0T@!'LK?N^5KLV]/*=,#)+;-'MC?^ M*%D;"HV..ZDX-J1WFVW1(NIJ,LC:;+VL\:L!$QVJI+ED9-FP?1*"5R.U3]3G M>^4)=4E4'HC,R@0OH/`:F%,O:V?F+*T7F`$-DB#<\JPT'>F8I1G`&;Q*H0*@"D0KL5"!6 M@40%TAX@&0'3^RN,(#(K$Z;YM4ALM4@HQ^Z3/,4<01'N:$BH(9&&[#0DUI!$ M0](^(ID$7?X*DX@,3$98TZXNS5S9@@TC#;DD*,(E#0DU)-*0G8;$&I)H2-I' M))<@+\FEV[L>7U8(NS.#)[%A2+<_=VO$5D,"#0DU)-*0G8;$&I)H2-I'I$1A MDY$2I0OKB.R+[:G(GS:8[M$W#'!A`:7+*A&1\V?(3*PF6X%<"\9V)W+!!)3D MPDHGJLIVIS(I%"3N=B2T.;(32%](B18+H3YI)D=+!(EKIT(;$,E+V*@E+V]X M!D<%;AIARZ91Q('M363OV,J"<*61X(B#BP/(G7' M5A=XUFS0GT"0>/F$3'O1V>[-U0&.6`O8Y$1LW78A.T"*!8G'3N38[DQ)*?T@ MMN0QG`Q_P6/"ECVFB%+M2N5L&6FXV@6)YQE2Q"4KU,MZYJJ5S1H,CMQ.J`Y9 M+$@\="*']I0J3S\(+3E,#KJ2Q9]:G#L5V7H&*?6MK+-;WG#0IN#*XA:$7)Z6 MN#U9J/[S-L,USEF#\>,KB\=/Y/C.>*ZYKWX\BB0<_?]BXE-Z(K=%'*F MU]V0L0`:J*Z`LZ[;:*A#$8>N\KLK-"`?<]95/M&AE$.=O.P,.8CWG?E8N>80R"7>#]93&P*^Q6*LU$?$"8.5MV,L;[!+,=<: M[%+"6;1+MCMVE3ZEG/%>G^21`=;@R/S`%[#\P\]E(J,,#86D6A;0X-!0EMO= M.G7'QA"NKXA\#XH8U)/?7:$!^5C72G2(7)B1B%2>.D8OP.AE0XGJ(]JB\[DQ MQ""X[QB/X-#A@W/(7$D!<[J[_!P``__\#`%!+`P04 M``8`"````"$`T2++XB`'``!S'0``&0```'AL+W=OE^>GC?// MU_33TAFU77;>9Z?Z7&R<[T7K?-[^^LOZK6Z>VV-1=".P<&XWSK'K+J'KMOFQ MJ+)V7%^*,]PYU$V5=?"S>7+;2U-D^UZI.KF!Y\W=*BO/#K,0-O?8J`^',B_B M.G^IBG/'C#3%*>O`__987EIAK5QRNY[;]0957GX MY>E<-]GC"7A_\Z=9+FSW/RSS59DW=5L?NC&85NW+!TG:]+X$!AGW4 M%(>-\^"':;!TW.VZ#]"_9?'6:O^/VF/]]EM3[O\HSP5$&_*$&7BLZV<4_;)' M")1=2SOM,_!7,]H7A^SEU/U=O_U>E$_'#M(]`T9(+-Q_CXLVAXB"F7$P0TMY M?0('X.^H*K$T("+9M_[Z5NZ[X\:9S,>SA3?Q07ST6+1=6J))9Y2_M%U=_<>$ M?&Z*&0FX$;@.&+FA..&*N M7'-UG^*<*\*5*\+#[0>Y++Y]NN*LR[;KIGX;P1J`"+:7#%>4'X(-D2=F06;N M6N(@8VCD`:UL'%B\D),6JNUU&\Q7:_<5*B3G,CM;QJ<2D9#`M1[ADPGYCE7#S&I1R MB)FGC'"8L!A]>)3$Q+#$*F>M/K@34GJNS1:L9,0ZC&THL:&40)0CSA0&QQ\: MF'T^G.CKD4.0!EF8@6>1DE**E`4EPKQ:VRF!*"D<*@Q2=\W-/IM&2/4Q2)^< MN90&Q3:4V%!*(.(QSEZZQ[=[?2]-MPH!J>4=V5!L0XD-I02B;N(4,!S8^Z=H M;#;&1B<@M=M&"E+%8^]J7(I,TH%G#'2)DA(EEBKS`%&.V.,UCN^D@DT$>L4$ M#,(H:F5OCEU""H(AI0;X<5OLXQI^F$FX(G1>_-8SGQFO#:DP3'KNM4T;._,' MR+(Y@)!ED#%P&0F(^L=`P5[SB%0WR!>MU//(LL]@C`-1I%F%MO\ M_9EE0P$ARR!CIC(FW@C;-=0W5MB@3YRLE%)D&63,5&93%N9)+*]-ESBIZI1_ M:#+IC1C;#1L=2-KMZ5(H$E>U4N21L"<3KH@7&<+`,^=L89XD_VHD8;`E><@O`MCMR6OD\QB.]3B[G1]U-N&%?XH&&Z='$BT+)GUO%]PR6(;#/LW(8=!%1%\U1$Q>G4CO+Z!<]D MX"5CNY:P.#!:A`]@"4P8=V!J#'&X&[JSA#O#.BNXLQK0B9_`4=9#,(#OX(AK2'X7P-'7D/PDA._5`_:GX0/,Y_:-W32$;\`#^"R$KZD# M^#R$3Y>`NS*"<.1UR9Z*/[/FJ3RWHU-Q@/![_;)JV*$9^]'Q]Y;'NH/#+L@0 MG-3`X68!O=C##\N'NN[$#WR`/"[=_@\``/__`P!02P,$%``&``@````A`.=: M29P+`P``(PD``!D```!X;"]W;W)K&ULK%9;;YLP M&'V?M/^`_%YN(2%!(55"U:W2)DW3+L^.,6`5,+*=IOWW^VPN"H15K=27$#Z. M#\?GNYCM[7-56D]42,;K&'FVBRQ:$YZR.H_1[U_W-VMD287K%)>\IC%ZH1+= M[CY_VIZY>)0%IGBM:J)1&TQ`KTRX(ULF>KR%OH*BP>3\T- MX54#%$=6,O5B2)%5D>@AK[G`QQ+V_>P%F/3@@#XM2JF*P,,P<_F>F:I*F*T<.W`7X9K#_#6D4IUSS0GLLA)*E[] M;5%>Q]6R^!T+7#N6M>T%[DI3O+)LT2V#:__RE;T,W85Y]_5"IQ5OO+C#"N^V M@I\MJ"]0)QNLJ]6+@*PWH648;/F?*V"')MEKEAA!8\!^)63R:>=[X=9Y`OM) MASE<8[PQ(ND1.FL@;]`(WGR`1LVB->I,:M&'/G`A>B*H1TP%@5$?($BSQ"@8 MF;8>*SBT&.\2%(PAR0"9JH1%'Z!2LT!Q0#F^DML.])K,`3*5"\4Y:F&\^R#:&]&SI0GB))@!G]81TIU]XHWH#G<%!Q!8>3^5O`QPB%T>C:4%H9YZJ_T08/GS>[ M?P```/__`P!02P,$%``&``@````A`,!EH6N[&0``&94``!D```!X;"]W;W)K M&ULK)W;?US\ MO7]^>3@\?;JGA_O7ND_G[]=O?Q\WM]]:0L]_KB:7E\OKQ[O'IXN.PN;YU-L'+Y^?;C? M[P[W?SWNGUX[(\_['W>OU/Z7[P\_7]C:X_TIYA[OGO_\Z^<_[@^//\G$'P\_ M'E[_W1J]O'B\WZ3?G@[/=W_\H/O^UV1^=\^VV_\`\X\/]\^'E\/7UP]D[JIK M*-[SS=7-%5GZ_/'+`]V!G/7F;XF0B\,?A\*>1IE\,HL)74#IJ(]`\7WS9?[W[Z\?K?Q]^ M)?N';]]?*=P+NB-S8YLO_][M7^[)HV3FPW1A+-T??E`#Z/\O'A],UR"/W/VK M_?OKXIZ-B'YQ1_[E]?HP9B\O+C_Z^7U\/A_G:B]H][(U!JA MOP-&1@K.;$'Z:PNN/DSFUTM3]TBQN2U&?\^KC\RV=TM_;<'I],-\NEBMV]L= MJ7)I2]+?O?YX_/AUP5-IN3D MEY]W9FJ>;(PM'O&=F_LYX-@40&/?6+DU9CY=4N^BT?U"\];?GZ>+Z<>KOVFN MN;>:+6HF4A&PPDPLQNQ.@U"#2(-8@T2#5(-,@UR#0H-2@TJ#6H/&`U?D_#X" MU%=_1P2,&1,!]MV6@1<2Y6Y6<)&=!J$&D0:Q!HD&J0:9!KD&A0:E!I4&M0:- M!X2[:8#_#G<;,Y\N:<3W'7XRU1V^TYAIH1?-50AZ21\#("&0"$@,)`&2`LF` MY$`*("60"D@-I/&)"`BYYW<$Q)BA28RFTM[9T\5,NGMK16,1Z25]1("$0"(@ M,9`$2`HD`Y(#*8"40"H@-9#&)R(BY$.(R'3Q@?"9JX(QU,:$?;GMR)SFPCY* MM%>240IZ$1?;`0F!1$!B(`F0%$@&)`=2`"F!5$!J((U/1`AH)?X](3"&9`@L MH3]>")8J!+VH#P&0$$@$)`:2`$F!9$!R(`60$D@%I`;2^$2$@#;9$`(SO9PY M!HP9F)?4,K"U(AJ1?4R4).@E?42`A$`B(#&0!$@*)`.2`RF`E$`J(#60QB]5E[,/;G]^\G;56)*CHB-J8EJI4=&+^A@`"8%$0&(@"9`42`8D!U(` M*8%40&H@C4]$#"@3A!B\8U08,S`JU#JPM:*Q4=%+^H@`"8%$0&(@"9`42`8D M!U(`*8%40&H@C4]$1$RF+4(R?%C39VI&+OM^:X$VLW)57JO.[U2]KQ&%B")$ M,:($48HH0Y0C*A"5B"I$-:)&(.EXD]'Y\]$;CN\20!HL[+^M.>N@6,RG/0H0 M[1"%B")$,:($48HH0Y0C*A"5B"I$-:)&(.EED\B=X>4N[Q->MHA6^GYUG4QO M=/?N51R>G3E&,D-EV8-[E7,\H-`Q%1CD72\.A<*S'Y)NG2'*$04(8H1)8A21!FB'%&!J$14(:H1 M-0))QY._A./-*?2[3AS,$;9QK3\8+)(Q42=#`1=T<_T.48@H0A0C2A"EB#)$ M.:("48FH0E0C:@22,3%IF#\8WOMDP*9SU.?[U7>FIJ+MI,_YG$@GP$[CIJN^ M&*,051&B&%&"*$64(Y09^6L$HZ2]W@ M;EBE4M.05=/VP?IR/5%F(A90CN0U2:EB5HTV*1E6J2:EK+)-6EVKK"YCP;$F MR:"8Y.Z,H-AB0'!AS MM=4+3(AHAVY&Z'%7[9R*G1`RZKK?,NKJG]U, MU)UE+#A6OXR"R0']*+PQ#]F4T7=WAZ8N8PG,!]V,;V6J`_W;JMP"$')!AR)& MSGSLT$CH$E8Y6RFBC%%K7GK&Y&N^9][7/VW6YSNL0U/W&9G`>,JDBY1'C'5& MJY*!5=TOM+:F-^TL/9G?Q_8D%/!^4;5IFQ^;#E%K>+P%TQZ-QJ93S=K/M;8.#&U! M#T7.%IN/'1HQGZ"M%%'F;)%YZ3&3**''SGZ*3)W6GFNXUDX7:N^U915-L7UW M5@$/G(9=L4,4(HH0Q8@21"FB#%&.J$!4(JH0U8@:@62(AK*YV=I\P/G<9_TT M]FV4V+=;B^2SM;D^$70J+KA#%"**$,6($D0IH@Q1CJA`5"*J$-6(&H%$4&CP M_I9QT]II4T$W(N@#VO(1Q)958^/&:?H0(0H118AB1`FB%%&&*$=4("H158AJ M1(U`,D2T@Q)3V_@.QJ2-ZF36HKGO]LE<;6X#IW*.[VQ1048AJB)$,:($48HH M0Y0C*A"5B"I$-:)&(.EX6JN%X[T-TALQ,"7;T+B$#HT4C*S*#&%G7F^]8Z=B\PFB%%&&*$=4("H158AJ1(U%E"=14V74 M3#+I1^V-L='EGOY#B%F'9GYX>N3Y#\-C;='6V/.RRG9#9]Y3:5L1JZ0MM4^( MG8L4K6J(X11OUB'1`P#MK,H\)7!NG:L4*$1;$:/N6X;F>T4Q MHH21ZX8IHHR1'-FJS^5.Q6XM&#GS):**D6MJC:AA-!`BDPW[(7IC-';)LQB- M'9*'>`MUWAE0J,PL^\8AGE71PFJ^$#911L*3C$3#*M618U;9JB:SF1I)"2MH MV77=1X_*E%4BOEJ5#:M4FW*K,BN>JW&A3@T+MB55*D$L6>4Z1N609WZF&E&S MJG/,>KY2EAL6B/J].Y:S/4TGY_0O(U>+<8?,6:GG%-CSVX+'&M5].W#6J6AQ M,OUK/EE=JZ"'5F$^:^5J\VZNM1,Y%0_7V")*4+NN.Y\KQR9F(GPY&36(343J:DV8-7H@-U9E9V)U+(>GF0CZ.%\N5BD?#`E'9 ML4XRUZ<\XYVDEY:$RQP;6-U4PJK1F\BP:BVR2,TP:J(/6#4Z.G=615NS;BU:ZC/> M\"0[D5-Q_&(V;3[5\??GI7[ZGW"1T8Z1LFKT-C*GXNIS5[VW$BW59J[@@J(1 MV'VZ(-"^D6.*,7(UQ73(?S1%7]AH MM[^4I+C%V6N!G4]Z%=]L>%+!B%4N5X@1)8S<([/4H9%V9:QRYG-$!2-GOD14 M,7*V:D0-(WS82^>.,CSO&]O&BHI:A^BQ#SL_:.LB%>4N8U&SMMP,%YY4,&(5 ME??,J]DDMBJ[&,P6]#_Y,")A.]1[/#M*E;)J]&8R5HVV*>?U MU1TGBOF@1R,AVUE;7L'0H9&"D571HQCNRS&BQ-EB5>K0B/D,;>6("F>+S9>( M*BQ8(VI$01DV"QRXS=@E9O*=HA"1!&B&%&"*$64(%#HT4C*R* M-I1VWZ5/0&*G8-,)HA11ABA'5"`J$56(:D2-10/'['-SX.9'[(UM3'<^)T+3 M(3KN83<$K5%Z1=OH&K*S*O-Q>+<>S=5Z%)YD*V*5M*4V>+%3<5,31N[0.W7( M:Y>W'+2;L(Q5LD:5_.1.Q346C%R-):**D32O5J[:J=A\PZ@-AQR<9$N$^GV# MTUA1,V.'1`\`M)O;@I3[NW`OU:EA:%6>K8B1V\C'B!)&KANFB#)&(EG1?2YW M*G9KPZU=SCWJ(H+RJ:J1M2LZAQS64@`L>:U27QUK5R#'[278BIV+GQA:-'+-SH6.;_NYLC%6C-Y(Y%3<@YP;( MU$CA`6CX4]9)4>RNM/,J;C^W"(U MPZB"!1<4C#G5STX;%HC*CG82ZDKG=!(C5YVD0VHZ M4?NV8&$+'FN4G4XZU;%C]I.,1$[%48HMXF/VQ50=8"14F M,K;EQGK.]A0 MV$0O>=>^?N^H]\TLUQ(K!1F#W`?,5%_0GF4YE;Y@^,B$/(ALN M0K+!&Y:]1Y^WC2>HB^[$S-\26^0=CP4.#;?`3BC]Z1L[,SRI8,0JERS$B!)& M[O0H=6BD71FKG/D<4<'(F2\158RWZ(US=E:Y^2QD-'H>$;%*=DLUG<16Q>?LR]5$;>H2MG-LK26U;11-VO)&HX M!D[#][U#%"**$,6($D0IH@Q1CJA`5"*J$-6(&H%DB,Q!G`Z1V?>?^0+:A3W0 M\R?M#IGG['T\)DLUA0:V(*E<1/J"C$)418AB1`FB%%&&*$=4("H158AJ1(U` M,B+F=$A'Y'W?%%QT!TUB_V.1F-Q6ZG,6`1=TVX4=HA!1A"A&E"!*$66(`Z?BKK]#%"**$,6($D0IH@Q1CJA` M5"*J$-6(&H&DX\U)AAX-U*'/G9^6Q@XL(6HRVK)J;`EQ&AO:6QI(9-A^0BHC]>'MB"_B*" M*$04(8H1)8A21!FB'%&!J$14(:H1-0+)F-#V'&+ROK>8+XTI%12+Y%RF,ON` M"WJ+"*(0480H1I0@2A%EB')$!:(2486H1M0()(-BCA#T7/:^@=(=1O@+^](B M&1.]_W4J-WGU!1F%J(H0Q8@21"FB#%&.J$!4(JH0U8@:@61,3!KJQV3\1&EI MLU9OF\M(.EZ=VP=.Q5[>(0H118AB1`FB%%&&*$=4("H158AJ1(U`TO'DKW,< M;^1J%K)(.EZ=,P3+7N4<#RA$580H1I0@2A%EB')$!:(2486H1M0()!W_FY+R MY5!2KC^QO64533)]$@B3DK7DMD\[5XRC%B**$,6($D0IH@Q1CJA`5"*J$-6( M&H%DB(:2\O>E@$O,RRU26RKU#"!P*H[`#E&(*$(4(TH0I8@R1#FB`E&)J$)4 M(VH$DD$9RLO?DXGT2;D;$5/].>CMTJI&QTVO<2$"%#I+K(H0Q8@21"FB#%&. MJ$!4(JH0U8@:@42(5N=EZ:U*U/>IV*`[!#%"**$,6($D0IH@Q1 MCJA`5"*J$-6(&H%D3$PZ[">$W3/LLP\<5\9.N[CXR[PZ(]FR:G0JLY:\[;$K MQE$+$46(8D0)HA11ABA'5"`J$56(:D2-0#)$.F/Y$%41HAA1@BA%E"'*$16(2D05 MHAI1(Y!TO$F4?\=\91-N.5^IT]_MJD_+79#4G!8XC0M17XQ1B*H(48PH090B MRA#EB`I$):(*48VH$4B$:'U>-M_*939OD9J4M..=BKV\0Q0BBA#%B!)$*:(, M48ZH0%0BJA#5B!J!I..'LOEW+13K/I]GUVX9R?E*#9C`J;C@#E&(*$(4(TH0 MI8@R1#FB`E&)J$)4(VH$ZF)R]?)]OW_=W;W>??[XN'_^M@_V/WZ\7-P?_GJB M^?[&O)6LQQ?/^Z^?+F]7R\TMS7SD.76%]DT;LT$8NK*B*^WG?J',FJX,6;M= MW6QNJ<5#UFZH3/N=5FUM?;TQ/6^@S'I"5X:LW:XF=#_M)WBU-;IBCCP&K*VF M=*7]Q5LH,Z,K0]9N5W.JIWVR!V7F5*;-O^#*@JX,EEG2%7K\-="V)46!GL_@ ME=OE:G-+)]!XA9ZC4)G!^"PI/H-E;I<4'SJS&[)&\:%CU($K*XK/8)G;A6G; MH#6Z8CYA.&!M06VC3[H-7:$6T,>M!JXLJ06#]=PNJ1\,^HT^MT-E!OO!DOH! M?4QBJ![J!_2L?N@*19N>&..5V^EZ#96YGUYM; M^O#L0!FZ8MZ)/G2%[I3>^#MTA>Z4OA,W<&5"]T._1SITA?IH]R$"W:\GU$?I M9QNQS.V$^@']%`5>H=]7I#+#5\@[]-7^H3+D'7K9ZL`5,T@&^"U5/VC)3&`# M^BU5/:2_I<$Q>(-;:M%@@R84%/J=[H&F3B@H]-O20UL4&W=NPI=5F.WAO]&J)33!XA5X4L3%O#T!_T,LA M-N:-`7B%WOZP,2\.P"OT$HB->7\`7J$7/VS,:QV&KJSIRE`9>N?#QKQ!8*#, M;+DQ;_7%*_0ZYHUYN2]>H;NT"_V;,5>K/VQKR4&:_0V[0I/JT/KOKY\N7SQY]W MW_;EW?.WAZ>7BQ_[K[0MNV[?)__\\,V<3';_\6I_M.B/P^OKX9'RE,N+[_N[ M+WMZ4?3U!\H>OQX.K_P?5/75K\/SG^W6[_/_"P```/__`P!02P,$%``&``@` M```A`-./UQ3]$```XEH``!D```!X;"]W;W)K&UL MK)Q9;QLY$H#?%]C_8/A];/6APT*<02PUN]G8!1:+V=UGQ983(;9E2,IDYM]O ML5G59%7U(7OR,II\*A;)8K$.2>X/O_[Q_'3Q^_9PW.U?;B^3J\GEQ?;E?O^P M>_ER>_F?W\POB\N+XVGS\K!YVK]L;R__W!XO?_WX][]]^+$_?#M^W6Y/%Z#A MY7A[^?5T>EU>7Q_OOVZ?-\>K_>OV!=YYW!^>-R?XY^'+]?'UL-T\-(.>GZ[3 MR61V_;S9O5QZ#?MR\DH.VZ?-"=9__+I[/9*VY_MS MU#UO#M^^O_YROW]^!16?=T^[TY^-TLN+Y_NE_?*R/VP^/\&^_TCRS3WI;OZA MU#_O[@_[X_[Q=`7JKOU"]9YOKF^N0=/'#P\[V($S^\5A^WA[^2E9UK/%Y?7' M#XV!_KO;_CA&_W]Q_+K_41YV#__8O6S!VG!.[@0^[_??G*A]<`@&7ZO1ICF! M?QTN'K:/F^]/IW_O?U3;W9>O)SCN*>S(;6SY\.=Z>[P'BX*:JW3J--WOGV`! M\-^+YYUS#;#(YH_F]:SQ1QT#=DZ=22E_C]MG[3YS;@+T[+)Z?F]A(L M`!YQ!%___6.:3C]<_P[^>8\R=UHFX1(KDG#.Z-2N)2@D,!*4$E026`GJ"%R# M65K;@//^#-LX-10A&C2*E(I8A5I(X),Q(L^6<8R:F! MRP@A)[*2O$HH-&2E5J2UDB*%(D:14I%*$:M('1-F)=@7LU)W-J*PXJ0;8]`F M[I`D38R9"\]HW^RV'5L(A'FV$!?X%CON_MO='H(5[*'C_#/(0EC_^M*) MF0+1O+7.*FE1"(!))I+[&J4RF#.$R6S";U`1I,CX1J-2HTHCJU&-*&E6SPWF M*J"_;C"LHV+?010;K$7!%!T&\U)37Q2DDT14C$72"@1;M9H)E2CEM]P<:Q4& M-BW-),GX*=@@0&IJIH9;SE5%L>4Z7`KJC]:GL(B*3>11"F$J<@W51J%4[$`= M5FNE:.F%*[LAFJ>^AW<=F-&HU*C2R&I4,\0MXRJW-U@&"[W8,A[E\!)9)N7' MM7)EM4M7#6]\]6DE2(CU5`\4"Q M`"L7D&9BNS7IZ5L`/P-7$L9G\+Y`B(5E?#0>Y:PBR,1-6B5>"GPOWK.*C:U4 M<%I$:7,.T_E4V,F0YL%#+TDJ^'ZED27D)\MNM,EQ-7V3<9.[:C,V^4A`P.(T MMJU'Z2Q*,BT:-"1*A6!;0.!K;G]`AE!07VI4$0H#K48UH487-X.K16,SO,_S M?$4+/D^N<9=X-.7A4F2'%4JY]?5?TS5)\8,5OE:@%`:%-)MFHNTSI*?O3C:) MIR2I8-**T.`"K%A`DLS$=FO2T[<`?C2N5!XZFM_VKWW549S*L.*.S\8CYKDM M&CP(+Y4UGWXWUBH2A0RB2'VI4:4'6HUJ-I"9QR5B9I[A"]R(\R8!DI46LIJ5#/$+0-Q_"V6<>+",AZ-9'27+]S`$FQVDF-E'@H,3%_;U*`IBJ[1%89VZ@B6IX'V% M1H90E-TUJ@@%75:CFI#.[JEK*H92R%D-=J-%6,=W*R/9G0:.!`BO2S0&,KNC M+A$@A)2A&<$[VS"21$[B,SQ)!;-6A."(P\!,J+>=B\C%QP,UZ>I;!/=4U_`, M'=%Y6=[917JP1\R#6Q3O4MS:->J*L[Q&!E&DOM2HT@.M1C4;R,WC:OK8/",7 MV;<`<2$*"W26<>FR/=DTEWT[2HT%2M05!TJ%#,T8I,J@/@1"-=#J@35#W#)P MJ]YB&2!\)+:[^.J(=2@_>G2+T4''=/5D$M[.;(#^E*U`)U1S#F M.=-;.;W*["/3<_O_E,XIU9T3HK',[@>..:R7BK)M@>HIL\_$AP$&WW=)I?^\ M2UID?`9J+LOG6LB?)=1CY$ M(IT6*`5[=>$@F3F`2,R M\PQG\LR)"S-X)#*Y.+,5#AP)C"@5!T:-C$9E4$_&JK24U:AFB%L&O/0MEG'B MPC(>C61R"/G-P)&KBU+P$GF6NKI>"C-YKF\N:NF[.;X0#RL*QCQG>HL#ID6/QZIG#>@1[]=^0B8[9H.*13!ZF M#V>@YK(H17/)CU;KL;FXP67/,Q(*=&^3M8T,+7H54.RWLK"F\C[-< M5-:&%MEW'S$??J-P7]?&-0C12_]%`'DN595`]EY+U M'^JBUBU-9W.AR-!T?4'7QWR2"L&@"BAV/K$"*U:031:Y*(!J4M2W`GX*(,5. MX5UW''YD*J,^HI$J$*6@OHLW+6RZ#E+!;?V,\/6(JP*G23X1@PP-XB M0B-#*"2F4J.*4-!E-:H)Z4HP=P5W'`'>YWN^;&>!P:.12K"9'LP*)4643(2# MK$D*K!M)B6M9H!0%AGD^D=68(45]UQ(#`^XFV+2B@8,KL&(%BSS-Q59J4M2W M`NZCLEN1AW->/>B"L_1=W<6@U)CO^H%Q/8@#(V2"+@H6I4:5'F@UJME`;AY7 MM,>^.W*%L<:/VF07&9UEX*5UK#07OYU9!2G:S5JC0B.C4:E1I9'5J&:(F\'5 MXV\P@R_?V5U%Q,T@7'?E/M?RQ@IF4*C04D:C4J-*(ZM1S1`W@^P.HLLRXABZ M4<@]@KA)>UUIM-:HT,AH5&I4:60UJAGBVY>-PLB>=4>0(XKWK-!:2Q4:&8U* MC2J-K$8U0VS/+KDPSX^._/Q?\3=:>&HG%#+`*J`0*O27D2C%FJ,TE\U1D"+O M,AJ5&E4:68UJ1/Y;2FXP6>^_SV"Z#8!?X3>Q(398BP8-YJ7Z?\6/FN$EV*K5 M3*@,\P],5@5=_F-+]F*W_/C[M37RW'<1>1:"M%6;LB*=AU MFZ0Z/,^K%U6\K)%(ER^B$ZB1A&\:DN"5CL@%)4D-KJGJEA)KLB2%:YI-U,]: M2*)O3?Q80.HMQ^+$Q>WWR/V8IC5X*EN\U10'PDLKU7$LK11Y5($#L4[-)Q/Q MBQ!#FOMJ1%^EDM3@_%60HODMGS]=R/!4TYB^^;FY7;$58D->B(ZR!%5B@(>:]+$_FG5H8$!NU;DM3@_%60HODM(9P_E7]'4I-` MW_S\%&2G,)S]I[HC0!1WLP$->CBV$B'T%S0P($,HZF8#&E!?D530936J">D& M=^I*_+_NG]@HQ/[I$?R0A,YTU!9W&*RQQFYYKJQF6)C$_U%ND9KC0J-C$:E M1I5&5J.:(;[GMS4V4]W8$(*;T%Z!="J^J5L%*;K/:XT*C8Q&I4:51E:CFB%F MAME`KS/L!T=T-8M2 MK+U-Y-_*%$&*;I()Z@F5`0W,6`5=L91HD6R0(O5U4`^(FQ62'#/KB"LY<6$_ MCT1I*A:UFJ$4.-F023NE9#5`NJA'FJ="PI`$J.N?K22IP355W5)B1DM2M*8; M]2-;DNA;$S\6V4B,'(ON&&;8,XZ2)%'%:0>?S,Z MF0F#&!K35_SX@HRD^HS22%5!BN:W-+__"?N-_-:SIB%]TW-KRX;A?;%%]Q$S M;`<@785#R(6I5B0UZ(?K($5&*!#1K\'$]ZZ&1@P:MR2IP=FK($6S6SZ[_&OV MFD;TS=MC6+W1,O0LB$:^0*2I/C!"JO;>8?T2K?^SF\_;P M9;O:/CT=+^[WW]WC5YN^OL7^V;!W^6SION>#<*/>F<,[S7U2[RS@G<:AY3M3 M>`?:J@YMTQMXYZ;KG=D$'D_;_&9?:LMAFLX1,*"+PX([UPN+ZEP3+*ES10FL M")Y=I7>QGDZ6[MN/KG>290&?V^MWX!L`&-/USGJ6+EWAVC$&WG$%IGX'GN7[ MJ8O?P3-^N^:X2Y?PL$VMYRY;P@,F-?^4+S^!8^DWX&%12_?XIJYWLJ5[\)%^ M!YYJ!&.ZWH&?0"[=KQGU&/A!(ZRLZYUU=K-TO_'38^`'?$OW\SQXY[KU(7C" M\.OFR_:?F\.7W"?4>S_<<+G2GS>G^#9PE!TPZ-IX5G2 M6W@FT>0*"HO'_?Y$_W`3M$^G_OA_`0```/__`P!02P,$%``&``@````A`+-K M_+A`$```9U$``!D```!X;"]W;W)K&ULK)S?<^.X M#Q-EX-HDSMG?W[K\O*!(""O-^?>Q>C\;/-ZOWO8OGZ].?_W M']%OL_.SPW']^K!^WKUN;L[_VAS.?[_]YS\^_=SMOQV>-IOC&5AX/=RX'M[VF_5#T^CE^=(?C::7+^OM MZ[FV,-\/L;%[?-S>;Y:[^^\OF]>C-K+?/*^/,/[#T_;M@-9>[H>8>UGOOWU_ M^^U^]_(&)KYLG[?'OQJCYVWZ/MYC^$^9?M_7YW MV#T>+\#-+T3IJ9J#>GSUL'M?? MGX__VOU,-MNO3T>8[@G_JM%S1VU1GQC M!/X:(_[T8NQ/KF:-E9Z6@6D)?['EA3<>357G/Y7_AK M6EJWV]/CU+2#OQ\9Z)5I!G\_U!TLSV:8\->T"VA6>H9Y;=K!7]/.\X8XU(/` MTW&@(E#/L3_,HUX;0O`/TW1VX<\FWN2]:?0P<-0_VEZ'-<7(\2ATO-'`$6/X M>!0__B`O8?2H%6;&.RQ\/(P?]8_V3D]'^J5>ILVJ7ZZ/Z]M/^]W/,TBEX./# MVUHE9F^N;.%ZUS'19H!3"0!6OK+R69FY.8?H@K5]@*SUX]:?3C]=_H!,\WW7OW=:HY)"*QJ[DD4K:>=`D%"02)!8D$205)!, MD%R00I"5(*4@E2"U39P)`??\B@E19B")02)MG1VP_')G-'T3TDK:"1$D%"02 M)!8D$205)!,D%Z009"5(*4@E2&T39T+`A-W=-B=(?`P:6?" MGUZQP&]%V&PI2"A()$@L2")(*D@F2"Y((M40RRG"K(4)!0D$B06)!$D%22SB7.CZNPM]W!-(!V?MO??[G:P M$&'[T>&``/9J>@>GC+CW;\@5!55+:&5[P<1=V4LM"J"_=OE[`=L+AJT(EW_4 MVD82M\0VQ'I+6D.VB"6;M!6A[:RU#<3Q)1QT'%]V^`S.DN@TI7:=IHD/IQ[K M[F>NBQ9&Y+J(W=FR4W3M6@J-R&^VW-.9QXQ$YCH\?*WA,%'J>+Y<85;W=)Z3"[E/6?1`P7V.34]V[SE:GD_\[AZBC.UL/ M!KD+8LPV9@M4]:\(4J$30D1Z`8S]&8O("`6][HU1U=M_0BKL/T6D^P^N/79G M&0I.]>_.@CJTV+/0GWU4E8.[6R-_2DG;J`#UA.$2593M0XDB1&0^)M1C/D$5 MF4\ERA`UYEW/@/\'/.%7;X0[3R*>#\P)5\+P]O6Z7J'(GEH5?:%3^ M=9,C/._ZFIT`([1S:IDV3^<85;UC2E#5.Z:4CVD\9F/*T,ZI,;E3HPX2=M#R MJ?EC]W9J^V$]2M4QF<^-1DXPMZAW;K0J:$K=C0-#8]Y"D4&6^9A0C_E$VDHE MRL@69`O78^I((#V&%>KA13=SM(`_;:!"D=Q]#MRI([%R+/BD5;$)7Y`&,]M2 MHE"B2*)8HD2B5*),HERB0J*51*5$E42U@]PI4J<*>XK>R<3Z$`+VT']WJIBJ MW&ZG77_*=X*DPH9+B4*)(HEBB1*)4HDRB7*)"HE6$I4251+5#G(=KTXYMN.M M;/+.')CSD3T'&MGG8D^@I42A1)%$L42)1*E$F42Y1(5$*XE*B2J):@>Y#E=' M(=OA[WC9G)QL+QMD'90]@982A1)%$L42)1*E$F42Y1(5$JTD*B6J)*H=Y'I9 MG7QL+UMA_8']BSX_.6G&(-I8+;P64<*7QW128>8)"?4TC(S*/>#S+41,*C2? M2)1*E$F42U1(M)*HE*B2J#8(E@@,U9DU=6IQ9JU_;31R]PAJ4&!-#Z$>+R_1 M%BRD]JGMC=FA/!QD*T*5:XOM$V)2M3.&Z+I]K*6$K''Q0VV&*K=']O#+284] M%HBHQY5$)2+7/-M[5Z1"\S6BCJG^)0=@7QZ`#7(B0*LLM,2&L'2MZ>95,VDK M0J1?H%`?FL82)8@H#%.),D3.*9C'7$XJ=&N!B,RO)"H1T5`KB6I$'5.DSK9V M#GUG->JCL)TL?8U4%)"7)ZQNLT"5XP8>XDNC"O3)WV-&PD%&HFX5"^085:8K M+PC82DI0X1[\6+9(4=5[8UFWBHTI-ZK`Z7'"JA\%VG)5['/2%:HH,$I"UDP% M;!`5JK1C9N,K9KE&@=._-95NM@?51^)+R5FVU\@M.$Y886[AFX;PAZ+0&I1^ M]<&H@G%3.1A[5R,VZ>$@.Q&I<+G&!F%18C0>,\B04V=`8A@Z1U))HOL2$EG0J1ON/)](K-1XT" MI[.30:+J+A$$E.FL0Y6ZJ5%-?TP>)I^7M]9&)6JV9'*&I1))]I6H#^LX)\3 MA8.,1*1"-\8X1KVPQL&835"";4XM+)-*S-WWWD2&MFBMY]@_M*>[G[#576!# M9Q`R2MI!X.V5V)!ZK+!'?11BS# ML$2_,`W?RS#:5C`USZ+IF&7A<)"=B%3HX-@@6.7J0[0I#\P$F_0&1HJJ=Y*, M<0DM^9RZM$GRC9S!9IW!B'#1Y@OL2'U6%&/ZH:O1/`8(TY7)X.'%\O>V1'+ M"IFO$0P*9V1!R'*)-0*33T3#<%##"%5T5H@E2A#1N%)"/>/*4$7FVM;66'[3(WL#ZV:OD`%TT)Y4,Z:L47I+!S4 M,$*5&Y8LF\1&93:6P03^YWX8D:"=4[G1/`W,,'MO)D-;O6/*<4S.`V(J#BJF M1V=<C'6<`UORY#PU5X;.W%CRPAGWD!O,D M(DLC)Q^TJ#>R6A6Z)C3F5<(['9*145D?S,42)60+S:>$>LQGTE8N44&VT/Q* MHE(VK"2JG8;.M,$]NM/6GZX;N;OP$='Z72"B5+:4*)0HDBB6*)$HE2B3*)>H MD&@E42E1)5'M(-?+L`GH71R#7H=3Y6V6=1'1XV!!J"<&EZ3"Z`H)]32,C&H\ MPGT7KX#$I$#3B42I1)E$N42%1"N)2HDJB6J#.LKL<')U9^R==:'D;%UH9%54 M%XU1^/99[S-D:53J@QO*4;SD&0ZR%:'*M<4V>#&I:,;,Z*GHG:(*LBJ-RWH< M-,_)#%5NC^SPDY,*>RP048\KB4I$KGGVY*I(A>9K1,U*<1)45E@$ M:.1$@$!+54Q0#1VW3OEAQJ@L6Q$BVLC'$B6(*$.D$F6(G,,*C[F<5.C6`A&9 M7TE4(J*A5A+5B#JF2-5*[,W%.ZM1EU;LXA;4+)67V=&3':H6J'+JX),KL@XQ$W2H6R#&J3%?>U37?O:("HNCTJDQ1U7MC6;>*C2DW*C5;U..4 M590+M.6HQ.X55108)2'+/'_(5*C2CKD>\7?8:A0X_5M3Z:8`567Y0'R9HHQ5 M%X,B5A-?;EV,.65A5._4Q8P*[D#%5U>9?9"=B%2X7&.#8#^H0U>6V;$1Y'^: M7-<\"XR?:&N8X`+A"YJ>\S([FG4'(X!'F2VQ(/5;8HSGG7,_8 MI-38QNG,NF,W4E0MY`.1HDLG3B8RU13W`S^VK!=0UVKBJ7?!+HW*9"+V6`\' MV8A(15%B.C>+R^-/HP3;]$Y_BJK>>\A(A?WG!K$,PUQ48$-G$#)(6D>B^1(; M4M*I$.D[GOH\J=5L%I_@0V= M0<@H:0>!MU=B0^JQPAY-F7TV8IW5V,;I[&24P![6B1)>,1EV*%166/!HQ/8Z M[#&^"(RJ=W4NC0K"7S^+9)E]D)V(5.C@&$WK,OL5_\PBP2:]T9VBJO'=AH,:1JBBPT(L48*(JD^8,E3UCBG',;E/"%:+ M*-"6,RZQQ%%%`5$BZAU$A8,P^T_?]_E3`^TX`[#FS]F`P@\M]0?6L#I[8X9% MEK(,1V1:&`NCZB^7+TF%(1D2Z@G)R*B@;HH-8XD2LH6JE%"/^4S:RB4JR!:: M7TE4RH:51.I7L,B%>MKTKUKIW[=YV>R_;A:;Y^?#V?WNN_K%JK':<+98_YS6 MW70.7R"'P3#^V9O,/T,/\@I\GV:NOCC2=06,P3<;NJY?S>/X9ODKH+(--]JS\[#S"M1DYZI0)T>< MP!55KY-7H/8Z5V4[>07JK7-53>VZ$L"5KC90:IVKPEU'&]^;JY=IY15X"WJN MWJF55^!EZ+EZM59>@7>BY^IU6GD%7GJ&6>ZZ`I\=S=6'1;(-?%X$$=!U93F; MPY?W98MD-H>OV4L.7Q>8JY?NY94[&-==][C@RJ+S"KSP/@\[K\!+[G/UYK/L M)X$KZ@5H>05>9I^K]Z#E%7B!'>:FN?_+=L7"S]R]K;]N5NO]U^WKX>QY\PA) M9=3\S,)>_U">_H^C^;[CE]T1?N`.\C[\JA;\H.$&WLT>7<#C\7&W.^)_0->7 M[4\DWOY/`````/__`P!02P,$%``&``@````A`/8RUW4R`0``0`(``!$`"`%D M;V-0(9QMQ$() MH-W^O;3KZHQ>>4G>EX?G',KYSM39)_B@&ULA6A"4@96-TG93H:?5(I^A+$1A ME:@;"Q7:0T!S?GY62L=DX^'!-PY\U!"R1+*!25>A;8R.81SD%HP(16K8%*X; M;T1,1[_!3LAWL0$\(>0*&XA"B2AP!\S=2$0#4LD1Z3Y\W0.4Q%"#`1L#I@7% MW]T(WH0_+_3)2=/HN'=IID'WE*WD(1S;NZ#'8MNV13OM-9(_Q2_+^\=^U%S; M;E<2$._V4XL0EVF5:PWJ9L]W;[[.0MB6^'=6*MG;,>E!1%!9>H\=[([)\_3V M;K5`?$+H14XN`3PWOOGG_,O````__\# M`%!+`P04``8`"````"$`(0:P6YT"``!C"```$``(`61O8U!R;W!S+V%P<"YX M;6P@H@0!**```0`````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````````````````````"<5M]O MVC`0?I^T_R'*>QM*NVE%)A6E3*VTJ4A)NT?+=2[$:F)GMH-@?_W.9$!2/+;R MYOCNN_ONIT-N5E49+$$;H>0XO#@?A`%(KC(A%^/P*?UZ]B4,C&4R8Z62,`[7 M8,*;^.,',M>J!FT%F`!-2#,."VOK41097D#%S#F*)4IRI2MF\5,O(I7G@L.= MXDT%TD;#P>!S!"L+,H/LK-X9#%N+HZ4]U6BFN.-GGM-UC81C,JGK4G!F,:&'7\8!$W4^2<%;"%`W'.2L-D&A_0>Z!N:3- MF=`F)DL[6@*W2@=&_,*T#7*<9JG+Z6&/!=K9=ZMM`>JSZD*FJW@UAO:KMO*0%4#17,[GVFDR:JF)Z M[8@F8B$%#@JV")UPKAII_1"K^&NAR@RGE\Y^-E@!KQ[:T`UF?+;"B33@Y_>` M0U\!3=GJ+PI(OA*VS:8K.:;-8K_CLL`5X/5[VQ@AP1B:P,+A.NTAO8#C.;@X M`3/T8PX3AX&_X#!XU=_F[YCNL9AIZC5_/.K+$S!7)V`^^3&>3$VR3+@]RG!S M[MI[/TZ)![(/\02(O^X'14GPVYEW(;UM_F9_?Q/RU3S5J;K#K;=]H/J7)"F8ANQ.\:U\?T'N\6W2I3,R+1@. M=K;5.12XY_2Y_6>(+Z[.!Y<#?"D[=R3:_QW$OP$``/__`P!02P$"+0`4``8` M"````"$`9A[&PO=V]R:W-H965T&UL M4$L!`BT`%``&``@````A`/8!=3>M`@```P<``!D`````````````````)!(` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@` M```A`)@X$).Q`@``?0<``!D`````````````````_!H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`"@A[-!F`@`` MHP4``!D`````````````````1R@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-8_E#:%!0``D18``!@````````` M````````GS0``'AL+W=O&PO&PO&UL4$L!`BT`%``&``@````A``L57:B4 M`P``5@P``!@`````````````````QX(``'AL+W=O&UL4$L!`BT`%``&``@````A M`%]9CN%E$```.E<``!D`````````````````HXD``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``& M``@````A`$>"U>Z@%@``YX```!@`````````````````+*(``'AL+W=O&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`*PSO8C?`@`` M10@``!@`````````````````<,$``'AL+W=O&UL4$L!`BT`%``&``@````A`*8O MQ+/H!0``S1<``!D`````````````````2,P``'AL+W=O&PO=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-$BR^(@!P``&PO M=V]R:W-H965T&UL4$L!`BT`%``&``@````A`-./UQ3]$```XEH``!D````````````````` MN?\``'AL+W=O&PO=V]R:W-H965T&UL 64$L%!@`````F`"8`/`H``*`G`0`````` ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 14 0001193125-14-188620-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-14-188620-xbrl.zip M4$L#!!0````(`*8XJ$0>CH'(=H$``'IM!0`1`!P`;W-U)8C"=`UUG`W1WLDG/F=E]"=0VDVC&D7(D.9V<7[]%RNY8LAS+-UII M8-#3EF3S*U:Q+BQ^^N5O+X^3P;/(BR1+/PW1B3DX$.-!E@[^\*X_#_`)&@P>RO+I[/3TQX\?)WD^GG_- MR2A[/!T8QOPG_EZ-[FPPL$\PC'#ATG4V3<=G`[KPD9^+N(3;!V,8Q]D`FX@: MIF68]C=LGIGV&7'^;_'N[.DU3^X?RL%_C/X3;H8[X0DRN#ZY/ED`]N^#FRPM MX.['ISA]';B3R>!:/E4,KD4A\F>9O#IYY_Y)DOXEQ??S?OE![?X?1-V-..>GZNK\UJ3(*$;LO<%4 M=_S\[B)I^V:X%9W^\>7SS>A!/,9&$P%HRGT:E>W)O-;B_(I;\'8*:#@3+4R5FAU/E: MW`V4U9S);_TT+)+'IXG4;?59G(_R;"*ZV:=ZXB$7=Y^&4F.-N6:>O!3C+LS2FS(;_77S$.>BN)R6:AF'I7TPRM)2O)37A_,MN#5O%0++M&[!-4S3I'JF4-\X'(S%*'F, M)V!H%U^CX2`9?QHFXUN+,.(X[-;SD.MY%-94$G*#XL`VX)/0"!AAD<<0"EAT MBV^MX;EE.10QQ_KEM!N`"NQL<3ES1^!DIA-8\,>7Y8/(Y3J=BP>1%LFSN`!W M]B@^9T419;E([E-_9@O?\C@M)LI9N.,_IT4I_=1745[>?8M?-I00D7-O'Q8.;CN5?X3^FR7,\@5L+M_3C/'^%>?A[/)D*C;*R(Q.%%J6& M']B6`9;E&8X=@6Y9'OR([?B!SV^1_#E,A^>,8V;7!-8)3T,$^[2C)O)E.VH! M[5!JNI87&F848(.RB(`9^0&HB@=B<+AKV=XMNB6DLB-<1]S9BI;NO"B**81L MO<*(.V&L1EZ'IZYX,@B55@(F4AE`#L9P+Z0%>*]OMUS%K_(C]T>73_(KBJ^9\GIB_'7Z^%WD>@06DM#E(?,-PJD)^F^%!B1AB\C4127=W.+=!]ER+.S3)\@5%R4*%Y>6IR`(]MU#,\Q0>]\\%BN MA4/#,1G&D>=$"+X2EA9R"SIHGB#R)L[M<>U)16?"7S!MG:H849N"%F+#90P9 MH'G@P'Q�N;OHT#ZG+7JU31'I[;)GBTO>CB*M!UF5Y!+";`[XT7E@=W6CYD M>?+/GBUNF`W/E8.OR>=]`&N6\)XBA;S@'&&S"?6=X:_$>17GE_E-*4,@96E@ M?NK9G?$N!"6W3R*_[1;R=A6`*=<0!1^UXE\%ZSWE_IBBP':;*+HA6V_J>XYA M7HKD+$T@(P/_)[9&[/Q,U]J'ODU4_>ZL[6O@UM+`(0.!+QQ_3N+OR20I$U%4 M6<;N'KM[4M!Q](@/SSDWZZ'CRO&OS#`#`2G6*%%>"OY_(I2[2L?@T"$&^*?Z M_"K/P$[*UZM)#,XJ56'3TZ->J02NBRPS@@`F1!'$,R2`R,:W#1\B&1<23)OZ MIHQGK%M8C#$W';0JM=P)<5V.*ESL@\[@R/8L[EL&IAX%G4&VX5#D&"X*(QPZ M#,2CUFGP4Y"'UR3S/H8EO9%A7@%Q2_Q](OIK&Q!Z4(1H4P5:!M]J_S#]=Q#> M@B+$DTCT>$(A=F>$M"T!*R#4X7Z$=0[+2A'EK!Y;;;#"O5=*VK(^I@$V@3S7 ML"RV586LO?H5/CY-LE14Z=JJI(38LS9 M1E>VKZ:J;UT0_]-RMC2T!O&,1XGI?(15W$RODC]^"DIX\E"YM9#J'1X3@BWK4:$MQ9*`_ID MDOV0F[Y@`$$V_5[>32?S$.%:C$3RW.L0!X2`G4:`LPFBUKCG.GN-)[UV"&#& MU$&M$4]S\,UB;1DGJ1B'<9XFZ7U12PCNDE'2PSDF-L0`B'%BU[.\]5CJV(-9 M-GXMGD4Z[:].(P<6::NNU.UCK^.+$AB2^`QN#>R^C-/[!/3<+0I1+HIF,;_3 MB-T+J<-#C`W(47V#!C0P>,BP$3(W"EUFFK;%:PB[8&FK3%8W]WCY M0`0\?F/);!UZ7;@5]&JP\W&5+8-O6U!Z>%LT58?5PWW\)U6.MP93!A%C0KY%EU6 M/V?Y.O[Q!0*T/(&!]4\_S>&Y[2"K74$7A]Z^#?"65,*"U%O_)S<]"'98ZV9` M&X054PDW]`^<')]%9Q;1D*H'HZV`'(RD"@MT!EZL39JB"@%=9"BO$S).HM/B:7 MV5494G/X*U8?J>_%@QC+<*^'G@0<)\5.,VIM&WO3,%=LM/=RM45JG\7!39M< MC:%"*\].S(X!_)Z,Q:R6]27^,\O]:5%FC[+I-!>%+`V\-5QJZ!)U'=NUPB@P M;!S"(LPL1S:@8\,/.;(]SV0\C*K9-4\00-X.R((0YHJ_V!PIY?:SM?3R3OY3 M>P3,(4'V`X0-AAQN4`(_XOFV:_B8@]XS,Z+(GNVSP1\U_9OC69!#U=MY>7>3 MW*?)73("S?$AV0%YY>H[BHMT.43961[S.5K7Z]91+:0T9G+8"L^AEX);C@GE M[`69"%O4WDHQPC`P+>J9!@T="HIA!X:#,#=(P`EW'=^U($)!LAM8UB:<#1>& MPV/G&%GH@-#E24JE"#;#O)?H"3T<>M4&+KM_37M;\+LL=0#3PHR^P)*$;8MO MA=/TP-HI]0R*91P>(MMP`T(,QR6NCTR/>WY4S3+@M-3AN77)_SX@P002A`Z' MB,SU%F.[V633`FF?6V@`D9D6?^$$?MS9"B*R`CNT&41E$81F%#-N>`ZW#%CH M0DPQL9!#JT-VV^RGS4N*/YU8D!2CB5SGMW1!@-BQF/VBS(1M![G;@1;5,60A M5K?&=P`=9R?Q%N;>L1W0W?P@I"V@TCW;+C%=@[1VH(1/BR)D"K@80)JP!RG MCOZX)$)D"?G^F!GPC$3()LD!D&]YHD1[,H M>DB2LUKY]W!L!!^&).?=6=O7P`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`LGZ MCW$6L6R#D543N=O"-#_R,F=V")+)M-R$N(%7@=A[K_U8P5VQ_"84WV?(MDQF M,,JH0LR9O?N0**U2@:=J%LZ@I8'+BVKF;-M".G]N??B(AGU>^;9VIE7(.HX92M0 M7#QSC$@87RZ,1[JA,GJMCN>JLQ!0^FUW,-@E'.PAD+S1R MJLG;8,T#F[O![&0J2PJU)Y79JZ&8&QA*.Z#&GCP(:RP-"I;5&S&:YDJ&5:(K MQE&>/+AORW))%F[S7VX!;.F_6I';8G*UB=RE8\K58C'N&1TP(FB+B&JX5 M.D:`&!B"YSDD<*J#W@:"U*AQ)&$UAD;M1I9S)&7))@>$*60FB!?`:_I@K67[/4K[YE5_%FK6;:UB"BUJ!&T^>.,!LRJ\MUL_JR/LU`4A"FU7AI:&?'?TZK+^]QZ(`W M-=OMT:\+07=Y,:DVURVS=0LU&>_70VE25XQF$>B7.`&(J:3DF7G('EJG/%%O MUC&_AV"I5-'O!=M22T_S.'UMV.M4=WZ*:2,Z"FTZZ\CW)JU3V04(C>,8%4^V M-/QK\33-1P]P_^7=5OQ?^LI)7+8,-<[?K`72#OQ;YH[`9^1B#TRL^@1@21). MLU4`ZP$U\D.1@KN=2);6\:,\IJ=>OOSA@U*2 M&5=\^"+R45+L>5]AW4F/$!,`:AJVRV#*0]JFT>)]%\?L6XN2\,&I;CINW9` MN<[9-7U&#Z%*X@K2Z&%K'WP7[I4KD2P M):487&A$-9N`:LRWF$RD8.$G=96`SM`/N^X9O^PSF.;`,SBW?,"-*$&>,N,1<:M3KA*+3 MTE^5`#[BTH\D]6YR+6!-^IO7;!T+5#,..S["%TV=6*[ M>1Q@#9#F#F,C9F-F0"(7 M&!2%MN&Y-H'LS@55)X'\KVIR@(MF`WX7,*U!0"3&,B7^".[?;'/_J\:_8M]H M=E,OBY#5PHWJW!-+(U^QUWW$V>L(C[8H;B=-#>_NQ`CR^?!E]"#?XG<-`=]E MVA[H]W"]PFHWL%Y9W@32`C74#1AW,XK2$T&T$5V=!VT5Z\*8D<[DKR[%= M*XP"P\:A;U!F.1(_-OR0RXTGD_$PNB4R/9US0748_UY;K?9!]^13QT5.9!LD M\)!!*3,-U\0V07G`?;"5DNBN)MW%`0LD M:RR/70"_M:T5LU<;HO9`;$67:$.WY(6LTNSQ%Q7[&;/>@?` MARH=:\6.MBXECT5R]BV/I8;_7?]RNC20M_&%:9F4K]?B7K7[I.77^''C/8P= MAPD"OKQV8:#AX%OH__?7R\^7OUZ$-X.+KWXU]+8QOB%P_Y^]*UUNV]C23S#O M@%*26TX5R'!?K.M441*5^$YB.XYR,W?^N)I`D^PQ"#!H0#+S]/.=TPT0W&2M MI"@Q58Y(HI>S;^@%FNF3=IX'XM;[=S>!?EJK]^KU=J/4;7<[I4:EVBMU6XV3 M4K/7[;>JO?-:HWEB0!]"PJ2!HRB^QRN@H[8G@/U+$Y_CEUK'Q/6G,MX)7&P;>#2"MPGPQ MFSZ8'-\04,HX,.@BH`3'*G1FQ44_],]`]"V#63/T+%7JI7IU$=@%L)8%^)0+ MDL';T)=?_EMN6X1IQ5ZE4J7MFZUZ47:7P)I#G;T"R27E@T,3W:A>+`:OU77J5T!I)L$.+TXIBH^]3^9S9O8-*UW)6+?;#EY&\*^ M\SR:-UAH^6`;AH\3(RJ/#(BAX M01ZX],L?H)&V"V%F%[SA#*0^">ZPE'V3#%;Z9Z>=\Y,6TME&'3)XCG2VUFF7 MSAJ=?KW7K7>:U8ZQJ?\(DF-?7?YCE!P#2_HV=70R"^2;HU]['W]Z^ZYT\O[B MXOVOKYW*-#EVSM^_NRC]_O9_^Z^=ZOR'\]ZO;W_YSVOG0DVD=M[)*^=C-!'A ML6.'N'C_`>T[T^3(SG,QELXPHLN@Z500WG3GZ'0R$;'Z&R/$.<$`"Y%%$.,< M86F&KC$&`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`9IXL2"Y(R>)NQ5,6N8BB#@.JFC\KLD''Q#5Z`8R[]2_(`6:HA!0(.!#)2\ MI'JJ2`"`KSR11#&3K3"`_*)T4G:R"T?_*/]>1O>1.=D"HPG/DU.&P.SPH^(N MR!QZ:AH`^ZF,)RIQ4@`:.1/Q&?1"][\`JTKX+`Q'$N'-N@TQB(`;T3]0GP'= M&%0@<$8Y-7*X"(BW0T(#NL&'JUH\$B(*H\QCS.CGD&G(SQ?931P9.H+DA^@+ MT,GHT`BC6(J$Q0.]%6WT$'$\HQ:"CVAU::00\Q,MHS3P>8J!=(C.+`?`%\B# M'1-3M;Z*2N#4E'"GUVR,/(G5G-3$RK+#%N1*:>EF_;E>7AQBJ0^-`C&1)/0B MGI5-J5W%FN(C-+2?S7T=P5MZ\"S'&;U7L6 M.3EI`H/\-Y-]H_D)_=R:^+DYN1(:8]S4HA`,!"I;]159O8%A*:^B'0C6\:+: MKB@MF?TYK]>3@@A1(Z4%GKE4$Z(2N`%-X%2TL!!AH+=D+`H$7Q@"+3>@[8P% MG,.BT86[F_OH!2(8(KY:-0K4\MM:TZVVN]_CL[$]R5#2&EY!< M#M,DC6DRG084$>`S20E$2L.'$LE8W2#SPD25"ZI*IJP(6Q$RME@3,3,H`"?V]AS\WQ)D,@D!`$;(CZK@6<;%"4RCS2R M>7@%`SZJV"=IB2$5KL-O:W44A12ED-U&CC(:2;9LM&4`XN)Y::S+3H^%8,,; M7-=XV(RI)*#7!RH[,51DZ\W&2B)*+K'#.)I`9NMNNU.S.GD&)TUGYJ]@6@>= M,=*WM9K;:55LZPU$(3,BK)A1LZ'9ANUX]H!,C)/,3\5<)?.LWFRT M&IM2E]V^E*]6*M_=\#5\L5"7=6_,7^D',CA:! M<1LQ^88@1<;I*S$*(UAY#SE2Y*=>8DP]15[`-V2[&P22#[>E\9&NFA8TWZ8) M8)45F6#;GN)`6@E.(8$)BB<1Y(!:#F1(AD)_!F60G;'3&\P<+YZ1UL(\SXYY M9$.<201(X`SC(E!Z!E>-AQYD*=E ME,F!FS8N)(]S\+\MK>`Q.-`'C(&)HBF')4Z0QXT531 M-DPP:`L/P3JF)'+Q84H6^W4&.&M"B?>"HD`=P%]MBV^`*M>V-;9LNPHPV;25R,*D:)RH8-Z2SB.JS!;< M1@J_+$HA?5\2L_E[OZCR7J[L;;?NM[*W=ZO7K`9^J-]W-_=A6?%1Z]IEQ1>\S/Y7HY5] MTDK,O:J7-TQ`'V[=\7/GRO6+O?,E,P]&\COUV`*:]:U+UEXOM:++V;(08W7? MRZ,O?=Q5NR<(Z?-:3LMI^K;%Z=L;Q0HK2^VJ;;?=[MRH[YU7VSV4'-X=Q5J] M]K@H[K^IO%ZDN5:Y=0MYSV6D3;?=[.Z':-\7U;K;?0HBOD]K9I_/DOB'$L*7 M1;5]BSF:UQKHBR@1P=TL=+"]C0%W]."UNMNLMW=BR6]%G&V2I.I6#[LD7NXN MB6W:_.=$M_T/U*^O:;Q?_^;GCN6-+;J&7;9[7`O_^.WV+91YK/+)TX]D7K7< M>O?.;OO:+T7_!%9Y73;=5O?-KJ.<6%S4[!P/_T@H3AX+. MH:"S-M8OW)IB]C@6KDLYE'4.99VG$[^\W++.L\U5[TR/1WY;M_]6_U#A.6ZW M'OE4UGVM\'1JS=VKSSXE`L^G9G&H].PN"=B>\7_!E9ZJVZSO9E'F4PV6JFZK M@F^V6?N*-K??=9?2-G."';8[U'L.]9[MN.S& M(819H$>M<;A?Y5#O^:J45':ST?#Q7<-]"?/8FQN>6_S_?"H7AWK/[F+_[1G_ M%USO:34.&[<60L?.G=<\OTQ;_YQJ%H=:S\/8^T5PQY*TZ\U1M;59<`MMY@?J M-!ZH_>$(IJ^<3;3F#*S\RPLYGFGM,>8+5#BE.MYK;:C[Q8Y*$$\:XXUBMNI_'(E:/]-Y;/\?RFJMNH[(EPWQO7NEOO M'JJ`+[2>=:@"/D16^-3CCA=U8)K'8:;JUQ6.G[8JM:AVK@ M0]C]K=V@5;RAY'T:%ZZCBJ6YC,9>XEN\ZF_=34;]-(ZF9PW<3: MZK7MW[GF^H85=S"_Z&Y3EX?Z?6=3'VKJZR^;L!-PF9COFYB#82Z>F'_G&R@* MCP\74>SV%<`.WG3L'.'#2XU;O=18"!?NE@SNH`K==AN5W6R`W@&RK?L<6[?- M:O13D6D3[FY=F.];D6VXE4IUWX3ZWBM1W4[CD37YN9OP]WPY8BQ'=&'LWDE] MS:W6=U.FVRG2M<>^`^>YU>&>SUN$`_V>_EN8&W,M>/)O0O;E+HO=$.=PJ\6+ MKNP?*/BPUO@6[T:^=F]VYRG?F[WR!B.(PE$I4)?2MRM$G<$,?9=>9AS>46SA M2NSJ#J_$?O2Y#S7O_5KYOUMB'/8`',KE7$%NUW9]+^D6D>T^A=,,]Z=Z)_",*"7##TE]9J^CH<&^/)1#M\.\M\<*?]3L]ZN=SKM3Z>]2JMZUN^4VIUJH]3H MXM/)2:M>:M5.SMIG]5JSTCSY1!U_)#0MENMJT\O%YNS#L4,VKC04$Q7,7J^$ M_OQ0J[_E:W)FQ>KR2DUZN6:=U6PK=B'\]:7HQG='"^XO,Y*!'":+1;>6V6BQ MN:96[+G6I7+7`C_M-HX%GEXWQTW?R4Q$/%)A"5._;E$D8+\;I7G-P<$B?:]E M1D;$\SB:.`F>8>`2_76=*\E[5E1X&07TBD2%X$:<"/P-Y(A.U?!H2P?M;%$: M*&(4NYT%[%2AB&>0US36DC9]#%(TD5J7G;O+-3W0J3'0[2AO2J`UQFF=(HRN@^!!-B&AM-(*[-]A=)0G08) M3QF9:]0QX>HVG57C<#M=7[03'\U>FX_2BT8A@_(!X:W#3T&QUZYWN>:U4 M[72ZI4;KK%?J-MKX7[];[5?:O4JSVMUD&K:Q,XGF49D"I?3!DL8IT(;ISP\- M7[B#\R>]`>0V?\ML6U:^B0E#7XTE"QO)O';`6IT*K2`Q\E+YX)/$0Y%`K2%= ML0B-`$.^E$XTBR/&F,8DIN@^5%]H]U/L^!+"-H$D09W12B6PGF.!\>F-H\]W MM=$;.LF"BYX8))9"1]1A1J\E(11^V?FP!"^K)J$#R^D[H4Q('@6][X3(,CI# M3"["F>-#MJ`S)+$DO`,J@I=M204(A=R0Y/Y]+'Y+E?V_'70D3&$7_(AU:P0R)!9G$#2Q2$3YKC=&!MH4.AR6TGM7GBK;_J5!/D]. M$X;ABLF:S&P774;OGT'<"./39CDW>Y`9'&=(1BOOID`K$(:5?"!ER/9H&,N_ M4N(3$5I-,M4O.SW/8S,UHH&!$A^@#ENP#`5&`;=4Z*4Q,6)%S[D[6%L,';)F.RBV1IB<4TYV;PB*T9@%>D;;Z"_8V) M22R/R3C2V0Y!9_@19Q1%/K'(1Y=X5G;^"!%- M.'^4?R\[L*\PT;334G@D:*1Q'JN#<5AV+V8@(==+)L'Q1$A"/BB8#7BD$&VU M\4D3&@>#@)S&9^0"BJZF7Z[(0%:1\$&53Z0G4O***2%Q$S9>00(%E/PJAY'U M9:S`-M)&Y5MG9QW<.-<::R((1`N;:WLX!K=``5O\A`%`EL`OPIR9+AHR4V.@ M`-W1_`OY01I-D4`0D3%(-O+!"PA)E,XVL&;`C25H-I@M0\.4R.%QF'^( M5!#.D)AC#,R-3Q&)ZY^DH*!-0R67^@>20HCZ72#NA2`JF$9AG+]"M!;LJ&"XB[A3455&J6<*7 M98.\!/Q4+`-25L/X:(@!C)&A#=PL(]8@`XU522?EA,G5N9`0$S%$)LB+HD]> M<%%\]9)WRGV^"HUR(+J(`=>B.6\88YK+?2&"SC6(V6+'6,L6V)1`%B=<.QU& M(-)NGO"K`FODBD5V-RZ5MN93U)2CFJ-!]&*#8"7P9HXL7UMFEY89"Y.-[CKL M-2ATS$(TDA(,L"S41KBR^*@0T;%4>9%-.2YIF\5X=J0QTD/\ MX'TFJ0H"BY7F_O/!*9K,5$_3)RBCTF/)MFV>KKGYKGYB($5$84*^]1)RS.J+ M@"N*)X5KB&/*W?X/Z!B+'\LAA;K.YS"ZXC'&%$C/!0T1!>3?6!HU@8-/;#B0 M`U>FI7WKP,\9*(QW(LVSHK?`#'9$BQ9!F<1/TP*1B370U^5VVQ#0C]%,!&Q( M*<,UH2Z1R,3<`!#I'P>L-K)6NH`16=TTYI6/9.`1\D:,I0D9C.TQQ$`W*>`0 M3"8R#VM,)E),7N8@V)EW=#;%GQFK321!2!+H$"2?8V,C\=J!(PJ,T"UF'$)S MW+<8ZV7(9W8_RP8@2]8%S`_R(!]`NQ3H+;I-G%DR:-+=SR_?JM(V9;[XK;EFV3SK5N6*+)8+):^*GXU M9#LK-B7S5?BSW&V9N)]^IFZ",[R)%:Q""]\&L,R+B'P=E0]F^%70^XE^0A@% M<[GY\?#W)+[_';-E?98LVYE]7B3*AI&/F_AW5)2]8Q(=T]$LSU,54[,[BAFH M?<5U7%?I=_V>9W<-NV]T3XE)"+:4AF8B"[84D87I@$7Z]P6D M?PNVE";FR#9%IP5;2GNR805;RJ4G@`NV%)%\>%%IS$)^(@T\.EZFLV!+$6PI M(HFY4;;XG"0HV%($6XI@2Q%L*4V!@`5;2D48@BU%P.6"+:6AB&)3=%JPI;0' M.!1L*9<-E@NVE!/H>YO`F?.!>87\!$P>'0\)%FPI@BU%@+R-LL7G),'MV5(. M=O)@]81#+TQC&M]GMR3]-@Y3TJ51P0_WU3N>4,24/T2SQ-0UY\>?W[H_IB3] MD6'KV0=I2`9T$D89PZZ>-X714/ M,VCNA]\4]5I3E^)Z91A/3G/@+QT\3!`D$SS#P@X2^$O"@LYL>":8OFF;AF?JBN\X&@C&<10O`!%9 MNAK8>M?T/;_SPU)5[8?YX3=#\^"M%57:_[!7Y?H7P9T"%/"!I.$]^5(@YOAU M5,X!:SO[6N19'L9#=@KI*#+;4)ET[<-OEN78^HK,MAS2:Z>&7A;]MQR682E< M?Y#3!YK/#G,ZR.UU/:=OV#!R0U=,T`S%-\V.8IA=OZ-;ON>9UK%/![T16F/G M8E/Z#^%$`AG*2DJF_-1D*:SR%#$>=,SQ2((T82<1)(('$*3G(0!V!/C2@F^V MN^,!(6_[X-N:>-U^KHOXUQLAG]*LL'>+L,ZFJ&!E^]Y.D`YJUIN[H/M).B*TC=;\RJE]$&;G&6\3LBIB-,U, M)'GB1;//<,G8R8F.CA<:V77UVK)ZZ/#\N2UD`?#O!!(^8TN?IF0,C],'1W4TA*0US4%HT58\/^@KKF8%AA?T+=_4FD6&[`\&Q:3@'%8\ M#VA%9M+O2<9QDY?8D4O22TSJ!^=BPBFN62.#E48B9%/CG)*049\B@]:0 MTUB3$K<,*YVY"R/&>K>NR8Q,0R08C6:,_.I)"T."?).10-0:I.8.Z5!! M:O)P2O&4`F>2@V<9JCI.HB%)Y_PMC&9<(G\7B*]F9,$/AP1A\PYF8T+RDS&; M,6I-'&E<,H^RS$4:QK"DHRAD3**,**^(!Z4`.`W?8,9Y&7$HBV>RXBZC\%,3JR/`WCC$\`H_1DK+J\+\C'ROCD M:%8V558]>/^NVBD^#)CM,)XQ\C[IHR8[CLOZ`G]JNK6\??XZRA@&.7,@9ZY< MT/NM<%*N0.-S'DQLF%%_OG\W9R4&'4,F31Q1A/1PT:PR^GDG*R\OM>+]NZ4P M%X*I*E-6(8E?T`=F2U%!`Z6P-F2(W\B^K5K%FQ@\DGL*9I-'1_O(QTM8N)0_ MMS=N^)[?TPRGJ_3MGJ>8GF4HOJOW%-TU3-TS#,OUN&:RXMG.+I.YYE6G,VZ+5PBK5].&6/38E7OWV]]?&H MMD6_-'7+XU_2_D]]M7[2:T_#&LG[$W1P_@GG-4;N4NF_R[?RG)%EGZ[^C\"F M_VFG23EME/5S.O]6V)M2-7S$E8^G)[/[=.*/*))3".(+R8]N31H.R+]QOFS. MUQZ!(UD+V:F[F;TPC=I&$/NN.VC=-&M--HS6'?&I.=@K77;MV@GW:P,>^[(T M-4?FRJ93.S1[GND7ZRW$+>PJ95'`):D[8^X_M;DPE.,8C)T30539-"_N-.R5 M(]OU*3./8D)V/O$INV8#HDIM]C_\P=\%IH!(.1F,8^CC_>S49F4C.K93KRY7 M=M73\,:=-.U&UHS#Y%4UQ:18LMT.%H&F&)#O6'XO#B?'I91^Z>-EHVD[]1(R M9>/0E,[-&_258QTF7:\I5L.0+??`N\&Y.R)?DEC!R#[)B13>IX3'0T]N5)2- M#G:?>H'9FQF_L[(I5GTPJ!4VQ6F`06E*OMPQWO'4U)UW69[6[8\:/\Z\/FOWZTJ_<4TVNV>Y^[;4'6I^$U[;\L#`\KWM2>70:1:[AJTNMA42[/AV=J[#E&7/;.('VW!T1D6JY2UK>H1-]FS?D*]NJ#2.TPJ9HHGQ3\Q(5SB?K M3 M4[@PV]OV<\IX$Q)LDQMS3G+;FCS\35K;]44^.V%&!\TN\>F\6>*3#>+5PHOD M'B&?/^:TRS?Q*$DG+'&J,RM_W#LENNFYKN9[CM+3+54Q54]3/%M5%2W0S)[? MU;L=,VANM<6,2T6B2U'-ZRQR*FEH8I,ZBPN*Z1V(PEO)$.S8.S($KZF>^,S+ M*9_1U-.1ZQ[^W9>;]+O(D+379DA^9Q3O_\-790]7);S[^;ID?;NKZ3>*6=DV M;W7_C,.-3,\]29)_N\-2))?2LIS[<_[\QGPS'NX;M#$];5O:Q/J:=U^__?G' MT=6I;N:U@P5.-GKV<`'&@P]1KT\B=RD1_/4JC25YCF\A=XRR6O(.-&#'5>W= MDU2\)JAX4_#83?"C\PF\B7!E':FUS>>PUJ=J)GD8U;/04>,C;[HA6\9ILJ"V M$LXQ18+%YAMPUJI-%O^<8A0BMG-*J]]<3.,K+_T8WTN4%664KK!>Z:>:\,81 MMX93WG=8"W_X^]KFRAP*/FF^)W-ERT;](]+GE$)TI:FR:M8^CK56%.TW\H=" M8XYIT'<]]^"-FWR]\\'JQ`(S^E\_>,9_0M&>*XL MV=9$:G7I%UFN,/"7!DP(0$<`.B_Z^F2:D@'E":"8RQE66`<%K"-@G>;X+Y<+ MZYSMMVIM>32@EE"SK;Y`>'YU[`.S(+05X7'U!E0$;=.'P/E@%@+I.=U'P/&, M_P4C/9IL&:=)RFRJLZ3)MBIR-R\6P!#`CP!^7JP>$$XI[`,2^3DE\9#F15K[ ME-(QOPE.>)_`>P3>,_I?/_C&?\+QGML4QS<6G$=W0:4H&B3K3\GS$)@/?NQ]ZO= MK5W]V-S3_8*"Z0UNHAHSU&S M$,5KU2S\P2`MR/!W&M[1B.:49-^Q"WLO8&$[FJ5KW4`)W*"GF$Y'5]Q^5U6Z MAN-US&[/T_O::P4L6EY[P:E1>T$[8>V%@[];0,SM@I@%V-PR_&0]V'P;SE(P M@NP`=DJB,"=#Z8[$9$2/7,=Z!W]3ET]UX.[X8[5D5V\`FM*DK\_U"OY',@LC M=&6.KLV[(F>F[&JM4^O=!VTX#6#_;;5)3Y,1R3+P_,-(&I$6:KYSZ"KR#1QR M?>J[2[3J7_,Q.(%MTVM-MKR+TVQ=5EUQ"O1"(QE"?DV(!&WKJVP\CU'CXS.> M[!WZ#'IK9:,9LBJ**UUNN$%(<+_F>:N`S5NQEM48#=R=%'&>W88SO,N/A\^? M[])L$"59D1X@8..KNM?3+<7T?%4QS2!0_+X6*'TCL'W+-&VWVVMFP$93U?_: M,$13W07GCYO+<$]$1ODJ&&WRRN-O8\VLQ5>;*6=2ZB$?0E9^KK_2Z!L*)PJ? MOSBS(O@F@F\B^":";XU#:D7P303?SAFF%<&W5D&U(O@F@F\B^-98K6^*CHO@ M6VLT6P3?+CAX).0G@F\B^-90V8C@VV6'CH0$]VN>-PB^U0RB/3DME<.E<1(- M29KU_BYH/ON2Y.2`L3?'A+O=GJVX1M=1S+[J*YW`7NS- MV$_LK3J;I:[!5'C8#I_<=6_95S!N\Z\SMK+L2J@.7D,7XU`Z84:&DO\8ID.. M.]!%QZ?'[=A?1+I/0[8!8\?N6,="UC&IB$':$GQ#2E_3\!LL&>D[&8QC\)'N M80'*TDT\N(8FV)#X8*3;*(QE*,@3.A@G\?*NU=^@ M`7XAG%:*+C)G!!Y$0:9TD"_&+J-%=Y#0<"X^4#?"ZN:YQR:#JYC^D_ M!,0RP6`V?P_A@6T)6EQTA/=L,8_EZ\M.)XL9P'OAR:64X!-P%-I MB$-1(AH3"7I%X8>'4IHI@76@YM'L&CJ=2X,P&TO3-!D0`LHQ2I/)LWE:Z14T\DC`N'ST#-ZRH6JK M/=VHGZ7>8T_E)[WR01_Q$JS_N2X%(+0PGE6WD@P4((=68%IA^F&+E,!1R&`X M:3J#[C#[-DU`0Z'3N(BE<)##,L9UGDR@I^'/>4P01P2R2@DL\G^@QTP&*\MI M+HQ,&A8IO@KZ!*+A^IYMHTT_5[4)_U]1%[?RW?"Z2WEWMF_PKO38"_>EREG;OYQ0^.%LX MNX96.Z_A"-/;W`7=3](1H6VTYE=.;2K"G6>\39$D$:1N:&K1JA?-/L,E8RP'\., M@;=E'&!8P2&W@-E*F/\ES/4&NQ7'>`%Z^$CS,6O[`7K";,:HTBD,-K!NR?6[ MP3L!+;D]%HM6Y`/:E>!F#Z(S]*UM]];-^Y7NV"<#;]JSK%L,SFFG MF]\V?=,+<*XYEK:&FW5AH)UC-^#(=)N6]P5!=B\0@&UZ?&#UU,$7D@=A-KY- MDP4/T2PQ=>W[@=I2`9T$D;9OSXHQG.JL+ZJ]2S35(*N;2G04D=Q[;ZGF%8'WF*[03?P M?F@_-./#;XICVRY<7$IGMV&^5M;F!DQ3G"?I+"C2%.O@'*2HC>YYOA=8CN*H M:@`##S3%[5@^_-7U7;L;]!W#?NVE_,-+*3A9E[:-K1=)\DP_:IO"GK[H$)NYHW:$/VM`8^-9BYK/3:3)GG=@5+O-PC%-`?E?+.0O)+A?:[Q5U93U4/YJ`&!Q[RUL M*8/9W@%_O^-T>P8\X+EF3S'-OJ:XX.!0%0@7]4 M0@!,T.PBSQ9F-VX8(X"VUT4)-HD1L"9$E$!$"424X,5G191`1`G:BR^)*(&( M$H@H09/00Q$E:*J&-]>*BRA!^Y1>1`DN&.46\A-1@DA$"9HB'!$EN&",6TAP MO]9X@RC!:WC_:E3@-D4BYGR&_.JY'P_Q$,9T`@\>*$I@]&W;\H.NT@_TGF)Z MCJ:XCJXI3J!9MFIU#5USFQ4EF$N(8?4+\3"9/PL8K-Q+YO>6"/\R>H#A@FO) M'P[I@DB=3N!;^H'@[3S6,`BG-`\9L[6,%/D1-I&2:4A+JOU)2&%&8LY)CP^, MP_2^)(CG#//74I=4^.TYYTHX2=*<_E->@N>FY>D2J8YXPX89:1/+N6.@5EG"Q9*8?AO%-DWN@C MC'J&'1\E*+P9"=.L'#2+BQ0YW+40)]+/3,+!&/J6/I&TS/X=%6E,DK\KB6_AI#HUP,/'Z4 M1,-%681'FC%IT&R:\+"/O"*^Z4*7)JQ,"VL!?J3D84YVSF-[)J/.;'G+;3C#2ZR.1PYCN(%CJE8NAK8>M?T/;_SPU)5[8?^ MX3=->W+4[`#C7A7L7P0M"AGZL'#">_*E0`WX.N)L+A6>.W@!'1Q)9$'@:+:E M.HIC@J#,7C]0.GT[4&Q'M3IZQ_&Z:A'O_;L4_>(E.,!SPHD'EUH^]6T.J M5]%GGH"R)X6>]W]%P"D91=!=KGRHG*,1_,M]43*9)FF8SIB7!==3`KXRSA,X MG(1[0F5UI-'"2X.YK\BF0MW(5P-XD^AQ4Q`K^.+H#(+BXT/X[FF1HBM7.F(Q MR9\4N7G_;G$K5ZB5JC<95Y(,U)J.Z`"KA:'OF\3,^T3/K&`>)ZM&].)DSM[P MO;AGR2MYO22OA3Q>DQ9\<(`[0._8M\A<8J@;Z=*W9*I;59@U4L-^5.1V?)VZ MP>6INLP28?FTNXB'>,`8%5&$6T!1?BAA+A;_U$+G&K.]BE3Z\_H;EF:+6W90!LP*P[$D&D\85EJW[19_&X0,6\LKQ*Q,VG\)R=OWO;HV(EU2!]^\=HM5U$ MQ[0];V@90W/4,AP;[;?!H&]8?:OG>(.A"W8]6VV6TB9BX[ZK\*$EFKT_$W,_ M@TITF/9+;\U:MG&P'-=PS'[KN%[7&179G.(8M#],QCW73F$#6L3-`_ MXE"6D2NI5+*0^36Z*&;^(:IP]N8:E&`D;)HL9A.<0PK6MC2'_UG$2_;P>H22 M#L8311H^#7$V)F.,5D(PNG&,LPQ94&-M^`B0!)0W_E>9OW<&>@H>PF"D4(.; M%3N>*(F")02\N&O[:&()U/&2+F`XE:R-$U:+`.^Z3Z);2/VLI49'$P?>1SBV MT=/;::>J1OL(]E2\"#^RE8[[^!3`V?P8YHOT'GV>EC39L#]LM[M6S^@,42F[ M9MOH^%;'Z/G^T.U;'=?K^O7*6?3AD('1DVJ$#DWB`X],5]IT&^X\_`V>8H)L M``OSS&(P0B>+,`QSH@" MN&U0'C'-VZ51`7D0S4)U:C(C$<"Y"E&^"OTBGB2S/4F%:QFQTWX9A5>$B?/% M+$AGE$$)8S1P<:1N#FJLW-4M0"@D6W[GD+TNI!8*[?22(C," MYE3ANL*3R'B^K6V)^;:6YZ_.MWU[)J>^5GE/>J9%-37`3(D0YC>Y!4Z8Z)16 M@Y6*ZSBL48!H%\%$H"B?$B[%9ZI!G4F$+?I/%RS[I6*`WXZYV1J+=;2P0OH4 MS3`.0*Z?7LMX4TEG0E.,#,XKQ2&GZE@A5@$XT3ZQ'F*CD!`QPP"5R+M4,'+) M`0XE;*`@I6!/&MB=*O$(SHP)-<:?)ID^EG`J*`XH1K#.MEF5XC=+Y*KT_CWX M)TFEJ,KVZHQTW5';M6T/97;/<"A-8O9<8VBU!R.G9]I]LZXB'"GU%RAN8#'P M2?#"AI!`Z^7W^S@L@T6*=`:*?(WR7.N!$/H*1FNJ2W]#J&R*-GPC;@&:F^8/ M0N(!VQ2."\RW/H%QT M*7B$F!#Z)863.!9#S(N`HB!N\23/SP9I9F2+^1P6O22NDSKG3%C4XK`!7^L?BNB2^0Q$R^C= M3+R&KE@>L"J;A+/@.F/)RR%N3+RGU])K*$!;-E;0E\T279R2);_X-QW3^!D7 M!DRC=&*@5+]FF"+4V;`)\,2=-Z8\BGUP,$:U=]MQ^^<:J9H+O#M2F MUJQXQR`/WP$33]X6L?8N!=KWU*5UY(\<'QNT#OJ>X?3[/:/G#'O&P!ZTS('O MMT`Q'EHOMM0FK1(),MT@`@W/_I*T;]WSDO0-EXXW751V[WY/^0&7:CY]^^^/ M_J+WL=VD-EMWO%=>#@$XY/7I>A-]9S+<@/FN4N9*OTRUU^*KK)W+/;WZ/RS[ M_/%>1'G<&_M4;O>P3%5SB)7*U"7J+A/^@"AY#$3\$>8'ER9'?8VWB*O,P(Q< M=7'VJ,S6D-'V;'O/\Y=K`^PK2^^T]S./ZJ$DS8Z0=73'L_9+ MQ:?5W.)#D"_'8$32Z['%A6T<1F#<]]J]V=(=Y]DU&WCEZ>W6SMT&#B)"[@LB M"$EGSQKAJ=L?75DOF\O*KNO'%BO>,9RNCMYI;;71)R52;-VT=U;>1R%27+WM M[;G/V-,R3SZGP22,@XOPL<7&=NWA'OL(.;KM[&S7'ZW<\-R=S:^CD!JV[G;V MK`V>NB'R1Q(;F'$.\7;)>1IRF=NC"Q5CJS9UCWW`VL?7&_/>,L7=/1AT%#+% MJX%`J4M_HD-\8UG4/>UN:@W^]HR_.@!1.ZP]UQY^==S3CO%[V]5=]W&LC?HC MYY7IZ!W_H'F;.R'E@*BP6GI[=Z^O,6&:)H1U-6*>%09K`47]\+8L>:K;G5(O MKE]?FNW-1U]Y1BVNN=OSYJ87CKX([]CJPVZIO)0WAC1Y48BV<;JC8GAZY'Z4 MFDNM*;4\/HB;4LNFU+(IM=RO[V::NN%JU M#$VIY7V35L^VU-*I>;7V?4&T=+_33&QK2BT?@?5\W6SO^<9`_8`&J\1WGW:I M95NWME-JCRU2ZB)`FE++._&7H[O6GJD'!`5EJ5;5@V;H5;PT&C\F,>4IX MN_.H\1T:V"YUP(V*SMU+\S^B,'OPIK=NN]OS;7M@=`?PEM/NN8;O>EUCY'5Z M';?;\OR.O=5HU(-W?:61J-OU>54M1W54JOCUZG14Z[;IJ)45-R[S:7%Q$7`+ M;H6J6DE66%!2]J8/;CL]M9D0UDP(4_[:3`AK)H0U$\*Z3V!"V..,7?F3!UL/ MY=RI`4/JN>)2+16F.-C`/T%#H8@9@D*O0@+2NT"[Y^',D[ M8QRK50[8_1,MK(GV"9)B+L3R M:;+(@18TRP+GH>39"4N,;/FU!7!'.B/Y45F!1U"0AKJ0"NK%=YN'*B-SAR!- M)L5(5KD-GJT$T.<;W]?%P>9%E"^6TUSXI(E!Y7"D/RW&4P44*:9PPY?%C%\< MR"'TZXOO*E-HQ$#P&&=ZK4'@(H>=_99),<&Q*95@'G.TQ%MR+R34\MIFF1178&1?[&(]3$!B(%#C!YZQRI!![\=U- M9$_E('&`O6284O/A#*Q3>']EE7\6$QHO>P)RHN"SD!&)V,VSZ@M,R>+#))GA M?\\3Q`U-G,:)*_B#,C>MG)@FEN!Q:&(.&I@M$9!T[73E1$CG+.'9-,2T0G)6 M9AY+?27''8MQ.EH(:$XNHC$(P\LH36*&]6\:>LWCNK(J/RVC]@I'?6T>M`S2 M$@_OB?9V-HO@S$[D.'`PG+\"9^C:98+DA[WCD<:YWO%$CKQ'(&B?X^OR^6+^ M'I\5PP%*(JZ/7J@J"MB41)FV2FBC'$1I??\$Y M)QTY*E36&52U=(H M]!5DL]@7,\2*"6$LNL/\L#&`$YF-IH_@@-@^,\BP?\#6V\H#+1[03.SF%IX;`QQ9)4)=A!F&Q+U%@_:?]>QLG_/0:$7G/!`P3@0QF7R`PA\?;5)B M0A9"`'N*_P,F!$N7"8::Y&1"T!:,P/D,K%,\6-/H?$K^;?%GU"L7\UER'89L M8A='C)F&7D743L-9H>JQ?AC-5WY$Q)?P1`>5Z8*EH(U`FT8YC9T%SX6=3"$/ M6-_A%R[0$@O(2L*]A@&?*PJ9NFR;.'VYZW/'N8?8B`02$`[;L)F M)\=%P3O)%3NO1!+RF*+T,@R;DDF>85B,G6;<5ZE:,ZE]3X%_W+%XK*UWCJ][],ZP>JWFRN$= M./KO)/VJ\?QV]/X/SM/WO=G1\?=,[AJ"7(?++,QIDVD(##O%&*J*N07 MID%ZSJE[47)QH@U"JMDIZN)AB4!I%4OOX7>C226YDN5I@&+-P"HE[2+,I\E$ MPU(F4;LE"W7PG?!L,=-FT668E26GG*SA),R)UEM$LPDGL5).6HE-A7+1*X#Z M&C=^EB#RL`HU$T!3SF"1PU,%.C%3=!&,I["W=`G3G#0Z6Z1QE,L"\;/H6\YE MC6FH?AM6$5]/*-\:QOSA<$I$KZ!O7O#219EL3+FV;E(45;THLY$,/*;QS@,LT$@I8:A%6$XU MQMQ"D0A=JI`MRIZJ5<(GFM)PN,2<*-"<*ZR.+%$R.S'"[HE!6.Q[R]=;'9$; MM#JZ[;?T2G+P(>M_.G6I_RDD3GE?2^,+6XJPT=ZN5*^*>GYQ_&"A9YM5\ZU[ M9M5NR%)MRFRY=T]L/>!2S:=O__W19P:/+?5VRT"(#:J!-G/(?%N]B?XH8R'* M/37S(8X/XF8^1#,?HID/L>6[NP?Y[-VG+Q]9S<`K2^_4O+G[CI!U=,?;]MG.AVC7?,3,?4$$(>GL62,\=?NCF0^QJQKKM)Y?3V9;-^VG M/1_"U=O>G@M3GY9YTLR'N!-_.;KM[+EI9OV`?N7M/I3]**2&K;O[[M#_U`V1 M9C[$/?BO?7R7*>XM4]S=@T%'(5.\&@B4NA2T'>(;RZ+N:9??-O@[GK[*3P=K MS[7HNXY[VG4\A*N[[N-8&_5'#HZ'Z/@'S=O<"2D'1(75TMN[>WV-"=-4K=?5 MB'E6&*P%%/7#V[+DJ6YW&J(8_/6EV=Y\])5GU.*:NSUO;GKAZ(OPCJT^[);* M2UEXK\EZ>]K&Z8Z*X>F1^U%J+K6FU/+X(&Y*+9M2RZ;4;N7@AV%U+#U3JL&4^>/V1!I2BWO4Y:W[T+?^H'\JNWN'$8X"IEBUJ%[<5.H M\%2KWAK\'4^1PM/!6E-K69\][5IKV=8]LVGZN[G6TND<]`[(G9!R0%18EFY9 M-7"*&A/FZ5:\-1@\)C/F*>&MEKVI?TN2"4XVIRVM=*.6?\6VT6F845*9AJ9_ MPX%&9;_8^2(=3W&Z/(W1U*YP%&E4-GQ>,PHT#G.M;$-+#8!Y^/%91`U@HY4F MM8%,.RU-K>8!]=2:&!9)%BD_F46RS_#@C^YOV+>XNSA?9#E6+9HG)611QE.) M95]F6.-TD6MI0+.'X:]Y2,.>@SA>T(CA,^ZU#1!QP^-4@UW%R\3B@2?*P)V6!\%N$O;S[BS3%'_\\^70"KY^'<9C2]W!T M])QVP%V:L:TTH#D>1_,90#_'&9JYMLBP!?5%\!7P!:_38-P\H''4X64Q4#@X MQ:&:-)8S^@J[FR8)3=(\+[!1[`LW\?8,P1@G\7BVF$@X87S-,1A;_QVA$V(Y8(.V")@4>V*E&-I#S1WLO>V;I\7W8M+Y98>@=7 M`38)D>F#]%J,M\4AI1H]+GAZRQW@]-ADANW.,7@9I/+KZOCZXF0%\_D,^`;/ M016'F785Y5/1/CPX!W2>XQ3Q`HN\$'8ZCXA\^#M)YA.D++7QKCR]CE3P/A[V M<)*)UN+J'X6T@Q/E_YPI^]=)`I2T@46R$-AH4D47X@*(6,R!5:8;RV=*U,$: MV(Q&U5J(NC@V)I56HI1"K;C^,VJG1ZM&':@DK8/1XE)PDY%6<(1I8I;=G_9S&[ M+K6<;2*'4>/U10X"^;^$]HWB)YX4TF12B!/NV+ZM1*$.\[!5DNHKO+J%8#E9 M!7L6T!E7C^W*H46Q7])Z/2H0$=8+'HBM3#=&>1/2(.HX424LL#"`MR0L%(17 MEH`G-X"M38,)CD]6A2ZHNU)'5Y#`2'RU*A3PR>\M5S<]_T>>UPRR)TV^T5P" M((II_T"HDUH-CO@TN,3IY1.4"T&6Q"2FY"B#3(Z+0/4\YS$5<-J+6=P;Z%J% M#245KC$6`\=I)@,C\'(I;W+W?!X`W@)]U_*V!'_?8F14"3,9B2(4)?AR39PDNR3,;C!0ZC MZ-XT3D%G#2N)B@QZLZ'R*((*93V@/SY'P[#D6!IA\;UEZU['$F?RALD0>?(" M!T-@1]+6+3,F<.:X8#-\#`@3@B^AC^6]8UH?RVWA*KM#P8J$5D8&9+8*,13G:Z&-A"=*\ M^Q2)4K)'IDN/@!P!>/TL^A;2R!(IS5!(P%-1/D,!`NNCQ)L(W3";H88$51'A M1@JI`Y*@F+F M%.6`L`996>"#>(3?I\&_%]'XJV2,(>+[;6S\*[D(M7^]_8O/,8F,24(2Z!S0 MD`N8`:&Y``+6$^@E8$`A M'/VSL@L2Y6A,XB&8/)K!<@IV;@R&WVR&@*\GUPJQI"@E&)\JOV!@WOPKAM*#UTH)V(ZHF9QR(#&H)^`],+:$W8>:1'X MYN;M(5GE!J_PM$TBL#G)"R1^S*<)T(%9!"@-IV"154?P@-^+:F`>C+^"QN.9 MJRC`X15T4_Z,)[!]]"AO]B?YO`J/4E\6":"RX\+W$F)C`MIYAN9%:;*SJU)7?*PYR,>GH1.N%XP`@0LS"R]N0$6VH``[Y5;%'.B_3",B&IS%"XN)> MB?<#;5J<&B$B<(MB;[IX0_B5TJ@AS8SNIK+GTD,)BF,,()!J+?3$%>HF8`A$ M\HOOBI5+22O1><5^K99-H_F<#0=VK?(@FJ%BF<#*HT0,A\I*$8TO4(F+SA^[ M3(#I)LK+R-$IRCFP!4X7`+DN.)5DXR0$YDK)H>&-!"BX:,`3+Z5E`4444(SI MPGH;@VV<16>1^`[.'=-.01L4;I++^^&,%'L1R/ZH0L&=@M[>?!M M^%>"[/IWR#Z_PF7E@5O`*PK?7Q1CI`+:ML2B/!5:&'$`)\8'8'T*1:1E2`I' MGZ6@+N"SPD4C383'""$#B:1KT^0*OI_JDBTJGHNT?[/%V5DTCLA@#_*`Y.LE MB&6*3Z$1QZ)>103N',V9.)RQ`WP9SI(YL=**&2WQ/,.'^(RAA!:>*>L'Y,-L M,9[JB%K@D#&-'HL+8TA(L"M%ZRA)&KZQII#30=I8F&7$)1IBI3,W-) M^TBQZ(BKQHF8,L<^\P1.:RBV(+X>/9@P+HX8L"0YX M3D`IQ1.RC9GC,PT4T:R,3Y0>!X7=EFT]";R4^](;"#*I`N0KK`/0-_D'!R4?PC]&,"'-BDOI?`J_"6U+ MZ%YV4^OB=!>7L3\10!^E8P9H[!;'(EC(G8[VJ3A']C#9$L3)N&6TJ0RNH7M-+MJX8YE3A.D49 MH+?TO6WY8@JJY[,[H`Q!Q3R0B*U6>2\3OJ@FXP28^,1SR/PFMR!3=8F(019B M4L1P.#@LHOB1(F^J.92*!<;)OM.0-3G'2(7,3D#XXJ=B\GE3S.AH8]#\.*RV MH'.1.)1IPY"%'VO?*@`GVJ2S@5%,N<4UVDVT"Z!2*V>&,\,5WC8@H3 MXVP13PKC)(PNR?F(T#N0#D`939'IMRQ+BC'+8CD<1[WJP]YPFN#5&P+"D?3G M"BMSCN.QKZ44TK[W7;G,]Z9NFO[N,X0/HH.0U?X*XPD@M@_.*H`A1.AZNKV/ M9=:%C-A"O7P,QU^C/-=Z($6_1ADZP")6A-H8O?AJ8LC\08ALJKT0,58F--E+ MI\&,9XS?)/S(_9\&',!1#QGYW24HY-&O^4@@],9F>LLOW+P^+/&JDD(T6S_\ MJ)&`$=J+O5H4:VD(IQ=$U!343CPA3MW$C`D[X8]F*98^2E&K(R5G8<^1@D1# M#;5I$:3)2N(63Y+4`]T=&MEB/H=%+XGKI-(4GI7\K9C:OF#K&3"QB#%]0U8Y MD()78#$@2CN4CRL]+*B:@0I2A.3,%J?_B$@KG&4,GHA(!;\&?P:K@G7Q!.S9 M:R5P`#_#&4ZO9=JQ`&W9VD)G,4MT<4IPR6@2@2;0*16K8T@VXPGP&%LV4"U= M,TP1&AU4E!,OT*B@9&"N*$',/BQ0G04B5@0/B\`EQI]FUQ(W"94\J![K!@0) MU(A%I&)A_QA]1U(OZ-@S-*<+<)G#;,D8@BT5^@H/QR0JO%BINY8MM#MP]6W# MU*TZ#5.ORMEW:.U^0%L?/*L-NK`79-&8"P"BV0(%)E:MH.<)7EI`&35!/OKC M*::E+B-*Q&,4AAX64=0KZI083@R@9HIQR7A!P3Q"/BU&\A1#?ABJR9/Q5R!> MCBQ/ZZTXOJ`^E3TA'RJ[4C($Q>XH02[7"+^%Z3C*Z`!?HK6#Z9Q)=%*=3<22UQDT6.=O>5;NY6TT0)QQ$>\$U2C?JB-L_5<3] MU4U7O6$.*R*5BJCB,KM)'J&SS05(9.]DI8U=)`@U%)*&I&%=S)J1R+KW1=8= M^P;(G'MY^,JSQR5ALEJ4K#:U3%202>;R2^E%=JG,YY.K`7)8E&%.DADX?!F: MF4*#(B6X$B'E0I(B/BK-G&P:AI0+*)(H9:XZ+B(J*Y_%C+HXZ$N?.).YH.(< M?R3.HY-9XD1X.&R]LJU-+JDLC0W*CH/"XT462D,PT2F[S^5U'!FC`H@,C.&4 MB@JEMN'\`YTU<,8FH%141TY#]9T_DEE,S!%P:.(%=$+T5X=UT@ MDK>!N^"ZG9J<0J5/I:B5Z%>XYIULW+G.+1390W2;HSR\X$.X@?6$V@,Y!0A' M6XF5:#:>8=A;5,,JFY''[:8E)0<+1WUI!?!6HW'$%1'!A,TH^*8U1TE3DP:,9_B3D$5)1B:CU@S@`"S86LDVH!X6-2R8N M#/_BG57[EPOI1/J1C7AI(PIK=PM)*^6L(GXJU<;JR1+2%KFPJ`,&[]SS.ASG M`D?=!/.?/I5^;K*)8A1EQ]G7!USMC:YFOK'[7'9@#8]@?NH;CM3I&=]@>&!8LXG:\GN<- M>XP./(7B$#:V(%)M:[!)^I8)"/AK")U"0P9HK6 M&S_X&-W4`S.;BFS77H9\L?;>I.";/T$#PD^?!3 MW*;<>&5$7*84!:]TY8(JM:DJ9^FU!1;BSO@2DKH"QV/+8A,1C2KE<$4*LSD< M3G3I%J&Q(;;!F=)SEC/KW]=%")<74;Y8D;&B%`NE[(GV"4-X)2A1<1$TU,I; M71B=%@D9KB8J4C)T(X[+.Z,U".0;8^*,JQ?]I*NVJQ>!81EY!:02N997 MBT0:1[F84V!G7.QC/$X78/[HB`>,9*)04FJJ;B![&A;%7YNN&FFG?&NTNLH_ MB\DY7_SZO>0S<3T.L9MG-UZ>HA@\_.]Y@KBA(EQ,/^`/2A5$6?\@EF!Q*PO* M6&8J?"XJGS-Q#4FI0"6FE36*40H*$,.F8V2D\O8825^IW0'-(//'6AA?1FD2 M,ZQ_AX7?Q2'AS:BERFC89I$K8$B@)C\`+Y M&?*P04.=LHM=YJ((.:#A.,^64Q0DGG*!?Q3?@@R*,5>$BZ`GQT@XE9,IM?G* M;4&2D"!GQQ%&>W59V2`\\Q>RPEV4>*PI:,BK,NQ$ZZOEBN^^$3O(07MH)Y%K[4QB"# MLWF`E>>_OFSQSW,,JHF?KZ))/L7Q4JT?7FJG&'=)\??JQI:&CZD]NN3KS@]% MUZ!9>)8737).\1\FD_NT\&PV=02A%3+$\WGEC_B`PZ6&)A'F!2/:43R@L7;>+9!EDNNRN_6^;Y2P6#,O/B M8A$G>#?C.E-D16&#PN&_C/(T4>Q,94V^<\L7%KD,0:AN7J6`+;^>AR(AOV9' MI>F#RY$4Y@75F^1XU20-YM%$W)`1=]?GH*]S(SDSQH&(:J\NDB9C+IZE^RHS ML.G2H+@40Y0J(Y2$@I@N&?'7JA\H*O&I2N=2E.S@/2LA0R?@3`DR%\I,U#Z* M"S(&/&9PP4^JO2HMF_[/[S_WRQ\'/_\H&$IJ^5E6+7=8QV=KF8@4)VV(_JBC M<#\EZY#7P`L\6@9?%O<1T,Q'^A0E#NSG7R3P-I9H%B;DTF4Y^:*NH4XG@TG\ MIC0[45\&DQ`-&93QF*[5M?DT2"^"<7).;NTXH]XA:"G-1)DY<$`$TB\4$?$8 M@VMR[4Q:'"?:NR#+1?WM$J)0HR&J:"&J6%&0(_/):7B1@!A#%)R&,<9BLJ\` M(F"%C!CN<)%>H]HY#S%(#^^=I6&(?1F8NIKQ))G&<\;4DC$!>&\)R5A0KHG)Q"BZV-@V# M63Y%D[7Z9TD%8;@+VD0Q4"M?B&?46T.X"\66"X3=CT2\SH!(X-I70B\)7N`J M[HG@#:J4/%#1EHBO4^(OL*X7/2G&))P%.FQ<-L4X)XRLH/B%4HDL.4DZ(A<@ MV#3\(M;M8[%=IHI(]EVX9!D1LW)[K6+A\'_6VSD/;`K&6UQ\- MV];`Z/+H+0C\=$'RB-]]N/2.Z]CM[@`\J<[(<(9#U^BVAGUC,#(MLV.. M+*?CU"O:BNC1_I)MSXC84 MB(V!QN=D$/YT"$SRK!#GAXWN\#NZTF/^!#9N<0?W/XLDYVLH MXU!<*B`^%):ZZC%B)@$009S-+IU"($I6"`:B#PJEH&D&Q)%4)=A`F MVQ(UUD_:OY?QL8P(;I-)2.(+7S'H$FX7A"%E?"(YQ5M5+!1$_X4)\-,8XXKT MAOQ)%_Z:4J$OZF?.%NCKXE$O[P&%N8JZZY^1&VN$//LG[0-C+4F5M`B%/:+_ MH#PC%(K#)?!&OT/6P..:Y-/*C11Q*^ILK400%DV):UCE5702GNAT78!/.=B# M@*JPIIB:!)%V*:V-CI?1&F\]$3Z8I&+4S MV;N1_HQZY6(^2ZY#<0^^.&*B*3[,9DB@A>VN MOB0NNG%$^KI!"M+7`@[^O/:CKV\D-`] M6]C`-UR\HXNI>*'.Y)*]MN>MJ:R#OUPI63ULJ9%)ST)(;\'60FC1EO(2`[*\ M!!,#$\YC8..'B+P!)7%0(NE%I>$-6L%I0$:_XJ.0TUZHUDPJ%XH4%-;75A4( MV]BX5;-87,-4.KS)"Y&R^=L#F<1=L^<[/0_=ZW[+<"R_;_AFOVWTO;9O.CUW M-+3M>IG$S575NUU57>7'6YGK@.VB_?6%[[88I'[XB+M=)@]ZJC M`D-1EF!9T9<_/PUN05._[YEMM^49GN,YX"N/^D9OU.X;;:_E]JR>YP]:6)F$ M.++AG0J6Y'ZK4+P5V7+@?OI_@!59.YI([ANR!]F-)X2<+@OW`\+<'K7,H>LX M1G_0=@U8J6=TVB,?F*0'7VEW^H.^#S#[`'.G6E2\&VQ5_%2N6[RE4K@_POS] MV>?@VR&1X)KM'I"W9_1LS#F/[*[1=8<=8V!Z3J_?ZW5LRCD[+]\`:[3\"AIN M`*$*ZV_84.1#FIQ%#U#I_.!,[;Y\8]J^565J9TC(+:=K^R/+-EJVTS.E$_@LM@Q,FL@-3?4M&-M=)YW5[7RJ' M01'U1Q(7O4V8580,JR.<%IQ8LU,!\V8@U@"\1GAA5D<*L`]X0PET?<[I1W3( M/R*0%60\Z`(V"X[67>6-W[.IF.O^>+ M+++0[7UQ(:(78KVA(D-_CV)L?@8V7AYB4!!4?745-@%_#\%/A;^4KFD-D8;< MX[JM=?KB(#C9_G1NKNZO%O=WBVL?-;:IK+L>VMVAO\TT%Y<(04\45=[U,VK( MIK%N,<17(:G"#ABIMP1S28+99@7.RJYO(^9;I3:_?E3LO'SC=MJW4%$!H0JM M<++Q*'P,9GP`/=R4448WT8]0NNK[F*U/W@Q%%60950!!+OZ.RI281(23AJ(BYP&B:MN#;PXM&P!M&6UPQ`#\;LOH M#?V!`1\<^D//&IF.PVI.`?P.L"S'2S+09>3!?,+RQOK1V7GYQF^;52MJ:=+S+J?U0`BN,[]J>,XM\+X-Q^HLZZY[0'F; MLGNH1,D>A1_Z)*9KWZ+R=@C*UQ!8<"7@,]M$T9=.-W`("$/\/Y3[E\&,7;7 M;G&L3:7T-E!L)?S9+3Y&X6^VX0PL6WGW@W(+MQ6+$=\IEZEKB!>4#2#]_5L4 MP"HPVWKM'T1]9@UA1X.@W;E-]RT!LIR8X&LB<*X&?/D-G8+ZBD/OY1O+Z52] MO1MA6'+T\,Y8.,EJ8>)O2V90`7Z5R+>"L>SBT+WF@,L3YK-01+6Z/+^[KN8. MF/Q@V55/]C:@K/?O1'ROB*@^GA)T.GW3:UL>G-WAP'#,8=OH==LV^'==X'1[ M@/_E9)NY%*G:#I:U-L`HG*!/?`S:O[5.^V_:_X9$RE!6T-=/A*'8-GW7<=>G M4>3.-R3&'Y%Z6X+GK/+M5HPZI.X,[\^&HEG21S#WWL?KS?P:2BL+/5'+K5+U M+C`Q-O#"H-J!L#J3X&V\]_JE-76-G7;7'8X&1ML:]@W'7]HN+X+8+FF:72[CF?T M^\..8[<&HY8[9!XT,>SMKBW%6<[X/EAMP6$A!#7B+56,WEIJL/<\SH&)#&?2 M:E7#7KMF=O;H`QP6*>`!>FW[GD[!`YUU$&2V:>X/X%(P+UT:Y@)V#T.G@WJ#,RN[[OM)V^ M<'T_.*W_JT1Z;MO^4A,`G*<>OL,[.&^++I!4(O_@`-MFI]V!GSS3=E<`!DNL MXP\MRP#8L-T:]F4=>I8Q]+JC8==K^UUKA&1VT9S^8"L@;P/!8]%8@NQ;N]+8 M)AJ;1T9C^,'W=J:Q132NP%Q+(MN6[]H/<9`M(K)5>R(+@.]_D&T\R"82^4AH M?/^#[#"-CXO$]SC'-G['O+>LKL2#/D;9UT]B[-_N@'9_:@SXK74@N+-FQR3>$(7?@9)>GG MX-O?43[%-O5@M.*-EXC7QW:)5QA4[5"MT%R#W6UVQ$Q/86Z/;8P%D='6\5';<`7):( M9Q^YG_;GY)'88Q]8L58+;N\!\4%X!>1;9X]EF()7/'/-T;D%X'UEI`\*NWG? M#/6*P/T`CV%WQ?/0W!D!L'FK#0AHM]H=U("M%MJU;==28\[S11JJ>%BU!K9* M?YA".[9.3/,&/:*`=4!30!H[X%^W=U/^#L9H/ICNO53_06`$F]W?T<`A&+W: M@VB;7GM',]UD,N[FB(EMTX=WWC8M!8M15]AK\1/\S'W`SM`.S,;3\"+\]>4T MS^<_O7Y]=75UDH7CD_/D\G7_[?_"$0.)8YIMIVW_\KI\K5PJ"VE@Q)M?L)7X M)/HI_#;'T6WY[]0G1)M@YVKLSOCKR]MQD/6N?P_^2=(^-KCI?HNREV_*N@1N M*D+Z#D7;-)IG_(U?7J_]])M?7LN]"2R\KJ#AEWG9KX(AR8,T'X`V?8/X-%HF M_`?6*'Y;/!C&$^4QV[!-7'JB//3+:V7Q7UX+6CX(8?G(/1W"?@"LQ6C!R!;L MU\^2JJ0LG@Y5/Z?!)/PCN`B?V1G=;`/5DK8K%E/ONA?&XRDV+:L2=/4NZBV$ MO<\>/E_/P_7B?^7A9\5>%1^CE@Q%':-6R3<4G1`5W^19$H["!<=$N(]%CU@B MW?,B6B7264NJ];#=9`C*%S/6&?4#8OI17>`@#GX+XR0/GQG=-H?B:TG$G0PL M[$M"HX\H]ZFJ"67%/-, M963O$R^QDC3%2_IB)LXS)*&\^W:,-)2AV=L.]Q.CFWH'N=YD^RU,SM-@/L4Y M>4MIK`4*\6=)-[H2?VQTHY1U>OW3GY^>%;5D7X9C(Q=)1O+!9'=PHE_TK(I( M]DZUX\2.W=1`W(EP]G:$LP]/N*8&XIB(UGA,3X.$C<=T='1K/*:CIEOC,1T/ MM1J/Z8B)6"^/J0;8L=LNH<>TFBMAC\'WIG5@RC9WPIXF69M+84^"G$U!^C'6 M\AT+(S6U,PTC[ M;I;1\K:@&SVV)[JUFL#+@]`UBH&&\+1ZS.3O]D^N9V\''1&UFMC7$=&J"6C5 MGT:-\7X,U+*\ENNCKK*LFAJ$2T/`NVF*K@XNLEIB]>=\E`(>Q`@.Y=&G0*FF MA*K.A&D*HVI"C:)LQG9J3HS-93/][A.A05.Z]+@T:`J2:D>:1X]1'A)FJWXP M6_N&N6FA_9#'LK@2=#AR-6&[XZ%6$[8[(EHU8;OZTZ@)VQT#M9I$;JVHT011 MCX5231"USH1I@J@UH4831*T1#9H@ZN/2H`FBUHXT=0HH[AWFNMQ/K02.]TYG MM^76"V:@LPO_N0O,.*^4`!;SGN4K%V$`9S-\P[_^Y;7\F9?`MY;>5\>_+B\B M_@:R=K#%2C0Y=7D)_.7==O$%@/ZR!-4DN@3\EKC#]_Y87(1ID">EC-MFYXS7 M]>_3L@/P'2^B>-/"Z_!:KKGZ\B^OE;VO!5T&O5=01T)6_G4+'`JC`L``00E#@``!#D!``#M76UO MVS@2_K[`_@>=%SC<`>-FAVX:1I$2"M#<>[M[@O"T8:V[S*I)>4D_A^ M_0TEV9)L4:)CV91\_=+&-E_F&8[FA3.DWO_R,O6=)Q"2_Z7==@8#YP-G#'P?%L[O+O@@2`#.D+QPQJ<+ MYX;X[MPG`8[FW%/V]9%(^(>C_O4<_.KWZ\&]9/ZZD9`-+&')%TZYZ=G;]JG M/[9/WP[/3R]/WUY>_/3O=&L^6P@ZG@3.W]R_8V-LB3TNG,')X"2%\:_.`V<2 M6T]GA"VFE#$>YYV[()0,"'6T+]:F];-967[7/SML79R/^.KC+D,\%P5$@E)X@%L6.:M@I'*NS*Z4#[/G'0X#BIN;HC3Y2ANM# MB=_GDJHI;GPB)1U1\+8EW'#40T+H$P%;+\`60P<3"*A+_.I!W:%&F\(.I,<# M5$Y8#S$+I5L$3(!)^@0[DZH=LG+B;XB7,*"KNNB!0G0S/6Y3UT*LNMYH502?Q=]4\FD!\=^ MQYYP&;C`/_>-.#W5P7&N6MTIDS"FCSYTI81@[ZCU$U?)@X"[7R?<]]!KNOUS MCM:N:IDVG&"OF%:LC'TR&3;IS=3,73>@3]BF2HA&\QT&,;J<@:!N`%[8J/M, MA+=7R(435H@9'Q@Q!^_V988F"Y\6]%2]N0^]T=H/KP=I/$.%J"+#B[%1Y<:E M=.0*45S/)64@Y0.,E:U.S5(QJ&TG.@C&1+UO_+0/I$73'01O7V!8BS9*_=T; M#7E`_`&@Q9ZCI#'OGK/Q/;J47F2\KA>?@(\%F4VHV\7H>Q\+SP` M.>2K`&;EN,J>&!-&_QM2=\.91'/O12++O"SE.9T3^$-X":Y]U+#;4/%(?_2#8K^%X+0$U94S5\K(;&?MFTBHP MV*N(%,ZR;X@8AD]I$*T%\]"U43H;F+OOYV++>?>N,"-/>0`S+A0E^[43!I/5 M`'#EML%XRAB\FZ0_5?8SPP3L`01_*M62>..1;H'X`)]4M1\@<",^MPNEC"LV<%2`)KV MEJB?3]6S`IXNA7;/I40>]T9H^?28MAK%"M+5;EJ?4.^.W9`9#8BO[!MGH3NL M`U?>T0J>.(.33W,ZRV*#KI)G(-/&!I4J\ZK\&?Q/A3]/Q`\]G."&"+%`F_<; M\>>@H=ZLKQ54B4P6`EAO9H/6#S`"7'\OWM8L%AA-8YMTHQZ+Q+C49!7UL(P@ M986^<.::PLCO9@/+)\Z]9^K[&II7/]N@;3WIC M4G(SM;NAU^R%76Q@&$!`*`/OE@B&EE&FXE#T5JA+=4@,.MK`8VRKBJQ3:O>K M*[*D$^$N!\0_-[:^LM7N<8N.5,49:K0V#6"Z[#\2?+H1;RXGX[I0S^$"20Y/ M7/SS]+3E/(,Z51!^QD\S0;E`+%>M\Y8SET@`\DWKA!4-"BU>PXJ\5BOPYPVR)WF[0IH(A M_&U+BQ)>-"CZ-N.%R49U`O\U]JR.I9#9^RWLDAE?!V&E*$?B_&H?43Z@G&AK MCP!Z'D>Y8$*]13O7RH&MMI^C#C7?T/J/50.VGKK^*8P%M M^4=!%QL8T*PGHJ$A.MO&2B%%).MLG%RUD$OI9CNKU)9R-J^EM4*5+VB1L_04 M&Y223G8*#22@5ZAR2!_PH?)YF.0MAE'DS-KU M1FG!HC:RQ-$)=ND'5R(K+@K`N`S[MQC2RQL40:(XH:(I* M:Z["UN.MS`.<&^\TL@"Q"&;Q5M9NM8?6<@G:RZ;M'/E=)Z/DL'Y1CV\[A84[ M69H4YD=T3.F8104+[F(H")/$#9]!YH6?XB?2^\\\ M&:0X"`1]G`>JRF?(H^3A*QAD,JI5?6GPR*95Z-KST4@3L27DG86FD?M4%3TJ MIHS<16LUU'!OOF^A-E>/]`&YIC8P!!`)'R#Z7V?"MQG"SA43*'$N#=<2__8A M%JON5,EO=#VO!IM15QN8;DZ/;%G1`VA@&*58_E+X4&VU9#?,N9;TEY M1NSOV%K=L!Y#2;]ZH4D.<6T-*-6U-IC6:GZWP;3>M1Z8UDJWC0&M]ZL'FLP; M<@R1;+[JQC:*^*#O&K!/0&XOI,-H[? M8*(JZW/2*_K`>Y=!:\2'*`-4,1],!ZT1'U:[JU7RP730;_M+VNM8R"+,3F)4 M-H#97*"#*"%\^U+)]90&'6WB&?*NBTZM`.U5&26X#`:P='V."^"%B>;4J['D M[0L(ETK0U7F7][-2R30A`J[5^VK59@$:M*((3=/8[@;3*X+JM4VVG91E(ZLR M]L0T8TO;R..,>V*:L9O6R!/?NS)MN[V71IX$K\9]7[N!\ M::Z;J'D)0C7!4!ZO3!P[3:%=,WFV9>!T;"F\ZKFB2-5]>PQRZ$T,M-9 M/;/*BU^;=/_57OACD%#05!7^W^GKDHUP35GQ-S89[K1K"I2_\6\S9]G(@N9# M<&HCS];(>V?U<\IKPHA?8YK\VO0&$IVV,S5=[?%0G M*R;@A67IVKQH;N-OKR0IH7%`GC^3``0E?BEK,VVM4OTO+KXJX\Y=T*;0-(TM M'^7<%(W<6X*SR]+(^-P8Z]IB-C+:-@:[ILMVBY;K;3Y6K=;OZ;=A3!3?`[BG M3\J=R9*3NOO,H!ST%0/94)4%9(;G]K9'%W4[ZO>6V=$0`R$-0-XHMQ MN\]$>/4@.HZFET>3'UQT+N8^]$9K/UAZ#7BS7T6MJ%$GW-$Q#1^OCV`(0=?) M(HX!7Q#?>`TV6ELYX3*=^7P!,(!0>QO+47D_>Z]VW/*1*.ED]Q4A95@R%3/E M:]E(AV4K)F@?Q48&O:^!KM6FC'5 M$(F[]E7M7JW0%>[A-9KFY1=-I'VHTNUUHWPC/E9MZR_@IF37D>=K!1BJW&[# M@ZC]"KP21!W78^7NU)[IJEB<1C>,JC,)8;G&&)C;!(&)W8D!S-1^+1L?`\%E MTOR^H\AY)!+PP_\`4$L#!!0````(`*8XJ$3,Q'IHZ`\``/O?```5`!P`;W-U M&UL550)``/H9&M3Z&1K4W5X"P`!!"4.```$.0$` M`.U=;6_;.!+^OL#^!YT7.-P!YS@O;7<;-+MPWHH`:1+8[FYQ7PI&HFUN9=%' M2HF]O_Z&DFQ)MD11LF1*WGXI4IDO\XR&,\.9(?7AM\7,-EXPXX0Z%YV3H^.. M@1V36L297'0^#[O]X=7=7>>W7W_\X<,_NEUC,#"NJ>-@V\9+XXN);.WW>-WH]/C\^-WYV>__#?>FLZ7C$RFKO$O\]_0&%I"CS-C<#0XBD'\ MIS&D#H?6LSERED;?MHV!Z,6-`>:8O6#K*!S4#N$:P%"'7W1B"!?/S#ZB;-*# M:E\^W0_-*9ZA+G&XBQPST5$,EM;UY/W[ M]SW_UWAKH,-RU\WC9+WM!3\&K3DYY_Z<]]3T>:H`Q\AL(?[7737KBD?=D]/N MV.2]SEG3.F;.93W3'$N)\'=PGR*4,P"O9ES0WEMB<:]J1C M]7:E=``]OPY=$$XQQ^/XECCP-@FRGRCW5\R5C3@G8X*MHH0KCKI/"$^(X<(O MH,#0[A2[Q$1V]:#N0/W-\`ZDAP-43M@C8&9"$S$\Q0XG+WAG4C.'K)SX*\2G MMS9]Y7>.11@VW1VHWAYK9W*O"3=M\1@/O=D,L>7C>$@F#LB;B1RW;YI@;URP MB4_4)B;!O&]9OE0B>Q=]4\FD>\=^Y[S`:Z`,_JP;<7RJO>-8$V54)4FF\_B,%!=1DQ76SYC?JOB%FU0I9.6"%F6##,P];-8@XF"U8+>*J6 M9^/'\<8/Y4$JSU`AJL#PPD:J!]8K`)!ALE_GXO@R&X$5>/T/E`7\Q%=;V#6CBM_9!/DD+]\ZJZHP\'<6X'( M.E:2\I3.$?P17KB7-FC8HAS<(V5ULU+J/]7`(,7YF@%[]6#?\-?S-H,-(P2. M\]Z9$,Y:.PNV_##1ME8EH3YE8\!7+@(%)ZZ;$:$<\B>T%!."M@X]U'N"GHD- M?A"NUW"4):"AC*E:7G8CHVXFK3<&M8J(=):Z(<(V?$;.@UKW(H[;L\BL%[;IB0XUT@-3B;P"=;H6'B//=HM1M]U]/[32&2). M:5*#WG52ZL_0G>'9,V8%R4QTK9'&*0S!3.\9=]><*49IV@`AO=:ZRD`4&21H MAJ6&'4ND4(.G8J@JTK_!Q+WDS'52HYC3;2A=R1RM3B+#A*9.$C*SK#J)VDZB M[IV::O*?/H5`(QC8!&&VJ%VA+%5]^4IGC/BSKWD\WIT@-.^)`J`>MEV^>N*7 M!'6/3\)BE9_"QU]7;OT`FYB\"*/^*53%P5PV>L;V12>W>4\/[=[,LT$.K&L, M$@GK5[`1_K9Q&/'KSX0'\U<84:6@AMWEDRU>"6A&V/7.A01E8ZUF>,V\R5JS M]Y3S6\HPR.F5QT#)FPA-CWF;VEO%J;M@4ZX970FD'FKZ/$-8@XL:/Z$V7`*)@)$P;V*(=D.,8LG7Z_Q&(/S;0E7$[SS8-,"FY5;1-COR/;P MXUC\=U48FB"TQ``ZN+^B,*R4Z3/894S\*$&..E7HV#P\TJ6AU/4`,6E:]QND M!=O`9O(%6W24OPU2 M35KJ(Z76*Q&)U500ZY]UTK;V)J*8>@ZY:3UT(KB;S8$B899$X#.'^(W&.NC^ MA!9DYLVD'FJRC18J887E4IEH4XE5>_#$6(ET3L)+YW?.=E(DS;*5&T@'I_TP M_I86D_%=UD,'@B=&+<^,E]/?$P??N7B6M1QE/30A2,\FY4:&5'HV"E&NVZ_2 M\^`0:?(0,BG[S/'8L^_).,L:J_34@6@@]HB2]1+]KHTZJ6Z-MV@\A9JD=EVI M^!F\\&AO^#A>NX9WSLW"Q)R+:A'&EM!4FK#=84`]^/V],O@-=!(4MPR1C<&/ M<#WF\/!^EUO*XD\SD9<82@?FZ"CKMNT>I3AAZOTJ\1LE;M[J'%^:EZC230>W M/\]O&77<)[04*CT6>9-JAKQ>:R1155:?)3$A9JX&#\LIBU:&AKW'C,Z*Y/U7 M5-"LH)E!F869N&GJ]/CXN&/,&:&,N,N+SFG'\#C02>=!C5=M.+=+DE6QQNRA M0%B`+6O4Q_I1)]Y4?:#!JC4`=KY0JR;XX^"S"P`C\3[3_J)EXJU:"!!'G<\I M_>];2^4E(3?C19?0:]L;[`3BO!Q\I-E. MM;]HF7"KI[/C\-42K/K?NY*PU\>"M@A_D7QYG`>Y'GNT"DZT2X!L%91(ML;Y M4#B_IU\HE%;&?MG2EM52,IL;YXPT_;'FP'`P\ESD6+%UT7&9AZ.'H&OPPKVQ?1UST>'!&>*&BHDBL\K4S46K1)=: MK0Q^H:1`A%N74U4Y[NH.F$7,T;67KIPYTGJ-".^;0\.[6=T107U[*%!W2:=$ M['AW*.R(JJ8B<#\?"KARJ:.($;\<"B.R*G@CJ)H\OHK=F9(%39'CVUSGO^`; MEY]9B@"WWH\K6YX=L:#U+IUZ3C8"?3"NFN1@6X3V8!RUB@[R1YPY&+^NEDLA M(C[I'.@/)!6Y(38WQXH M]D)IZ)`7[PZ4%RK%*B$+?E9E09-OL8Q_TZ[QQ&9_BD[C-3$#'&RL^93,Y4&8=F*D*GCN==Z)/C[E1PX M_Q2J4E<=F#:9_8#=("0-)BKG6@ZEKIHPB6_+FZZ'[-4^0&K$)!V^7WRAZ^*+ M:JA\H")_,,*OR*UF?Z/Z]@:$9#,KNXLXL^DEWOEB?<"U MWF79I^:%MJ$2KGH.K':$;2B.JP%]9H2C#55R9?FAMH-I0]E$I`&\-E3[ M5\`#V?:O#0<`*F!!]JZA#<<"*F#`MFO9A@,`%0"7[7?U'Q.HM)BF`;YQ?84G M#3ZE5[(X2-?YNQ*Y5=7M]JX)YU;5V91AR@X%-YIRMEN?GV_.)Q'71<[<]^[` MNM,16OQ!W*D@&+Q=<1Q*E(I?(IX\%IP16-EE1"V?PGM%S,JY9C;91NO1%G-\L8.T1'HEJQG<85$;0@?!F-K?I$N,81=(`7G9[35?) MFAA;O.A;R>^GYXI-[C)BPMKU:9+'LU/;ZHULIZN76(D26,^HS>K6&'^1*P6^ M=QU?"W>**/$&Z>=<7F>Q>BN^HX2QT,"-Y$>F[$56S+%$!6MN^40M4WWG6>&I M-%TT[9/)GQ"QP&/;S2DL-93>XT2I?F$BXU2+4&G?Q*F%4[1PIQ$'G4IL8[/=N[,V\/.!E<$^\S%'\;HHSU<$1A\Z<]8*F-.84B M%VU()M:XJ@H[6VW(/-;#KYT"EVW(5]:Y9TG>B94:ZVE#9G-?+)*$)HMF/YN2 M@%@?$!.<0\Z2Q[#U39>\0!NMQ]RR*=X0V.!]-H#DOFF"JVB%1HY'+NK&#SII M#.Z]`3V)N20%I8>VU?T!P\"GCE'5(E*CXYE;/VE)[Z5]WW[C1SWIK/P;9C/S M6`I=*_FJU;6#)JFIC\U?M7RW=([%$7QG$EUEE<&PM)9Z#IV(.R9#>Y-SWF2[ MI1Z*?8^!CVCXB23)I<<90)0'T/@EO9ROX^G^XEVH2=?W],94*KAWP8^*:3OE MD;0@#@B09Q<2;5I!I:[D1?:[SDT,JG35@LF%?:Z_8T[Z'[*#^/(^#8J1%UWE MB>")G#':H^,J>]FT=96LODXQGZW8I6;7J M$"57+&$)DE90OTNB5.:Q&\PR]1I-"^@],O[%;FP9[!'"_VQN#\+'7Z_Z&WN` MV`]:*KH]H7NOOX2<9-$+G--=61IZO_!YP99))UT1-6 M`J?4)#8)%TVX7ORT?Z@^1O2*.IS:Q/(SMY+H3*UA!5G/`IG M7?N&7CG>J6BPDB&[M??OF/JRLPFX%[Q[:A M9<$=^*9#"[J:#\%"^W!L9[T#3]HKM#SP9-J_OVH>O`3X_P9P;/#M;O8$U&L% M@#??W]S>W/SX\>/:=0TJ[5IWUC?@ZHKF]%N@TRWH7*M(K<@O,V=K&[>@%?EJ MZ$+-1T\#`VES"]2&TKIJM*\:G87:N&UT;IN]_XT^[6QVKKEZ\\'/^M_1P^A) ME*()9M>SZXAY_PGFCNVAI]<;S=Z!@66!&4[E@1GTH/L.C>M0J!6:"Y`S;>_3 M1<3"CU?7NG;5FV]?GN;Z&UQK5Z;M M^9JMQQ)B86E)E7Z_?T-^#9[VS%N/2'ER=.(E!@5!YA/XKROZV!7^ZDI1KYK* M]8=G7/R*,_S%=2PX@TM`=+CU=QOXZ<(SUQL+7H3?O;EPF:Z%Y;HW./V-#5?H M71HXAS[.0>G@'/X6?DWB[`+@)[_.QID&]6.R@D0W@9(6_@/':4Q-^.%#VX`& M510GSW$7D4X\381BL8X>$VAAGSMNJN%$UE+S7HG`K7>UTK3-#0[%&VCY'OV& M!.=50PF=_+?PZY>!KB,2?$3JLV.9N@F]P:OGNYKNT]R(C9\N&!+<[/7'26(6 MN-!SMJX.2[DD>#TEM7BQ7G&BM862X.('VE=?YQ?`-#Y=F,9+N]EM]GK=E[[: MZW=[+\J+QU[ATG353+-'\'6:?W(BCQWO6=MJK!0>V@;YQMZB4,+57 MTS)]I.2]Z>F6XVU=N$`%PQW2YO?\EUY:&G_NRJK(&K1=I=&(0>F!,">`L@)A M7B"2&3CD!K[C_`#)4"RV9W4/99IX8O2Q@;8'/0DHK@I!"N*5_""?U'Y?+N".8S8?NH07 M!8&7:%864I?Q/%_DTI5@;NLHRJ&F.NI)B6:M!MMB?2.8TS;R1XBPH$6*(4E7$=9A+.8N8MH?#A2H803,$ISQT"69HY.\UB;L$>/Y6G1F M+O1;W?X>4IHSB&8-]GD'][#82QS=]_:M)_1M1_J+&ZH7[" M`T(PST,<2XU:T4L4,_6]`\'ETM1_@RY>#>;"-]3/,-_AV-:=-7QR/._!<:&Y MLH-25-\M7,WV+&+2P/C7UO.Q#1/H3Y<+[:,X7&O+24QI59?ZK."U6I%.\!X\ MH@6(J0$"/0!6!(2:`*H*B.@"#LJ0L>SI$B]Q%%Z,"7'L48FV#!VG4\=I^PP\ M8-JZM3704R8J[<@;T&-OP,*NU]9X6!D:DI1Z=8.=40#6^O8D+@OK*>./?=SUCT6)^3);Z$VS%':Z:LALGN9``M%B()0+`CD`B)8$*/U&JPF#-X@ MH5>H(M<#L4)A9([0&']L_A&#W+[1-(.DA%@XJ`CXI^F_O3D6WG^#V@3S-\V% M=W@+#2XY4+%!F@29P5!=(E=(*ZO)OG*C0SL$D:9IF!M8.+A2!9$,<5\`D"P! MR1-$,Q5%-A\O!8.7T/-=4\?.\;!(LFI%#THW#U-R";35RB6[:,"[9FT%#W.> MCDZ\D#C-U8)+CX4S@]AI)EF=Q/=W@'7O( MIH'NF^]D@K%HXOP<68DI;VK3GW4-9E]M]8X+(E0`[?4@S?QHLQ_]B)4!5!MP MMP-8']SPV&L$#BJ)G]P7[5\UZ5_?P0OU0O_B97IDT`%]BS_KV+E;+QRAV#M4 MV^MP*TG15CO7&65>O2]-2&%(EV"BQ5<9Q9A;^[V^ M$I9+^^6KN`U$,P!IBWK%3M2>S0UJW`VIJWB%%@E5HCO&>FG758?8@_KURGF_ M,:`9\(L^)+%%7[T,4-%CX.+GP=)6B5=^_#L'W(XR9:V"E'Z+]C5H]C=#_(75*5Q=QWA?++%^Z;(UA6DP-7>B][!BY!Z$7,)1L]S M,C(?:B*T+JP3O5@=6=N[$%(B>1[TO:PP"W[D62:0')F'H91>)X2:I!,$8WF= M"4UD.P?0SJAYX6Z5\IJ3K2F+Z6+P!`;S^6@Q%\IT+'AC4!XL$T=5T>A8_"'N ME)4^6Z;5;D1I$S]\5-V,H-DJ20#GCK8%2RRZCXP5$=5WFF=ZTV7B$,%= M\/^BD_D8$W/D@$TCUO9#H]$)FT!$+A[G2IX:N:/_B#]E[PRVA]M435LW-U:P M=&7HV!Z2:`0C?WBC3>`;]-,S,@N5U,)'LLK%=)3)$BX4`NO6)&MFEZ04?#G:"&2JS&=Q82`V96,P?FRLFMCW3AIXWT/_8FAY9 M64H^NA#>.VO-S%J969R.*P$%RC`WW)MTOR@5"2(R`14*O@=BA9%2I[EJEKF7 M;/;R0XHQ4N.4L;A*%O"R>SA93PN&K$1_H=?N=G+0$MG_J<.R3(HDZ!,5A%H1 M+Z?WD^@2&M*\H/N3$O.VDWPP-!AF#`-Y`K M*AN,4&FV9FA"&TW'KQR'9,(H$64T7BTZL`W\#]ZV_ZY9>'7IP!]JKKM#;;?? M\+Z!C$*%+2W'\IM)(>8Y5[47[O\D*[OQT1CD0T0R&/B`R@9$^%F@V$#7=(R1 M;>25\/7;WB*V#^:?+\%H<@^F#^!Y-!M/[\]HX]S77)^OE>V#E7>CQ_%D,IX\ MGMG6PMJZ?BM5&LIU.@[;B#\(" M#J/B!%5]-=D75'C3+U_&BR^CR6(.!J@),YQ.%JAZ'TV&X]$<_#QQ?`@Z?Q<* M6W$=;,W%\UFFT&C$Z/"IF@ZQ^SQK"Y(DC8Y0F&61QCV#PB"+>8.N_.:[Y MY^&ZZNR7?91"#&A)-9@;>!TZ(1H#+!`'#O*$0W62@2DPA>`(56%M.[6ZGF0U.($L2:"H8E@V,F6F9,%CBD98+ M2L054D`RW?J>CYK;J$'*^C:C243B$M&#N;?1[O6RF8D(E`2'9$?Y&,K>[8\S9N"&$J>FUUPRGQ> M"KYD9:G!?*U,LW5HP1V?%7_N8^(+I[1KLK`33K,]ST:?1Y/Y^+<1>)K.A6[L M9XBZ!"VYGI`$G#*;YYB3BT7JE$UD:KO1;.7P)=L.NK.8?W0?0]KE%$^"[V,H M&\L%;,JU;6Z([;=]EVQ,G)G>[W?0UM_6FOM[[LZBPF1"K&0E3S\H]EHJYT\ MOH0?:5*7C5E427+:"4,,%K`D_"24(YV>H8N_T%9087VYT20B08KHP5QV-UO9 M-=5!'E`DX:BJB<&1)@=[R&T\48-=)%PJE%+B,)>EI&>D@&F^W6PL,_/0DNSG M16)$E6#>@*TTVYD,46&2\%/)ML0AU_Z;Z1I7&PU?N>V%\LAE,&O-WBXUWO*)EH M!8T@N<8L*IJ8W\Z3<:3B.`AS*4KX10Q'GC]=/CJ.X!:EX8I"O"F,TM1KM'AWS M#L_T#262JTI#F2`4*HB3&BTEW'R]GE^#96BF&:GUQUE/LHI^NVLO)G;8N@'%H)9H@H@&4!)`Q@ M:?SOX:K%+K6*73PNZ"H*,'I75ZX7!%8U9$?'P#:>4$YE*YR"M/RKG7R%V"^" M;B=`(G+)5D,B6;I*J$:[#U611XR6LR)BB]J4ZHC!4V)@]'SD9O>HZY5[;'!1 M*JX`YJK"?*AH@]YH1P6"E(ZUV+.&ZS15/<54?LPQ!6>2,7&R/5/+> MS(W'Q%A:"@%\I:C!OC^UTTZP%9,F"5:G6AA'ZLGT?*D@RHF\-("RO%$.'KQ5 M'B/1:C1#(/`W+_=P"5&M:.#5@*@6)!D](Q<_:*9+%KA/E_C/U.L4*PBH&1?# MT;=K>G?!R=HQQEBOW6XV7YHXQJAX5".-HZ*.$TD6S.X#NTMW#@NNBE05Q7%RQR9$@H M@,EL;9BGB1OM?H+'4"B(2!6_\K%FB]53+>9-8G'`IE%8X"WY",Q=?\*45!H* M2R[74'M=9@Z%KDVIW>IT%F58G5(F5MGQ$[Q>):%<_B73&0^+@ZSDG`S*1'$0R MW9#AX=$'='73RSRYK8P$,6P5J<6\$+'5[J6P1@<[L/SP7)XP![#/0CA]M?J` MT#@^FKY'E9AFX>-Y`,8D.-@'."0C`,.,/&!L77SU4G!YD"3TLH9^!LU,SA5, M]Y.IO9J6Z9O0FR#?L%:/ZEDK*E;)B?5C#K]_M*Y2T@U2P%TM6NT4%BZ*M9I/5(Y/Q(71:@:'\R&,/ MUCA]C&ZJ9]V`K3U"V_%A^O*T]&>XS_XG%&"+$J71Z3>ZO7"&?S(`H0S.\_8G MZ1Y0;6M4=T$+>VJP1$V\!:$K>7)#_S![GF9P7=2MKM*HK::??W MC#WR7A5345_*U4HP4)64IR@]2L'0*IN>5>W9!,&\^Z[91B=F(&[:!7!`1+.PB MN/.8K)YN,I^RH`2_'">X6)-/Y;#.LQ3*UB&(\]AH5!1C<9YON!-PUXER,;"XOS'/<`O^@/NLC>:IS_'.?)C MF;.'2"]9_H?EH[CMY:<;I)8UB&?$IP93,MZ/;><7[7BQ575EP>7KFXQSG?+)T M8`V1?D\)=WU228=M%8@&T0!YHL^.JJ2"0:1)`<3Y8TB0-P-YN.A3!C$(BF/@8/! M,@!P;UI;/W-97=;3`B$(56"-F%:SW\W$()0E!PA5#`O:1N.GKXN1T",("Z(J M#X>HV3(`P7935E$J@8!4NQBJJ?1R0)'F.JPZC0T:5HX7,50FAABNN6+QAA"F MEDNH^]/EZ$-_PYN69JC;/K6'FOXO"J3C(R6H?(`S`%,;8-EDHHM\B.0B",1S^8%0.7IX&`W)*;L/T]EH M_#@!HV_#SX/)XPC,!HL1"#[/P70"AH/Y9Z'85HCU&,-E'2D$Z/7&%EE$ MX8;VRG!F(G-PQK!C\H](UB*;.')/<,M^7@!;1THP=V=Z_5Z"J>@N)L&'M]5C M'J$HOC=+AJ/;"@,NC9MT3YQ_6B98$#,DARY:8]N`'_\-=RG3#>G/<9JH2.S8ACG3S MO.G6]WQ4#:.^7_;+RDO$EX,<3=@7,+74.!1$:%A'!&)!1*XP1.JR5$LUX^^@@ M!F`YHN+[!&O4(K=M>QK":3_TS1@>,+/%^U?CDL/CEZ@M-Z; M8QF'JT43;Z:B$-X[7DIKR+I/HH_/"FU&(@OGL3^XBN0"]N>([_.)W*O+=U?, M>?V@R.:'_/TRYW5&RH6.+IYE<)9`TW5G:_L><*$.S7?MU1)2`IU6`.PWTE1S MHY!!OS^V2-.B]7KQAW@.[\5R9ATZ5IL=6E.3].+7XU4W0V4V@]NP76K(Q,;J MCLT5$MM;U]G`_#'LZ",\XSJ2+_-0;JL=W@\0I!8]-%W5!)71!&[QG!(FL6A. M&BHBEB.7!#R8MF;K)AX31("11IX7+,#(>%-L:3E&/Y-"S$MJ^LUP`B=^-\9> M,HB(#A<4B2&F?K/5A-E.AMDB\2H5N5'NV-TE!$C3-GWX9+Y#8XR:*.,!#FH3JK% MOK*5WC!9@//=CHY]X"R$7LMQ+C>H!S=<9;GAE=4-$M"=%>R,6*?Z4C*>'UW' MJP!QD$P.+XT]ZZJLE+D(#5-->:1R6Z+#=IHHPUG(_@^JW.Z@P'FRW+^D`#M/`H8 M*<]TK%S`?_7@?C(C7;19;X$>-3T8@5 M`B?Y4T3)\`AMZ&H6OB_"6*,BS".KGMYA>&-21MP4I>)(>8$J[-=FT=N'0H'! M)2@QD?0B,3&LUFFH&C647((2$RF21\:`C%+'XADA;#F.\<.T,E\H_9DG+?_? MW;DU-XX;"_BOX.%4;4Z5=X]$72SE31YK=E7Q6(XESR:U#RF.1-D\D4D?4O*. M\^L/`8(D>`'8E$@T-'G(CFVRT=WLKW$'>)G@:.E/^$E9R9M(P7^*WDDS\^@= MZ+*#9RZ#V`=^N1UQO&X..'IW@F]^!Q;U8W"7R]O?%W=WJ)@68CO'HV@:)GA1 M1BAVC&_=<+.G"V#K#H!L)@,!89!BT,&42;]_G>>^;P71>*?!,Q_5@"N(Y_3/FJL-NS+?J MFBT&D%D=LD`J*WR#262Z&#++%C7?N^H-!.HJU``?RS7J3PJ<"6M=,WFX7)UK M8+:&]SU9P_ML$%>*P*LB2>8-3'86KV^15G31\)U\D8_D801B\AJ`8ZF73&"F ML&2"R!W:(IX6K(HO7,^,,8R0ZO"J@J/"!RA$C$<\&MD8K&L)B-4,,GT(YF" M)-:0\*>9CB11DB1:\OY:02#?91OK2@1E<=*)J5]CG!Y?_2WVM1L[\D`UP$Q= M"'E!3(VZOQ=>ZET=[(/#+@I5#_/*GM:>TDHJ0,C7B[]I)+01VC;L,PZ MP3*]-$M#K4Q>M2OP*(D(!T^(J-[03DNE&O!#*RPK1TPDS:2)C;9,M$XU42\_ MRB`L,R3WBR$4[Z"2U+3]5W6]#HY[ET29^A+W%JSLD"3">U(==C5H(._ M]DQH93[8[O;>J:UZL@,@U`]<%.&RD#$XP[#XBCEG MYP2!LZT=8SC;)L"JLE8^5XSX_:?EESE9S_Y!YO]XF-^OYN0O-_/[^>?%&G5_ M1@U!E=Q7.`,)_L"Q0^?6B?^[\&;\2,D'^X,>)RG_J#7OZ4T(:F6@MU1>:[MZ>;"SZUJW^IA#CG`7O&,-><,Q= M'];DJQ=?Q6:OH`\\[_?':O:H8/%N/(,JNG-L3NHZ9IX3-\!"MI;:/[PX`=FK M+49E41*VM2Q6^L2.]R_1!J6Q3-=2N`P`0E#91FB(7@RS5)V#'E16>LTF32ART)9<7P' MGSG5:_O>8?5NXHF*/J0M]0`>\TV04/,/]B=.+LCO112.OU)NOZU_3ROA-.XA33"#LWCG,OV_V1WH3<,W) M,J!7$3FKT@=\#LIH-)*A%LDEJ6"BVOJMG[:S;>:S\NO9_:^+F[LYF:U6\_7J MBGA=+22JW_S1LH5LUX9D7116$E%1I\HC4F<@I1)GOW(1%VB?:(`%F*;0T2P\4?VQ4;,LY?BNQ!%W,7FF1.UL2<6C2%`VW,83)QVMKHU&0W'12Z,.5F^ M%>,@%9IV*@#'P"N-1Z7CT?[S2]13#%Q[7]M[R3V+P86H`+@E,;!Z12@B.205 MA(S#R38Q%J@EKRI+M--0%5"5*)0,1^7@=S_X-YUA\S>.]+@]R<,8).0T@*\$ M[)6Z\510/+W,1"'#<+I9C`9FC.O1$\EDQFCGH3*P*H$H&X]!A+!<>>9M5X>H MEGKQ]]OH$\;G^D@^8>UK&BFITP6^UN^:3^(*$MEZ"U$F/X(+IV_=JJFLO[VF M18HKJ-@08W2SN%NO%?$5F][=DM5Y^^MMOR[O;^>/J)S+_^]-B_4^3N50-'S3R M&C*G\85>`"*3!W'8XZ5#:X%A9'B9,BX$O8([Q1BA2MO$KYNR.%@>3!(F1//- MB'YXO51\`96&IMEW>IV<2U!!A4EUS3GVQ:OIGQX?Y_=K(M0R?S6+$6#]4>4) M'&8V?(GN%]OU#HYG1S:KMUPJ7]'*C5P/<*]B-!DGY&S2Q>J"/-PMEJV9:&4F MTG6&M,/TQM?<;"-Q>__M55*!ZB.I/A#S+-6X!H.F^`[S8]07?8T^;3R4#IO= M@;RID2V`.M#XZPV2*S3XI?:)U&3FQY@)H+:-CFLL+H\Q]]7QMM0%%`?OP,^O MQJ2N0<"*\$$]A1%H*<;84&-T!?_ M%<&2C_2BK2@Q[7KU,9U[1F=,BP6#3WN>CO@>8?XZ=DR?;(0%-4);3%<%2RZF M2[9BQ/2]<_ADAR\/@?_N;IWMS<=3Z&P7WF>7MN2B1NILSH M(1OJK&/(3DDEN]1!=EH4)N/MP",FA19?,4?V&R7J_82#?J`J43]^!JIEILM4*'X M"0:H*7C!U*0_`B26M-3+:K9TX:SJ9HN;.LCH9DM#>`#9I(F++R^+G-9L:2K\ M8K)*X^G$21_2*8)G%U.;+5WZCY_M\'6^6IO?;#F1J_82C:G-EO3`MC:;+5"A M^`D&J"GX]D=K:@$22W8`XD4U6[IP5G6SQ4\=9'2SI2$\@&S2Q,67ET5.:[8T M%7XQ6:7Q&EMK,&DUNYC:;.G2?ZS9LGR8/\XNH-ER(E?M)1H3FBW9U=WR*!*> MT8M_5C!X.=9X,,XHYE?,40%H")YH@Y78L.],>4!#Y43EXW;'?$WNEJL5,OGE M`"\`7+`1A4.?ZO#F')S9<^"P^\!#Y6H$Q0LZ"95J`6ZE]@?)2&0JBV3"D%W[N:&!VB"IC;X<,6JGH.!SI,4O=X_.FQ\9*2;[L/(7=.(C MU:+!RGU^F6HLBRQW))-&$G%(]+1CGB68Y^](D)D79XJPKS<;SG84!NEJ!4C#2*S\ MJVTW(NIK1I'ESV-2T'2L\GK:F\IH0!^V;<>ZPDCL_!\/\_L5\CAL;;`I&4$? M+4TUJATSK7H2@X_FPW?#R6A<)`-]%/5<>ZR\/6YLSU_HR.I_(U=^)UHTSELD M&R/6#K9ZL%5F-0K,P;/MN?]A#=&H51KZ>W?+?IAYVX?HFR<=S>6.+YVU]ZOH M-_%XUZT;;O:TC>O4;3QNO1B=::1EW<%'(4^2N[-$#4A.!7:0@*@$[7RF:I!, M#Y(I8L`>:%27LC2X?G$B3Z(/EG6%7R[==.%LE%S%KO42I M"?@"R+&5M$SBRRYC@43;256U;+=GII6:B%!K_P+$[\ M9PK`[PN<5B&0"4*GX$2;8A#6O\T?^06/A@!0CB<)`P6[T3"@K=[`>:%G=+T[ M60_TLQ\X[K,7D[KY6`>V%])UT:R9R'[:QXW&[?\>PP-M&]X[A^5N;7]7??+V M"],-8NL6@%>0#8=3D>2<(N)@%.&ZD$09(FC#.HB"/B13B-T5%'47(YT0DP*N M?_GA6=QO!\%/=BH8OZKM#-E2JNKF:YB6ZQ+E'OR`:7TX!.ZW(UM]LO8?[+K& MP1E2#`%7!X[#7`V":RM(-X>42L6"R]DE<--)8M$9_C856?!"H>/T:?GEX7'^V_Q^M?@Z M1]^4T#)@+>:<,Z;8)4M0F4))*XHN]:*W]E5N;:A]7/=R4H4NT,6`?8M>6CC( M6-[Q'LLFD:=Y06AK-@GY*>V%)?*0=FVT:Z`P_OCH/,?[.1'W:D!A2A=?UCD" MK66QB)#SGMTHZ\3#0\I]3JHW=+<`JM4`[V6P>I9(328M&:K$W>O4EHG6J29J MK7W505BJ415^0>-(F%^##>U7OZ";HDHMP'W(T7@@0B3._1HQTG^^=4*K5;B% M!1T89;25>)&[`0V72`\_O_R,KRM5?4[Y2[JQD6H"#JY>M!"E>\T2,22C*I=&(LEAO?$-XN8]/85L]YCC+NMH:R5DT>4IL% M,^.S3ZB9H`AH3^SP\1!]J4.4'^B]Y.QJSYJ/ M#Q"`0&&]5N#0'/6'!1K7/N'222*>,/FL$DQ+0*OZNO!`O*C.?G/IL03L,(*M M>S@&;9^PT#SYM/VE61)ZX*RR\Y?>DF],ZW]']75U9R,XO%59">@YE.P4R7*" MJ,?"DF341UX&;/O:]JN]/SH/3K!ZB?K-LLB`O:PS*X$T`M\=.)KR2>I4;MP. MH"MBR#*(=XAN"1-.(NF$B4=*1^V;;N5-9VV#*_(6V?Y.9:*"V2AN960U9&-MI M*^W$@4T6DW+(*OUC"ER+,#PV`HN_@`Q5K`7\%MS!4`E4+,X/#&^=YH5,W)5UF+1SVI:<:1__JE M1__7OR+6Z"KZ1[GRN2*>[SG&092+03D]F<>0L'FSW2V?;H\Z?>"#!"!OZL6J M3AWPYOS1-,.,"DU6C;!Q'7..'VC;9$LTV82#)AL$9X$OD%]P>/,WCK,-/T>& M,OR7;^R>5M9JE`&'W7@Z24B+11(JDU=J7"I)Q6)AUJ:U MZ:4G[+ZRM\1L&O@D"M.(NU@J.WN;N<%_Z^XFMW_;=5?!4 M^Z9>KNK4@=_F.T[;R_)I4'K#()5,_J"R\5!KU6I+M/J*FVV+9E_5&:T1/FCD M%B`$>.1'F&__B>9W=^2^=^?%@]?YO?K*^)5?S;T="&P!, M2A`/_M[=?-2=;`U^W83$4=`)6HU%@3@!))%8N@''2W=B?ZX:S]??1C(H"5\0 MCU5^,HI-VJRX]5]MMWAD19,W32`R4P?D%6:C M-3Z.R.^SMW)Y].K7_3!!HS=IN.RWX[N?DOW45,F?38%AG]6=8.@!7%8\!<&AX_1YU&-(F5_U\A4 M6B@TC,;#`=^)SUY%'?(Y37D+HKRN."\%A1C->?O08E:Y15A\0G?<-MHL.^A- MDNX0__BH6W]/-4",7@/:2Q4!4HI@Y%V\CPZUP]V[_+J<1^?=\8X.F\CCEU:O M_>R&'6>[KKA(^DQA.LDX24/P@L?!A#><\N7$=[>SDO@\?W*]^=HG8FGD#U8> M%G7=.\>J<(Z?.6>7<\X![AQM1)^%2P[^TYV-DR?H7?910_C)K:? MG>7NL^T&;"G?PIM_WSAAN-Q]LH/@(WIT]DH/)Y0&V\D"M>:+4[4$M[H&5IHS M>%F$%D:RTMC]=U%Y?$?3PB-QD6P?-"^4Q*5B)0XM7HK'2C*W1(G#B1T1_6M' M'12OG(URRB9Q"_J6J//!R6>-LSR-DSE")_+72]3AO(URW-YG74[U"6WJ=[3R MKU`$O`!LV$MZA5P<&TD1!.(>S]:>D5;.2#IDLLT$XE((",(\:'4^06+I$+B; M`U]"K^Y[5CZKEYVR`N`3S::#<6"9) MA!)!*N%BL4!JU5Q^T%MFW%9NG#Z>H(&9APOD&!S26">5]EV?HP9HU'&]Y5NZ M^%^DW[KN/:V7S1D97@W?GL!V=3)Q%E#(O5^H%/B1B/+2"AA)?$ M#DHUGMT6W)(.-%*C=Y'1(3,Z8*(8T_8%,*U&`4ZZPJ&(_-D9GJG6^V#3G6ONWSX)-W9+<)K*CK1'FN[TVDA8]7%C.;,H\HF^!FBYL*` MTF,(&:/I_;11-R[?KL:_#>`L4^)D,E^3Q_G7^?W3?/57$Z):=7;7#&V3)L5%)RS-NK3(Y>+MPSS9)/%8",^95823& MO=1@E-C?O#C;X]Y9[MA%&\Y6N#>0K62K&])L($`G)V"MP"N;I@/>TDQDTV5= M7'KN%DPFWX#QSHY\8.5\X&<^F!MP(EOS<,Z1V33'( MCV93#*]^X9*,Y+II933H37O-`3>O;N[&+PSZDOF7P32PBF[F.%S*%U[4VH]* M^>#'NS9$N^9U%)[5.D%KJ.O1:%*&.)6=G%]L(+6YIC2@83%;S2;` M.;A`EH]NA+699>^A("A1!GYSZ-0JLU=Y/J<9S>(V["VUAAO:JY_#FE"M!E#E M*ESRDE%?NH%R_CWZ^IZ]3Y9\T/M>Z3%ZK%*/J_*;CU\=_SFPWU[$.4@I%L&DXW7\4QKZG:;N_?GG'N_B>YESC4C@W6%?'7JZ^3CX>9, MOM$\W50JI/6;#_Y'6/L%+@DERX'5@];Y_TG_Y5.PC)59T%` M#ZYB1]1$:J?/\'NU9W_:@?*4J/;DXZ2,\Y0&CRJ,KBM&,)E@PB03L7@BEL^2 MB?`@UX$P)8QI>VAT8[E%0@7__*W&C=\^<@^"W8B0H]H!59*U6OA2!N2Q;T4+ M"H<81%VXPF_H&3OA;'-PW]W#1\/1H0Z*Q,MVK=H!/BO#&E>UHE)]\N"6SM.@ M(T6E7S*U2**7@2-$R.XN-LK*7F6Y+RG)H.37"=V*?-C^-S(@19:2O'B7WSF) M\!3!!C7NZK4%C\1.DMT!H%9=_CY0T_-6UWXK9B=:E.U]_!3F_&1B=CH#K"9M M,J"_43)-W+M5WF^2?T8G_V+!X`-1>CU^<&?W!7E8"FHM'P\$D'_BYR5MJY:5-E M\$A5$2?SD0GPJ6YNK_GTE:\BXB>]51Z2\D?62,9?;ITKE4R8:$,`/-MJ2477 MQ&HL'E7!JP)2ZC,3B!0.1&*WJ$3J1OHUA;-."B*G-:J!NS/3B;0%*AXKQLM@ MX6L@OVUZHQKEJ]/=@04VD`$5XQ"_XN"^I\K,O.T7._BW0U55WQBB>$$KQ#(M MH)7-9#Q.>66RV$1F*@WWHI"6S+.RLV+H@O/71!8N6W4!E\=(Z0@48BIG!&0? MLOIAG:14:@`.H^%U0HEDZ@P)D/.MBN&@$SE\V=&F:ZL`9^&U\;6L[&0_T:3H MAQ#W>"4E.#GJY5XPAWAA799L61:]]_GPL?#"0W!DJ_U^L7V^-SA9S_8 M.>Z!;H!_<`+7WS8*BVXT0,]-G9@%7YV3KAL`K`!5+P"-M22"FH3I2:BBZ6*# M5%5ZWV"L;+O99QI_",]YIC>;-,\^!GR/8?I!PJO,8>8ELTYS0GV&[.Y+_5AI M]]=(Q"%$R[F%XG^(A)NW"4SW<-#3FVUC/;M*M>JE&A_Y;'>S@<'D>'-5Z M\,9Y=CVOQHF77XM)$JV>:JSJ"_Y8]=A79AY:)Z%0_`]1B^5M`B^='@Z'>BNQ M6,\?>3SFG"^1J\)B03]F@JW.`'KR:\4'NJCT6KM`Y'S!EY`2&R^<&`^GD[:2 MG0&K2_3Z+1O!J#ERH.;$`5.6H;0&7RLYRX#%*J>JSI/J_/N;&[!W.AO\591T M"?E*KCYX`^FX7[-B`)[`DO:8H,X%-\K:\BUK?W%A5V1Y/(0'FXT97,6.NM#F M6#VCK62QFJ]PB6F-3]D=HX#O.*U5E71!::U"??C:]+[5=EH3U+G\M':V;Q5I M[;)G_.LI;3.QR;[#)2:V_%S9KX$?MMZ=5)1T08FM0GWP%5.CWKCMQ%:<9"=, MHPOK@K;D6DN>UBYYCKV>T#:3FNPC7&)2$T*@FQER:3D7E-!*RD.9F_2MZ[;3 MF:#,YM6W'12.ZB'V->NBZ-M9GWJS_%A6?]1W^_CUKI](_= M1[!8V&7F?\$"\&2`E5[UW$DE\`?5B7"E+FUJI3T/MS/=8*2O0 M[RA=%K^ID3E3>IYU?*AUI-_,VSY$D7AOOSKJ`]^Z*,JD?'F"_N!FRV@R@F?+ MFD/OX_^G^K#]U%0C0E7"/JT.V[\L5_+51WR6V82#[CHDM%%B.]7]:&DM?+#= M;91@U_;WW]W#RXN_IUDW^D6UJ:JP;"I*=UIJJ!^X"3'MB3,J(:'%T`J?1`41 MH23V.UEJ0DPG7?J%I0NZ!HS:[^](D)T/'_*5=W_2,IU]O/CY3\%=_K>]^QQ/ M;:+GEA,Q*>6.4WR-DAO<9\_=N1L[2E^;C7_TZ`=\\/?NQG7"VO,$82_KY!^D M$7B>KS=)NF697)())HED$PX6;-_RTD5<:B>@LMLHC'.TPOW6C$]Z8"&E;M@; M<.;H;\3R/E&[O$.ZJB.Y1[3PA<&OMFU[W!^%^# M(FJ;G%CB>E&]$@O^I1/*JE)+-Z:6LDI>+)V*3`3KS2?=F&O!ORQ&&FE*)DT@ MC1R%4K5'Y,:#,/QXV.0@_]EW5[HL0?F.SHI[L!@!4>AX#GJ(2\.,5IM=%?[/#E\][_,ZR[RD'U"@8Q%7J`-QM> MC\9%:)8[0N41)A#_8H>VK+3R5OH-K-3.DB(8*W&2^0:9J,^N9WL;U]X_^*'+ M!J/!9,E?Q2%,J@]\6\ET4$%:*I)>PC78ESB(^YM_TPF;*#CB"7!I<)0>U`IJL71H]`W'DY3% M3`8_:J0;SNCASFK.SC)FG)T@'0J2?B*.U"9]X,BB*<]&I?UFA']M929]`16' MINVK47\REF)A0$W4BGUQI;->?OK;;\N[V_GCZB&<.6ZDCWHT^_^X$&S=TI!L=F@O236PC[:"MK-YX/!'0 M38ZQC$M)-LWR97'Q$]E1*+PHM',".G:*\G03A>U:T3XI]DN,-_- MKN"-A/T5%=!F\9JCLH%W,%! M_:,8W=&O6+%1+;CZ>/WF%S]'^>\:XKE4*/3C]Z=)KXR_3N+W]8;P>>I;,/6[ MCEMI8-"`K;80(RL_O7T.?.^0[%K*-C4IDW3=6QIS=HTJX$7NEL4[-4]OA$G, M]@8*>X%Q MPA\TD)*5!LZCHSYOSSR1E=Y0/U'9.)H]=A,AFUM4-[^Z#M_REZ<16K`-)=V' MSG(W#P_N*_61+,WD']*9S',E@_/99,3W@$?OTY4$J02D-'VZ%59BA5]CA;8$ M7!DPN7Q;MA8CLG]WW.>7"/_9NQ/8STY\XLYR=^ONC]%OX[$I84!.\NF:2M'( M1D/5P"O))CT.3U(`X27PX\(H4+R09%17*`:'L"Y]P1"\7=P]K>>WF.2=&-`B MFJ>XR2!V2PK6#-G'_*[E;KE;D8?Y(V!.HP[VG!CX`&UL550)``/H9&M3Z&1K4W5X"P`!!"4.```$.0$``.U= M66_C.I9^;Z#_@R<-#&:`226U])VNPJUN9"T$DZH$CNO>GGDI*!+ML$LFW:24 MQ/WKAY1D2[+$38LITW[IOA5S.><3E[/SU[^]SL/1,R`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`2CY0V:8C)/J#X:\7&_CV]*Y&/BL5%`LGJB;"V>$8G MTK%.VE(Z9CU_/+#E#O@<=]-KB-CW@5YXCRGD4UR$'J5P"D%@2KCFJ-MDX=XC MP/@#&`P=/8$(^E[8/5,W[$B;@Q:D9P-T3M@=XYGPLX6`)X`H?`:M214.V3GQ M%QY]N@[Q"[U!`23`CUI071VK-;F7D/HA_S-XB.=SCRSOI@]PAMAZ\ST4G?D^ MNT$B=L_=XQ#Z$-"S($A6I1>V.6\ZF73KO-^@9_89,&'_V3?'Q:FVSN>ZU0V_ M$F;P,01GE(*H=Z[%$W>)083]GT\X#)C4=/7/F-UV7:]IS0EZY6D-92:3T:3) MW8+/?.9'$FUZ9)%K?FVPS$3.2,"_0@$2:.S%X\$O;(LG;!#GMF&(3$(KEX7 M[,IBNX5)JD$<@KOIQ@_-F=2>H4.NTHN7*4>=7R[*D3ODXCRF$`%*'\",W]6% M63IFRG2BK?"8'^^5G_K@5#;=5O@M:O!WTPF.O'`,V(T=LY6&@EN,9K=,I`S2 MR^M\^07@&?$63]`_8]IW'XBT(Z@;H?<;C@"=X+4"LQ90C^*Z'N`B/* MKOL@7;(H*%->TSEG?P)>H_.0G;"F"&Z1LKZAE,I//0"D.=\PV%[]8=OLK^<= M!@P3CPG.6P(PR9'`3ZO3B:$C!08+I>+^W(Z!NDM6+0ZQ*1SM(WBTP-G\,H_18H8*(- M/[,!\OO>%X;S]GY@II+R&"PPX93T>T]H3#8`ACN_&[2GS)A?%`1K[OXLH<"Z M`!1P5U#Z5SYY%VZL9&HV.2.G-%_(/7V8E&'/IDO<>13X;V;X^20`$3[/OE_ M)$[0X].WF3/O3^Q//\[8U`&?_CKT9JOA0N\1A)^/JK^?]$[/14RXN^B:?0TO M_%_@D2L47+)O5D.:L*D9E=7%RO_R8_59SFH^R]DCC8C'G2(EHO3[]8_CBHP4 MG7M`(`ZNV=]H#9#BMMNFDW]%/2KSEMNC,45&O"#KVVV/O@D;5D)6\G/_U*2K M_H)-2+A-+P"O_P.6-635M]L:?>S&QRA1$!Z>/':TW\41C\#@T3%B8F6=MD7Y M-0P!N6`K:X:)&-=RJVW1-@8SR(\X%'WSYG5KL;99_]1-B,>_T<-R_HC#&K+* MOZ_I*5[Y9Z1,FT?\U4#L/ROW?3FF)FMQLDAB(8[])QBN184IP7.3NV-%!:[9 MW2-,F*Z;!'N]/3T]&C$&IH#=DL%MRJN0P(2ZB*G)(&G)>T),&`6?C]X=C6+* MF,.+U$R_6_!LR#M;Y'\ MUY--&V6_EDO-./;&VMW4HX$'C$]GGG>(E7Q0!C1U5\V=;WLSS\V'#G9OM]0 M_!2-FVNE[>D>`Q_`9T[--Q#I45_;Q1(/&RXS)0."]I:HC^=QR!9V((JVO\64 M,HSOIA/O5A_+LA8FK.;KP"%DR*>$W M+XPWS:5F?:UP)?::BWB1]+#%079F23_!9C,;M%YF#E"\;!"PPWG2"5GVW0MID_Q3[[U:L?QER/ M4M"MU=4.3VE*W))1)*2]T,0&C875R4[E:M"D@&YEMR'RHA`9M+M;YDU^@`Y$ MEZJ2H8_^$*2V1'73$8MK&EJF5WDYU;>U1K7)O2KI8(/^^Y5!3RE&UK6T1/&" M:>Y96B0[Y[07NDY/.QSA!2#1\C[T4@,N.ZP77,T0W[K2+C9X&(/(@P@$5QY! M3&JA!1L2DR2A#T6<:'2TP8_,.JRX![2ZVN%)4S8:B#1D+/_H2#Q;=,S(;6C< M"Z.P"ZV=+^_<\JCK`R,_&G-\&KC2GP%YQ+N/D)[:F2/EEC-='ZPW->[=`Z36Q&\ MQC"5+8LY+&X%[!K#HJ7XJ1W7N2;GIKK2!CUI>$L. MG)O2>AO@9*USW-P4WSNZ'@1^^!R])E+^3EVN!HKB9I2WJTFPS5`2Q8VYF@K; M>"V)HM9=S85M!I0^6,6<5'H,@H,;2F-]ZK/6@Z!< M7'-/JXO]:&_#3:'9V3Y?FEM#T6DH?$@WB*2#TU'3.V0>,+QK73?_-H51]^AR MW3#<#7[5(])U.W&7N*V.9%>K)[;%3$OP=M_2UQH\V2YUU?S7$6C5+>JJ]:\C MP.JKOO5N]+-HH,E>G[:B2E(V/\](H0\X%"N_Y58V!/J5G7-U;"N$>&'S(=!^ M[E'H:Q*>MAT"U9"%_=RJ80Y04O8W@,\B"V04@ZFN/0<[U>(DJ/X M!K$#&E">35D>);7.?P5,V@AX>@9-HP<%"&R3`GL(KZ\+Q<$G:FV/6K!]DBX?(,R"*_!.1+N]C@X1N(\D4M(+K]ZT+T.0KF;KETH_?!W4E-71Q,1JF)`=S/N MN4=(Q;ZV[<5&6XSR%54YL!/W6R%#\12OK,IV+50<"CT<5*YK+)8^ MB=89V$X7&K[TW_``T#&_NY]ZW!2QSA:\ZY%('6`ME=+;!2GM2.DJ_MC/=8A? MZ`W3%`E@,-FH4;6^U^@$CX&/D0^3QW3RE3_!G-)[@I\AX_E\^9V"X`:M;9MG M[+9\3NMRRJ617J:R4J-([[&F>E53JZ^37/UX-R"^[@$[&7CD`P$>!9<@_7\C M]@1#V.#Q$K#SRH?):<7^.P29`'LVY[?5OY*_"WC3ZFHE17DAX-*2]MTQNT\3*`F`=%OV%Q MD]>Z,F:HT'4P/&W4VS?A:;/K,'C:>&E!FZ'-?L/@9O6^H,FG*?89!A=K^3(K M;*W.0M<=8!C\W:?/':Z64.VSA]J\:@UFR6E2ISQD]7J*RD-=G*S8R])FT-W# M0;'V.QI\0+BD(%28WQHOSYT!]T]')JM#]/!#TYY M86UC;YE8V*XQ&8-%3)CB2\'=M/161RWI&AUM\C/!9SY3U@E@2X>MAVAY'WJ( M)Z]P%3Z);%;PI3&`G5K4V`<@2#)O$I3O$OLTO7H%Q(=44I):U<^*VSK+Q@:) M-X`)AC++DZ"Q97?[VBJO[UNO=K'"0[Q8A`E%7KBBZ`9-,9E[.H7!-7M;?6ZZ M1U]%*3Y9L(I=C[_=%KYZUFK7_=7;0EN=J^BHD]K*-V@/$G$[!;#BV'`]&;>'%5CQ=KF> MI-NMK;K\H(A2KVZ5F+,3M1IZA%?#S-2LF-8N74+]X=O6F=6N6-?PPZ.[=6+4 MK6P=@V.S,%4'5G@'.+=UQ[7+5=W9%=[0#:-5EL?-^A;]`=F/!H(5V/1Q?6*1AWA:JSTM*N$ MY!ZN9OD..7IN>L=,T3/+\LG1<[.4:3?H57*_P$6!6 MC7_X"GCQ,SGUU>:6:(_G<<@-KCK11Z9!IIT-;QD;TTHYAD6\^IC)"F)L4P:\ MX!\C^P'X,4G4'2:XAS$[T])2_/-%G)Y]3*+?K/8]YQM#A%$G8]M`Y3QFEQNC M17HJ;#2R0R>%"%":^'>R-]Q35P^XQ',/BN*5U?V&PLTK%"4HB%I;*%X!P!.KW9GV;3F:^8L)Z MM/P=!JLB_5^]?V"R.@0FK"]]PF&0WR5UI)D/8N-K7T,$(W#+M)+@AE&!9I!I M].D)<;Y,*0X])EB*MZ;)"`/C,*?NFS>7;U?346QPRA_=>(%A*&!A_;--VM9W M46[O4Y!;U\,F!S?S!:.(']22C'%!8QMT?_5>X3R>2^6;%2C!%>+@:Q59Z^<83+<93TL)=<'L1\5[/ZW$(&;",Q%VU'6 MPQ(']99BI4ZNTW-0'"D%89V>@^+H.P73.+R%4]'-I=/3!D=CKF%(UE;^NS7J MI.=0L845"L&".WO0[#N3!7.Y_6ZZ%E%NT-6K#RCE7O(T2D#J%&@QH!W^$SV& MAT2S2XZ?HMF3;U%,$.4/4Y)G<(U)\:]"SAL,9:7\AO\$@CCDII/*'3*1U.-4 M]^M$?I&(&_F3:E5I1:>;#;2_+ZX)1E&6K%.PB4C/!54OJ^4@E-$!I;`9]6K+ M(T#**TH#3]16EZY`LY0`)@V)X=5544L8:7RV+F><:#O-"M7X])Q3;F^UDP<=$7TE(*H MZ^E##?Q"1?R,G2ZN+\2&7JC*,V8BPZWK)64T;+ZY0F`62.'Z>X^:T!G9/5VO MF6F(67=QZ*Z7QS0$5NHV=KW294.L-AW4[5Y==`ZF-E;\=M5IG(,R#SAI573- M/6":>4J:559S%D11(&*[(FC.P-0F?L7UXE"&*TV>6.!ZY2:3]=8@,M;UDDPF M\&FY:]M54G(&,.'FS#-FFI5I=Q:ICO)7FU5O=Q?5/O*HFU5RWRF,=0,3L6=,(('5,T0JW=P?<=,2AHA2U M@N[]`3KYDJM"]N$`F5[,1C7D8P7AGP\0:@==E9'[Y8`#.& M9V,9N![=9HS/QF'O>I":,3X;M9G[KCX_=!EEW6I3C[`AL:R@RL@E'!.55^9KV6L08##8Q?]VM2?2'BJD+*;@/CI>)7U>?GUFI]EOVI M&2:F45GF1*NKS4I=9ZB">WZ3*10LLS'LZ#!ELI@,DH9ZL(M840E.JZLEGD`8 M`C^*O7!E_)9>U9(.AUIKMFJM=4/E-\QC:Q8@`FU>I:C0T=PMGA6Y7P_(^@13-Z/7ND=OI3FZGA[3`W)"*TJS/)F/*98(S/B(;J*I MIWVT2YT9_H.<'51UD)HG73>T=X"?3&5T/4&\`_C$6HKK:>,=@%<5@UU/$.\` M-)E>[WH:>2/+9'V!4+5BZ;H"'(W^:)@.XVBLA[DIJG5,\!YD MAS3!=;=[%Q4<8?\GKZG`R.7Y']%R."^?KQ.;::*],BT"3[S7WV'T MQ`F&:,9+W/#4\G./ELOQ"0S&;4:T\F+TBT<"Q8LMY38V7_1C2%Z]46(M@KIBH]?BT6C@0>(A7'OY;8L"GC:K#-+K92IKF-%[ M#P9,1FHGAC4:RNHK.W5R6,ENULN"`MX+L$9&%=?C.'H\ M"XPE6M>#/OK!NI4MU_50D3[5T7+9^%J3E.M!)=N"5V(EWE[@R9`\2>L\;8Z[ MAY:T@,R9'\%GUL:&8ZGQ$;>^>1=P75C['K!/(C)-]S'3(`UF"C[8X3X%,&*K MI&_$ZF;:1<2^L(;1F@59UG8?,^TB8G=Q1",/<5DB?;:B)[RJ\QS0,ICGQ[M= MQVN,PY`=,_S'_D$K3F8%-WYEWU`:@^`R)KP(2W),I+J3B9>VP4"#%AI;K9=. MS('BG=S*FK5(OTODD6C'Y?K!?*+:R_Q@%^OL\S0XHYJ9S'8I]6YWMD>M/M7, MSG;X0'U\H%KUK9E5[O"!MB(#,"F[G5TOE0*ND/8G&J3A:=B44 ML_%Z3&F_08SV.#&M)F]:39X\5#Y*>.1]/W:@!A2XA7!9V-PZO!O3NX7M-XR> MV9$"@GYL)L;S']#MWRO?#6F,3\LTKT773 MBTVL-P\9]PTM-M&N$:?=-YP,Z/0NZ]D-PI-V2,\^\WT2@R`+1Z1YC/3&#U9R MA5,2;J'W",/D7>KTI621CBUN;R7/5T2-PE*@[F>1FWN"IX#29.U>`\T/(NID MD8\Q7GJA]HJJM+:9KYR%6FKO"G4_&]PD1[#I!E=TLII-IKO;ZX(+)9_4]<([ MC7`3;F+7=8`V:`F/;M<3#1J!ICJ?7,\8:+/2Y'@U"???C8>N;GB10C#Q7@$= M3+V=[`-<`P:_%^:)1^<`@2D47;2J7C8DAHRF!_8%>>C^+9O)E!]%7YMU=IC. M#^`,K9>0%EN:G>V\RI+1HOUZCJR'W8?]E)S4Y?BI/JCK@ITA;,ISRG71KAE> MJM-P>[*=O6OW/*80,A(Y\%5K:YF//%ORBG]PV?[5B M(%P`'CZ,9NG%>"O.E:MK:>?Q-GX$96FQBG?;JBWM4)PXR>@$G_G_C"$!J\
%YTQ-8<]YPMYF*#K,$`=LHU/@,4`^&+=*N?+1=EW+B8"D?J^3+[4;/\HO9( M%H4(>66]4ALG1!V+M!>^_ZVJZ*-.5SNYBDS#2;S[99E$]I2WO,]`:I"9[OIR MI.YO*+3S6BC?,E9D2H5(1GUY\@,E&=&VU-Y^MX M&ES,Y>).*P'6=7-Q4X1JU437;<5-P=*S2K@>#]`4/1-MV?7P@*88KNQUSE?_ MT]%::D31[5<)'Z*1^;XP]]UTPJ,_5C=AXNM"L^2=I]6;8E\`GA%O\03],P*\ MYF9H"OPW,_Q\XN,81629ZJC9/S;5T^S//R[.-G30P@]6HD1C?BC)'[(I-NG$ MD)P$2V4.[XN$?Y@_;UJU+,N:6WJCIOX<_P:$AD]9%SNF3A\C'X8PVS39?DGJ M"V='SP1?8$1Q"(.D5*O$HMAPL(.)M]8U(#DB]@+PGEB(Y-&H9?D],0GI;BJM\^V;? MD5G\FQ[V^V;TUQ1"5?;_!@:SW7C+J#U<>7^E2A6HD:OJ3CQW;8_?<`38 M670-D<>6E!>N$:-W9.:AS`.2'U6I=Z1LC:SIG)LT)XRXWNM*`J(.5B,^NOT$]UYU/8SE-4_'-2\[2SA%V-QA>?%8\,`D93MF) MR>Z8"OR'$Z"-,4L/68%E2Z_S[NQ6730.>U"$S>H/A[UH3O^Y1R%-RD`5J5JF M_ZO:BYJ=K:21XSE;KD\`4?B<9>R;<*;=W8KSUR.(@4WO0?KLHAY+JEXV.+GV M(/G-"V-0$$4*!=Q2$@7\Z/6UPE5F7DMR=QG$Q$.4[6]V:O*XAN2?8?ID@MZ7 M:SZ>#>Z_8!R\P#!DI-VPRP+-X&,(TAB.U4_2[ZK?WT[!@S));.G!""1Q*E*N MU/WLBL+D-VK]Z_\#D(J81.YL)-3G<=7H.*D!%CRWM[A8#.+B9 MCXET:61J*K]FO\@C.R3]AL&-WB=2]QL&-P]>".@81#%!BI`;42<;?'RG3!:X MHA&<,_U!1/=&H]W1$W4E==?=P&:H;:X)USW!9NAHRM^N^X7-0!,+3:Z[B\UP MTA=G7$\3,%U?2A7#=1^G&6`&&J?K*9QFP&F(L3E@?SD`II24<[0^'M#2T?G6 M@+UU,SC(##`MDT8.V4&^U["%YW`=!/Y6IND MV7!`AWCE;6[>=B!1L#OS&KF]M^1H\&IPE5>\!B+:-255JKD; MCV:I4'MRO:^(]$*574+6P^86U^!DXT6Y9I]\'V7%AF#9DQQ[6M96Y*$JU(9R MCW*`'=JV)K#LXTZM>>S+ZLW:TVM]=CE0!ZU+NNS04W!RUO=Q>S&-8`ZC]$Y$ M3#](3,``^<,19;4H5&Q!LS$LY=J9?(<6;`YCXS;ZJAO.8R/`]G%S;]:)&>ZX_:-O[2KKL=FH'8_7%CV?WPZPGGEKM4 MV#_^'U!+`P04````"`"F.*A$7[Y6QAH)```\4```$0`<`&]S=7(M,C`Q-#`S M,S$N>'-D550)``/H9&M3Z&1K4W5X"P`!!"4.```$.0$``.U<76_;-A>^'[#_ MP/EBZX#)LN,F6XRD0SZ:PD#:!(ZW%;LI:.G8YBJ1&DDY\?OK7U(?-FW)C&0[ M78?I)K'$\YQSR.>1^"&)9[\^A0&:`Q>$T?-6M]UI(:`>\PF=GK=^>W`N'JX& M@]:O;[[]YNP[QT'#(;IFE$(0P`)]]"``CB6@$7YBE(4+].#-(,0_H3$6X"-& MT M,NKWV&LS/G55B*[[\?UMVBBM;[]!J6W_:=QTE%Q&( M4EA24HYC(N9KJ3&.U2E(U*!I[/36[*EB)P[+Z^]+[NI0KC)RE!5PXIG0YW$% MC+;QY1)F-O6QFQ8:UIX2IN2+=7,!7GO*YFY66-X,7LRYNMJV0;-2C3TJ8'T@ MY3!54!X-GKQ9.427E&,(G8.0Y:BTK!PG9,3+4;I$8[H&1F(^!?D!AR`B[$$U M9:A[3PA4WC`>7L,$QX%*\^\8!V1"P&\A+"4GXUC"FD%,5R9OM)Z&I#]YIYL4X34_\ME40N M!LHU#Y.`+43\\Y;58IE$GH8/$T))DFZWTT4.RN'F3^4*I;Z0X>S,W?2PZ3Q6 M-^T[^B;Y[>'`BX,$>*N.,W!F80-&7-TFJ=P!N5+:)F.XF M-X2J.R_!P3T322I7`18BTY2F:Z@`GRH"[.SU%&5+1TCW3U2P@.B^S$>7.-`] M`'J8`4C14+E2K8,UU5X6:.Z5DKH?+'&9`!9F#C:RMUG;Z3JK3 MM^8Q0#ZA,.GBSGKVAF)^[G&L0IURCQW1"VC;`/3((8 ML65OM6K!.S[%E/POJY2Y1ZF`T@WRFWFBFOF8>R)2J(8Z'J;SPDJDJH=-[1:)'%**6$BJZ MLO-[NLGO0QR&F"_TW<$(@%814!ZBH7\'^J6B9,8"'[AX^W>LYHO:=M=[075O M5A%T.P41&(Y_0*GKAN[Z=&=7C;C'"SP.0-VBU1D>@W]+\)@$*EG8N2/8U;== M"MU-*61.T=NG2(WOFJM^%QFDX^T1?MJ5:ZL#.Z%'FX2FOO0#A(;,7O7FUQ?QH)0$`)EOIO5Z"\Q7,]/''#8OG1I%\#Q[L-W]"K_U:R'OI@R M1GIH=DA=9`[MJCC91Q5IA$83+SF[JR.+FC[MROBYRDROT<"7G_+54,1^$>SZ M*"SW;4[_&FV\[,"QSIVALC<[YX4E0-L@LN'_^1=0EFV9=;MW$VO??N'[29HX M*+ZI;*YGG:*WFQ MJZ"P!+E%!<8UGP7[0:2V*(V'\H"-,@ZCC"$(R8DGP4^,+AXQ]W>0AM6-71O% MUOF$N.)\\EE[.[>%=43SJ7+3YQ^"T7P5)EN$,9JQ$L%UX7:^ M"^N"UC6BAO\7Y7\UM2L455>!S8E="_76"]>GAF4+BHTF#J")]5=_1TSB8`AS MH#'H5TIN&9W>DCGXZ1S[3O*JBT[(23+*5Q?&"[1*"NFL_DL"U'_T1\M#F*#D>^2^_A[WO"5(&`70 MRLYA[FF\_4MF-^(L`JX?-KFYV]Q!`;W^Z70BZHWVR[+*/`QQ!4 MK+*R+:GRK?;P+ZGMYF5>H=(*4E+IM=M<2=W/7//S:76T_GGUF:HZXQ+1TF^] MM^R"@-*-%FZ9ESBR0/21D^,Q"CS]3EY;G=+*SIE.'R@_T2*=D;HUHF)G!YY*S< MU,]E8\.-2FGD&/UCKX;8W+JC4O0E*/FU5_SB)B"5,C!@V>^]LMC<5*12#DM0 M\LM9P48GS]S`"H2"NQM857"C'_!47[1;1W#FIEVK^OE_4$L!`AX#%`````@`ICBH1!Z.@FT%`!$`&````````0```*2!`````&]S=7(M,C`Q-#`S,S$N>&UL550% M``/H9&M3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`ICBH1+I2S.[E#``` M$:X``!4`&````````0```*2!P8$``&]S=7(M,C`Q-#`S,S%?8V%L+GAM;%54 M!0`#Z&1K4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*8XJ$3,Q'IHZ`\` M`/O?```5`!@```````$```"D@?6.``!O`L``00E#@``!#D!``!02P$"'@,4````"`"F.*A$.T"X!+`] M``"G3`,`%0`8```````!````I($LGP``;W-U&UL M550%``/H9&M3=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`ICBH1+JR\FFJ M'P``#SX"`!4`&````````0```*2!*]T``&]S=7(M,C`Q-#`S,S%?<')E+GAM M;%54!0`#Z&1K4W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*8XJ$1?OE;& M&@D``#Q0```1`!@```````$```"D@23]``!O XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

Accrued Liabilities Current [Abstract]

Payroll and related benefits $ 2,763 $ 5,827

Royalties 4,813 4,374

Professional fees 733 749

Other 1,593 2,082

Accrued Expenses, Total $ 9,902 $ 13,032

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

+ Details

Name: us-gaap_AccruedRoyaltiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 16 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity
3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Stockholders' Equity

3. Stockholders’ Equity

Stock-Based Awards

We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended and restated (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. To satisfy the exercise of options or to issue new restricted stock, we normally issue new shares rather than purchase shares on the open market.

Total compensation cost related to stock options for the three months ended March 31, 2014 and 2013 was $719 and $662, respectively. Net cash proceeds from the exercise of stock options were $93 and $301 for the three months ended March 31, 2014 and 2013, respectively. As a result of the Company’s net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.

The following table summarizes the stock option activity for the three months ended March 31, 2014:

 Options

Outstanding on January 1, 2014
 5,271

Granted
 1,168

Exercised
 (22 )

Expired
 (319 )

Forfeited
 (70 )



Outstanding on March 31, 2014
 6,028



Compensation cost of $687 and $732 related to restricted shares was recognized during the three months ended March 31, 2014 and 2013, respectively. In connection with the vesting of restricted shares, during the three months ended March 31, 2014 and 2013, 89 and 106 shares, respectively, with aggregate values of $521 and $743, respectively, were withheld and retired in satisfaction of minimum tax withholding obligations.

The following table summarizes restricted stock award activity for the three months ended March 31, 2014:

 Shares

Issued and unvested, January 1, 2014
 653

Granted
 403

Vested
 (276 )

Forfeited
 (16 )



Issued and unvested, March 31, 2014
 764



X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 17 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P960X.60V,E\Y,V1C7S0Y965?8C)C95]A-39F M-#9C-&(V-#DB#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I7 M;W)K#I7;W)K#I%>&-E;%=O'!E;G-E#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/DEN8V]M95]487AE#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]# M;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I% M>&-E;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-U;6UA#I7;W)K#I%>&-E;%=O5]486)L97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/D)U#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/E-U;6UA#I7;W)K#I%>&-E;%=O5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-3PO>#I. M86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R5]O9CPO M>#I.86UE/@T*("`@(#QX.E=O5]O9C$\+W@Z3F%M93X-"B`@("`\>#I7;W)K M#I7;W)K#I7 M;W)K#I7;W)K#I7;W)K#I7;W)K#I3='EL M97-H965T($A2968],T0B5V]R:W-H965T3X- M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P960X.60V,E\Y,V1C7S0Y M965?8C)C95]A-39F-#9C-&(V-#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z M+R\O0SHO,&5D.#ED-C)?.3-D8U\T.65E7V(R8V5?834V9C0V8S1B-C0Y+U=O M'0O:'1M M;#L@8VAA2`P-2P@,C`Q M-#QB2!296=I"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA M'0^)SQS<&%N/CPO'0^)RTM,3(M M,S$\2!#;VUM M;VX@4W1O8VLL(%-H87)E'0^)SQS<&%N/CPO'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO'!E;G-E M&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XV.#QS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P960X M.60V,E\Y,V1C7S0Y965?8C)C95]A-39F-#9C-&(V-#D-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,&5D.#ED-C)?.3-D8U\T.65E7V(R8V5?834V M9C0V8S1B-C0Y+U=O'0O:'1M;#L@8VAA'0^)SQS M<&%N/CPO'0^)SQS M<&%N/CPO'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^ M)SQS<&%N/CPO&5S/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ,S$\'0^)SQS<&%N/CPO'!E;G-E'!E;G-E'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&5R8VES92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XY,SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P960X.60V,E\Y M,V1C7S0Y965?8C)C95]A-39F-#9C-&(V-#D-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,&5D.#ED-C)?.3-D8U\T.65E7V(R8V5?834V9C0V8S1B M-C0Y+U=O'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]2 M1$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP M861D:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@ M/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXQ M+CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQB M/E1H92!#;VUP86YY/"]B/CPO=&0^#0H@/"]T&)R;"QB;V1Y("TM/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`V<'0G/@T*(%=E(&1E=F5L;W`L(&UA;G5F M86-T=7)E+"!M87)K970@86YD('-E;&P@;W)A;"!F;'5I9"!D:6%G;F]S=&EC M#0H@<')O9'5C=',@86YD('-P96-I;65N(&-O;&QE8W1I;VX@9&5V:6-E7,@86YD(&]T:&5R(#QI/FEN('9I=')O/"]I M/B!D:6%G;F]S=&EC('1E7!E#(P,40[*2!M87)K M970N(%=E#0H@86QS;R!M86YU9F%C='5R92!A;F0@F5D#0H@;65D:6-I;F4L M(&%N9"!A;FEM86P@9V5N971I8W,@;6%R:V5T#(P,3D[(&]F9FEC97,L(&%N9"!C;VUM97)C M:6%L(&%N9`T*(&EN9'5S=')I86P@96YT:71I97,N($]U7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^ M)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C M;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T M:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D('9A;&EG;CTS1'1O M<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXR+CPO8CX\+W1D/@T*(#QT M9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQB/E-U;6UA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`V<'0G/@T*(#QI/CQU/E!R:6YC:7!L97,@;V8@ M0V]N2UO=VYE9"!S=6)S:61I87)Y+"!$3D$@1V5N;W1E:RP@26YC+@T*("@F M(W@R,#%#.T1.04#(P,40[#0H@)B-X M,C`Q0SMU6EN M9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E;65N=',@87)E('5N875D M:71E9`T*(&%N9"P@:6X@=&AE(&]P:6YI;VX@;V8@;6%N86=E;65N="P@:6YC M;'5D92!A;&P@861J=7-T;65N=',-"B`H8V]N65A$$P.S,Q+"`R,#$S+B!297-U;'1S M(&]F(&]P97)A=&EO;G,@9F]R#0H@=&AE('1H$$P.S,Q+"`R,#$T(&%R92!N;W0@;F5C97-S87)I;'D-"B!I;F1I M8V%T:79E(&]F('1H92!R97-U;'1S(&]F(&]P97)A=&EO;G,@97AP96-T960@ M9F]R('1H92!F=6QL#0H@>65AF5D(&EN(&EM<&%I'!E2!F6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y&86ER(%9A;'5E(&]F($9I;F%N M8VEA;"!);G-T6EN9R!V86QU97,@;V8@8V%S:"P@86-C;W5N M=',-"B!R96-E:79A8FQE+"!A8V-O=6YT&EM871E('1H96ER#0H@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G M/@T*($9A:7(@=F%L=64@;65A3L@86YD/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@-"4[ M($U!4D=)3BU43U`Z(#9P="<^#0H@3&5V96P@,SH@4')I8V5S(&]R('9A;'5A M=&EO;B!T96-H;FEQ=65S('1H870@0T*(&-O;7!E;G-A=&5D(&5M<&QO>65E2!T:&4@<&%R=&EC:7!A;G0@86YD(&%L;"!E87)N:6YG2!S=&]C:RX@5&AE(&9A:7(@=F%L=64@;V8@=&AE('!L86X@ M87-S971S(&%S(&]F#0H@36%R8V@F(WA!,#LS,2P@,C`Q-"!A;F0@1&5C96UB M97(F(WA!,#LS,2P@,C`Q,R!W87,@)#$L,3$Q(&%N9"`D-C2P@86YD('=A6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*(%)A=R!M871E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L-S`P/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[ M($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX.3`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,C@Y/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L.3$Q/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XQ,2PY.30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/ M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX- M"B`\:3X\=3Y02!A;F0@17%U:7!M96YT/"]U/BX\+VD^(%!R;W!E M$$P.S,Q+"`R,#$T(&%N9"!$96-E;6)E$$P M.S,Q+"`R,#$S('=A2X\+W`^#0H@/'`@#L@34%21TE.+51/4#H@,3AP>"<^#0H@)B-X03`[/"]P M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`P<'0G/@T*(#QU/DEN=&%N9VEB;&4@07-S971S/"]U/BX@26YT86YG M:6)L92!A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ M6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^06UOF%T:6]N/&)R M("\^#0H@4&5R:6]D)B-X03`[*%EE87)S*3PO8CX\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R M(&%L:6=N/3-$8V5N=&5R/CQB/DYE=#PO8CX\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XQ,"PT-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XR+#@T.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT3PO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C<\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C@L.#`W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@S+#$S,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1R861E;F%M93PO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C$U/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XT+#,T-CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XH-S4Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XS+#4X-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@U,S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE: M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/B@Q-"PX.38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P+#8U.3PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT"<^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@.'!T M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQB/D%M;W)T:7IA=&EO;CQB6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=& M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$P+#0T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XH-RPT-C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.3@S/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV+#(Q,#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@W,34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L.#`V/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA! M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-"PT.#@\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C(R+#(R-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT"<^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\ M:3X\=3Y';V]D=VEL;#PO=3XN/"]I/B!';V]D=VEL;"!R97!R97-E;G1S('1H M92!E>&-E2!F;W(@:6UP86ER;65N="!O M2!T:&%N(&YO="!T:&%T M('1H92!F86ER('9A;'5E#0H@;V8@82!R97!O&-E961S('1H92!R97!O#(P,3D[2!I;7!A:7)M96YT(&)Y#0H@8V]M<&%R M:6YG('1H92!I;7!L:65D(&9A:7(@=F%L=65S(&]F('1H92!A9F9E8W1E9"!R M97!O6EN9R!V M86QU97,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!792!P97)F;W)M960@;W5R(&%N;G5A M;"!I;7!A:7)M96YT(&%S28C>$$P.S,Q+`T* M(#(P,3,@=71I;&EZ:6YG(&$@<75A;&ET871I=F4@979A;'5A=&EO;B!A;F0@ M8V]N8VQU9&5D('1H870@:70@=V%S#0H@;6]R92!L:6ME;'D@=&AA;B!N;W0@ M=&AA="!T:&4@9F%I6EN9R!V86QU92`H:6YC;'5D:6YG(&=O;V1W:6QL M(&]F("0R-2PQ-SDI(&]F#0H@87!P2`Q,R4N(%=E(&)E;&EE M=F4@=V4@:&%V92!M861E(')E87-O;F%B;&4@97-T:6UA=&5S(&%N9`T*(&%S M2!I;B!T:&4@ M9FES8V%L('1H:7)D('%U87)T97(L(&]R#0H@6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T)SX-"B!4:&4@8VAA;F=E(&EN(&=O;V1W:6QL(&9R M;VT@)#(S+#$$P.S,Q+"`R,#$S('1O#0H@ M)#(R+#@V,"!A$$P.S,Q+"`R,#$T(&ES(&$@&ES=',L M('1H90T*('!R:6-E(&ES(&9I>&5D(&]R(&1E=&5R;6EN86)L92P@=&ET;&4@ M:&%S('!A&-E<'0@ M9F]R('=A2!I$%%.R!);BU(;VUE#0H@2$E6('1E2!U2!E M2X@5V4@=&AE M;B!R96-O9VYI>F5D(')E=F5N=64-"B!U<&]N('1H92!C;VYS=6UM871I;VX@ M;V8@82!S86QE('1O('1H92!C;VYS=6UE'!E8W1E9"!R971U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T)SX-"B!/=7(@;F5T(')E=F5N=65S(')E8V]R9&5D(&]N('-A M;&5S(&]F('1H92!/$%%.R!);BU(;VUE#0H@2$E6('1E'!E8W1E9"!R971UF5D(&EN(&]U M6%L='D@:6YC;VUE(&9R;VT@=&AE(&=R86YT(&]F(&QI8V5N6QE/3-$ M)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49! M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!7 M92!R96-O&5S(&%S&5S+"!A$$P.S,Q+"`R,#$T(&%N9"!$96-E;6)E$$P.S,Q+"`R,#$S+"!T:&4-"B!R97-E2X@268@86-T=6%L('!R;V1U8W0@2!F2!F2!P=7)C:&%S92!C97)T M86EN('!R;V1U8W1S(&%N9"!C7,@:6X-"B!T:&4@9&5L:79E2!T;R!H879E M(&$@=&EM96QY('-U<'!L>2!O9B!A;GD@;V8@=&AE2!D:79I M9&EN9R!N970@;&]S2!T:&4@=V5I9VAT960M879E&5R8VES92!O2X@07,@82!R97-U;'0@;V8@;W5R(&YE M=`T*(&QO$$P.S,Q+"`R,#$T(&%N9"`R,#$S+`T*('1H97-E('-H87)E2!4'!E;G-E#(P,3D[(&5Q=6ET>2X\+W`^#0H@/'`@6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y!8V-U;75L M871E9"!/=&AE#(P,3D['0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO3PO8CX\ M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I M;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@-G!T)SX-"B`\:3Y3=&]C:RU" M87-E9"!!=V%R9',\+VD^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`V<'0G/@T*(%=E(&=R86YT('-T;V-K M+6)A#(P,4,[4W1O8VL-"B!0;&%N)B-X,C`Q1#LI+B!4:&4@ M4W1O8VL@4&QA;B!P97)M:71S('-T;V-K+6)A65E'!E;G-E(&9O<@T*('-T;V-K(&]P=&EO;B!A;F0@65E2!T:&4@97AE2!I&5R8VES92!O9B!S=&]C:R!O<'1I;VYS#0H@=V5R M92`D.3,@86YD("0S,#$@9F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R M8V@F(WA!,#LS,2P@,C`Q-`T*(&%N9"`R,#$S+"!R97-P96-T:79E;'DN($%S M(&$@&5R8VES97,@9'5R:6YG('1H97-E('!E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[ M($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS M1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B!4 M:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA2!F;W(@=&AE#0H@=&AR964@;6]N=&AS(&5N9&5D($UA6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@ M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D]P=&EO;G,\+V(^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($]U='-T86YD:6YG(&]N($IA;G5A$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L,C6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X97)C:7-E9#PO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($5X<&ER960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M,S$Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C8L,#(X/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM M5$]0.B`Q,G!T)SX-"B!#;VUP96YS871I;VX@8V]S="!O9B`D-C@W(&%N9"`D M-S,R(')E;&%T960@=&\@$$P M.S,Q+"`R,#$T(&%N9`T*(#(P,3,L(')E2X@26X@8V]N;F5C M=&EO;B!W:71H('1H92!V97-T:6YG(&]F(')E2P@=VET:"!A9V=R96=A=&4@=F%L=65S(&]F("0U,C$@86YD#0H@)#$$P.S,Q+"`R M,#$T.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/ M3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\+W`^ M#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S M92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X M)2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($ES$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8U,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C0P,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9O$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO M=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($ES$$P.R8C M>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%\P960X.60V,E\Y,V1C7S0Y965?8C)C95]A M-39F-#9C-&(V-#D-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&5D M.#ED-C)?.3-D8U\T.65E7V(R8V5?834V9C0V8S1B-C0Y+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'!E;G-E'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52 M+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D M:6YG/3-$,"!W:61T:#TS1#$P,"4@8F]R9&5R/3-$,#X-"B`\='(^#0H@/'1D M('9A;&EG;CTS1'1O<"!W:61T:#TS1#0E(&%L:6=N/3-$;&5F=#X\8CXT+CPO M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/CQB/D%C M8W)U960@17AP96YS97,\+V(^/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@ M/'`@$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*(%)O>6%L=&EE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C0L.#$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C0L,S6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG M/@T*($]T:&5R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL.3`R M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@ M$$P.R8C>$$P.SPO9F]N=#X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+#`S,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA"!$:7-C;&]S=7)E(%M! M8G-T'0^)SQD:78^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3 M13I#3TQ,05!313L@9F]N="UF86UI;'DZ5&EM97,@3F5W(%)O;6%N.R!F;VYT M+7-I>F4Z,3!P="<@8F]R9&5R/3-$,"!C96QL<&%D9&EN9STS1#`@8V5L;'-P M86-I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H/3-$ M-"4@=F%L:6=N/3-$=&]P(&%L:6=N/3-$;&5F=#X\8CXU+CPO8CX\+W1D/@T* M(#QT9"!A;&EG;CTS1&QE9G0@=F%L:6=N/3-$=&]P/CQB/DEN8V]M92!487AE M3I4:6UE"!B96YE9FET(&ES(&%S"!C&5S(&EN(#(P,3,N(%1H92`R,#$S(&EN8V]M92!T87@-"B!B96YE M9FET(&%SF%B;&4@8F%S960@=7!O;@T*('1H92!E6QE/3-$)VUA3I4:6UE M"!C6QE/3-$)VUA3I4:6UE$$P.S,Q+"`R,#$S('-I;F-E('1H92!F86-T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO6QE/3-$)VUA2!C;W5R'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!F7-I8VEA;G,F(W@R M,#$Y.PT*(&]F9FEC97,L(&%N9"!C;VUM97)C:6%L(&%N9"!I;F1U#(P,3D[F5D(&UE9&EC:6YE+"!A;F0-"B!A;FEM86P@86YD(&QI=F5S M=&]C:R!G96YE=&EC('1E&5S('1O#0H@;W5R(&]P M97)A=&EN9R!S96=M96YT#L@34%21TE.+51/ M4#H@,3)P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU" M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM M97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`P<'0G/@T*(%1H92!F;VQL;W=I M;F<@=&%B;&4@$$P.S,Q+#PO8CX\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+#(S,CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-S4Y/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C,L.3,R/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR,RPU,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]P97)A=&EN M9R!I;F-O;64@*&QO$$P.R8C M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M,3`L,#0P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/B@U+#8Q.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]355(\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XW-S8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/C$L-3,Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/&9O;G0@$$P M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L-C`R/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A<&ET86P@97AP96YD M:71U$$P.R8C>$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(T,SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XV-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L(&%S$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^ M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C$S,"PX-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($1.04<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XU,2PT,#4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ-S0L,#@P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^/&9O;G0@$$P.SPO9F]N M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X-"PR-#4\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@2!I;B!T:&4@56YI=&5D(%-T871E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE(')E M<')E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q M,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@ M6QE/3-$)T9/ M3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"=" M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T M=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R/@T*(#QB/E1H$$P.S,Q+#PO8CX\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO M$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/ M3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT@86QI9VX],T1R:6=H=#XT+#`P,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XR+#@T-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L,3,P/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(L,C6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X- M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA! M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XR,RPU,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X M<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]- M.B`P<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B!4:&4@9F]L;&]W:6YG('1A M8FQE(')E<')E6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T* M("8C>$$P.SPO<#X-"B`\=&%B;&4@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T* M(%5N:71E9"!3=&%T97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-A;F%D83PO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$L,#8Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CDW-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T* M(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(X/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C,S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@ M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^ M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA! M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-RPX M,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^ M)SQD:78^#0H@/'`@#(P,4,[ M1$Y!1R8C>#(P,40[*2X@06QL(&EN=&5R8V]M<&%N>2!T#(P,4,[=V4L)B-X,C`Q1#L-"B`F(W@R,#%#.W5S M+"8C>#(P,40[("8C>#(P,4,[;W5R+"8C>#(P,40[(&]R('1H92`F(W@R,#%# M.T-O;7!A;GDF(W@R,#%$.PT*(&UE86X@3W)A4W5R92!A;F0@:71S(&-O;G-O M;&ED871E9"!S=6)S:61I87)I97,L('5N;&5S6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@ M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M.R!-05)'24XM5$]0.B`Q,G!T)SX-"B!4:&4@86-C;VUP86YY:6YG(&-O;G-O M;&ED871E9"!F:6YA;F-I86P@2!F;W(-"B!A(&9A M:7(@<')E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M)SX-"B`\:3X\=3Y52!A M;F0@9F]R96EG;@T*(&-U$$P.S,Q+"`R,#$T+"!T:&4@8V%R6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D]. M5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$R<'@G/@T*("8C>$$P.SPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/ M4#H@,'!T)SX-"B!&86ER('9A;'5E(&UE87-U6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)' M24XM3$5&5#H@-"4[($U!4D=)3BU43U`Z(#9P="<^#0H@3&5V96P@,3H@56YA M9&IU6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM3$5&5#H@-"4[($U!4D=)3BU43U`Z(#9P="<^#0H@3&5V96P@,CH@ M475O=&5D('!R:6-E2P@9F]R#0H@2!T:&4@ M9G5L;"!T97)M(&]F('1H92!A2!L:71T;&4@;W(@;F\@;6%R:V5T(&%C=&EV:71Y*2X\+W`^#0H@/'`@ M2!A="!A('1H:7)D+7!A'0^)SQD:78^ M#0H@/'`@6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#6QE/3-$ M)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$ M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DUA$$P.R8C M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C@S,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1R:6=H=#XT+#(X.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XS+#DQ,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$Q+#0T-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/"]T86)L93X-"B`\+V1I=CX\6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M)SX-"B`\:3X\=3Y02!A;F0@17%U:7!M96YT/"]U/BX\+VD^(%!R M;W!E65A$$P.S,Q+"`R,#$T(&%N9"!$96-E;6)E$$P.S,Q+"`R,#$S('=A2X\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQD:78^#0H@/'`@$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#@V-CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C@L-#6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C$P+#0T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-RPV,#$\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.#0X/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#8W-3PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@W-3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-3@W/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T* M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/&9O;G0@$$P.R8C>$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XS-2PU-34\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX] M,T1C96YT97(^/&(^06UOF%T:6]N/&)R("\^#0H@4&5R:6]D("A996%R M$$P.R8C>$$P M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@ M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L M:6=N/3-$8V5N=&5R/CQB/D%C8W5M=6QA=&5D/&)R("\^#0H@06UOF%T M:6]N/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-U$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!A=&5N=',@86YD('!R;V1U M8W0@$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@W+#0V-CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C<75I$$P M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E M;G1E$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY+#$V,CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPY-3(\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/C8L,C$P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YO;BUC;VUP971E(&%G M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1&-E;G1E$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG M;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS-BPW,30\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^#0H@/'`@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@'0^)SQD:78^#0H@/'`@2!A8V-E<'1E9"!A8V-O=6YT:6YG('!R:6YC:7!L97,@<&5R;6ET('5S M('1O(&UA:V4@80T*('%U86QI=&%T:79E(&5V86QU871I;VX@86)O=70@=&AE M(&QI:V5L:6AO;V0@;V8@9V]O9'=I;&P@:6UP86ER;65N="X-"B!)9B!W92!C M;VYC;'5D92!T:&%T(&ET(&ES(&UO6EN9R!V86QU97,L#0H@:6YC M;'5D:6YG(&=O;V1W:6QL+B!)9B!T:&4@8V%R2!T:&%N(&YO="!T M:&%T('1H92!F86ER('9A;'5E(&]F(&]U6EN9R!A;6]U;G0N(%=E('!E M&-E M#(P,3D[2!H879E('1O('1A:V4@ M86X@:6UP86ER;65N="!C:&%R9V4-"B!I;B!T:&4@9G5T=7)E(')E;&%T960@ M=&\@;W5R(&=O;V1W:6QL+B!&=71U&ES M="X\+W`^#0H@/'`@0T*('1R86YS;&%T:6]N+CPO<#X-"B`\+V1I M=CX\6QE/3-$)TU!4D=)3BU"3U143TTZ M(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W M(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y2979E;G5E(%)E M8V]G;FET:6]N/"]U/BX\+VD^(%=E(')E8V]G;FEZ92!P2!R971U2P@'!E;G-E('=AF5D('5N;&5S2!D971EF4@2!T:&4@2!D969E2P@2!M86YA9V5M96YT+"!B87-E9"!O;@T*(&-U2!A=F%I;&%B;&4@:6YF;W)M871I;VX@86YD(&%R92!A9&IU6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!- M05)'24XM5$]0.B`Q,G!T)SX-"B!2;WEA;'1Y(&EN8V]M92!F'!E;G-E(&%S(&-O M2!G;W9E M$%%.R!);BU(;VUE($A)5B!T97-T+B!! M8V-O2P@=V4@:&%V92!R96-O$$P.S,Q+"`R M,#$T(&%N9"!$96-E;6)E$$P.S,Q+"`R,#$S+"!T:&4-"B!R97-E2X@268@86-T=6%L('!R;V1U8W0@2!F2!F$$P.S,Q+"`R,#$S(&EN M8VQU9&5D(&-U6UE;G1S(&]F("0Y-30@86YD#0H@)#$L M,3$Y+"!R97-P96-T:79E;'DN/"]P/@T*(#PO9&EV/CQS<&%N/CPO'0^)SQD:78^#0H@/'`@$$P.S,Q+"`R,#$S+B!792!H M860@;F\@$$P.S,Q+"`R,#$T(&]R(#(P,3,N/"]P/@T*(#QP('-T M>6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M)SX-"B!792!C=7)R96YT;'D@<'5R8VAA2!S=7!P;&EE2!S=7!P M;'D@;V8@86YY(&]F('1H97-E#0H@8V]M<&]N96YT'0^ M)SQD:78^#0H@/'`@2!D:79I9&EN9R!N970@;&]S2!T:&4@=V5I9VAT960M879E M&5R M8VES92!O2X@07,@82!R97-U M;'0@;V8@;W5R(&YE=`T*(&QO$$P.S,Q+"`R,#$T(&%N9"`R,#$S+`T*('1H97-E('-H M87)E6QE/3-$)TU!4D=)3BU"3U14 M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@ M3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y&;W)E:6=N M($-U&-H86YG92!R871E(&-H M86YG97,-"B!O;B!T2!A6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P M=#L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N.R!-05)'24XM5$]0.B`Q,G!T)SX-"B`\:3X\=3Y!8V-U;75L871E9"!/ M=&AE2!T#(P,3D['0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!O9B!3:6=N:69I8V%N="!!8V-O M=6YT:6YG(%!O;&EC:65S("A486)L97,I/&)R/CPO'0^)SQD:78^#0H@/'`@$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%=O$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@Y,#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX,S,\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2 M1TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9I;FES:&5D M(&=O;V1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\ M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$Q+#DY-#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@ M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ,2PT-#0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.R8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X- M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@'0^)SQD:78^#0H@/'`@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S92<@8V5L;'-P86-I;F<],T0P(&-E M;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG;CTS1&-E;G1E$$P.S,Q+"`R,#$T/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$8V5N=&5R/CQB/D%M;W)T:7IA=&EO;CQB$$P.RA996%R$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D%C8W5M=6QA=&5D/&)R("\^ M#0H@06UOF%T:6]N/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($-U$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!A=&5N M=',@86YD('!R;V1U8W0@$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/B@W+#8P,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($%C M<75I$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XX M+#@P-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,RPQ M,S(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L-C6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS M1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%- M24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P M.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($YO M;BUC;VUP971E(&%G$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1&-E;G1E$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C8Q-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH M-3,X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/ M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"=" M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C,U+#4U-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA! M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,30L.#DV/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$ M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI M9VX],T1R:6=H=#XR,"PV-3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C M;VQS<&%N/3-$,CX\+W1D/@T*(#QT9"!C;VQS<&%N/3-$,3(^/"]T9#X-"B`\ M+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0Q,"!A;&EG;CTS1&-E;G1E$$P M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DYE M=#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X- M"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1&-E;G1E$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PT M-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#DX,SPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M8V5N=&5R/C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDL,38R/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R+#DU,CPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*(%1R861E;F%M93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$8V5N=&5R/C$U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT M+#4R,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-S$U M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#@P-CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V-30\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C$S,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R M/@T*(#QT"<^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C M>$$P.SPO=&0^#0H@/"]T$$P M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,V+#6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,30L-#@X/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XR,BPR,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO2!O9B!#;VUP86YY)W,@4W1O8VL@3W!T:6]N M($%C=&EV:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I M=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+51/4#H@,'!T)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE('-U;6UA2!F;W(@=&AE#0H@=&AR964@;6]N M=&AS(&5N9&5D($UA6QE M/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)' M24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE M/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O M;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/D]P=&EO M;G,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q% M1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]U='-T86YD:6YG(&]N M($IA;G5A$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C4L,C6QE M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4 M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C M>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($5X97)C M:7-E9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@R,CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*($5X<&ER960\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XH,S$Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8L,#(X/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/"]T2!O9B!297-TF5S(')E$$P.S,Q M+"`R,#$T.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[ M($9/3E0M4TE:13H@,3)P=#L@34%21TE.+51/4#H@,'!T)SX-"B`F(WA!,#L\ M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@0D]21$52+4-/3$Q!4%-%.B!C;VQL M87!S92<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS M1#8X)2!A;&EG;CTS1&-E;G1E6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($ES$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8U,SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[ M/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A M;&EG;CTS1')I9VAT/C0P,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT M$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($9O$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q-CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P M.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($ES$$P M.R8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`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`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DUA M$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO$$P.R8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%!R;V9E$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R M:6=H=#XQ+#4Y,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XR+#`X,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$ M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D/B8C>$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[ M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@ M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO2!O M9B!396=M96YT($EN9F]R;6%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P M<'0[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@34%21TE.+51/4#H@,'!T)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE M('-U;6UA6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3 M25I%.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\ M=&%B;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/"]T$$P.R8C>$$P.SPO=&0^#0H@/'1D M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V M86QI9VX],T1B;W1T;VT@8V]L$$P.SPO=&0^#0H@/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI M9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($]355(\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@ M5$585"U)3D1%3E0Z("TQ96TG/@T*($1.04<\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@ M86QI9VX],T1R:6=H=#XU+#"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0 M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D M/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E M;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$ M$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#$V-#PO=&0^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/B@V+#,Y-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/ M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@ M34%21TE.+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1.04<\ M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C6QE/3-$)T9/3E0M4TE: M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/B@U-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XH-2PV,3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/B@Q,"PU.#D\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U) M3D1%3E0Z("TQ96TG/@T*($1E<')E8VEA=&EO;B!A;F0@86UOF%T:6]N M.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.R8C>$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^#0H@ M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P M<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.SPO M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H M=#XQ+#4S.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#8P,CPO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T M9#X-"B`\+W1R/@T*(#QT"<^#0H@ M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T* M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^ M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\ M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X- M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^ M#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO6QE M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS M1')I9VAT/C0S.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`] M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-#,\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO M=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE: M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE. M+4Q%1E0Z(#-E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*($1.04<\+W`^#0H@ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/ M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/C(P.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(S-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T* M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[ M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P M.SPO=&0^#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U& M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@5$58 M5"U)3D1%3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^ M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$$$P.SPO9F]N=#X\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!A;&EG;CTS1')I9VAT/C0X,#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\ M+W1R/@T*(#QT"<^#0H@/'1D('9A M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R M/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS<&%N/3-$-#X\+W1D/@T*(#QT9"!C M;VQS<&%N/3-$-#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$ M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DUA$$P.SPO=&0^#0H@ M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED M)R!V86QI9VX],T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;B<@8F=C;VQO6QE/3-$ M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA M;B<@8F=C;VQO$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4S+#,Y-SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@ M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$ M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^ M#0H@/"]T6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#5E;3L@5$585"U)3D1% M3E0Z("TQ96TG/@T*(%1O=&%L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[ M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#XQ.#0L,C0U/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T* M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@ M6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[ M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T2!'96]G6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T.R!& M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM5$]0.B`Q,G!T M)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE(')E<')E6QE/3-$)TU!4D=) M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T.R!-05)'24XM5$]0.B`P M<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@6QE/3-$)T9/3E0M4TE:13H@.'!T.R!&3TY4 M+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L M:6=N/3-$8V5N=&5R/@T*(#QB/E1H$$P.S,Q+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;B<@8F=C;VQO6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;B<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT M+#`P,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#@T M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(L,3,P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C(L,C6QE/3-$ M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA! M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X- M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4 M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\ M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,RPU,S<\+W1D/@T*(#QT M9"!V86QI9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=& M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M M(&%L:6=N/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$ M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T* M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@ M/'`@6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P>#L@1D]. M5"U325I%.B`Q<'@[($U!4D=)3BU43U`Z(#$X<'@G/@T*("8C>$$P.SPO<#X- M"B`\<"!S='EL93TS1"=-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@ M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+51/ M4#H@,'!T)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE(')E<')E6QE/3-$)TU!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I% M.B`Q,G!T.R!-05)'24XM5$]0.B`P<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B M;&4@$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX] M,T1B;W1T;VT@8V]L6QE/3-$)T9/3E0M4TE:13H@,3!P M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z M(#%E;3L@5$585"U)3D1%3E0Z("TQ96TG/@T*(%5N:71E9"!3=&%T97,\+W`^ M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N M/3-$8F]T=&]M(&%L:6=N/3-$$$P.R8C>$$P.SPO=&0^#0H@/"]T M6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@5$585"U)3D1%3E0Z("TQ M96TG/@T*($-A;F%D83PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT M/C$L,#8Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CDW M-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^ M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/C(X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^ M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,S M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT^#0H@/'`@$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@ M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X M03`[/"]T9#X-"B`\+W1R/@T*(#QT6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX] M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-RPX,C8\+W1D/@T*(#QT9"!V86QI M9VX],T1B;W1T;VT@;F]W$$P.R8C>$$P.SPO=&0^ M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N M/3-$6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\ M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE/3-$)T)/4D1% M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^ M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA! M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@6QE M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA6UE;G0@07)R86YG96UE;G0@6TUE;6)E M'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)S(P('EE87)S/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO2!A;F0@97%U:7!M96YT/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PP.#$L,#`P/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N M/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO&-L=61E9"!F'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N M/CPO'0^ M)SQS<&%N/CPO'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^)S$P('EE87)S/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)SQS<&%N/CPO'0^)S,@>65A&EM=6T@6TUE;6)E M2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)S<@>65A'0^)SQS<&%N/CPO'0^)SQS<&%N/CPOF%T:6]N(%!E'0^)S$@>65A&EM=6T@6TUE;6)E'0^)S,@>65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`M($%D9&ET:6]N86P@26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB M2!3:&%R92UB M87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO&5R8VES97,@9'5R:6YG('!E2!3:&%R92UB87-E9"!087EM96YT($%W87)D(%M,:6YE($ET96US73PO'0^)SQS<&%N/CPO M'0^)SQS<&%N M/CPO&5R8VES M92!O9B!S=&]C:R!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#DS/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2`M(%-U;6UA2=S(%-T;V-K M($]P=&EO;B!!8W1I=FET>2`H1&5T86EL*3QB&5R8VES960\+W1D/@T*("`@("`@("`\ M=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2!O9B!297-T2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`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`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-C,\'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO M&UL/@T*+2TM+2TM/5].97AT4&%R=%\P960X.60V,E\Y >,V1C7S0Y965?8C)C95]A-39F-#9C-&(V-#DM+0T* ` end XML 18 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues $ 23,537 $ 21,164

Long-lived assets 17,826 17,933

United States [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues 17,406 16,040

Long-lived assets 16,729 16,925

Europe [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues 4,001 2,846

Other Regions [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Revenues 2,130 2,278

Long-lived assets 28 33

Canada [Member]

Segment Reporting, Revenue Reconciling Item [Line Items]

Long-lived assets $ 1,069 $ 975

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingRevenueReconcilingItemLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information - Summary of Segment Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Dec. 31, 2013

Segment Reporting Information [Line Items]

Net revenues $ 23,537 $ 21,164

Operating income (loss) (5,618) (10,589)

Depreciation and amortization 1,539 1,602

Capital expenditures 647 480

Total assets 174,080 184,245

OSUR [Member]

Segment Reporting Information [Line Items]

Net revenues 17,778 17,232

Operating income (loss) (6,394) (10,040)

Depreciation and amortization 776 777

Capital expenditures 439 243

Total assets 122,675 130,848

DNAG [Member]

Segment Reporting Information [Line Items]

Net revenues 5,759 3,932

Operating income (loss) 776 (549)

Depreciation and amortization 763 825

Capital expenditures 208 237

Total assets $ 51,405 $ 53,397

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 20 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies
3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Fair Value of Financial Instruments. As of March 31, 2014, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

We offer a nonqualified deferred compensation plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2014 and December 31, 2013 was $1,111 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments.

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:

 March 31, 2014 December 31, 2013

Raw materials
 $ 6,815 $ 6,700

Work in process
 890 833

Finished goods
 4,289 3,911





 $ 11,994 $ 11,444





Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2014 and December 31, 2013 was $29,081 and $28,390, respectively.

Intangible Assets. Intangible assets consist of the following:

 March 31, 2014

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,338 $ (2,866 ) $ 8,472

Patents and product rights
 3-10 10,449 (7,601 ) 2,848

Acquired technology
 7 8,807 (3,132 ) 5,675

Tradename
 15 4,346 (759 ) 3,587

Non-compete agreements
 1-3 615 (538 ) 77





 $ 35,555 $ (14,896 ) $ 20,659





 December 31, 2013

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,795 $ (2,701 ) $ 9,094

Patents and product rights
 3-10 10,449 (7,466 ) 2,983

Acquired technology
 7 9,162 (2,952 ) 6,210

Tradename
 15 4,521 (715 ) 3,806

Non-compete agreements
 1-3 787 (654 ) 133





 $ 36,714 $ (14,488 ) $ 22,226





Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.

We performed our annual impairment assessment as of July 31, 2013 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We performed our last quantitative impairment test for goodwill as of July 31, 2012 and determined there was no impairment. That quantitative assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179) of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2014, we believe no indicators of impairment exist.

The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation.

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV tests, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first quarter of 2014 were recorded based upon shipments into the distribution channel while revenues in the first quarter of 2013 were recorded based upon the consummation of a sale to the consumer.

Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Customer Sales Returns and Allowances. We do not grant product return rights to our customers, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2014 and December 31, 2013, the reserve for sales returns and allowances was $329 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at March 31, 2014 and December 31, 2013 included customer prepayments of $954 and $1,119, respectively.

Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 11% of our accounts receivable balance as of March 31, 2014. We had no significant concentrations in accounts receivable as of December 31, 2013. We had no significant concentrations (greater than 10%) in revenues for the three months ended March 31, 2014 or 2013.

We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,792 and 5,997 shares were outstanding as of March 31, 2014 and 2013, respectively. As a result of our net losses for the three months ended March 31, 2014 and 2013, these shares were excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive.

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.

Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,778 and $1,125 currency translation adjustments recorded in the first three months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

CURRENT ASSETS:

Cash $ 84,193 $ 93,191

Accounts receivable, net of allowance for doubtful accounts of $284 and $299 13,287 12,957

Inventories 11,994 11,444

Prepaid expenses 2,016 1,712

Deferred income taxes 68 71

Other current assets 197 200

Total current assets 111,755 119,575

PROPERTY AND EQUIPMENT, net 17,826 17,933

INTANGIBLE ASSETS, net 20,659 22,226

GOODWILL 22,860 23,782

OTHER ASSETS 980 729

TOTAL ASSETS 174,080 184,245

CURRENT LIABILITIES:

Accounts payable 4,114 4,834

Deferred revenue 954 1,119

Accrued expenses 9,902 13,032

Total current liabilities 14,970 18,985

OTHER LIABILITIES 961 677

DEFERRED INCOME TAXES 3,435 3,437

COMMITMENTS AND CONTINGENCIES (Note 6)

STOCKHOLDERS' EQUITY

Preferred stock, par value $.000001, 25,000 shares authorized, none issued

Common stock, par value $.000001, 120,000 shares authorized, 55,842 and 55,632 shares issued and outstanding

Additional paid-in capital 339,651 338,674

Accumulated other comprehensive loss (5,575) (3,797)

Accumulated deficit (179,362) (173,731)

Total stockholders' equity 154,714 161,146

Total liabilities and stockholders' equity $ 174,080 $ 184,245

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31931-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31928-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=21917399&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 24

-Article 5

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

OPERATING ACTIVITIES:

Net loss $ (5,631) $ (10,226)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation 1,406 1,394

Depreciation and amortization 1,539 1,602

Deferred income taxes 131 (410)

Changes in assets and liabilities

Accounts receivable (402) 512

Inventories (586) (312)

Prepaid expenses and other assets (280) (1,545)

Accounts payable (683) 2,263

Deferred revenue (153) 37

Accrued expenses and other liabilities (3,009) (989)

Net cash used in operating activities (7,668) (7,674)

INVESTING ACTIVITIES:

Purchases of property and equipment (647) (480)

Net cash used in investing activities (647) (480)

FINANCING ACTIVITIES:

Proceeds from exercise of stock options 93 301

Repurchase of common stock (521) (743)

Net cash used in financing activities (428) (442)

EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH (255) (16)

NET DECREASE IN CASH (8,998) (8,612)

CASH, BEGINNING OF PERIOD 93,191 87,888

CASH, END OF PERIOD 84,193 79,276

Cash paid for:

Income taxes $ 40 $ 27

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3044-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost $ 1,406 $ 1,394

Net cash proceeds from the exercise of stock options 93 301

Income tax benefit realized from stock option exercises during period 0 0

Restricted Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost 687 732

Vesting of restricted shares, withheld and withholding obligations 89 106

Restricted shares of common stock, aggregate values 521 743

Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total compensation cost 719 662

Net cash proceeds from the exercise of stock options $ 93 $ 301

X

- Definition

The amount of adjustment to stockholders' equity associated with an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.

+ References

No definition available.

+ Details

Name: us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred tax expense from write-off of the deferred tax asset related to deductible stock options at exercise.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11283-113907

+ Details

Name: us-gaap_DeferredTaxExpenseFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (j)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.

+ References

No definition available.

+ Details

Name: us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 24 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Shares, Issued and unvested, Beginning balance 653

Shares, Granted 403

Shares, Vested (276)

Shares, Forfeited (16)

Shares, Issued and unvested, Ending balance 764

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 25 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 26 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

The Company
3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

The Company

1. The Company

We develop, manufacture, market and sell oral fluid diagnostic products and specimen collection devices using our proprietary oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our diagnostic products include tests that are performed on a rapid basis at the point-of-care and tests that are processed in a laboratory. We sell the first and only rapid point-of-care HIV test approved for use in the domestic consumer retail or over-the-counter (“OTC”) market. We also manufacture and sell oral fluid collection devices used to collect, stabilize and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Lastly, we manufacture and sell medical devices used for the removal of benign skin lesions by cryosurgery, or freezing. Our products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, research and academic institutions, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our OTC HIV and cryosurgical products are sold to retail pharmacies and mass merchandisers as well as to consumers over the internet.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Balance Sheets (Parenthetical) (USD $)
In Thousands, except Per Share data, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

Statement Of Financial Position [Abstract]

Allowance for doubtful accounts $ 284 $ 299

Preferred stock, par value $ 0.000001 $ 0.000001

Preferred stock, shares authorized 25,000 25,000

Preferred stock, shares issued

Common stock, par value $ 0.000001 $ 0.000001

Common stock, shares authorized 120,000 120,000

Common stock, shares issued 55,842 55,632

Common stock, shares outstanding 55,842 55,632

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28368275&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses (Tables)
3 Months Ended

Mar. 31, 2014

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

 March 31, 2014 December 31, 2013

Payroll and related benefits
 $ 2,763 $ 5,827

Royalties
 4,813 4,374

Professional fees
 733 749

Other
 1,593 2,082





 $ 9,902 $ 13,032





X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the components of accrued liabilities.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
3 Months Ended

Mar. 31, 2014

May 05, 2014

Document And Entity Information [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2014

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q1

Trading Symbol OSUR

Entity Registrant Name ORASURE TECHNOLOGIES INC

Entity Central Index Key 0001116463

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Entity Common Stock, Shares Outstanding 55,841,785

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: osur_DocumentAndEntityInformationAbstract

Namespace Prefix: osur_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 30 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information (Tables)
3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Summary of Segment Information

The following table summarizes segment information for the three months ended March 31, 2014 and 2013.

 Three Months Ended March 31,

 2014 2013

Net revenues:


OSUR
 $ 17,778 $ 17,232

DNAG
 5,759 3,932



Total
 $ 23,537 $ 21,164



Operating income (loss):


OSUR
 $ (6,394 ) $ (10,040 )

DNAG
 776 (549 )



Total
 $ (5,618 ) $ (10,589 )



Depreciation and amortization:


OSUR
 $ 776 $ 777

DNAG
 763 825



Total
 $ 1,539 $ 1,602



Capital expenditures:


OSUR
 $ 439 $ 243

DNAG
 208 237



Total
 $ 647 $ 480



 March 31, 2014 December 31, 2013

Total assets:


OSUR
 $ 122,675 $ 130,848

DNAG
 51,405 53,397



Total
 $ 174,080 $ 184,245



Presentation of Total Revenues and Long-Lived Assets by Geographic Area

The following table represents total revenues by geographic area, based on the location of the customer:

 Three Months Ended March 31,

 2014 2013

United States
 $ 17,406 $ 16,040

Europe
 4,001 2,846

Other regions
 2,130 2,278





 $ 23,537 $ 21,164





The following table represents total long-lived assets by geographic area:

 March 31, 2014 December 31, 2013

United States
 $ 16,729 $ 16,925

Canada
 1,069 975

Other regions
 28 33





 $ 17,826 $ 17,933





X

- Definition

Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

+ Details

Name: us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Operations (USD $)
In Thousands, except Per Share data, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

NET REVENUES:

Product $ 23,537 $ 20,962

Licensing and product development 202

Total revenue 23,537 21,164

COST OF PRODUCTS SOLD 9,610 9,135

Gross profit 13,927 12,029

OPERATING EXPENSES:

Research and development 2,481 3,357

Sales and marketing 11,340 13,874

General and administrative 5,724 5,387

Total operating expenses 19,545 22,618

Operating loss (5,618) (10,589)

OTHER INCOME (EXPENSE) 118 (47)

Loss before income taxes (5,500) (10,636)

INCOME TAX EXPENSE (BENEFIT) 131 (410)

NET LOSS $ (5,631) $ (10,226)

LOSS PER SHARE:

BASIC $ (0.10) $ (0.18)

DILUTED $ (0.10) $ (0.18)

SHARES USED IN COMPUTING LOSS PER SHARE:

BASIC 55,762 55,449

DILUTED 55,762 55,449

X

- Definition

Total costs related to goods produced and sold during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfGoodsSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicenseAndMaintenanceRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(a))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueGoodsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total amount of expenses directly related to the marketing or selling of products or services.

+ References

No definition available.

+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 32 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

Commitments and Contingencies
3 Months Ended

Mar. 31, 2014

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

6. Commitments and Contingencies

From time-to-time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, based upon the advice of counsel, the outcomes of such actions are not expected to have a material adverse effect on our future financial position or results of operations.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes
3 Months Ended

Mar. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

5. Income Taxes

During the three months ended March 31, 2014, we recorded foreign deferred tax expense of $131. During the three months ended March 31, 2013, we recorded a foreign deferred tax benefit of $410. The foreign deferred tax benefit is associated with certain Canadian research and development and investment tax credits and DNAG’s loss before income taxes in 2013. The 2013 income tax benefit associated with DNAG was considered realizable based upon the estimated scheduled reversal of the deferred tax liabilities recorded in connection with the acquisition of DNAG.

Deferred income taxes reflect the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2014 relate to the tax effects of the basis differences between the intangible assets acquired in the DNAG acquisition for financial reporting and tax purposes.

In 2008, we established a full valuation allowance against our U.S. net deferred tax asset, and management believes the full valuation allowance is still appropriate as of March 31, 2014 and December 31, 2013 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state income tax benefit was recorded for the three months ended March 31, 2014 and 2013.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward]

Options, Outstanding, Beginning balance 5,271

Options, Outstanding, Granted 1,168

Options, Outstanding, Exercised (22)

Options, Outstanding, Expired (319)

Options, Outstanding, Forfeited (70)

Options, Outstanding, Ending balance 6,028

X

- Definition

Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Gross number of share options (or share units) granted during the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options outstanding, including both vested and non-vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 35 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
Share data in Thousands, unless otherwise specified
3 Months Ended 12 Months Ended 3 Months Ended 1 Months Ended 3 Months Ended

Mar. 31, 2014

Customer

Mar. 31, 2013

Dec. 31, 2013

Mar. 31, 2014

Up Front Payment Arrangement [Member]

Dec. 31, 2013

Up Front Payment Arrangement [Member]

Mar. 31, 2014

Accounts Receivable [Member]

Customer Concentration Risk [Member]

Mar. 31, 2014

Maximum [Member]

Other Intangible Assets [Member]

Mar. 31, 2014

Maximum [Member]

Building [Member]

Mar. 31, 2014

Minimum [Member]

Other Intangible Assets [Member]

Mar. 31, 2014

Minimum [Member]

Building [Member]

Jul. 31, 2012

DNA Genotek [Member]

Mar. 31, 2014

DNA Genotek [Member]

Product Information [Line Items]

Fair value of plan assets $ 1,111,000 $ 677,000

Useful life of building and other assets 10 years 40 years 2 years 20 years

Accumulated depreciation of property and equipment 29,081,000 28,390,000

Fair value of goodwill 25,179,000

Impairment of goodwill 0

Percentage of excess of fair value on carrying value 13.00%

Amount of goodwill at period end 22,860,000 23,782,000

Reserve for sales return and allowances 329,000 279,000

Deferred revenue 954,000 1,119,000 954,000 1,119,000

Number of our customers, accounted for significant concentrations 1

Percentage of concentration risk 11.00%

Concentration rate of accounts receivable 10.00%

Significant concentrations in revenues 0 0

Number of third-party suppliers to manufacture DNAG's products 2

Number of anti-dilutive securities excluded from EPS computation 6,792 5,997

Accumulated foreign currency adjustments included in other comprehensive loss amounted $ 1,778,000 $ 1,125,000

X

- Definition

Deferred compensation plan fair value of plan assets.

+ References

No definition available.

+ Details

Name: osur_DeferredCompensationPlanFairValueOfPlanAssets

Namespace Prefix: osur_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Entity Wide Revenue Major Customer Threshold Percentage

+ References

No definition available.

+ Details

Name: osur_EntityWideRevenueMajorCustomerThresholdPercentage

Namespace Prefix: osur_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of significant concentrations in accounts receivable.

+ References

No definition available.

+ Details

Name: osur_NumberOfSignificantConcentrationsInAccountsReceivable

Namespace Prefix: osur_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition

Significant concentrations in revenues.

+ References

No definition available.

+ Details

Name: osur_SignificantConcentrationsInRevenues

Namespace Prefix: osur_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669646-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32022-110900

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13537-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=28364263&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Description of risks that arise due to the volume of business transacted with a particular supplier or reliance placed on that supplier. At a minimum, the description informs financial statement users of the general nature of the risk.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6374342&loc=d3e7102-108593

+ Details

Name: us-gaap_ConcentrationRiskSupplier

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Fair value portion of asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=25499696&loc=d3e19190-110258

+ Details

Name: us-gaap_GoodwillFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13854-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13777-109266

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

+ Details

Name: us-gaap_GoodwillImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_ProductInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name: us-gaap_PropertyPlantAndEquipmentUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of fair value of reporting unit in excess of carrying amount.

+ References

No definition available.

+ Details

Name: us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount of estimated sales returns.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 15

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406750&loc=d3e47468-111626

+ Details

Name: us-gaap_RevenueRecognitionSalesReturnsReserveForSalesReturns

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 36 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Tables)
3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Inventories

Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:

 March 31, 2014 December 31, 2013

Raw materials
 $ 6,815 $ 6,700

Work in process
 890 833

Finished goods
 4,289 3,911





 $ 11,994 $ 11,444





Intangible Assets

Intangible assets consist of the following:

 March 31, 2014

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,338 $ (2,866 ) $ 8,472

Patents and product rights
 3-10 10,449 (7,601 ) 2,848

Acquired technology
 7 8,807 (3,132 ) 5,675

Tradename
 15 4,346 (759 ) 3,587

Non-compete agreements
 1-3 615 (538 ) 77





 $ 35,555 $ (14,896 ) $ 20,659





 December 31, 2013

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,795 $ (2,701 ) $ 9,094

Patents and product rights
 3-10 10,449 (7,466 ) 2,983

Acquired technology
 7 9,162 (2,952 ) 6,210

Tradename
 15 4,521 (715 ) 3,806

Non-compete agreements
 1-3 787 (654 ) 133





 $ 36,714 $ (14,488 ) $ 22,226





X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information
3 Months Ended

Mar. 31, 2014

Segment Reporting [Abstract]

Business Segment Information

7. Business Segment Information

We operate our business within two reportable segments: our “OSUR” business, which consists of the development, manufacture and sale of oral fluid diagnostic products and specimen collection devices and the manufacture and sale of medical devices used for the removal of benign skin lesions by cryosurgery; and our molecular collection systems or “DNAG” business, which consists of the manufacture, development and sale of oral fluid collection devices that are used to collect, stabilize and store samples of genetic material for molecular testing. OSUR revenues are derived primarily from products sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations, public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Revenues from OSUR’s OTC products primarily result from sales to retail pharmacies and mass merchandisers and to consumers over the internet. OSUR also derives revenues from licensing and product development activities. DNAG revenues result primarily from products sold into the commercial market which consists of companies and other entities engaged in consumer genetics, clinical genetic testing, pharmacogenomics, personalized medicine, and animal and livestock genetic testing, as well as, products sold into the academic research market, which consists of research laboratories, universities and hospitals.

We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income (loss). We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues.

The following table summarizes segment information for the three months ended March 31, 2014 and 2013.

 Three Months Ended March 31,

 2014 2013

Net revenues:


OSUR
 $ 17,778 $ 17,232

DNAG
 5,759 3,932



Total
 $ 23,537 $ 21,164



Operating income (loss):


OSUR
 $ (6,394 ) $ (10,040 )

DNAG
 776 (549 )



Total
 $ (5,618 ) $ (10,589 )



Depreciation and amortization:


OSUR
 $ 776 $ 777

DNAG
 763 825



Total
 $ 1,539 $ 1,602



Capital expenditures:


OSUR
 $ 439 $ 243

DNAG
 208 237



Total
 $ 647 $ 480



 March 31, 2014 December 31, 2013

Total assets:


OSUR
 $ 122,675 $ 130,848

DNAG
 51,405 53,397



Total
 $ 174,080 $ 184,245



Our products are sold principally in the United States and Europe.

The following table represents total revenues by geographic area, based on the location of the customer:

 Three Months Ended March 31,

 2014 2013

United States
 $ 17,406 $ 16,040

Europe
 4,001 2,846

Other regions
 2,130 2,278





 $ 23,537 $ 21,164





The following table represents total long-lived assets by geographic area:

 March 31, 2014 December 31, 2013

United States
 $ 16,729 $ 16,925

Canada
 1,069 975

Other regions
 28 33





 $ 17,826 $ 17,933





X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 38 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies (Policies)
3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Principles of Consolidation and Basis of Presentation

Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiary, DNA Genotek, Inc. (“DNAG”). All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.

The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2013. Results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results of operations expected for the full year.

Use of Estimates

Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to contingencies and accruals, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors which management believes to be reasonable under the circumstances, including the current economic environment. We adjust such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity and foreign currency markets, reductions in government funding and declines in consumer spending have combined to increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.

Fair Value of Financial Instruments

Fair Value of Financial Instruments. As of March 31, 2014, the carrying values of cash, accounts receivable, accounts payable and accrued expenses approximate their respective fair values based on their short-term nature.

Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

We offer a nonqualified deferred compensation plan for highly compensated employees. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and Company stock. The fair value of the plan assets as of March 31, 2014 and December 31, 2013 was $1,111 and $677, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments.

Inventories

Inventories. Inventories are stated at the lower of cost or market determined on a first-in, first-out basis and are comprised of the following:

 March 31, 2014 December 31, 2013

Raw materials
 $ 6,815 $ 6,700

Work in process
 890 833

Finished goods
 4,289 3,911





 $ 11,994 $ 11,444





Property and Equipment

Property and Equipment. Property and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold or otherwise disposed of, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statement of operations. Accumulated depreciation of property and equipment as of March 31, 2014 and December 31, 2013 was $29,081 and $28,390, respectively.

Intangible Assets

Intangible Assets. Intangible assets consist of the following:

 March 31, 2014

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,338 $ (2,866 ) $ 8,472

Patents and product rights
 3-10 10,449 (7,601 ) 2,848

Acquired technology
 7 8,807 (3,132 ) 5,675

Tradename
 15 4,346 (759 ) 3,587

Non-compete agreements
 1-3 615 (538 ) 77





 $ 35,555 $ (14,896 ) $ 20,659





 December 31, 2013

 Amortization
Period (Years) Gross Accumulated
Amortization Net

Customer list
 10 $ 11,795 $ (2,701 ) $ 9,094

Patents and product rights
 3-10 10,449 (7,466 ) 2,983

Acquired technology
 7 9,162 (2,952 ) 6,210

Tradename
 15 4,521 (715 ) 3,806

Non-compete agreements
 1-3 787 (654 ) 133





 $ 36,714 $ (14,488 ) $ 22,226





Goodwill

Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisition of DNAG in August 2011. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the fair value of a reporting unit is greater than its carrying amount, then we would not be required to perform the two-step quantitative impairment test. Otherwise, performing the two-step impairment test is necessary. The first step of the two-step quantitative impairment test involves comparing the fair values of the applicable reporting units with their aggregate carrying values, including goodwill. If the carrying value of a reporting unit exceeds the reporting unit’s fair value, we perform the second step of the test to determine the amount of the impairment loss, if any. The second step involves measuring any impairment by comparing the implied fair values of the affected reporting unit’s goodwill and intangible assets with their respective carrying values.

We performed our annual impairment assessment as of July 31, 2013 utilizing a qualitative evaluation and concluded that it was more likely than not that the fair value of our DNAG reporting unit is greater than its carrying amount. We performed our last quantitative impairment test for goodwill as of July 31, 2012 and determined there was no impairment. That quantitative assessment determined that our DNAG reporting unit had a fair value in excess of its carrying value (including goodwill of $25,179) of approximately 13%. We believe we have made reasonable estimates and assumptions to calculate the fair value of our reporting unit. If actual future results are not consistent with management’s estimates and assumptions, we may have to take an impairment charge in the future related to our goodwill. Future impairment tests will continue to be performed annually in the fiscal third quarter, or sooner if a triggering event occurs. As of March 31, 2014, we believe no indicators of impairment exist.

The change in goodwill from $23,782 as of December 31, 2013 to $22,860 as of March 31, 2014 is a result of foreign currency translation.

Revenue Recognition

Revenue Recognition. We recognize product revenues when there is persuasive evidence that an arrangement exists, the price is fixed or determinable, title has passed and collection is reasonably assured. Product revenues are recorded net of allowances for any discounts or rebates. Other than for our OraQuick® In-Home HIV tests, we do not grant price protection or product return rights to our customers except for warranty returns. Historically, returns arising from warranty issues have been infrequent and immaterial. Accordingly, we expense warranty returns as incurred.

We began selling our OraQuick® In-Home HIV test in the third quarter of 2012. From launch through November 2013, our revenue recognition practices with respect to the OraQuick® In-Home HIV test were different than those customarily used in the consumer package goods industry. Under U.S. generally accepted accounting principles, product revenue cannot be recognized unless the amount of future returns can be reasonably estimated. Because our OraQuick® In-Home HIV test was a new product for which we did not have a historical record of returns, we did not believe we could reasonably determine a return rate. As a result we initially did not recognize revenue when we shipped to the retail trade. For these product shipments, we invoiced the retailer or distributor, recorded deferred revenue at gross invoice sales price, and classified the cost basis of the product held by the retailer or distributor as a component of inventory. We then recognized revenue upon the consummation of a sale to the consumer either in a store or over the internet. With the passage of time, however, we concluded that we have sufficient data and visibility into our distribution channel to develop a reasonable estimate of the level of expected returns. As such, commencing in December 2013, we recognized previously deferred revenue and its related cost of goods sold, and began to recognize revenue for this product upon shipment to the retailers or distributors. Accordingly, revenues in the first quarter of 2014 were recorded based upon shipments into the distribution channel while revenues in the first quarter of 2013 were recorded based upon the consummation of a sale to the consumer.

Our net revenues recorded on sales of the OraQuick® In-Home HIV test represent total gross revenues, less an allowance for expected returns, and customer allowances for cooperative advertising discounts, rebates, and chargebacks. All of these allowances are estimates established by management, based on currently available information and are adjusted to reflect known changes in the factors that impact those estimates. These allowances are recorded as a reduction of gross revenue when recognized in our statement of operations.

Royalty income from the grant of license rights is recognized during the period in which the revenue is earned and the amount is determinable from the licensee.

We record shipping and handling charges billed to our customers as product revenue and the related expense as cost of products sold. Taxes assessed by governmental authorities, such as sales or value-added taxes, are excluded from product revenues.

Customer Sales Returns and Allowances

Customer Sales Returns and Allowances. We do not grant product return rights to our customers, except for our OraQuick® In-Home HIV test. Accordingly, we have recorded an estimate of expected returns as a reduction of gross OraQuick® In-Home HIV product revenues in our consolidated statements of operations. This estimate reflects our historical sales experience to retailers and consumers, as well as other retail factors, and is reviewed regularly to ensure that it reflects potential product returns. As of March 31, 2014 and December 31, 2013, the reserve for sales returns and allowances was $329 and $279, respectively. If actual product returns differ materially from our reserve amount, or if a determination is made that this product’s distribution would be discontinued in whole or in part by certain retailers, then we would need to adjust our reserve. Should the actual level of product returns vary significantly from our estimates, our operating and financial results could be materially affected.

Deferred Revenue

Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue at March 31, 2014 and December 31, 2013 included customer prepayments of $954 and $1,119, respectively.

Customer and Vendor Concentrations

Customer and Vendor Concentrations. One of our customers, Reckitt Benckiser, accounted for approximately 11% of our accounts receivable balance as of March 31, 2014. We had no significant concentrations in accounts receivable as of December 31, 2013. We had no significant concentrations (greater than 10%) in revenues for the three months ended March 31, 2014 or 2013.

We currently purchase certain products and critical components of our products from sole-supply vendors, and if these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its products. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.

Loss Per Share

Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options and unvested restricted stock. Common stock options and unvested restricted stock totaling 6,792 and 5,997 shares were outstanding as of March 31, 2014 and 2013, respectively. As a result of our net losses for the three months ended March 31, 2014 and 2013, these shares were excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive.

Foreign Currency Translation

Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.

Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than functional currency are included in income in the period in which the change occurs.

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss. We classify items of other comprehensive loss by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our balance sheet.

We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and as such, the results of its operations are translated into U.S. dollars, which is the reporting currency of the Company. The $1,778 and $1,125 currency translation adjustments recorded in the first three months of 2014 and 2013, respectively, are largely the result of the translation of our Canadian operation’s financial statements into U.S. dollars.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for comprehensive income.

+ References

No definition available.

+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2144384

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for determining the fair value of financial instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155942

+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2175856

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2175826

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2175892

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-URI http://asc.fasb.org/subtopic&trid=2144439

+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-URI http://asc.fasb.org/subtopic&trid=2144471

+ Details

Name: us-gaap_IntangibleAssetsFiniteLivedPolicy

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2126999

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4492-108314

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Financial Reporting Release (FRR)

-Number 206

-Paragraph b

-Subparagraph i, ii

-Chapter 2

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4556-108314

+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

+ Details

Name: us-gaap_MajorCustomersPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2155824

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197196

+ Details

Name: us-gaap_RevenueRecognitionDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18823-107790

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for sales returns.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 15

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406750&loc=d3e47468-111626

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name: us-gaap_RevenueRecognitionSalesReturns

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

Stockholders' Equity (Tables)
3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Summary of Company's Stock Option Activity

The following table summarizes the stock option activity for the three months ended March 31, 2014:

 Options

Outstanding on January 1, 2014
 5,271

Granted
 1,168

Exercised
 (22 )

Expired
 (319 )

Forfeited
 (70 )



Outstanding on March 31, 2014
 6,028



Summary of Restricted Stock Award Activity

The following table summarizes restricted stock award activity for the three months ended March 31, 2014:

 Shares

Issued and unvested, January 1, 2014
 653

Granted
 403

Vested
 (276 )

Forfeited
 (16 )



Issued and unvested, March 31, 2014
 764



X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 12 Months Ended

Mar. 31, 2014

Dec. 31, 2013

Finite-Lived Intangible Assets [Line Items]

Gross $ 35,555 $ 36,714

Accumulated Amortization (14,896) (14,488)

Net 20,659 22,226

Customer List [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 10 years 10 years

Gross 11,338 11,795

Accumulated Amortization (2,866) (2,701)

Net 8,472 9,094

Patent and Product Rights [Member]

Finite-Lived Intangible Assets [Line Items]

Gross 10,449 10,449

Accumulated Amortization (7,601) (7,466)

Net 2,848 2,983

Patent and Product Rights [Member] | Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 3 years 3 years

Patent and Product Rights [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 10 years 10 years

Acquired Technology [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 7 years 7 years

Gross 8,807 9,162

Accumulated Amortization (3,132) (2,952)

Net 5,675 6,210

Tradename [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 15 years 15 years

Gross 4,346 4,521

Accumulated Amortization (759) (715)

Net 3,587 3,806

Non-compete Agreements [Member]

Finite-Lived Intangible Assets [Line Items]

Gross 615 787

Accumulated Amortization (538) (654)

Net $ 77 $ 133

Non-compete Agreements [Member] | Minimum [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 1 year 1 year

Non-compete Agreements [Member] | Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

Amortization Period (Years) 3 years 3 years

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 41 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

Income Taxes - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Income Tax Disclosure [Abstract]

Foreign deferred tax expense (benefits) $ 131 $ (410)

U.S. federal income tax benefits 0 0

U.S. state income tax benefits $ 0 $ 0

X

- Definition

Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Paragraph Question 1-7

+ Details

Name: us-gaap_CurrentFederalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_CurrentStateAndLocalTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_DeferredForeignIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

Consolidated Statements of Comprehensive Loss (USD $)
In Thousands, unless otherwise specified
3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Statement Of Income And Comprehensive Income [Abstract]

Net loss $ (5,631) $ (10,226)

OTHER COMPREHENSIVE LOSS

Currency translation adjustments (1,778) (1,125)

Other comprehensive loss (1,778) (1,125)

COMPREHENSIVE LOSS $ (7,409) $ (11,351)

X

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358780&loc=d3e565-108580

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358780&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax of other comprehensive income (loss) attributable to parent entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569643-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (c)(3)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 43 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accrued Expenses
3 Months Ended

Mar. 31, 2014

Payables And Accruals [Abstract]

Accrued Expenses

4. Accrued Expenses

 March 31, 2014 December 31, 2013

Payroll and related benefits
 $ 2,763 $ 5,827

Royalties
 4,813 4,374

Professional fees
 733 749

Other
 1,593 2,082





 $ 9,902 $ 13,032





X

- Definition

The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20, 24

-Article 5

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 44 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

Business Segment Information - Additional Information (Detail)
3 Months Ended

Mar. 31, 2014

Segment

Segment Reporting [Abstract]

Number of reportable segments of company 2

X

- Definition

Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.

+ References

No definition available.

+ Details

Name: us-gaap_NumberOfReportableSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 66 151 1 false 21 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.orasure.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Consolidated Balance Sheets Sheet http://www.orasure.com/taxonomy/role/StatementOfFinancialPositionClassified Consolidated Balance Sheets false false R3.htm 104 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.orasure.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Consolidated Statements of Operations Sheet http://www.orasure.com/taxonomy/role/StatementOfIncome Consolidated Statements of Operations false false R5.htm 106 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.orasure.com/taxonomy/role/StatementOfOtherComprehensiveIncome Consolidated Statements of Comprehensive Loss false false R6.htm 107 - Statement - Consolidated Statements of Cash Flows Sheet http://www.orasure.com/taxonomy/role/StatementOfCashFlowsIndirect Consolidated Statements of Cash Flows false false R7.htm 108 - Disclosure - The Company Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock The Company false false R8.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock Summary of Significant Accounting Policies false false R9.htm 110 - Disclosure - Stockholders' Equity Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Stockholders' Equity false false R10.htm 111 - Disclosure - Accrued Expenses Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses false false R11.htm 112 - Disclosure - Income Taxes Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes false false R12.htm 113 - Disclosure - Commitments and Contingencies Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments and Contingencies false false R13.htm 114 - Disclosure - Business Segment Information Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Business Segment Information false false R14.htm 115 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies Summary of Significant Accounting Policies (Policies) false false R15.htm 116 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables Summary of Significant Accounting Policies (Tables) false false R16.htm 117 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Stockholders' Equity (Tables) false false R17.htm 118 - Disclosure - Accrued Expenses (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) false false R18.htm 119 - Disclosure - Business Segment Information (Tables) Sheet http://www.orasure.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Business Segment Information (Tables) false false R19.htm 120 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation Summary of Significant Accounting Policies - Additional Information (Detail) false false R20.htm 121 - Disclosure - Summary of Significant Accounting Policies - Inventories (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesInventories Summary of Significant Accounting Policies - Inventories (Detail) false false R21.htm 122 - Disclosure - Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssets Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) false false R22.htm 123 - Disclosure - Stockholders' Equity - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureStockholdersEquityAdditionalInformation Stockholders' Equity - Additional Information (Detail) false false R23.htm 124 - Disclosure - Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfCompanysStockOptionActivity Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) false false R24.htm 125 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockAwardActivity Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) false false R25.htm 126 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses Accrued Expenses - Schedule of Accrued Expenses (Detail) false false R26.htm 127 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) false false R27.htm 128 - Disclosure - Business Segment Information - Additional Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationAdditionalInformation Business Segment Information - Additional Information (Detail) false false R28.htm 129 - Disclosure - Business Segment Information - Summary of Segment Information (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationSummaryOfSegmentInformation Business Segment Information - Summary of Segment Information (Detail) false false R29.htm 130 - Disclosure - Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) Sheet http://www.orasure.com/taxonomy/role/DisclosureBusinessSegmentInformationPresentationOfTotalRevenuesAndLongLivedAssetsByGeographicArea Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) false false All Reports Book All Reports 'Monetary' elements on report '120 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2013' Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 105 - Statement - Consolidated Statements of Operations Process Flow-Through: 106 - Statement - Consolidated Statements of Comprehensive Loss Process Flow-Through: 107 - Statement - Consolidated Statements of Cash Flows osur-20140331.xml osur-20140331.xsd osur-20140331_cal.xml osur-20140331_def.xml osur-20140331_lab.xml osur-20140331_pre.xml true true XML 46 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

Summary of Significant Accounting Policies - Inventories (Detail) (USD $)
In Thousands, unless otherwise specified

Mar. 31, 2014

Dec. 31, 2013

Inventory Net [Abstract]

Raw materials $ 6,815 $ 6,700

Work in process 890 833

Finished goods 4,289 3,911

Inventories $ 11,994 $ 11,444

X

- Definition

Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(4))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Accrued Expenses - Schedule of Accrued Expenses (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Accrued Liabilities Current [Abstract]
Payroll and related benefits	$ 2,763	$ 5,827
Royalties	4,813	4,374
Professional fees	733	749
Other	1,593	2,082
Accrued Expenses, Total	$ 9,902	$ 13,032

Business Segment Information - Presentation of Total Revenues and Long-Lived Assets by Geographic Area (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	$ 23,537	$ 21,164
Long-lived assets	17,826		17,933
United States [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	17,406	16,040
Long-lived assets	16,729		16,925
Europe [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	4,001	2,846
Other Regions [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenues	2,130	2,278
Long-lived assets	28		33
Canada [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Long-lived assets	$ 1,069		$ 975

Consolidated Balance Sheets (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
CURRENT ASSETS:
Cash	$ 84,193	$ 93,191
Accounts receivable, net of allowance for doubtful accounts of $284 and $299	13,287	12,957
Inventories	11,994	11,444
Prepaid expenses	2,016	1,712
Deferred income taxes	68	71
Other current assets	197	200
Total current assets	111,755	119,575
PROPERTY AND EQUIPMENT, net	17,826	17,933
INTANGIBLE ASSETS, net	20,659	22,226
GOODWILL	22,860	23,782
OTHER ASSETS	980	729
TOTAL ASSETS	174,080	184,245
CURRENT LIABILITIES:
Accounts payable	4,114	4,834
Deferred revenue	954	1,119
Accrued expenses	9,902	13,032
Total current liabilities	14,970	18,985
OTHER LIABILITIES	961	677
DEFERRED INCOME TAXES	3,435	3,437
COMMITMENTS AND CONTINGENCIES (Note 6)
STOCKHOLDERS' EQUITY
Preferred stock, par value $.000001, 25,000 shares authorized, none issued
Common stock, par value $.000001, 120,000 shares authorized, 55,842 and 55,632 shares issued and outstanding
Additional paid-in capital	339,651	338,674
Accumulated other comprehensive loss	(5,575)	(3,797)
Accumulated deficit	(179,362)	(173,731)
Total stockholders' equity	154,714	161,146
Total liabilities and stockholders' equity	$ 174,080	$ 184,245

Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
OPERATING ACTIVITIES:
Net loss	$ (5,631)	$ (10,226)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,406	1,394
Depreciation and amortization	1,539	1,602
Deferred income taxes	131	(410)
Changes in assets and liabilities
Accounts receivable	(402)	512
Inventories	(586)	(312)
Prepaid expenses and other assets	(280)	(1,545)
Accounts payable	(683)	2,263
Deferred revenue	(153)	37
Accrued expenses and other liabilities	(3,009)	(989)
Net cash used in operating activities	(7,668)	(7,674)
INVESTING ACTIVITIES:
Purchases of property and equipment	(647)	(480)
Net cash used in investing activities	(647)	(480)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	93	301
Repurchase of common stock	(521)	(743)
Net cash used in financing activities	(428)	(442)
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(255)	(16)
NET DECREASE IN CASH	(8,998)	(8,612)
CASH, BEGINNING OF PERIOD	93,191	87,888
CASH, END OF PERIOD	84,193	79,276
Cash paid for:
Income taxes	$ 40	$ 27

Stockholders' Equity - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	$ 1,406	$ 1,394
Net cash proceeds from the exercise of stock options	93	301
Income tax benefit realized from stock option exercises during period	0	0
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	687	732
Vesting of restricted shares, withheld and withholding obligations	89	106
Restricted shares of common stock, aggregate values	521	743
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation cost	719	662
Net cash proceeds from the exercise of stock options	$ 93	$ 301

Stockholders' Equity - Summary of Restricted Stock Award Activity (Detail) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]
Shares, Issued and unvested, Beginning balance	653
Shares, Granted	403
Shares, Vested	(276)
Shares, Forfeited	(16)
Shares, Issued and unvested, Ending balance	764

Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 284	$ 299
Preferred stock, par value	$ 0.000001	$ 0.000001
Preferred stock, shares authorized	25,000	25,000
Preferred stock, shares issued
Common stock, par value	$ 0.000001	$ 0.000001
Common stock, shares authorized	120,000	120,000
Common stock, shares issued	55,842	55,632
Common stock, shares outstanding	55,842	55,632

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	May 05, 2014
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1
Trading Symbol	OSUR
Entity Registrant Name	ORASURE TECHNOLOGIES INC
Entity Central Index Key	0001116463
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		55,841,785

Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
NET REVENUES:
Product	$ 23,537	$ 20,962
Licensing and product development		202
Total revenue	23,537	21,164
COST OF PRODUCTS SOLD	9,610	9,135
Gross profit	13,927	12,029
OPERATING EXPENSES:
Research and development	2,481	3,357
Sales and marketing	11,340	13,874
General and administrative	5,724	5,387
Total operating expenses	19,545	22,618
Operating loss	(5,618)	(10,589)
OTHER INCOME (EXPENSE)	118	(47)
Loss before income taxes	(5,500)	(10,636)
INCOME TAX EXPENSE (BENEFIT)	131	(410)
NET LOSS	$ (5,631)	$ (10,226)
LOSS PER SHARE:
BASIC	$ (0.10)	$ (0.18)
DILUTED	$ (0.10)	$ (0.18)
SHARES USED IN COMPUTING LOSS PER SHARE:
BASIC	55,762	55,449
DILUTED	55,762	55,449

Stockholders' Equity - Summary of Company's Stock Option Activity (Detail) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding [Roll Forward]
Options, Outstanding, Beginning balance	5,271
Options, Outstanding, Granted	1,168
Options, Outstanding, Exercised	(22)
Options, Outstanding, Expired	(319)
Options, Outstanding, Forfeited	(70)
Options, Outstanding, Ending balance	6,028

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $) Share data in Thousands, unless otherwise specified	3 Months Ended		12 Months Ended			3 Months Ended					1 Months Ended	3 Months Ended
	Mar. 31, 2014 Customer	Mar. 31, 2013	Dec. 31, 2013	Mar. 31, 2014 Up Front Payment Arrangement [Member]	Dec. 31, 2013 Up Front Payment Arrangement [Member]	Mar. 31, 2014 Accounts Receivable [Member] Customer Concentration Risk [Member]	Mar. 31, 2014 Maximum [Member] Other Intangible Assets [Member]	Mar. 31, 2014 Maximum [Member] Building [Member]	Mar. 31, 2014 Minimum [Member] Other Intangible Assets [Member]	Mar. 31, 2014 Minimum [Member] Building [Member]	Jul. 31, 2012 DNA Genotek [Member]	Mar. 31, 2014 DNA Genotek [Member]
Product Information [Line Items]
Fair value of plan assets	$ 1,111,000		$ 677,000
Useful life of building and other assets							10 years	40 years	2 years	20 years
Accumulated depreciation of property and equipment	29,081,000		28,390,000
Fair value of goodwill												25,179,000
Impairment of goodwill											0
Percentage of excess of fair value on carrying value	13.00%
Amount of goodwill at period end	22,860,000		23,782,000
Reserve for sales return and allowances	329,000		279,000
Deferred revenue	954,000		1,119,000	954,000	1,119,000
Number of our customers, accounted for significant concentrations	1
Percentage of concentration risk						11.00%
Concentration rate of accounts receivable	10.00%
Significant concentrations in revenues	0	0
Number of third-party suppliers to manufacture DNAG's products												2
Number of anti-dilutive securities excluded from EPS computation	6,792	5,997
Accumulated foreign currency adjustments included in other comprehensive loss amounted	$ 1,778,000	$ 1,125,000

Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross	$ 35,555	$ 36,714
Accumulated Amortization	(14,896)	(14,488)
Net	20,659	22,226
Customer List [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Gross	11,338	11,795
Accumulated Amortization	(2,866)	(2,701)
Net	8,472	9,094
Patent and Product Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	10,449	10,449
Accumulated Amortization	(7,601)	(7,466)
Net	2,848	2,983
Patent and Product Rights [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	3 years	3 years
Patent and Product Rights [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	10 years	10 years
Acquired Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	7 years	7 years
Gross	8,807	9,162
Accumulated Amortization	(3,132)	(2,952)
Net	5,675	6,210
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	15 years	15 years
Gross	4,346	4,521
Accumulated Amortization	(759)	(715)
Net	3,587	3,806
Non-compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross	615	787
Accumulated Amortization	(538)	(654)
Net	$ 77	$ 133
Non-compete Agreements [Member] \| Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	1 year	1 year
Non-compete Agreements [Member] \| Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization Period (Years)	3 years	3 years

Income Taxes - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Tax Disclosure [Abstract]
Foreign deferred tax expense (benefits)	$ 131	$ (410)
U.S. federal income tax benefits	0	0
U.S. state income tax benefits	$ 0	$ 0

Consolidated Statements of Comprehensive Loss (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (5,631)	$ (10,226)
OTHER COMPREHENSIVE LOSS
Currency translation adjustments	(1,778)	(1,125)
Other comprehensive loss	(1,778)	(1,125)
COMPREHENSIVE LOSS	$ (7,409)	$ (11,351)

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2014 Segment
Segment Reporting [Abstract]
Number of reportable segments of company	2

Summary of Significant Accounting Policies - Inventories (Detail) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Inventory Net [Abstract]
Raw materials	$ 6,815	$ 6,700
Work in process	890	833
Finished goods	4,289	3,911
Inventories	$ 11,994	$ 11,444